Gene "Gene synonym" Ensembl "Gene description" Uniprot Chromosome Position "Protein class" "Biological process" "Molecular function" "Disease involvement" Evidence "HPA evidence" "UniProt evidence" "NeXtProt evidence" "MS evidence" "RNA tissue specificity" "RNA tissue distribution" "RNA tissue specificity score" "RNA tissue specific NX" "RNA cell line specificity" "RNA cell line distribution" "RNA cell line specificity score" "RNA cell line specific NX" "RNA cancer specificity" "RNA cancer distribution" "RNA cancer specificity score" "RNA cancer specific FPKM" "RNA brain regional specificity" "RNA brain regional distribution" "RNA brain regional specificity score" "RNA brain regional specific NX" "RNA blood cell specificity" "RNA blood cell distribution" "RNA blood cell specificity score" "RNA blood cell specific NX" "RNA blood lineage specificity" "RNA blood lineage distribution" "RNA blood lineage specificity score" "RNA blood lineage specific NX" "RNA mouse brain regional specificity" "RNA mouse brain regional distribution" "RNA mouse brain regional specificity score" "RNA mouse brain regional specific pTPM" "RNA pig brain regional specificity" "RNA pig brain regional distribution" "RNA pig brain regional specificity score" "RNA pig brain regional specific pTPM" Antibody "Reliability (IH)" "Reliability (Mouse Brain)" "Reliability (IF)" "Subcellular location" "Secretome location" "Blood concentration - Conc. blood IM [pg/L]" "Blood concentration - Conc. blood MS [pg/L]" "Subcellular main location" "Subcellular additional location" "Antibody RRID" "Pathology prognostics - Breast cancer" "Pathology prognostics - Cervical cancer" "Pathology prognostics - Colorectal cancer" "Pathology prognostics - Endometrial cancer" "Pathology prognostics - Glioma" "Pathology prognostics - Head and neck cancer" "Pathology prognostics - Liver cancer" "Pathology prognostics - Lung cancer" "Pathology prognostics - Melanoma" "Pathology prognostics - Ovarian cancer" "Pathology prognostics - Pancreatic cancer" "Pathology prognostics - Prostate cancer" "Pathology prognostics - Renal cancer" "Pathology prognostics - Stomach cancer" "Pathology prognostics - Testis cancer" "Pathology prognostics - Thyroid cancer" "Pathology prognostics - Urothelial cancer" "Tissue RNA - adipose tissue [NX]" "Tissue RNA - adrenal gland [NX]" "Tissue RNA - amygdala [NX]" "Tissue RNA - appendix [NX]" "Tissue RNA - basal ganglia [NX]" "Tissue RNA - bone marrow [NX]" "Tissue RNA - breast [NX]" "Tissue RNA - cerebellum [NX]" "Tissue RNA - cerebral cortex [NX]" "Tissue RNA - cervix, uterine [NX]" "Tissue RNA - colon [NX]" "Tissue RNA - corpus callosum [NX]" "Tissue RNA - ductus deferens [NX]" "Tissue RNA - duodenum [NX]" "Tissue RNA - endometrium 1 [NX]" "Tissue RNA - epididymis [NX]" "Tissue RNA - esophagus [NX]" "Tissue RNA - fallopian tube [NX]" "Tissue RNA - gallbladder [NX]" "Tissue RNA - heart muscle [NX]" "Tissue RNA - hippocampal formation [NX]" "Tissue RNA - hypothalamus [NX]" "Tissue RNA - kidney [NX]" "Tissue RNA - liver [NX]" "Tissue RNA - lung [NX]" "Tissue RNA - lymph node [NX]" "Tissue RNA - midbrain [NX]" "Tissue RNA - olfactory region [NX]" "Tissue RNA - ovary [NX]" "Tissue RNA - pancreas [NX]" "Tissue RNA - parathyroid gland [NX]" "Tissue RNA - pituitary gland [NX]" "Tissue RNA - placenta [NX]" "Tissue RNA - pons and medulla [NX]" "Tissue RNA - prostate [NX]" "Tissue RNA - rectum [NX]" "Tissue RNA - retina [NX]" "Tissue RNA - salivary gland [NX]" "Tissue RNA - seminal vesicle [NX]" "Tissue RNA - skeletal muscle [NX]" "Tissue RNA - skin 1 [NX]" "Tissue RNA - small intestine [NX]" "Tissue RNA - smooth muscle [NX]" "Tissue RNA - spinal cord [NX]" "Tissue RNA - spleen [NX]" "Tissue RNA - stomach 1 [NX]" "Tissue RNA - testis [NX]" "Tissue RNA - thalamus [NX]" "Tissue RNA - thymus [NX]" "Tissue RNA - thyroid gland [NX]" "Tissue RNA - tongue [NX]" "Tissue RNA - tonsil [NX]" "Tissue RNA - urinary bladder [NX]" "Tissue RNA - vagina [NX]" "Tissue RNA - B-cells [NX]" "Tissue RNA - dendritic cells [NX]" "Tissue RNA - granulocytes [NX]" "Tissue RNA - monocytes [NX]" "Tissue RNA - NK-cells [NX]" "Tissue RNA - T-cells [NX]" "Tissue RNA - total PBMC [NX]" "Cell RNA - A-431 [NX]" "Cell RNA - A549 [NX]" "Cell RNA - AF22 [NX]" "Cell RNA - AN3-CA [NX]" "Cell RNA - ASC diff [NX]" "Cell RNA - ASC TERT1 [NX]" "Cell RNA - BEWO [NX]" "Cell RNA - BJ [NX]" "Cell RNA - BJ hTERT+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]" "Cell RNA - CACO-2 [NX]" "Cell RNA - CAPAN-2 [NX]" "Cell RNA - Daudi [NX]" "Cell RNA - EFO-21 [NX]" "Cell RNA - fHDF/TERT166 [NX]" "Cell RNA - HaCaT [NX]" "Cell RNA - HAP1 [NX]" "Cell RNA - HBEC3-KT [NX]" "Cell RNA - HBF TERT88 [NX]" "Cell RNA - HDLM-2 [NX]" "Cell RNA - HEK 293 [NX]" "Cell RNA - HEL [NX]" "Cell RNA - HeLa [NX]" "Cell RNA - Hep G2 [NX]" "Cell RNA - HHSteC [NX]" "Cell RNA - HL-60 [NX]" "Cell RNA - HMC-1 [NX]" "Cell RNA - HSkMC [NX]" "Cell RNA - hTCEpi [NX]" "Cell RNA - hTEC/SVTERT24-B [NX]" "Cell RNA - hTERT-HME1 [NX]" "Cell RNA - HUVEC TERT2 [NX]" "Cell RNA - K-562 [NX]" "Cell RNA - Karpas-707 [NX]" "Cell RNA - LHCN-M2 [NX]" "Cell RNA - MCF7 [NX]" "Cell RNA - MOLT-4 [NX]" "Cell RNA - NB-4 [NX]" "Cell RNA - NTERA-2 [NX]" "Cell RNA - PC-3 [NX]" "Cell RNA - REH [NX]" "Cell RNA - RH-30 [NX]" "Cell RNA - RPMI-8226 [NX]" "Cell RNA - RPTEC TERT1 [NX]" "Cell RNA - RT4 [NX]" "Cell RNA - SCLC-21H [NX]" "Cell RNA - SH-SY5Y [NX]" "Cell RNA - SiHa [NX]" "Cell RNA - SK-BR-3 [NX]" "Cell RNA - SK-MEL-30 [NX]" "Cell RNA - T-47d [NX]" "Cell RNA - THP-1 [NX]" "Cell RNA - TIME [NX]" "Cell RNA - U-138 MG [NX]" "Cell RNA - U-2 OS [NX]" "Cell RNA - U-2197 [NX]" "Cell RNA - U-251 MG [NX]" "Cell RNA - U-266/70 [NX]" "Cell RNA - U-266/84 [NX]" "Cell RNA - U-698 [NX]" "Cell RNA - U-87 MG [NX]" "Cell RNA - U-937 [NX]" "Cell RNA - WM-115 [NX]" "Blood RNA - basophil [NX]" "Blood RNA - classical monocyte [NX]" "Blood RNA - eosinophil [NX]" "Blood RNA - gdT-cell [NX]" "Blood RNA - intermediate monocyte [NX]" "Blood RNA - MAIT T-cell [NX]" "Blood RNA - memory B-cell [NX]" "Blood RNA - memory CD4 T-cell [NX]" "Blood RNA - memory CD8 T-cell [NX]" "Blood RNA - myeloid DC [NX]" "Blood RNA - naive B-cell [NX]" "Blood RNA - naive CD4 T-cell [NX]" "Blood RNA - naive CD8 T-cell [NX]" "Blood RNA - neutrophil [NX]" "Blood RNA - NK-cell [NX]" "Blood RNA - non-classical monocyte [NX]" "Blood RNA - plasmacytoid DC [NX]" "Blood RNA - T-reg [NX]" "Blood RNA - total PBMC [NX]" "Brain RNA - amygdala [NX]" "Brain RNA - basal ganglia [NX]" "Brain RNA - cerebellum [NX]" "Brain RNA - cerebral cortex [NX]" "Brain RNA - hippocampal formation [NX]" "Brain RNA - hypothalamus [NX]" "Brain RNA - midbrain [NX]" "Brain RNA - olfactory region [NX]" "Brain RNA - pons and medulla [NX]" "Brain RNA - thalamus [NX]" ABAT GABAT ENSG00000183044 "4-aminobutyrate aminotransferase" P80404 16 8674565-8784575 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Neurotransmitter degradation" "Aminotransferase, Transferase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 53.3;liver: 136.5;pancreas: 54.2" "Cell line enhanced" "Detected in many" "Hep G2: 44.3;MCF7: 28.5;RH-30: 25.1;T-47d: 15.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA041528, HPA041690" Enhanced Supported Supported Mitochondria 1500000 Mitochondria "HPA041528: AB_10795690, HPA041690: AB_10794674" "unprognostic (1.77e-2)" "unprognostic (3.27e-1)" "unprognostic (1.00e-1)" "unprognostic (2.71e-1)" "unprognostic (2.90e-1)" "unprognostic (2.05e-1)" "prognostic favourable (5.36e-5)" "prognostic favourable (5.93e-4)" "unprognostic (1.71e-1)" "unprognostic (1.30e-1)" "unprognostic (1.56e-2)" "unprognostic (1.04e-1)" "prognostic favourable (5.44e-8)" "unprognostic (2.10e-1)" "unprognostic (2.48e-2)" "unprognostic (3.80e-1)" "unprognostic (1.50e-2)" 2.1 12.6 26.1 2.7 39.3 1.7 3.2 19.9 43.3 2.2 5.2 10.9 0.1 17.5 2.1 5.0 3.0 2.8 2.7 6.2 20.4 30.9 53.3 136.5 2.8 2.8 24.5 26.1 5.3 54.2 4.0 22.1 2.3 14.3 9.9 4.2 2.6 2.6 2.5 1.4 2.1 8.4 2.1 14.1 2.5 3.9 6.3 11.8 1.0 12.7 0.4 3.3 6.4 1.1 2.2 1.9 8.8 5.8 1.6 2.5 1.8 0.2 0.0 11.8 6.7 1.9 0.6 0.5 1.4 0.8 0.7 0.2 4.4 0.3 1.4 0.5 0.8 3.0 0.7 2.8 0.9 0.8 0.6 1.9 0.0 44.3 3.1 0.4 3.0 2.5 1.2 1.2 0.5 0.2 0.3 1.0 0.2 28.5 0.7 0.2 1.0 0.1 3.4 25.1 0.6 0.4 7.0 1.9 5.7 0.6 0.4 0.0 15.6 1.2 0.2 0.2 2.0 0.9 0.0 1.1 0.1 0.3 0.3 2.0 1.4 1.1 3.1 4.1 2.5 3.6 1.1 0.8 1.7 1.7 1.9 2.2 1.1 1.8 8.8 1.6 5.8 0.3 1.6 1.8 26.1 39.3 19.9 35.1 20.4 30.9 24.5 26.1 14.3 11.8 ACADL "ACAD4, LCAD" ENSG00000115361 "Acyl-CoA dehydrogenase long chain" P28330 2 210187939-210225491 "Enzymes, Predicted intracellular proteins" "Fatty acid metabolism, Lipid metabolism" Oxidoreductase "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lung: 29.5;thyroid gland: 29.7" "Cell line enhanced" "Detected in some" "HAP1: 3.1;HEK 293: 2.4;HeLa: 7.3;RPTEC TERT1: 6.6;RT4: 2.5;U-2 OS: 3.7" "Group enriched" "Detected in many" 8 "liver cancer: 2.2;prostate cancer: 6.8;renal cancer: 8.8;thyroid cancer: 4.6" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA011990 Enhanced Supported "HPA011990: AB_1844465" "unprognostic (6.29e-3)" "unprognostic (7.61e-2)" "unprognostic (1.40e-1)" "unprognostic (1.53e-1)" "unprognostic (1.33e-2)" "unprognostic (7.66e-3)" "unprognostic (3.24e-1)" "unprognostic (1.55e-1)" "unprognostic (1.75e-1)" "unprognostic (1.66e-1)" "unprognostic (1.99e-1)" "prognostic favourable (1.58e-11)" "unprognostic (4.22e-3)" "unprognostic (1.18e-4)" "unprognostic (8.81e-3)" "unprognostic (1.06e-1)" 9.6 1.1 2.0 1.0 1.8 0.0 10.7 1.4 1.8 3.2 0.8 1.5 4.5 0.1 0.7 6.8 1.3 2.3 2.1 2.2 2.4 1.0 17.3 23.0 29.5 0.0 1.6 2.3 12.2 19.3 11.6 5.8 1.2 3.4 14.5 0.2 3.2 9.9 4.8 7.0 2.2 0.3 1.5 3.1 0.0 3.3 4.2 0.9 0.7 29.7 3.7 0.0 0.7 4.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.7 0.3 0.2 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 3.1 0.4 0.0 0.0 2.4 0.0 7.3 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.0 0.6 0.0 0.0 0.0 6.6 2.5 0.1 1.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 3.7 0.1 0.8 0.0 0.0 0.0 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 1.8 1.4 1.8 2.4 1.0 1.6 2.3 3.4 0.9 ACO2 ACONM ENSG00000100412 "Aconitase 2" Q99798 22 41469125-41528989 "Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Tricarboxylic acid cycle" Lyase "Disease mutation, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 121.0;skeletal muscle: 157.9" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001097 Enhanced Approved Approved Mitochondria 4000000 Mitochondria "HPA001097: AB_1078092" "unprognostic (1.95e-1)" "unprognostic (2.50e-2)" "unprognostic (2.35e-2)" "unprognostic (3.06e-2)" "unprognostic (6.51e-2)" "unprognostic (1.26e-1)" "unprognostic (3.99e-2)" "unprognostic (6.54e-2)" "unprognostic (1.20e-2)" "unprognostic (7.32e-2)" "unprognostic (1.64e-2)" "unprognostic (6.07e-2)" "prognostic favourable (0.00e+0)" "unprognostic (1.46e-2)" "unprognostic (9.60e-2)" "unprognostic (6.45e-2)" "unprognostic (1.12e-2)" 22.8 18.5 41.4 11.1 38.2 9.8 12.2 21.0 43.5 12.2 25.4 27.7 12.3 45.1 9.5 9.9 17.5 15.7 11.1 121.0 33.8 24.2 37.9 22.2 10.0 11.1 27.6 32.7 8.6 17.2 48.5 7.6 9.1 24.9 12.5 20.0 14.7 20.1 15.2 157.9 9.8 46.6 12.5 28.6 10.0 21.0 9.6 23.1 9.5 16.0 42.7 12.0 12.3 8.8 22.9 28.1 7.3 36.6 15.8 16.4 19.4 16.1 18.8 18.9 39.0 32.6 21.3 26.5 14.9 18.8 25.1 23.5 27.7 21.1 37.1 24.4 22.1 37.1 35.1 27.2 13.2 24.5 25.0 18.0 26.3 29.4 28.5 47.9 27.6 37.8 21.9 26.0 27.7 24.8 23.2 40.5 19.7 30.3 24.4 16.2 12.9 37.7 33.2 13.0 51.4 32.3 32.1 13.6 11.6 36.6 43.3 27.6 25.1 25.6 17.6 21.4 24.0 19.5 16.3 24.1 29.9 25.9 34.6 20.9 23.1 4.5 21.1 7.3 14.7 31.3 14.0 22.9 12.5 15.8 28.1 20.2 14.2 14.6 5.3 15.8 36.6 11.2 16.4 19.4 41.4 38.2 21.0 43.5 33.8 24.2 27.6 32.7 24.9 23.1 ADAM22 MDC2 ENSG00000008277 "ADAM metallopeptidase domain 22" Q9P0K1 7 87934143-88202889 "Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" Receptor "Disease mutation, Epilepsy" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 46.9" "Cell line enhanced" "Detected in many" "Karpas-707: 35.5;SH-SY5Y: 33.8;U-266/84: 13.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA050325, CAB079064" Supported Approved "Cell Junctions" "Intracellular and membrane" 78000 "Cell Junctions" "CAB079064: , HPA050325: " "unprognostic (1.20e-2)" "unprognostic (8.61e-2)" "unprognostic (3.38e-1)" "unprognostic (1.94e-2)" "unprognostic (2.89e-2)" "unprognostic (3.09e-1)" "unprognostic (7.84e-3)" "unprognostic (1.38e-1)" "unprognostic (1.23e-1)" "unprognostic (1.56e-1)" "unprognostic (3.71e-3)" "unprognostic (1.69e-1)" "unprognostic (3.47e-2)" "unprognostic (4.13e-2)" "unprognostic (2.77e-1)" "unprognostic (1.61e-4)" "unprognostic (4.70e-2)" 2.9 11.7 10.9 1.5 15.7 1.5 2.1 46.9 36.4 8.6 2.3 6.2 1.6 1.3 6.3 11.2 1.6 3.7 3.7 3.0 14.0 10.6 5.5 0.8 2.0 2.9 8.8 14.4 5.6 1.8 4.5 3.7 0.9 17.0 14.5 2.3 2.9 1.5 7.1 3.3 1.8 1.9 5.0 8.2 2.9 1.4 2.7 5.7 2.8 4.5 0.0 1.9 2.1 2.9 0.4 1.2 1.9 0.0 0.5 1.6 0.1 1.0 0.3 2.1 2.5 0.6 0.1 1.5 0.0 0.2 0.1 0.2 2.1 3.5 3.1 0.8 0.0 0.0 3.0 0.0 0.0 8.5 3.9 2.3 2.2 0.6 0.0 2.8 0.0 0.3 0.0 0.0 0.1 0.2 0.1 35.5 0.1 2.8 3.6 0.5 5.0 1.1 2.1 8.2 4.5 0.0 1.7 11.3 33.8 1.7 0.0 0.3 1.5 0.3 0.0 2.1 1.5 0.4 1.5 8.2 13.6 2.5 1.8 6.0 3.1 1.9 0.0 0.0 1.0 0.0 0.1 0.4 0.3 1.0 0.0 0.3 1.6 1.2 0.2 0.5 0.0 1.2 0.0 0.1 10.9 15.7 46.9 21.8 14.0 10.6 8.8 14.4 17.0 5.7 ADCYAP1 PACAP ENSG00000141433 "Adenylate cyclase activating polypeptide 1" P18509 18 904943-912172 "Predicted secreted proteins" Neurogenesis Hormone "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 33.8;lymphoid tissue: 16.5" "Cell line enriched" "Detected in some" 12 "SCLC-21H: 19.8" "Cancer enhanced" "Detected in some" "pancreatic cancer: 3.2" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA065887 Supported Supported "Secreted in other tissues" "HPA065887: " "unprognostic (2.68e-1)" "unprognostic (1.83e-2)" "unprognostic (7.09e-2)" "unprognostic (4.04e-2)" "unprognostic (2.23e-1)" "unprognostic (3.87e-4)" "unprognostic (9.58e-3)" "unprognostic (1.00e-1)" "unprognostic (2.34e-1)" "unprognostic (6.86e-2)" "unprognostic (4.16e-2)" "unprognostic (9.94e-2)" "prognostic favourable (2.91e-6)" "unprognostic (2.24e-3)" "unprognostic (9.22e-2)" "unprognostic (1.74e-1)" "unprognostic (5.74e-4)" 2.1 0.5 2.5 16.5 7.7 0.1 1.6 2.1 12.5 3.4 2.6 0.8 0.0 0.1 4.0 0.1 2.2 0.5 12.3 1.0 1.2 18.4 0.6 0.3 1.7 1.6 2.8 6.2 0.2 7.7 0.1 4.5 0.3 33.8 1.4 1.4 2.5 2.2 1.0 0.3 0.9 1.3 1.5 5.9 0.2 1.8 3.6 0.2 0.1 0.3 0.0 1.4 3.1 1.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.2 0.8 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 7.7 2.1 12.1 1.2 18.4 2.8 6.2 33.8 0.2 ADORA2A "ADORA2, RDC8" ENSG00000128271 "Adenosine A2a receptor" P29274 22 24417879-24442360 "Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "blood: 22.8;bone marrow: 28.1;brain: 43.9;lymphoid tissue: 59.0" "Cell line enhanced" "Detected in many" "Daudi: 15.0;Karpas-707: 20.7;RPMI-8226: 14.6;SK-BR-3: 29.7;U-266/70: 20.8;U-266/84: 27.1;U-698: 21.2" "Not detected" "Not detected" "Region enriched" "Detected in all" 8 "basal ganglia: 43.9" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Region enriched" "Detected in some" 10 "basal ganglia: 357.5" "Region enriched" "Detected in single" 95 "basal ganglia: 166.0" "CAB001943, HPA065566, HPA075997" Enhanced Supported "CAB001943: , HPA065566: , HPA075997: " "unprognostic (7.30e-2)" "unprognostic (2.42e-2)" "unprognostic (3.30e-2)" "unprognostic (2.04e-1)" "unprognostic (7.44e-2)" "unprognostic (1.88e-3)" "unprognostic (9.85e-2)" "unprognostic (3.63e-1)" "unprognostic (2.88e-2)" "unprognostic (4.57e-3)" "unprognostic (2.15e-3)" "unprognostic (1.87e-3)" "unprognostic (6.81e-4)" "unprognostic (1.50e-1)" "unprognostic (9.78e-3)" "unprognostic (1.30e-1)" "unprognostic (7.10e-3)" 1.0 2.4 1.9 10.4 43.9 28.1 1.5 3.4 3.8 0.8 2.0 1.7 0.3 5.4 1.4 1.4 1.0 0.9 2.4 3.5 2.4 1.8 3.5 4.3 5.1 14.8 2.6 1.6 1.2 0.8 0.0 2.1 1.4 2.3 1.6 0.8 3.3 2.7 1.5 1.2 0.9 2.6 0.7 1.3 7.5 2.8 2.0 5.7 59.0 1.3 0.9 8.6 3.8 1.3 17.7 1.1 13.7 9.0 2.2 22.8 11.2 0.2 0.3 0.4 0.1 0.2 0.1 0.4 0.2 9.3 0.5 0.9 1.7 0.1 15.0 1.0 0.2 0.3 0.9 0.0 0.0 1.8 2.6 0.2 0.0 2.1 0.1 0.3 7.5 0.1 0.0 2.8 0.0 3.3 0.1 20.7 0.0 0.2 5.2 1.6 0.6 0.0 0.1 0.7 14.6 0.0 0.1 1.5 8.7 0.4 29.7 0.1 0.3 1.4 0.2 0.9 1.4 0.2 0.1 20.8 27.1 21.2 4.7 5.1 0.1 3.0 0.8 4.8 8.6 2.6 20.1 9.6 16.1 16.9 1.1 17.7 22.8 18.3 13.7 2.2 9.0 1.1 21.4 11.2 1.9 43.9 3.4 3.8 2.4 1.8 2.6 1.6 2.3 5.7 ADRA1A "ADRA1C, ADRA1L1" ENSG00000120907 "Adrenoceptor alpha 1A" P35348 8 26748150-26867273 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 45.1" "Group enriched" "Detected in some" 5 "ASC diff: 1.3;HAP1: 1.8;NTERA-2: 2.4;U-2 OS: 1.5" "Cancer enhanced" "Detected in some" "liver cancer: 0.9" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA029678, HPA029679" Approved Supported "HPA029678: AB_10602108, HPA029679: " "unprognostic (1.27e-1)" "unprognostic (1.68e-2)" "unprognostic (1.99e-1)" "unprognostic (3.57e-1)" "unprognostic (5.04e-4)" "unprognostic (1.97e-1)" "unprognostic (9.55e-2)" "unprognostic (3.08e-1)" "unprognostic (1.58e-2)" "unprognostic (7.47e-2)" "unprognostic (1.71e-2)" "unprognostic (6.06e-3)" "unprognostic (7.41e-2)" "unprognostic (1.52e-2)" "unprognostic (1.30e-1)" 14.5 0.7 7.1 1.1 3.9 0.3 3.4 6.2 4.9 0.9 1.5 5.9 4.9 1.0 1.8 2.0 0.9 0.6 0.5 10.1 11.6 2.0 0.8 45.1 3.9 1.4 4.7 4.7 1.0 0.5 0.3 0.6 0.3 3.8 10.2 0.7 0.6 4.6 11.2 0.6 0.9 1.3 2.4 1.9 7.0 1.2 0.5 4.2 0.0 0.6 0.1 0.6 0.6 0.7 0.3 0.0 0.3 0.0 0.2 0.4 0.0 0.0 0.0 0.0 0.1 1.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 2.4 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.3 0.0 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.3 0.0 0.2 0.3 0.2 0.0 0.0 0.0 0.0 7.1 3.9 6.2 4.9 11.6 2.0 4.7 4.7 3.8 4.2 AGRP "Agrt, ART, ASIP2" ENSG00000159723 "Agouti related neuropeptide" O00253 16 67482571-67483813 "Disease related genes, Plasma proteins, Predicted secreted proteins" "Disease mutation, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 19.4;epididymis: 49.8" "Cell line enhanced" "Detected in some" "CACO-2: 2.6;CAPAN-2: 2.7;HeLa: 1.5;Hep G2: 2.1;HMC-1: 1.8" "Low cancer specificity" "Detected in single" "Region enriched" "Detected in some" 13 "hypothalamus: 19.4" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Region enriched" "Detected in single" 16 "hypothalamus: 18.9" "Region enhanced" "Detected in some" "hypothalamus: 3.9" HPA041017 Enhanced Supported "Secreted in other tissues" "HPA041017: AB_10795498" "unprognostic (1.32e-1)" "unprognostic (6.26e-2)" "unprognostic (1.13e-1)" "unprognostic (4.16e-1)" "unprognostic (3.15e-1)" "unprognostic (1.10e-1)" "unprognostic (3.61e-1)" "unprognostic (3.34e-1)" "unprognostic (4.68e-1)" "unprognostic (1.29e-1)" "unprognostic (6.74e-2)" "unprognostic (3.17e-1)" "unprognostic (2.80e-1)" "unprognostic (1.72e-1)" "unprognostic (5.63e-2)" "unprognostic (1.09e-1)" "unprognostic (1.18e-2)" 0.1 9.6 0.1 0.1 1.4 0.0 0.1 0.1 0.2 0.1 0.1 0.3 0.1 0.0 0.1 49.8 0.1 0.0 0.1 0.1 0.1 19.4 0.5 0.1 2.1 0.3 0.1 0.3 0.1 0.1 0.0 0.4 0.1 0.2 0.1 0.0 0.3 0.5 0.1 0.1 0.4 0.1 0.1 0.3 0.3 0.1 1.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 2.2 2.1 1.4 3.8 0.3 3.2 1.0 0.1 0.0 0.4 1.4 0.0 0.0 0.6 0.0 0.0 0.0 0.0 2.6 2.7 0.8 0.2 0.0 0.3 0.3 0.0 0.0 0.0 0.0 0.4 1.5 2.1 0.0 0.0 1.8 0.6 0.0 0.0 0.0 0.0 0.1 0.9 0.0 0.0 0.2 0.5 0.0 0.0 0.0 0.0 0.3 0.3 0.7 0.0 0.1 0.0 0.0 0.0 0.2 0.3 0.0 0.5 0.2 0.0 0.1 1.0 0.5 0.9 0.0 0.4 0.3 0.0 3.8 1.4 3.2 2.3 1.6 2.2 0.8 1.1 1.5 1.9 2.1 2.2 0.6 0.3 1.2 2.1 1.3 1.0 0.1 1.4 0.1 0.2 0.1 19.4 0.1 0.3 0.2 0.1 AKAP5 "AKAP75, AKAP79" ENSG00000179841 "A-kinase anchoring protein 5" P24588 14 64465499-64474503 "Plasma proteins, Predicted intracellular proteins, Transporters" Calmodulin-binding "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 39.1" "Cell line enhanced" "Detected in many" "CACO-2: 14.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 6 "basophil: 5.7" "Lineage enriched" "Detected in many" 6 "granulocytes: 5.7" "Group enriched" "Detected in many" 5 "amygdala: 34.7;basal ganglia: 98.5;cerebral cortex: 52.2;hippocampal formation: 56.3" "CAB004308, HPA053891" Enhanced Supported Approved Nucleoplasm Nucleoplasm "CAB004308: AB_626655, HPA053891: " "unprognostic (4.29e-2)" "unprognostic (5.89e-3)" "unprognostic (3.44e-4)" "unprognostic (2.30e-1)" "unprognostic (1.73e-1)" "unprognostic (2.24e-3)" "unprognostic (1.08e-1)" "unprognostic (3.57e-1)" "unprognostic (6.92e-2)" "unprognostic (3.02e-3)" "unprognostic (8.23e-2)" "unprognostic (1.42e-1)" "unprognostic (5.44e-2)" "unprognostic (4.49e-4)" "unprognostic (2.11e-1)" "unprognostic (2.42e-1)" "unprognostic (7.45e-2)" 0.7 0.8 17.3 2.2 39.1 1.0 1.1 2.9 21.8 0.7 5.9 0.2 0.0 1.1 2.3 0.6 1.0 0.8 1.6 0.6 9.9 1.4 2.4 1.2 3.0 2.9 1.3 9.2 0.7 0.5 1.5 1.3 1.8 0.9 1.0 6.1 0.0 0.7 1.0 0.6 1.0 2.4 2.2 0.7 2.0 1.1 0.7 1.3 0.1 1.1 0.0 2.5 1.4 0.7 0.7 0.4 5.7 0.3 0.9 1.0 0.2 1.7 1.4 1.7 1.0 0.6 0.1 5.7 1.3 0.6 1.6 2.1 14.0 4.3 1.3 2.7 1.0 0.6 3.7 0.3 1.6 2.6 3.1 4.2 2.6 1.2 0.1 0.5 0.6 0.6 0.1 1.1 0.0 0.6 0.5 1.0 1.0 1.0 3.3 0.3 1.3 0.7 4.2 0.8 0.3 2.6 1.6 4.4 2.0 1.5 0.1 0.3 1.3 0.3 0.8 1.9 5.8 0.2 2.1 2.9 3.2 3.2 1.3 0.5 0.3 5.7 0.3 0.2 1.0 0.1 0.2 0.5 0.3 0.9 0.2 0.7 0.4 0.5 0.7 0.9 0.1 0.4 0.1 0.2 17.3 39.1 2.9 19.9 9.9 1.4 1.3 9.2 0.9 1.3 ALDH1A1 "ALDH1, PUMB1, RALDH1" ENSG00000165092 "Aldehyde dehydrogenase 1 family member A1" P00352 9 72900662-73080442 "Enzymes, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 207.2" "Cell line enhanced" "Detected in some" "A549: 287.9;Hep G2: 88.6;RPTEC TERT1: 51.3" "Cancer enhanced" "Detected in all" "liver cancer: 399.1" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 6 "classical monocyte: 34.2" "Lineage enriched" "Detected in many" 30 "monocytes: 34.2" "Region enriched" "Detected in many" 6 "midbrain: 171.1" "HPA002123, CAB020690" Approved Approved Enhanced Cytosol 62000000 Cytosol "CAB020690: , HPA002123: AB_1844722" "unprognostic (8.46e-3)" "prognostic favourable (7.77e-5)" "unprognostic (5.59e-2)" "unprognostic (1.69e-1)" "unprognostic (1.49e-2)" "unprognostic (8.71e-2)" "unprognostic (3.64e-2)" "unprognostic (3.98e-2)" "unprognostic (4.53e-2)" "unprognostic (6.83e-2)" "unprognostic (4.45e-2)" "unprognostic (3.73e-1)" "unprognostic (3.24e-3)" "unprognostic (2.20e-1)" "unprognostic (2.36e-1)" "unprognostic (2.96e-2)" "unprognostic (1.90e-3)" 20.0 26.9 8.8 12.3 21.4 3.9 10.8 44.8 11.7 33.6 53.6 14.5 65.3 77.1 25.5 87.1 14.5 27.8 38.3 8.9 12.5 5.9 86.7 207.2 31.4 9.4 56.4 3.6 35.8 69.7 0.7 57.5 7.9 14.0 20.0 13.1 30.2 31.8 40.3 12.1 2.7 76.5 17.1 29.1 16.3 75.5 43.0 14.9 2.0 45.8 21.0 16.8 14.1 16.0 0.3 0.5 1.1 34.2 0.0 0.1 10.5 0.0 287.9 0.0 0.0 1.6 0.0 0.1 10.0 0.0 0.0 0.0 9.6 0.0 0.0 3.7 0.0 0.1 0.0 0.0 0.0 0.0 0.0 16.3 0.0 88.6 1.0 0.0 0.0 0.5 0.0 0.0 0.0 10.3 1.1 0.0 11.0 0.4 0.0 0.1 0.0 0.0 0.0 3.2 0.1 51.3 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 34.2 0.5 0.0 5.8 0.0 0.0 0.1 0.0 0.5 0.3 0.0 0.0 1.1 0.0 0.4 0.3 0.0 10.5 8.8 21.4 44.8 11.7 12.5 5.9 56.4 3.6 14.0 14.9 ALDH1L1 "10-fTHF, FTHFD" ENSG00000144908 "Aldehyde dehydrogenase 1 family member L1" O75891 3 126103562-126197994 "Enzymes, Plasma proteins, Predicted intracellular proteins" "One-carbon metabolism" Oxidoreductase "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 48.1;liver: 148.7" "Cell line enhanced" "Detected in some" "Hep G2: 23.4;Karpas-707: 24.1;RPMI-8226: 12.6;RT4: 64.5;U-266/70: 13.3" "Cancer enhanced" "Detected in many" "liver cancer: 40.4" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA036900, HPA050139" Enhanced Supported Supported Cytosol 640000 Cytosol "HPA036900: AB_10672273, HPA050139: AB_2681031" "unprognostic (5.93e-2)" "unprognostic (1.22e-1)" "unprognostic (9.12e-2)" "unprognostic (2.68e-1)" "unprognostic (1.10e-1)" "unprognostic (1.10e-1)" "unprognostic (7.12e-2)" "unprognostic (1.29e-1)" "unprognostic (3.05e-2)" "unprognostic (4.73e-2)" "unprognostic (3.05e-3)" "unprognostic (8.40e-2)" "prognostic favourable (2.42e-8)" "unprognostic (3.60e-1)" "unprognostic (1.47e-1)" "unprognostic (7.03e-3)" "unprognostic (7.93e-2)" 28.9 12.1 13.7 1.8 17.1 1.2 6.0 8.6 10.9 7.8 4.9 5.7 2.3 1.1 1.9 2.2 3.6 3.4 1.9 8.1 8.9 5.3 48.1 148.7 1.3 1.2 9.2 10.1 11.3 10.2 1.4 0.9 1.1 10.8 3.3 3.3 5.1 34.1 4.1 30.7 1.5 1.3 2.4 7.7 1.1 1.9 4.9 6.2 0.0 1.7 6.2 2.8 11.0 3.1 0.1 0.8 0.8 0.2 0.2 0.4 0.0 0.4 0.0 0.0 0.0 10.6 0.0 0.1 0.1 0.4 0.1 0.2 0.0 0.9 0.7 3.1 0.0 0.1 0.2 0.4 0.2 0.0 0.0 0.0 0.1 23.4 3.1 3.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 24.1 0.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 12.6 0.3 64.5 0.1 0.1 0.3 3.1 0.0 0.0 0.0 0.1 0.4 1.9 0.0 0.0 13.3 4.1 0.1 0.0 0.0 0.0 0.8 0.2 0.0 0.1 0.2 0.0 0.0 0.2 0.0 0.2 0.1 0.4 0.2 0.2 0.2 0.0 0.8 0.1 0.0 13.7 17.1 8.6 10.9 8.9 5.3 9.2 10.1 10.8 6.2 ALDOC ENSG00000109107 "Aldolase, fructose-bisphosphate C" P09972 17 28573115-28577264 "Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins" Glycolysis Lyase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "brain: 166.7;heart muscle: 56.9" "Cell line enhanced" "Detected in many" "RPMI-8226: 62.2;U-266/70: 42.9" "Cancer enriched" "Detected in all" 6 "glioma: 128.9" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003282, CAB020828, HPA067442" Enhanced Supported Approved "Nucleoplasm,Nucleoli fibrillar center,Vesicles,Cytosol" 280000000 "Nucleoplasm, Nucleoli fibrillar center" "Vesicles, Cytosol" "CAB020828: , HPA003282: AB_1078130, HPA067442: " "unprognostic (2.90e-1)" "unprognostic (4.45e-3)" "unprognostic (5.69e-3)" "unprognostic (1.43e-1)" "unprognostic (3.56e-1)" "prognostic unfavourable (9.80e-4)" "unprognostic (1.03e-1)" "unprognostic (1.70e-1)" "unprognostic (1.30e-1)" "unprognostic (6.03e-3)" "unprognostic (3.90e-1)" "unprognostic (3.24e-2)" "prognostic unfavourable (1.29e-7)" "unprognostic (1.28e-1)" "unprognostic (2.00e-1)" "unprognostic (2.74e-2)" "unprognostic (1.23e-1)" 26.0 9.4 86.7 4.8 78.9 7.5 9.8 100.1 166.7 3.8 5.3 17.4 0.3 7.0 4.4 4.6 7.1 3.9 4.4 56.9 64.6 54.3 3.3 26.2 4.6 6.5 69.9 51.4 12.8 1.6 4.7 2.3 2.1 98.1 6.0 5.6 16.5 4.2 6.1 1.7 12.5 15.0 4.6 34.4 6.7 8.7 4.6 23.4 0.0 2.1 0.5 10.0 3.4 3.5 12.2 4.6 8.8 4.1 13.7 20.5 8.8 7.4 0.5 3.5 14.4 7.2 7.4 0.7 3.8 8.6 2.9 18.1 4.3 0.7 3.5 4.6 3.4 9.7 2.3 23.6 5.5 3.0 2.2 6.7 2.7 7.4 6.8 2.4 7.8 6.8 3.3 0.3 5.9 1.3 4.6 18.8 2.5 3.5 2.8 8.1 5.4 3.9 2.4 0.4 62.2 0.4 1.0 9.2 16.4 2.2 17.7 0.1 9.6 5.5 0.9 0.3 1.4 0.5 0.6 42.9 12.3 2.6 28.1 7.0 0.5 0.1 3.5 1.4 11.4 4.1 16.2 12.2 15.6 9.2 4.6 11.5 20.5 15.1 8.8 13.7 2.3 2.2 19.5 8.8 86.7 78.9 100.1 78.5 64.6 54.3 69.9 51.4 98.1 23.4 ANK1 "ANK, SPH1" ENSG00000029534 "Ankyrin 1" P16157 8 41653220-41896762 "Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters" "Disease mutation, Elliptocytosis, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "skeletal muscle: 166.5;tongue: 58.3" "Group enriched" "Detected in some" 4 "HEL: 37.1;K-562: 39.0;RH-30: 49.4" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in many" "cerebellum: 20.1" "Group enriched" "Detected in some" 8 "memory B-cell: 10.6;naive B-cell: 9.1;plasmacytoid DC: 3.5" "Group enriched" "Detected in many" 7 "B-cells: 10.6;dendritic cells: 3.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004842, HPA056953" Supported Supported "Intracellular and membrane" 33000000 "HPA004842: AB_1844827, HPA056953: " "unprognostic (1.05e-1)" "unprognostic (1.30e-1)" "unprognostic (4.22e-3)" "unprognostic (2.31e-3)" "unprognostic (1.76e-7)" "unprognostic (2.03e-1)" "unprognostic (2.15e-1)" "unprognostic (2.52e-1)" "unprognostic (2.95e-1)" "unprognostic (3.21e-2)" "unprognostic (7.90e-2)" "unprognostic (1.57e-1)" "unprognostic (1.40e-1)" "unprognostic (3.86e-1)" "unprognostic (4.65e-2)" "unprognostic (1.40e-1)" "unprognostic (1.04e-1)" 1.2 0.3 0.6 0.7 0.6 14.8 0.3 20.1 3.8 0.2 0.2 0.0 0.0 0.4 0.2 2.7 1.8 0.2 0.3 18.0 0.6 1.2 0.3 0.2 0.4 0.9 4.0 0.4 0.2 0.3 4.3 0.3 0.8 8.3 0.9 0.2 0.5 2.9 0.3 166.5 0.2 0.3 0.2 1.0 0.7 1.1 0.3 0.0 0.0 1.0 58.3 3.8 0.3 0.4 10.6 3.5 1.0 0.2 0.1 0.9 0.7 0.0 5.0 0.1 0.0 0.0 0.9 0.0 1.4 10.0 0.4 0.2 0.0 0.0 2.3 0.4 1.0 0.8 0.2 0.1 0.2 0.9 0.0 37.1 0.2 0.0 0.0 0.1 0.1 1.3 0.2 0.1 0.0 0.0 39.0 0.8 0.6 0.1 0.0 0.4 0.5 0.0 0.2 49.4 0.2 0.2 0.1 0.7 0.4 0.0 0.7 0.0 0.6 0.9 0.2 0.1 0.2 8.5 0.0 0.0 0.0 1.4 0.9 0.0 0.0 1.0 0.2 0.0 0.1 0.0 0.5 10.6 0.3 0.5 0.1 9.1 0.0 0.0 0.5 0.1 0.0 3.5 0.9 0.7 0.6 0.6 20.1 3.8 0.6 1.2 4.0 0.4 8.3 0.0 ANK2 LQT4 ENSG00000145362 "Ankyrin 2" Q01484 4 112818109-113383740 "Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters" "Endocytosis, Protein transport, Transport" "Disease mutation, Long QT syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 58.5;heart muscle: 56.7;kidney: 59.8;skeletal muscle: 66.9" "Cell line enhanced" "Detected in many" "ASC diff: 16.1;ASC TERT1: 22.5;RH-30: 30.8;SH-SY5Y: 15.5" "Cancer enhanced" "Detected in many" "glioma: 10.3" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008007, CAB015178, HPA035970" Enhanced Approved Supported "Plasma membrane" "Plasma membrane" "CAB015178: AB_2242828, HPA008007: , HPA035970: " "unprognostic (8.33e-2)" "unprognostic (9.47e-2)" "unprognostic (1.33e-2)" "unprognostic (7.63e-2)" "unprognostic (2.73e-1)" "unprognostic (1.71e-1)" "unprognostic (1.54e-1)" "unprognostic (2.15e-2)" "unprognostic (1.23e-1)" "unprognostic (1.63e-1)" "unprognostic (1.79e-3)" "unprognostic (2.94e-2)" "prognostic unfavourable (2.41e-6)" "unprognostic (1.18e-2)" "unprognostic (3.16e-1)" "unprognostic (1.51e-3)" "unprognostic (2.04e-3)" 17.3 8.7 34.0 6.3 42.1 0.8 10.7 43.7 58.5 20.9 9.5 24.5 0.6 4.3 10.5 4.3 8.3 5.8 13.0 56.7 29.4 30.3 59.8 2.0 4.6 5.1 28.7 38.7 19.0 2.4 1.6 8.6 2.0 42.1 5.4 7.2 7.8 2.6 8.7 66.9 3.5 4.7 15.2 19.0 15.1 3.8 5.8 24.2 0.0 5.6 4.4 4.5 4.5 4.8 0.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.9 10.2 4.2 16.1 22.5 0.0 1.0 1.8 0.7 2.0 4.0 0.0 4.2 1.4 3.6 0.0 7.5 0.4 0.6 1.9 6.2 2.4 0.0 1.7 1.0 1.0 0.7 9.6 1.6 0.9 3.9 0.0 0.0 6.9 3.4 0.1 0.2 0.0 5.3 1.7 0.5 30.8 0.0 0.1 0.0 8.3 15.5 0.1 0.3 5.3 0.1 0.6 0.0 3.2 1.7 0.2 1.9 4.1 1.1 0.6 12.7 0.4 4.7 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 34.0 42.1 43.7 54.3 29.4 30.3 28.7 38.7 42.1 24.2 AQP4 MIWC ENSG00000171885 "Aquaporin 4" P55087 18 26852038-26865818 "Predicted membrane proteins, Transporters" Transport "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "brain: 185.1;lung: 53.5" "Cell line enhanced" "Detected in some" "AF22: 6.7;Karpas-707: 2.0;RPTEC TERT1: 3.8;U-87 MG: 1.7" "Cancer enriched" "Detected in some" 22 "glioma: 223.7" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005079, HPA014784, CAB058689" Enhanced Supported Approved "Plasma membrane,Cell Junctions" "Plasma membrane" "Cell Junctions" "CAB005079: AB_2274338, CAB058689: , HPA014784: AB_1844967" "unprognostic (7.23e-5)" "unprognostic (1.55e-1)" "unprognostic (3.19e-8)" "unprognostic (3.68e-1)" "unprognostic (1.96e-1)" "unprognostic (2.69e-2)" "unprognostic (1.74e-1)" "unprognostic (2.34e-1)" "unprognostic (5.38e-3)" "unprognostic (1.64e-3)" "unprognostic (8.98e-2)" "unprognostic (1.22e-1)" "unprognostic (4.14e-2)" "unprognostic (1.35e-1)" "unprognostic (4.10e-2)" 1.7 1.7 60.7 1.6 57.1 1.6 1.8 21.8 185.1 1.9 1.6 41.3 0.0 1.6 1.6 2.0 1.9 2.1 1.6 2.7 64.3 27.1 2.7 2.0 53.5 1.7 39.8 36.4 2.8 1.7 2.9 0.8 1.6 39.1 1.8 1.6 0.0 1.8 1.7 25.4 1.6 1.6 1.6 67.2 1.8 6.1 1.7 42.2 0.0 8.4 0.1 1.6 1.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.5 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.5 0.2 0.9 0.0 0.0 0.0 0.0 3.8 0.0 1.3 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.7 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 60.7 57.1 21.8 31.7 64.3 27.1 39.8 36.4 39.1 42.2 ARC "Arg3.1, KIAA0278" ENSG00000198576 "Activity regulated cytoskeleton associated protein" Q7LC44 8 142611044-142614472 "Predicted intracellular proteins" "Endocytosis, Transport" "Developmental protein, RNA-binding" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "pituitary gland: 25.8;seminal vesicle: 67.7" "Cell line enhanced" "Detected in some" "AN3-CA: 6.8;HEK 293: 8.4;SCLC-21H: 20.0;U-2 OS: 9.7;U-87 MG: 10.9" "Cancer enriched" "Detected in many" 12 "glioma: 36.1" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in single" "gdT-cell: 1.6" "Lineage enhanced" "Detected in single" "T-cells: 1.6" "Group enriched" "Detected in many" 5 "amygdala: 48.9;basal ganglia: 51.6;cerebral cortex: 144.6;hippocampal formation: 99.8;olfactory region: 50.5" "Group enriched" "Detected in many" 7 "basal ganglia: 25.3;cerebral cortex: 87.7;hippocampal formation: 55.8;olfactory region: 47.5" "HPA056430, CAB079013" Supported Approved Vesicles,Microtubules "Vesicles, Microtubules" "CAB079013: , HPA056430: " "unprognostic (1.40e-3)" "unprognostic (2.95e-2)" "unprognostic (4.35e-3)" "unprognostic (4.87e-4)" "unprognostic (6.83e-2)" "unprognostic (8.12e-2)" "unprognostic (5.13e-2)" "unprognostic (1.77e-1)" "unprognostic (5.07e-2)" "unprognostic (9.43e-2)" "unprognostic (4.15e-3)" "unprognostic (1.40e-1)" "unprognostic (2.14e-2)" "unprognostic (1.01e-2)" "unprognostic (7.42e-2)" "unprognostic (1.54e-1)" "unprognostic (3.35e-2)" 18.1 15.9 6.1 1.0 6.5 0.7 1.0 0.8 17.0 1.5 0.9 4.2 11.8 0.8 1.4 1.8 0.9 1.2 3.5 0.5 13.9 7.1 1.5 0.7 2.7 0.4 2.4 2.1 0.5 6.2 0.4 25.8 1.8 4.0 1.0 0.6 0.0 0.5 67.7 0.5 3.5 0.7 0.9 1.2 0.7 2.1 0.6 1.1 0.0 1.5 0.8 1.9 0.6 1.5 0.0 0.0 0.0 0.5 0.0 1.6 0.0 0.0 0.1 0.3 6.8 0.1 0.7 0.0 1.4 0.0 0.3 0.1 0.1 0.0 0.0 0.9 0.2 0.1 0.4 0.0 0.0 0.0 8.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.3 0.0 0.0 0.0 2.8 0.0 0.0 3.1 1.5 0.0 0.6 0.0 0.0 0.0 20.0 4.7 0.4 0.0 0.2 0.0 0.1 0.0 1.1 9.7 0.7 0.2 1.8 0.0 0.0 10.9 0.0 2.9 0.0 0.0 0.0 1.6 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 6.1 6.5 0.8 17.0 13.9 7.1 2.4 2.1 4.0 1.1 ARFGEF1 "ARFGEP1, BIG1, DKFZP434L057, p200" ENSG00000066777 "ADP ribosylation factor guanine nucleotide exchange factor 1" Q9Y6D6 8 67173511-67343677 "Predicted intracellular proteins" "Protein transport, Transport" "Guanine-nucleotide releasing factor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA023399, HPA023822" Supported Supported Enhanced "Nucleoplasm,Golgi apparatus,Cytosol" "Golgi apparatus" "Nucleoplasm, Cytosol" "HPA023399: AB_1844981, HPA023822: AB_1844982" "prognostic unfavourable (8.76e-4)" "unprognostic (1.62e-1)" "unprognostic (4.60e-2)" "unprognostic (1.01e-2)" "unprognostic (1.11e-1)" "unprognostic (5.49e-2)" "unprognostic (1.52e-2)" "unprognostic (4.52e-1)" "unprognostic (5.38e-2)" "unprognostic (4.67e-2)" "unprognostic (2.13e-3)" "unprognostic (1.31e-1)" "prognostic favourable (2.48e-4)" "unprognostic (1.13e-1)" "unprognostic (2.84e-1)" "unprognostic (1.62e-1)" "unprognostic (1.61e-2)" 17.0 17.1 14.5 24.3 15.6 24.9 14.0 20.4 16.3 17.7 24.7 9.5 24.7 16.8 15.4 20.3 23.8 13.1 16.0 12.0 11.3 11.7 23.9 15.3 18.6 22.7 11.4 9.5 15.1 21.4 38.6 21.8 17.4 16.7 15.8 17.7 13.2 20.7 29.4 20.9 18.4 26.9 13.8 12.0 20.1 19.5 27.1 12.6 36.7 22.9 15.7 16.8 22.9 17.7 2.1 3.7 8.4 3.7 3.7 6.1 1.3 15.5 10.1 9.9 3.7 11.4 15.8 11.7 10.9 12.3 11.2 11.4 6.2 15.2 11.8 4.8 13.8 11.2 11.8 15.4 13.8 15.1 8.3 19.8 6.2 6.6 9.9 10.1 19.8 9.6 11.1 10.1 17.2 15.9 12.1 12.8 12.9 3.5 23.8 4.8 21.7 9.3 11.6 7.1 2.4 18.6 29.0 3.9 7.7 7.1 17.2 9.7 29.7 9.1 19.3 7.7 10.3 10.1 8.2 11.3 12.3 8.9 12.2 10.4 7.2 8.0 2.6 6.6 4.8 3.7 6.1 2.1 3.2 3.9 2.6 2.1 5.3 4.5 8.4 3.7 1.5 3.7 5.9 1.3 14.5 15.6 20.4 16.3 11.3 11.7 11.4 9.5 16.7 12.6 ARHGAP1 "CDC42GAP, p50rhoGAP, RhoGAP" ENSG00000175220 "Rho GTPase activating protein 1" Q07960 11 46677080-46700615 "Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "GTPase activation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004689, HPA008285" Approved Approved Supported Vesicles 16000000 Vesicles "HPA004689: AB_1078194, HPA008285: AB_1078195" "unprognostic (1.06e-1)" "unprognostic (2.73e-1)" "unprognostic (2.05e-3)" "unprognostic (5.19e-2)" "unprognostic (2.48e-2)" "unprognostic (9.07e-2)" "prognostic unfavourable (2.14e-4)" "unprognostic (1.34e-3)" "unprognostic (1.24e-1)" "unprognostic (7.96e-2)" "unprognostic (1.35e-2)" "unprognostic (4.94e-1)" "unprognostic (4.79e-2)" "unprognostic (4.13e-2)" "unprognostic (3.49e-2)" "unprognostic (2.55e-1)" "unprognostic (9.24e-2)" 39.9 23.0 17.5 21.3 24.0 17.5 25.8 9.5 30.1 35.6 23.9 42.9 13.1 15.2 43.0 23.9 36.8 31.0 40.2 63.3 23.0 14.8 19.8 19.4 17.9 22.0 17.5 17.7 32.6 17.0 18.6 16.7 32.0 17.1 36.3 20.0 33.8 21.6 39.3 15.1 26.9 19.5 58.5 18.1 29.0 21.4 21.4 24.1 21.0 20.0 16.2 27.2 59.5 27.1 7.9 17.1 18.8 33.4 11.6 14.3 10.3 7.0 17.7 8.9 12.6 44.6 32.9 10.6 15.6 16.0 14.5 13.3 10.6 9.4 10.3 8.6 32.0 17.7 7.0 23.9 10.9 7.1 7.7 11.3 9.1 12.5 14.7 9.6 17.0 43.4 15.0 11.1 13.9 12.4 7.3 9.7 17.6 25.6 6.4 9.5 23.0 9.3 7.7 12.8 15.2 13.7 26.7 3.2 10.2 14.4 22.4 6.0 28.2 11.0 15.4 26.8 8.4 31.6 15.7 10.3 11.3 7.7 25.1 16.2 12.5 12.0 16.3 15.6 14.3 28.2 10.2 7.7 11.3 12.1 16.1 7.9 9.9 11.2 18.8 11.6 33.4 17.1 13.4 10.3 17.5 24.0 9.5 30.1 23.0 14.8 17.5 17.7 17.1 24.1 ATP1A3 DYT12 ENSG00000105409 "ATPase Na+/K+ transporting subunit alpha 3" P13637 19 41966582-41997497 "Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Sodium transport, Sodium/potassium transport, Transport" "Deafness, Disease mutation, Dystonia, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "brain: 146.4;heart muscle: 78.3" "Cell line enhanced" "Detected in many" "Daudi: 20.4;Karpas-707: 13.0;REH: 12.8;SCLC-21H: 48.3;SH-SY5Y: 20.8" "Group enriched" "Detected in many" 6 "glioma: 21.6;testis cancer: 4.4" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 2.2;memory CD8 T-cell: 1.7" "Lineage enriched" "Detected in single" 6 "T-cells: 2.2" "CAB033630, HPA045367, HPA056446" Enhanced Approved "CAB033630: AB_781528, HPA045367: , HPA056446: " "unprognostic (1.90e-1)" "unprognostic (8.65e-2)" "unprognostic (4.57e-2)" "unprognostic (8.20e-3)" "unprognostic (8.94e-2)" "unprognostic (2.52e-1)" "unprognostic (3.16e-2)" "unprognostic (7.66e-2)" "unprognostic (8.02e-2)" "prognostic unfavourable (3.44e-4)" "prognostic favourable (6.15e-5)" "unprognostic (4.02e-3)" "prognostic unfavourable (3.02e-6)" "unprognostic (6.84e-2)" "unprognostic (6.48e-2)" "unprognostic (3.45e-1)" "unprognostic (1.27e-1)" 1.9 12.8 34.0 2.5 30.8 2.1 1.8 42.8 146.4 1.8 2.4 4.8 0.0 2.4 1.8 1.8 2.0 1.8 1.9 78.3 48.3 54.6 1.8 1.8 1.9 2.3 39.9 42.6 1.8 2.3 1.8 3.0 1.8 94.4 1.8 2.3 17.3 2.2 1.8 1.8 2.0 2.7 2.2 18.5 2.1 2.0 18.6 6.9 0.0 1.8 0.0 2.1 1.9 0.1 0.3 0.1 0.0 0.0 0.1 2.2 0.3 0.0 0.8 0.2 8.5 0.0 0.0 0.0 0.1 0.0 0.6 0.5 0.3 1.6 20.4 0.9 0.1 0.2 6.0 0.0 0.2 3.8 1.1 1.7 0.0 0.1 0.0 0.0 6.7 0.0 0.0 0.0 0.1 0.0 0.0 13.0 0.1 0.3 3.7 0.0 1.1 5.2 12.8 7.0 0.6 0.0 0.2 48.3 20.8 0.1 1.5 0.0 1.2 0.9 0.0 1.1 1.1 0.0 0.3 1.3 0.9 4.6 1.9 7.1 0.1 0.0 0.0 0.0 2.2 0.0 0.2 0.3 0.6 1.7 0.0 0.0 0.2 1.0 0.0 0.1 0.0 0.1 0.7 0.3 34.0 30.8 42.8 66.6 48.3 54.6 39.9 42.6 94.4 6.9 AVP "ADH, ARVP" ENSG00000101200 "Arginine vasopressin" P01185 20 3082556-3084724 "Disease related genes, Predicted secreted proteins" "Hormone, Vasoactive, Vasoconstrictor" "Diabetes insipidus, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 44 "brain: 270.1" "Cell line enriched" "Detected in single" 13 "NB-4: 6.9" "Not detected" "Not detected" "Region enriched" "Detected in many" 18 "hypothalamus: 270.1" "Cell type enriched" "Detected in some" 6 "eosinophil: 6.1" "Lineage enriched" "Detected in many" 6 "granulocytes: 6.1" "Region enriched" "Detected in some" 10 "hypothalamus: 273.6" "Group enriched" "Detected in some" 645 "basal ganglia: 1065.4;hypothalamus: 1058.2" "CAB025318, HPA071892" Enhanced Supported "Secreted to blood" 19255 "CAB025318: , HPA071892: " "unprognostic (1.15e-1)" "unprognostic (2.61e-1)" 0.7 0.9 11.7 0.4 15.0 4.2 0.0 0.0 0.9 0.0 0.1 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 270.1 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.8 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 1.6 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.1 0.0 0.0 1.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.0 0.0 0.0 0.0 1.0 0.1 11.7 15.0 0.0 0.9 3.4 270.1 0.0 0.0 0.8 0.0 BAIAP3 "BAP3, KIAA0734" ENSG00000007516 "BAI1 associated protein 3" O94812 16 1333601-1349441 "Predicted intracellular proteins" "Exocytosis, Transport" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 39.1;pituitary gland: 88.2" "Cell line enhanced" "Detected in some" "CAPAN-2: 19.7;MCF7: 6.0;RT4: 5.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "memory B-cell: 4.9" "Low lineage specificity" "Detected in many" "Region enhanced" "Detected in many" "hypothalamus: 144.1" "Low region specificity" "Detected in many" "HPA015627, HPA015979" Uncertain Supported "HPA015627: AB_10603678, HPA015979: " "unprognostic (1.37e-2)" "unprognostic (3.93e-2)" "unprognostic (2.44e-2)" "unprognostic (3.92e-3)" "unprognostic (4.43e-2)" "unprognostic (1.10e-1)" "unprognostic (2.25e-1)" "unprognostic (1.06e-1)" "unprognostic (5.60e-2)" "unprognostic (6.75e-3)" "unprognostic (1.44e-1)" "unprognostic (2.02e-1)" "prognostic favourable (1.52e-5)" "unprognostic (5.26e-2)" "unprognostic (3.11e-1)" "unprognostic (7.12e-3)" "unprognostic (6.43e-2)" 2.2 20.6 30.6 1.3 16.5 1.2 1.4 0.2 24.1 1.4 1.9 9.5 0.7 4.3 1.6 2.6 1.0 28.1 0.9 1.5 19.4 38.4 2.8 3.0 3.1 1.5 4.1 39.1 1.2 7.8 5.1 88.2 2.1 18.5 3.5 1.1 0.0 4.6 3.0 2.8 1.5 3.8 0.4 4.2 2.6 7.0 7.6 6.1 0.0 0.7 0.0 1.1 1.0 0.5 4.9 0.0 1.8 0.0 1.3 1.6 0.3 0.1 2.3 4.0 1.3 0.4 0.0 1.0 0.2 0.1 0.2 0.0 3.6 19.7 0.3 2.7 0.0 0.1 0.0 0.2 0.0 0.2 1.3 0.1 0.3 1.4 0.4 0.0 2.7 0.0 0.0 0.2 0.1 0.1 0.6 0.0 0.0 6.0 0.0 0.8 2.3 3.4 0.6 0.0 3.7 2.3 5.4 0.5 0.2 0.0 1.8 0.1 4.2 0.3 0.2 0.0 2.2 0.5 0.0 1.5 0.5 0.1 0.1 0.4 0.1 0.0 0.0 0.5 1.0 0.0 0.5 4.9 0.5 1.6 0.0 0.3 0.0 0.1 1.8 1.3 0.0 0.0 0.0 0.3 30.6 16.5 0.2 24.1 19.4 38.4 4.1 39.1 18.5 6.1 BBOX1 "BBH, BBOX, G-BBH, gamma-BBH" ENSG00000129151 "Gamma-butyrobetaine hydroxylase 1" O75936 11 27040725-27127809 "Enzymes, Predicted intracellular proteins" "Carnitine biosynthesis" "Dioxygenase, Oxidoreductase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "kidney: 139.4;liver: 39.3" "Group enriched" "Detected in some" 5 "hTCEpi: 15.9;RPTEC TERT1: 9.8" "Group enriched" "Detected in many" 6 "glioma: 23.7;renal cancer: 59.4" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA007600, HPA027823" Enhanced Approved Uncertain "Vesicles,Actin filaments" 25000 Vesicles "Actin filaments" "HPA007600: AB_1845284, HPA027823: AB_10602394" "unprognostic (9.96e-3)" "unprognostic (1.80e-2)" "unprognostic (8.17e-2)" "prognostic unfavourable (6.65e-4)" "unprognostic (7.03e-2)" "unprognostic (6.66e-2)" "unprognostic (7.05e-3)" "unprognostic (1.13e-2)" "unprognostic (3.03e-1)" "unprognostic (6.89e-2)" "unprognostic (2.03e-2)" "unprognostic (1.60e-1)" "prognostic favourable (1.45e-5)" "unprognostic (1.71e-2)" "unprognostic (2.70e-1)" "unprognostic (3.22e-1)" "unprognostic (1.73e-3)" 0.9 0.5 9.2 0.5 7.1 0.5 8.2 3.9 7.5 1.5 0.6 4.9 0.1 0.5 0.6 3.6 5.7 3.8 3.6 0.5 7.9 6.3 139.4 39.3 0.6 0.6 10.9 4.3 0.5 0.8 0.5 8.3 1.3 9.2 0.7 0.5 0.0 2.2 2.0 0.6 16.4 0.5 0.5 7.1 0.5 0.6 0.6 5.8 0.0 8.9 1.6 0.7 0.6 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 1.0 15.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 9.8 0.0 0.0 0.0 0.5 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.2 7.1 3.9 7.5 7.9 6.3 10.9 4.3 9.2 5.8 BCAN "BEHAB, CSPG7, MGC13038" ENSG00000132692 Brevican Q96GW7 1 156641390-156659532 "Plasma proteins, Predicted secreted proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 15 "brain: 144.2" "Cell line enhanced" "Detected in many" "HDLM-2: 24.2;K-562: 34.1;U-266/70: 20.5;U-266/84: 39.4" "Group enriched" "Detected in many" 77 "glioma: 348.5;melanoma: 75.0" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 13 "basophil: 8.2" "Lineage enriched" "Detected in single" 13 "granulocytes: 8.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007865, CAB025862" Enhanced Supported "Secreted in brain" 98000 "CAB025862: , HPA007865: AB_1078299" "unprognostic (7.14e-2)" "unprognostic (3.14e-1)" "unprognostic (1.95e-2)" "unprognostic (1.90e-1)" "unprognostic (1.04e-1)" "unprognostic (9.03e-2)" "unprognostic (4.58e-2)" "unprognostic (2.02e-2)" "unprognostic (4.80e-2)" "unprognostic (6.87e-2)" "unprognostic (1.65e-1)" "unprognostic (1.30e-2)" "unprognostic (9.47e-3)" "unprognostic (2.76e-2)" "unprognostic (8.54e-2)" "unprognostic (5.40e-1)" "unprognostic (1.90e-1)" 1.4 5.8 51.8 1.6 35.9 1.3 1.4 10.4 144.2 2.3 2.4 30.5 1.3 4.6 2.7 9.5 1.6 2.4 3.1 1.5 40.8 22.9 1.4 1.3 1.5 1.5 26.6 21.5 1.4 1.3 1.3 0.7 1.7 15.1 1.4 1.3 4.3 2.0 2.4 1.6 9.0 5.0 2.4 13.0 1.6 2.4 2.0 26.7 0.0 1.4 0.0 1.3 2.3 0.3 0.6 0.0 8.2 0.4 0.0 0.0 0.0 13.7 9.5 0.0 2.6 0.0 0.0 3.9 0.1 0.0 0.0 0.0 0.3 6.8 0.0 14.7 0.0 9.7 0.1 0.0 0.0 24.2 0.8 2.4 6.3 7.8 0.0 0.9 2.4 0.0 0.0 0.0 0.0 0.0 34.1 6.7 0.0 4.0 0.0 0.0 0.7 1.4 0.0 15.8 0.0 0.0 1.7 0.0 0.2 0.0 0.0 14.3 0.0 0.9 2.9 0.0 7.8 2.8 3.7 20.5 39.4 0.0 2.9 6.4 1.1 8.2 0.0 0.0 0.0 0.4 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 51.8 35.9 10.4 33.3 40.8 22.9 26.6 21.5 15.1 26.7 BCAP31 "6C6-Ag, BAP31, CDM, DXS1357E" ENSG00000185825 "B cell receptor associated protein 31" P51572 X 153700492-153724746 "Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters" "Apoptosis, ER-Golgi transport, Host-virus interaction, Protein transport, Transport" "Deafness, Dystonia, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003906, CAB015350, CAB015424" Supported Approved Enhanced "Endoplasmic reticulum" 6800000 "Endoplasmic reticulum" "CAB015350: AB_2243544, CAB015424: AB_781567, HPA003906: AB_1078270" "unprognostic (1.02e-2)" "unprognostic (2.14e-2)" "unprognostic (1.19e-2)" "unprognostic (3.70e-1)" "unprognostic (2.36e-2)" "prognostic unfavourable (9.87e-4)" "unprognostic (3.25e-3)" "unprognostic (4.20e-2)" "unprognostic (1.27e-1)" "unprognostic (5.75e-2)" "unprognostic (1.38e-1)" "unprognostic (1.10e-1)" "unprognostic (2.11e-1)" "unprognostic (1.28e-2)" "unprognostic (8.61e-2)" "unprognostic (2.33e-1)" "unprognostic (1.02e-1)" 60.7 43.4 38.3 20.3 38.8 27.4 71.3 22.2 48.1 28.7 31.8 27.1 27.5 28.8 30.2 48.6 42.4 31.0 26.8 26.7 34.1 36.5 41.6 52.4 42.2 50.0 38.1 26.0 29.1 67.6 36.0 27.4 43.6 44.5 34.3 36.6 30.7 44.5 37.7 15.6 37.3 37.8 32.4 33.6 36.7 24.8 31.6 21.1 25.4 53.1 27.2 37.1 38.1 30.8 72.7 109.7 104.4 97.5 68.2 89.8 150.4 54.7 51.7 14.4 71.8 63.8 19.4 33.3 26.6 30.6 31.8 40.8 41.6 40.3 32.1 121.7 43.1 55.6 35.8 55.9 26.6 15.8 53.4 20.2 40.9 35.7 31.3 32.9 43.9 25.8 48.6 30.9 36.4 38.8 27.4 58.6 35.5 57.3 21.1 44.8 16.4 53.5 23.0 16.0 71.9 49.7 60.2 18.8 26.6 11.9 59.3 40.0 21.7 37.2 40.4 27.9 27.5 37.7 53.3 60.1 115.8 42.6 54.5 44.6 24.4 80.3 80.6 77.5 89.0 86.1 79.5 71.2 89.8 88.1 69.9 72.7 79.4 86.4 104.4 68.2 97.5 109.7 72.4 150.4 38.3 38.8 22.2 48.1 34.1 36.5 38.1 26.0 44.5 21.1 BCAR1 "CAS, CASS1, Crkas, P130Cas" ENSG00000050820 "BCAR1, Cas family scaffolding protein" P56945 16 75228187-75268053 "Plasma proteins, Predicted intracellular proteins" "Cell adhesion" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000443, HPA042282" Approved Approved Approved "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "CAB000443: , HPA042282: " "unprognostic (5.44e-2)" "unprognostic (2.96e-1)" "unprognostic (1.61e-2)" "unprognostic (1.67e-2)" "unprognostic (2.17e-1)" "unprognostic (5.43e-3)" "prognostic unfavourable (9.11e-5)" "prognostic unfavourable (1.24e-4)" "unprognostic (2.15e-1)" "unprognostic (3.49e-2)" "unprognostic (5.18e-2)" "unprognostic (1.77e-2)" "prognostic favourable (4.55e-8)" "unprognostic (3.38e-1)" "unprognostic (3.60e-2)" "unprognostic (8.20e-2)" "unprognostic (2.20e-1)" 16.6 12.3 14.3 8.4 19.5 1.8 11.5 29.1 26.7 16.7 22.7 31.5 9.1 28.6 17.5 11.0 9.6 10.8 20.4 17.8 14.2 9.4 21.3 17.3 15.9 4.9 18.9 13.5 11.3 31.0 9.2 13.2 28.1 13.9 10.9 7.9 14.6 25.7 12.5 37.4 7.2 25.7 8.6 10.4 28.9 28.7 17.3 20.1 0.2 11.8 9.7 6.3 13.3 11.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.1 16.2 7.9 2.6 3.0 2.8 15.2 12.8 7.4 9.4 7.4 20.7 13.9 0.8 17.0 14.2 7.9 2.6 14.6 2.7 0.0 9.1 0.0 9.8 17.2 7.7 0.0 6.6 8.6 7.3 11.1 5.5 25.4 8.2 0.4 5.5 22.0 0.0 0.5 10.4 10.8 0.3 3.5 3.3 8.6 12.0 9.7 13.9 12.2 2.8 4.9 6.6 2.2 22.8 15.8 13.7 3.9 18.8 3.5 1.9 0.2 9.9 0.0 10.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.3 19.5 29.1 26.7 14.2 9.4 18.9 13.5 13.9 20.1 BCL11B "CTIP-2, CTIP2, hRIT1-alpha, ZNF856B" ENSG00000127152 "B cell CLL/lymphoma 11B" Q9C0K0 14 99169287-99271524 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" Repressor "Cancer-related genes, Disease mutation, Mental retardation, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 13.7;lymphoid tissue: 25.4;skin 1: 17.6" "Cell line enriched" "Detected in some" 6 "MOLT-4: 32.6" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in many" "basal ganglia: 13.7" "Group enriched" "Detected in many" 8 "gdT-cell: 3.3;MAIT T-cell: 3.0;memory CD4 T-cell: 4.5;memory CD8 T-cell: 3.7;naive CD4 T-cell: 7.4;naive CD8 T-cell: 4.9;T-reg: 3.0" "Lineage enriched" "Detected in single" 14 "T-cells: 7.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA049117 Enhanced Supported Approved "Nucleoplasm,Nucleoli fibrillar center" Nucleoplasm "Nucleoli fibrillar center" "HPA049117: AB_2680639" "unprognostic (1.64e-5)" "unprognostic (4.66e-2)" "unprognostic (2.35e-2)" "unprognostic (1.87e-2)" "unprognostic (9.37e-2)" "unprognostic (5.97e-2)" "unprognostic (4.75e-2)" "unprognostic (6.07e-2)" "unprognostic (1.74e-1)" "unprognostic (1.40e-2)" "unprognostic (1.90e-1)" "unprognostic (1.12e-1)" "unprognostic (1.60e-6)" "unprognostic (1.07e-3)" "unprognostic (1.61e-1)" "unprognostic (3.31e-3)" "prognostic favourable (7.48e-4)" 0.3 0.4 4.4 6.6 13.7 5.2 1.3 0.3 3.8 0.8 1.3 0.1 0.0 2.3 1.9 0.8 3.9 0.3 3.0 0.8 4.8 1.0 0.3 0.5 1.1 10.8 0.8 2.6 0.2 0.1 0.0 0.1 0.0 0.6 0.6 1.7 0.3 5.0 0.7 0.1 17.6 3.0 0.2 0.7 4.9 2.1 0.4 1.6 25.4 0.9 1.5 8.8 2.0 2.3 0.0 0.0 0.1 0.0 0.5 7.4 1.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.3 1.2 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.3 0.0 0.1 0.0 0.0 3.0 0.0 1.8 32.6 0.5 0.3 0.0 5.1 0.0 0.0 0.0 1.8 2.6 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.1 0.0 2.0 0.0 0.0 1.4 0.4 0.0 0.0 0.0 0.1 3.3 0.0 3.0 0.0 4.5 3.7 0.0 0.0 7.4 4.9 0.0 0.5 0.0 0.0 3.0 1.1 4.4 13.7 0.3 3.8 4.8 1.0 0.8 2.6 0.6 1.6 BIRC3 "API2, c-IAP2, cIAP2, hiap-1, MALT2, MIHC, RNF49" ENSG00000023445 "Baculoviral IAP repeat containing 3" Q13489 11 102317450-102339403 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Apoptosis, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 46.0;lymphoid tissue: 46.3" "Cell line enhanced" "Detected in many" "CAPAN-2: 37.5;Daudi: 33.0;HDLM-2: 31.2;hTERT-HME1: 32.8;U-266/70: 22.0;U-266/84: 18.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "memory B-cell: 32.9;naive B-cell: 32.9" "Group enriched" "Detected in many" 10 "B-cells: 32.9;T-cells: 17.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA002317 Enhanced Approved Supported Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "HPA002317: AB_1846748" "prognostic favourable (3.60e-4)" "unprognostic (2.89e-1)" "prognostic favourable (9.35e-4)" "unprognostic (3.28e-2)" "prognostic unfavourable (7.28e-4)" "unprognostic (5.83e-3)" "unprognostic (2.23e-1)" "unprognostic (3.88e-3)" "unprognostic (9.62e-2)" "unprognostic (1.29e-1)" "prognostic unfavourable (3.03e-4)" "unprognostic (3.21e-1)" "prognostic unfavourable (6.66e-6)" "unprognostic (6.42e-2)" "unprognostic (6.23e-3)" "unprognostic (1.00e-1)" "unprognostic (3.85e-2)" 6.9 3.3 1.4 43.9 2.3 5.1 5.4 0.5 2.0 5.3 13.1 0.5 2.8 6.8 2.9 3.7 8.4 3.9 13.9 6.0 2.2 1.3 10.8 12.5 21.8 46.3 2.8 1.2 3.4 7.0 1.1 14.5 0.9 2.2 8.7 6.2 1.1 9.2 4.7 2.2 5.5 46.0 7.3 3.0 34.9 15.9 3.2 2.7 34.2 3.0 4.1 34.0 12.6 6.2 32.9 0.8 2.0 2.6 2.5 17.1 2.8 6.3 5.1 0.0 0.1 0.1 0.7 0.6 0.5 4.3 0.6 0.7 0.9 37.5 33.0 17.0 0.3 3.6 0.0 0.9 2.1 31.2 0.1 0.1 1.5 0.2 6.5 0.5 0.7 0.7 4.6 2.1 32.8 0.1 0.1 0.0 0.8 0.0 2.2 0.3 0.1 0.2 0.0 0.3 1.6 8.5 3.3 0.0 0.1 0.5 0.5 0.3 1.6 0.3 1.7 7.2 0.7 0.4 6.5 22.0 18.8 11.6 1.3 1.8 0.8 2.0 0.9 0.4 1.4 2.2 2.5 32.9 10.7 3.5 0.8 32.9 7.5 2.2 0.5 2.5 2.6 0.3 17.1 2.8 1.4 2.3 0.5 2.0 2.2 1.3 2.8 1.2 2.2 2.7 C12orf10 "Gamm1, MYG, MYG1" ENSG00000139637 "Chromosome 12 open reading frame 10" Q9HB07 12 53299686-53307177 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "testis: 85.6" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA038626, HPA038627" Approved Supported Supported Nucleoplasm "Intracellular and membrane" Nucleoplasm "HPA038626: AB_10674692, HPA038627: " "unprognostic (5.33e-2)" "unprognostic (4.41e-2)" "unprognostic (6.77e-2)" "unprognostic (2.44e-2)" "unprognostic (3.59e-1)" "unprognostic (7.56e-2)" "unprognostic (1.61e-3)" "unprognostic (2.73e-1)" "unprognostic (1.97e-1)" "unprognostic (3.58e-2)" "unprognostic (2.71e-2)" "unprognostic (1.39e-1)" "unprognostic (2.81e-1)" "unprognostic (6.41e-2)" "unprognostic (2.18e-1)" "unprognostic (2.16e-1)" "unprognostic (1.61e-1)" 16.1 18.7 21.5 13.0 18.4 13.7 17.8 18.4 32.2 17.9 15.1 14.0 18.7 14.3 17.7 18.3 15.9 28.4 16.6 20.2 19.7 21.3 18.8 15.7 13.0 23.6 25.0 23.9 33.3 27.6 20.6 15.7 11.7 27.7 14.6 11.9 14.3 19.4 19.7 22.4 15.7 13.1 17.7 14.3 12.1 16.2 85.6 12.9 19.4 24.1 18.3 15.0 17.3 15.0 26.1 31.1 12.2 27.4 19.2 33.3 23.2 13.0 30.1 10.6 16.9 11.6 17.4 1.2 8.7 14.0 19.9 14.4 27.2 14.2 12.6 20.6 12.0 14.8 14.9 18.9 10.8 10.4 29.2 13.0 24.9 31.6 27.0 13.4 8.8 17.3 14.4 18.3 18.6 17.7 0.7 26.1 13.3 61.4 18.0 22.1 17.8 29.1 17.0 10.1 29.3 17.1 14.6 21.5 20.7 9.7 19.2 21.1 30.2 12.9 11.5 19.4 18.3 13.9 13.6 23.6 24.5 13.9 24.6 11.5 14.9 7.8 27.4 12.2 18.3 20.6 27.5 26.1 24.6 18.4 31.1 22.0 25.9 23.4 6.9 19.2 15.4 19.4 33.3 23.2 21.5 18.4 18.4 32.2 19.7 21.3 25.0 23.9 27.7 12.9 C17orf75 "NJMU-R1, SRI2" ENSG00000108666 "Chromosome 17 open reading frame 75" Q9HAS0 17 32324565-32350023 "Plasma proteins, Predicted intracellular proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004061, HPA075333" Approved Approved Approved "Golgi apparatus,Cytosol" "Golgi apparatus, Cytosol" "HPA004061: AB_1078337, HPA075333: " "unprognostic (4.21e-2)" "unprognostic (2.49e-2)" "unprognostic (3.32e-2)" "unprognostic (2.28e-1)" "unprognostic (1.51e-1)" "unprognostic (4.73e-2)" "unprognostic (1.07e-3)" "unprognostic (6.36e-2)" "unprognostic (3.29e-1)" "prognostic favourable (3.13e-4)" "unprognostic (1.92e-2)" "unprognostic (7.80e-2)" "prognostic favourable (1.33e-4)" "unprognostic (3.09e-1)" "unprognostic (1.29e-1)" "unprognostic (4.27e-2)" "unprognostic (5.60e-2)" 6.9 17.3 16.6 8.2 21.2 5.7 13.1 25.8 23.9 8.7 10.1 12.7 10.9 10.5 12.7 15.6 9.9 14.7 6.9 18.6 13.4 14.8 19.6 12.7 8.0 10.8 13.8 14.1 16.0 11.3 16.6 17.2 9.3 21.1 11.8 11.3 11.7 11.8 11.8 15.0 8.0 9.2 11.0 11.3 10.8 10.9 20.4 13.3 11.7 16.4 8.3 11.3 9.7 8.9 15.0 13.7 18.4 12.3 13.7 16.4 13.0 13.2 14.4 20.9 7.4 6.1 8.1 10.9 9.6 10.6 15.5 13.8 7.2 5.2 9.1 11.2 8.8 14.9 17.2 13.1 22.2 6.4 16.7 7.3 13.3 13.3 13.2 10.4 6.1 6.4 15.9 11.1 8.0 11.7 14.3 13.2 10.1 10.9 29.1 9.0 13.3 7.9 18.4 13.8 15.9 9.2 7.4 20.4 16.8 8.5 7.5 20.2 19.1 6.4 7.3 8.1 12.8 3.8 14.9 15.8 17.8 31.4 6.2 9.1 2.4 18.4 10.6 13.2 16.0 8.8 16.4 14.5 14.6 15.4 13.7 15.0 16.1 15.1 3.5 13.7 12.3 10.4 15.0 13.0 16.6 21.2 25.8 23.9 13.4 14.8 13.8 14.1 21.1 13.3 C5orf63 "FLJ44606, YDR286C" ENSG00000164241 "Chromosome 5 open reading frame 63" A6NC05 5 127042558-127073492 "Predicted intracellular proteins" "Electron transport, Transport" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "U-87 MG: 32.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" HPA043240 Approved Approved Approved Mitochondria Mitochondria "HPA043240: AB_10962511" "unprognostic (2.71e-1)" "unprognostic (3.97e-2)" "unprognostic (1.11e-1)" "unprognostic (2.63e-1)" "unprognostic (1.62e-1)" "unprognostic (1.93e-1)" "unprognostic (2.94e-4)" "unprognostic (1.34e-1)" "unprognostic (9.67e-2)" "unprognostic (3.40e-2)" "unprognostic (1.43e-4)" "unprognostic (1.07e-1)" "unprognostic (2.26e-2)" "unprognostic (1.21e-1)" "unprognostic (1.32e-1)" "unprognostic (3.64e-3)" "unprognostic (1.07e-2)" 4.4 4.4 3.3 10.1 4.6 2.8 5.9 6.8 21.4 2.9 10.9 5.5 3.3 5.6 7.5 4.8 7.6 4.2 3.8 7.3 4.4 4.9 8.0 7.0 4.6 6.8 4.6 4.8 4.4 7.5 9.2 27.7 2.7 6.8 5.5 11.0 11.3 13.7 3.9 6.6 3.3 9.2 3.2 6.2 5.6 6.8 13.8 3.0 8.5 9.0 5.1 9.1 4.9 5.1 11.9 9.8 3.9 1.5 12.3 10.1 2.9 0.5 2.4 0.7 1.4 1.9 2.9 0.3 2.6 0.3 3.3 1.9 6.0 7.6 0.0 10.9 2.1 1.0 4.6 2.9 4.7 1.0 3.7 6.1 9.2 7.1 4.6 3.5 0.3 3.0 7.3 4.2 2.2 2.8 0.4 1.1 3.2 4.9 0.1 3.3 0.4 1.9 2.7 1.6 4.2 3.6 3.7 6.1 5.0 3.4 1.5 0.2 6.3 5.3 2.1 6.9 6.4 7.9 1.6 3.7 9.5 0.2 32.0 0.4 3.6 3.4 0.3 3.9 6.7 1.5 5.3 11.9 6.1 7.1 3.0 10.8 9.2 6.8 1.4 12.3 0.4 9.8 10.1 2.9 3.3 4.6 6.8 3.2 4.4 4.9 4.6 4.8 6.8 3.0 CACNA1A "APCA, CACNL1A4, Cav2.1, EA2, FHM, HPCA, MHP, MHP1, SCA6" ENSG00000141837 "Calcium voltage-gated channel subunit alpha1 A" O00555 19 13206442-13633025 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets, Neurodegeneration, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 10 "brain: 77.9" "Group enriched" "Detected in some" 5 "SCLC-21H: 30.5;U-87 MG: 17.2" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in all" 4 "cerebellum: 77.9" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA064258, HPA071902" Enhanced Supported Uncertain "Endoplasmic reticulum" "Endoplasmic reticulum" "HPA064258: , HPA071902: " "unprognostic (1.09e-1)" "unprognostic (3.73e-3)" "unprognostic (2.27e-1)" "unprognostic (2.78e-4)" "unprognostic (4.00e-2)" "unprognostic (2.29e-3)" "unprognostic (5.47e-2)" "unprognostic (3.13e-1)" "unprognostic (2.86e-1)" "unprognostic (1.14e-2)" "prognostic favourable (4.32e-4)" "unprognostic (5.31e-3)" "unprognostic (5.03e-6)" "unprognostic (6.29e-2)" "unprognostic (1.59e-1)" "unprognostic (2.61e-2)" "unprognostic (6.25e-2)" 2.2 5.3 7.6 1.0 12.2 0.7 0.9 77.9 19.7 0.8 1.5 1.8 0.0 3.9 1.2 2.8 0.7 2.2 0.8 1.1 5.7 5.1 0.7 0.5 0.7 1.3 3.9 7.3 1.1 3.0 0.7 1.5 0.6 7.2 0.8 1.7 1.2 0.9 0.8 1.3 0.7 2.8 0.9 3.3 1.3 7.7 1.9 2.8 0.0 0.7 0.0 1.0 0.8 0.3 2.8 0.8 1.9 1.1 0.8 0.8 0.4 0.0 0.1 0.0 3.8 0.1 0.3 0.0 1.6 1.5 0.2 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.6 2.0 0.0 1.2 0.0 0.0 0.0 4.5 0.1 0.0 0.0 0.1 0.9 0.2 0.4 0.0 0.1 0.0 0.1 30.5 0.0 0.0 0.0 0.2 0.0 1.2 0.1 0.1 0.6 0.1 0.0 0.0 0.0 0.0 17.2 0.0 0.4 1.9 0.4 0.7 0.5 0.5 0.8 2.8 0.5 0.3 0.4 1.7 0.6 0.7 1.6 0.8 1.1 0.8 0.6 0.4 7.6 12.2 77.9 17.4 5.7 5.1 3.9 7.3 7.2 2.8 CACNA1C "CACH2, CACN2, CACNL1A1, Cav1.2, CCHL1A1, LQT8, TS" ENSG00000151067 "Calcium voltage-gated channel subunit alpha1 C" Q13936 12 1970786-2697950 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Host-virus interaction, Ion transport, Transport" "Calcium channel, Calmodulin-binding, Ion channel, Voltage-gated channel" "Autism, Autism spectrum disorder, Brugada syndrome, Disease mutation, FDA approved drug targets, Long QT syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 32.5" "Cell line enriched" "Detected in some" 17 "HDLM-2: 46.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "NK-cell: 4.2" "Group enriched" "Detected in many" 19 "NK-cells: 4.2;T-cells: 1.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA039796, CAB079031" Enhanced Approved "CAB079031: , HPA039796: AB_10673019" "unprognostic (1.76e-1)" "unprognostic (1.19e-1)" "unprognostic (6.29e-2)" "unprognostic (9.35e-2)" "unprognostic (3.71e-2)" "unprognostic (1.60e-2)" "unprognostic (4.68e-2)" "unprognostic (7.99e-2)" "unprognostic (3.07e-2)" "unprognostic (1.03e-5)" "unprognostic (1.93e-2)" "unprognostic (1.01e-1)" "unprognostic (4.02e-7)" "unprognostic (8.85e-2)" "unprognostic (3.60e-2)" "unprognostic (6.90e-2)" "unprognostic (3.39e-2)" 3.8 2.5 8.6 6.0 7.7 1.4 2.4 7.1 11.7 11.2 26.5 1.3 7.4 2.4 29.7 4.5 5.2 4.3 7.1 32.5 5.5 4.0 2.7 1.4 4.7 2.0 2.4 6.6 2.7 3.2 1.5 8.1 5.1 3.9 7.9 3.8 6.5 2.4 8.1 2.3 1.7 5.2 28.8 1.9 3.5 7.2 11.3 1.7 0.0 2.0 1.1 1.7 12.6 5.4 0.0 0.1 0.0 0.1 4.2 1.2 0.2 0.0 0.0 0.0 0.0 1.6 1.0 0.1 1.7 2.0 1.1 0.7 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.4 46.5 0.4 0.6 0.0 0.0 1.1 0.0 0.0 2.6 0.0 0.6 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.5 0.2 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.3 2.5 0.0 0.0 0.0 0.0 2.1 0.1 0.6 0.0 0.0 0.0 0.6 0.0 1.2 0.0 0.5 0.7 0.0 0.0 0.9 0.7 0.0 4.2 0.1 0.1 0.4 0.2 8.6 7.7 7.1 11.7 5.5 4.0 2.4 6.6 3.9 1.7 CACNA1E "BII, CACH6, CACNL1A6, Cav2.3" ENSG00000198216 "Calcium voltage-gated channel subunit alpha1 E" Q15878 1 181317690-181808084 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 7 "brain: 30.8" "Cell line enhanced" "Detected in some" "CACO-2: 4.0;NB-4: 2.5;NTERA-2: 2.9;SCLC-21H: 2.3;U-266/70: 7.0" "Low cancer specificity" "Detected in single" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 8 "neutrophil: 1.8" "Lineage enriched" "Detected in single" 8 "granulocytes: 1.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA042515, CAB079032" Approved Approved "Plasma membrane,Actin filaments,Cytosol" "Plasma membrane" "Actin filaments, Cytosol" "CAB079032: , HPA042515: " "unprognostic (3.96e-3)" "unprognostic (1.89e-1)" "unprognostic (1.05e-2)" "unprognostic (1.54e-5)" "unprognostic (6.56e-2)" "unprognostic (3.16e-2)" "unprognostic (4.30e-3)" "unprognostic (1.18e-1)" "unprognostic (2.40e-1)" "unprognostic (9.48e-3)" "unprognostic (1.04e-1)" "unprognostic (2.06e-1)" "unprognostic (9.85e-7)" "unprognostic (1.74e-2)" "unprognostic (2.07e-2)" "unprognostic (1.16e-1)" "unprognostic (3.75e-2)" 0.6 3.0 17.9 2.1 19.7 3.1 0.5 3.9 22.5 0.6 0.8 1.3 0.0 0.6 0.6 4.4 1.1 2.3 0.6 0.6 30.8 5.8 3.8 0.6 0.6 1.4 2.4 10.6 0.5 0.6 0.5 0.2 0.8 4.2 0.5 0.8 0.5 0.5 0.5 0.6 0.5 1.1 1.0 5.2 0.9 0.8 2.8 2.4 0.0 0.6 0.0 1.0 0.6 0.1 0.2 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.0 0.0 1.4 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 2.9 0.0 0.0 0.0 1.0 1.3 0.0 2.3 0.1 0.0 0.0 0.0 0.0 0.8 0.0 0.1 0.1 0.0 0.0 7.0 0.0 0.0 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 17.9 19.7 3.9 22.5 30.8 5.8 2.4 10.6 4.2 2.4 CALB2 CAL2 ENSG00000172137 "Calbindin 2" P22676 16 71358713-71390438 "Plasma proteins, Predicted intracellular proteins, Transporters" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "adipose tissue: 50.6;brain: 118.9" "Cell line enhanced" "Detected in some" "CAPAN-2: 8.1;HEL: 23.4;HMC-1: 51.0;U-2 OS: 14.6" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in all" 4 "cerebellum: 31.2;hypothalamus: 74.2;pons and medulla: 118.9" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000106, HPA007305, HPA007306" Enhanced Supported Enhanced Cytosol 6400 Cytosol "CAB000106: AB_2068519, HPA007305: AB_1078386, HPA007306: AB_1078385" "unprognostic (1.10e-1)" "unprognostic (1.90e-2)" "prognostic unfavourable (5.78e-5)" "unprognostic (1.75e-3)" "unprognostic (5.80e-2)" "unprognostic (1.43e-1)" "unprognostic (1.59e-1)" "unprognostic (4.55e-3)" "unprognostic (4.28e-1)" "unprognostic (1.32e-1)" "unprognostic (3.06e-3)" "unprognostic (1.35e-2)" "unprognostic (5.54e-4)" "unprognostic (1.97e-3)" "unprognostic (6.30e-2)" "unprognostic (4.72e-2)" "unprognostic (1.04e-2)" 50.6 11.6 10.1 5.1 7.5 0.9 18.2 31.2 9.9 1.7 8.9 1.7 0.0 1.7 1.4 3.0 3.0 2.4 2.0 2.2 5.9 74.2 0.9 0.9 2.1 0.9 17.7 7.5 5.6 1.4 0.9 3.0 0.9 118.9 1.1 6.0 4.9 2.1 1.3 1.0 1.0 2.7 2.7 7.5 0.9 1.2 14.6 1.5 0.0 0.8 0.2 1.8 1.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.9 0.7 6.5 0.0 0.2 0.0 1.2 0.2 0.1 0.2 0.0 0.0 8.1 0.0 0.1 0.0 1.4 0.0 0.0 0.0 0.0 0.0 23.4 0.0 0.2 0.0 0.0 51.0 0.0 0.0 0.5 0.1 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 14.6 0.1 1.4 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.1 7.5 31.2 9.9 5.9 74.2 17.7 7.5 118.9 1.5 CALCA CALC1 ENSG00000110680 "Calcitonin related polypeptide alpha" "P01258, P06881" 11 14966668-14972354 "Cancer-related genes, Plasma proteins, Predicted secreted proteins, Transporters" Hormone "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "parathyroid gland: 122.2;thyroid gland: 55.3" "Cell line enhanced" "Detected in some" "EFO-21: 2.8;hTERT-HME1: 1.7;Karpas-707: 1.8;SCLC-21H: 3.4" "Cancer enriched" "Detected in many" 7 "lung cancer: 64.7" "Region enriched" "Detected in single" 48 "pons and medulla: 19.8" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in many" 5 "pons and medulla: 60.6" HPA059886 Supported "Secreted to blood" 96005 "HPA059886: " "unprognostic (1.97e-1)" "prognostic unfavourable (4.49e-5)" "unprognostic (5.99e-2)" "unprognostic (2.42e-1)" "unprognostic (1.17e-1)" "unprognostic (6.45e-2)" "unprognostic (1.28e-1)" "unprognostic (7.66e-2)" "unprognostic (3.33e-2)" "unprognostic (7.49e-2)" "unprognostic (6.74e-2)" "unprognostic (2.53e-3)" "unprognostic (1.02e-2)" 0.2 0.0 0.1 0.3 0.4 0.0 0.8 0.1 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.2 6.2 16.8 0.6 0.0 0.1 0.0 0.0 0.1 122.2 0.2 0.0 19.8 1.2 0.0 0.3 0.4 0.0 0.3 0.0 0.0 0.3 1.5 4.6 0.0 0.0 0.0 0.6 55.3 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.6 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 1.8 0.0 0.0 0.0 0.5 0.0 0.0 0.2 0.0 0.0 0.0 0.0 3.4 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.1 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.4 0.1 0.2 0.0 0.2 0.1 0.0 19.8 0.0 CALCB "CALC2, CGRP-II, FLJ30166" ENSG00000175868 "Calcitonin related polypeptide beta" P10092 11 14904997-15082342 "Plasma proteins, Predicted secreted proteins" Hormone "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "brain: 14.3;pancreas: 7.9;thyroid gland: 26.0" "Cell line enhanced" "Detected in some" "HEK 293: 6.2;Karpas-707: 11.0;SH-SY5Y: 3.8;U-266/70: 16.6" "Cancer enhanced" "Detected in some" "endometrial cancer: 2.4" "Group enriched" "Detected in many" 8 "hypothalamus: 13.5;pons and medulla: 14.3" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Region enriched" "Detected in single" 7 "pons and medulla: 10.1" HPA059886 Supported "Secreted to blood" "HPA059886: " "unprognostic (7.84e-2)" "unprognostic (4.07e-1)" "unprognostic (3.92e-1)" "prognostic unfavourable (3.42e-5)" "unprognostic (2.02e-1)" "unprognostic (8.40e-2)" "unprognostic (1.75e-1)" "unprognostic (7.21e-2)" "unprognostic (2.07e-1)" "unprognostic (3.32e-2)" "unprognostic (4.87e-2)" "unprognostic (1.16e-1)" "unprognostic (1.02e-2)" "unprognostic (2.33e-2)" "unprognostic (2.66e-1)" "unprognostic (1.99e-1)" "unprognostic (2.33e-1)" 0.5 0.2 0.0 1.6 1.6 0.3 1.5 1.5 0.8 0.3 1.5 0.0 0.0 0.9 0.4 0.3 0.3 0.2 0.3 0.9 0.0 13.5 0.4 1.1 1.3 1.0 0.7 0.2 0.2 7.9 0.3 2.7 0.4 14.3 0.4 0.5 1.8 0.7 0.2 1.2 0.3 0.8 0.4 3.9 0.9 0.3 1.4 0.3 0.6 26.0 0.0 0.3 0.3 0.0 0.2 0.3 1.1 0.2 1.8 1.2 0.4 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.0 0.1 0.0 0.3 6.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.5 0.0 2.0 0.4 0.0 11.0 0.0 0.0 0.0 0.6 3.0 0.1 0.5 0.0 0.2 0.0 0.0 1.2 3.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 16.6 0.6 0.4 2.2 0.0 0.0 0.0 0.2 1.1 0.8 0.1 1.2 0.0 0.5 0.7 0.3 0.2 1.2 1.1 0.6 1.8 0.0 0.0 0.1 0.4 0.0 1.6 1.5 0.8 0.0 13.5 0.7 0.2 14.3 0.3 CALCR CTR ENSG00000004948 "Calcitonin receptor" 7 93424487-93574730 "Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 10.8;kidney: 7.5" "Group enriched" "Detected in some" 6 "MCF7: 2.6;RPTEC TERT1: 4.5;T-47d: 8.6" "Cancer enriched" "Detected in single" 5 "renal cancer: 1.1" "Region enhanced" "Detected in many" "hypothalamus: 10.8" "Cell type enhanced" "Detected in single" "classical monocyte: 1.1" "Lineage enhanced" "Detected in single" "monocytes: 1.1" "Group enriched" "Detected in some" 5 "basal ganglia: 6.7;hypothalamus: 28.7" "Low region specificity" "Detected in all" "HPA028962, HPA061428" Enhanced Supported "HPA028962: AB_10602339, HPA061428: AB_2732661" "unprognostic (1.95e-1)" "unprognostic (2.43e-1)" "unprognostic (3.88e-2)" "unprognostic (1.88e-1)" "unprognostic (1.55e-2)" "unprognostic (3.43e-1)" "unprognostic (7.73e-5)" "unprognostic (1.64e-1)" "unprognostic (9.24e-3)" "unprognostic (8.70e-2)" "unprognostic (1.86e-2)" "unprognostic (6.68e-2)" "unprognostic (2.71e-3)" "unprognostic (1.46e-3)" "unprognostic (1.69e-1)" "unprognostic (2.49e-4)" "unprognostic (1.05e-2)" 0.3 0.7 1.4 0.0 2.1 0.0 1.3 0.1 1.5 0.5 0.2 0.0 0.0 0.1 0.1 0.5 0.3 0.1 0.4 0.4 2.1 10.8 7.5 0.1 0.9 0.0 0.8 0.0 0.7 0.1 0.3 3.2 2.1 5.9 0.1 0.2 0.2 1.4 0.0 3.7 0.1 0.2 0.3 2.5 0.1 0.1 2.3 0.7 0.0 0.1 2.5 0.7 0.1 0.1 0.0 0.4 0.0 1.1 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 2.6 0.0 0.0 0.5 0.0 0.0 0.0 0.0 4.5 0.0 0.0 0.0 0.0 0.2 0.0 8.6 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.8 0.0 0.0 0.0 0.2 0.0 1.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 1.4 2.1 0.1 1.5 2.1 10.8 0.8 0.0 5.9 0.7 CAMK2B "CAM2, CAMK2, CAMKB" ENSG00000058404 "Calcium/calmodulin dependent protein kinase II beta" Q13554 7 44217150-44334577 "Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Differentiation, Neurogenesis" "Actin-binding, Calmodulin-binding, Developmental protein, Kinase, Serine/threonine-protein kinase, Transferase" "Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 81.9;heart muscle: 39.2;skeletal muscle: 70.7" "Cell line enriched" "Detected in some" 8 "SCLC-21H: 41.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB006849, HPA026307, HPA051783, HPA051785, HPA053973" Enhanced Supported Supported "Plasma membrane,Cell Junctions,Cytosol" 680000 "Plasma membrane" "Cell Junctions, Cytosol" "CAB006849: , HPA026307: AB_1845941, HPA051783: , HPA051785: , HPA053973: " "unprognostic (1.88e-3)" "unprognostic (4.49e-2)" "unprognostic (3.55e-3)" "unprognostic (1.36e-2)" "unprognostic (5.25e-2)" "unprognostic (2.90e-2)" "unprognostic (8.78e-2)" "unprognostic (1.09e-1)" "unprognostic (1.44e-1)" "unprognostic (2.71e-1)" "unprognostic (1.17e-2)" "unprognostic (1.60e-2)" "unprognostic (5.23e-7)" "unprognostic (7.04e-2)" "unprognostic (2.34e-1)" "unprognostic (3.15e-2)" "unprognostic (3.95e-2)" 1.4 8.1 20.6 1.4 46.7 1.2 2.0 60.1 81.9 1.2 1.4 4.0 0.7 1.7 1.3 18.8 2.0 1.8 1.2 39.2 36.5 18.0 1.7 3.5 1.2 1.8 10.3 21.3 1.1 3.3 5.6 9.9 1.1 13.4 3.0 1.4 2.7 1.8 2.2 70.7 1.8 1.6 1.2 4.1 1.3 2.4 2.3 4.8 0.0 7.7 2.4 2.0 1.1 0.0 1.3 1.0 3.2 1.2 3.2 1.2 0.8 0.0 0.3 0.2 0.3 0.0 0.2 0.2 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.8 0.2 0.1 0.2 0.7 0.0 1.0 2.4 0.0 0.1 0.1 0.0 0.0 0.5 0.0 0.0 0.0 0.3 0.0 0.0 0.4 0.0 5.2 0.0 0.2 0.1 2.3 0.1 0.9 0.1 0.0 0.0 41.0 2.2 0.2 0.0 0.0 1.9 0.1 0.2 0.2 0.3 0.2 0.0 0.5 0.4 0.1 0.1 0.0 0.2 3.2 0.7 1.0 0.8 0.9 1.2 1.1 1.0 0.5 0.5 1.3 1.2 1.1 2.0 3.2 1.2 1.0 0.9 0.8 20.6 46.7 60.1 42.4 36.5 18.0 10.3 21.3 13.4 4.8 CAMKK2 "CAMKK, CAMKKB, KIAA0787, MGC15254" ENSG00000110931 "Calcium/calmodulin dependent protein kinase kinase 2" Q96RR4 12 121237691-121298308 "Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Calmodulin-binding, Kinase, Serine/threonine-protein kinase, Transferase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 5 "brain: 125.5" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Region enhanced" "Detected in all" "cerebellum: 125.5" "Group enriched" "Detected in many" 5 "classical monocyte: 14.2;eosinophil: 26.1;intermediate monocyte: 19.4;myeloid DC: 7.2;neutrophil: 17.2;non-classical monocyte: 16.5" "Group enriched" "Detected in all" 5 "dendritic cells: 7.2;granulocytes: 26.1;monocytes: 19.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA017389, HPA063713" Approved Supported Supported Cytosol Cytosol "HPA017389: AB_1845956, HPA063713: " "unprognostic (5.08e-2)" "unprognostic (1.81e-1)" "unprognostic (1.38e-1)" "unprognostic (3.08e-1)" "unprognostic (1.88e-1)" "unprognostic (1.12e-1)" "unprognostic (2.62e-3)" "unprognostic (2.80e-2)" "unprognostic (1.93e-1)" "unprognostic (7.76e-2)" "unprognostic (5.01e-2)" "unprognostic (1.70e-1)" "unprognostic (1.75e-1)" "unprognostic (4.13e-1)" "unprognostic (3.34e-2)" "unprognostic (1.67e-1)" "unprognostic (1.38e-1)" 11.7 6.5 19.7 7.8 30.2 13.8 8.8 125.5 45.5 9.0 9.5 7.1 2.6 12.8 8.6 5.3 8.3 11.8 6.3 6.9 11.2 5.1 7.1 8.9 9.6 6.9 6.2 17.3 10.5 5.8 6.4 4.1 7.5 9.1 12.2 9.7 6.2 7.5 13.2 5.1 9.1 13.2 10.3 6.2 14.1 7.6 3.6 5.8 5.2 6.1 4.5 7.2 7.2 7.4 2.2 7.2 26.1 19.4 3.6 2.2 6.3 12.3 9.3 6.9 13.4 20.8 19.4 10.6 10.2 10.9 8.4 7.7 9.7 5.3 19.1 8.6 20.7 10.2 8.5 11.0 6.6 13.1 16.7 9.5 6.2 9.5 14.1 21.6 9.1 12.5 16.4 7.9 18.0 19.6 11.0 10.4 8.1 12.0 23.9 17.8 5.0 10.5 15.6 8.0 16.9 8.1 13.8 26.6 10.6 13.4 7.2 8.5 17.9 26.4 14.3 6.9 5.6 5.8 5.6 39.7 23.6 14.5 12.9 15.1 6.8 0.7 14.2 26.1 2.1 19.4 2.2 2.2 1.7 1.9 7.2 1.2 1.5 1.7 17.2 3.6 16.5 1.6 1.3 6.3 19.7 30.2 125.5 45.5 11.2 5.1 6.2 17.3 9.1 5.8 CAMKV "MGC8407, VACAMKL" ENSG00000164076 "CaM kinase like vesicle associated" Q8NCB2 3 49857988-49870222 "Enzymes, Predicted intracellular proteins" Calmodulin-binding "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 36 "brain: 77.2" "Cell line enhanced" "Detected in some" "AF22: 5.2;HAP1: 6.9;NTERA-2: 24.6;RPMI-8226: 4.7;SCLC-21H: 8.4;SH-SY5Y: 5.4" "Group enriched" "Detected in some" 11 "glioma: 4.0;testis cancer: 5.2" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 12 "neutrophil: 1.2" "Lineage enriched" "Detected in single" 12 "granulocytes: 1.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA007656, CAB034931" Enhanced Supported Approved "Nucleoplasm,Cytokinetic bridge" Nucleoplasm "Cytokinetic bridge" "CAB034931: AB_2068550, HPA007656: AB_1078391" "unprognostic (9.47e-4)" "unprognostic (5.65e-3)" "unprognostic (1.42e-1)" "unprognostic (2.70e-7)" "unprognostic (2.76e-1)" "unprognostic (7.95e-4)" "unprognostic (3.09e-2)" "unprognostic (2.61e-1)" "unprognostic (1.48e-1)" "unprognostic (4.30e-3)" "unprognostic (1.72e-1)" "unprognostic (8.11e-2)" "unprognostic (1.00e-3)" "unprognostic (7.61e-2)" "unprognostic (9.51e-2)" "unprognostic (1.67e-3)" 1.2 2.1 20.7 1.2 77.2 1.2 1.2 0.5 62.8 1.2 1.2 1.7 0.0 1.2 1.2 1.2 1.2 1.2 1.2 1.2 33.4 11.7 1.2 1.2 1.2 1.2 3.3 23.5 1.2 1.2 1.2 1.8 1.2 2.1 1.2 1.2 0.0 1.2 1.2 1.2 1.3 1.2 1.2 1.9 1.2 1.3 2.1 6.0 0.0 1.2 0.0 1.2 1.2 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.2 5.2 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 6.9 0.0 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.7 0.1 24.6 0.1 0.7 0.0 4.7 0.0 0.0 8.4 5.4 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 20.7 77.2 0.5 34.0 33.4 11.7 3.3 23.5 2.1 6.0 CAPN2 "CANPL2, CANPml, mCANP" ENSG00000162909 "Calpain 2" P17655 1 223701593-223776018 "Enzymes, Plasma proteins, Predicted intracellular proteins" "Hydrolase, Protease, Thiol protease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA024470 Approved Approved Supported Cytosol 1500000 Cytosol "HPA024470: AB_1845925" "unprognostic (2.77e-2)" "unprognostic (1.27e-3)" "unprognostic (2.03e-1)" "unprognostic (3.39e-2)" "unprognostic (2.12e-1)" "unprognostic (3.32e-2)" "unprognostic (1.59e-1)" "unprognostic (1.10e-1)" "unprognostic (2.85e-1)" "unprognostic (1.96e-1)" "prognostic unfavourable (2.50e-4)" "unprognostic (1.21e-1)" "prognostic favourable (2.19e-4)" "unprognostic (1.61e-1)" "unprognostic (2.63e-1)" "unprognostic (2.62e-1)" "prognostic unfavourable (6.21e-4)" 56.2 41.0 23.8 20.7 22.2 11.1 61.1 26.1 20.9 40.3 44.8 18.3 23.3 14.5 29.1 44.5 56.3 40.1 58.9 33.0 26.5 13.1 41.6 13.3 58.6 18.2 27.4 18.2 32.4 26.8 53.7 12.7 26.4 23.8 27.2 44.4 16.5 62.5 31.9 48.1 16.5 22.7 35.7 32.3 15.9 48.2 17.2 24.7 5.0 29.9 39.7 35.9 28.3 38.8 9.0 41.6 1.7 29.1 6.0 28.7 28.2 45.7 29.3 9.4 6.3 31.4 43.6 9.0 43.3 62.9 31.5 17.9 23.2 36.8 0.0 14.3 48.0 28.6 10.1 68.4 29.3 11.7 10.5 0.8 15.0 2.9 28.2 2.4 1.5 23.3 22.2 49.0 26.2 62.4 13.1 12.2 92.6 0.9 0.1 2.1 5.2 38.3 3.8 30.7 0.7 54.3 2.7 2.0 10.9 22.3 60.9 13.5 9.2 11.0 95.9 29.5 24.5 25.4 55.5 3.6 6.9 0.1 73.9 5.1 32.4 1.7 29.1 1.7 28.7 19.5 24.5 9.0 20.0 27.7 41.6 3.6 6.4 17.4 1.5 6.0 17.5 1.9 19.9 28.2 23.8 22.2 26.1 20.9 26.5 13.1 27.4 18.2 23.8 24.7 CARTPT CART ENSG00000164326 "CART prepropeptide" Q16568 5 71719163-71721048 "FDA approved drug targets, Predicted secreted proteins" "Neuropeptide, Neurotransmitter" "FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 10 "adrenal gland: 67.5;brain: 101.4" "Group enriched" "Detected in some" 7 "NB-4: 1.0;SH-SY5Y: 3.4" "Cancer enriched" "Detected in many" 9 "breast cancer: 117.7" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "hippocampal formation: 179.9" "CAB025515, HPA046278, CAB079776" Enhanced Supported "Secreted to blood" "CAB025515: , CAB079776: , HPA046278: AB_10961570" "unprognostic (1.37e-1)" "unprognostic (1.43e-1)" "unprognostic (2.27e-1)" "unprognostic (3.45e-2)" "unprognostic (6.67e-2)" "prognostic unfavourable (4.36e-4)" "unprognostic (1.14e-1)" 1.6 67.5 8.0 2.8 22.3 0.5 5.8 0.1 29.0 0.5 3.4 2.1 0.0 3.5 0.6 0.9 3.5 0.7 0.6 0.5 31.1 101.4 0.5 0.5 0.5 0.5 1.0 4.5 0.5 5.3 0.5 1.7 0.5 54.1 3.3 3.1 1.6 0.5 0.5 0.5 0.5 1.4 8.1 8.6 0.5 3.4 1.9 9.7 0.0 3.4 0.0 0.5 0.5 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.0 22.3 0.1 29.0 31.1 101.4 1.0 4.5 54.1 9.7 CASKIN1 "ANKS5A, KIAA1306" ENSG00000167971 "CASK interacting protein 1" Q8WXD9 16 2177180-2196525 "Plasma proteins, Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 12 "brain: 30.4" "Cell line enhanced" "Detected in some" "AN3-CA: 4.5;HDLM-2: 16.6;HEK 293: 3.7;SCLC-21H: 7.7;SH-SY5Y: 3.7" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA055990, CAB079050" Enhanced Supported Approved Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB079050: , HPA055990: " "unprognostic (4.91e-2)" "unprognostic (2.48e-1)" "unprognostic (4.84e-2)" "unprognostic (1.71e-1)" "unprognostic (9.43e-2)" "unprognostic (2.05e-1)" "unprognostic (2.80e-2)" "unprognostic (8.02e-2)" "unprognostic (6.58e-2)" "unprognostic (4.59e-1)" "unprognostic (2.21e-4)" "unprognostic (2.67e-2)" "unprognostic (2.62e-1)" "unprognostic (9.70e-3)" "unprognostic (1.72e-1)" "unprognostic (7.34e-3)" "unprognostic (3.39e-1)" 1.1 1.8 17.7 1.2 18.1 1.1 1.4 15.0 30.4 1.5 1.2 2.3 0.0 1.2 1.5 1.3 1.2 1.4 1.2 2.5 16.4 12.8 1.3 1.1 1.1 1.1 12.4 11.7 1.2 1.5 1.9 1.4 1.2 11.1 1.8 1.2 1.8 2.5 1.4 1.3 2.2 1.3 1.2 2.8 1.1 1.3 1.8 4.0 0.0 1.6 0.0 1.2 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 2.0 4.5 0.0 0.0 2.2 0.0 0.0 0.1 0.0 1.5 0.1 0.0 0.9 0.0 0.0 1.2 0.3 0.0 16.6 3.7 0.0 0.3 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.1 0.1 0.0 1.3 0.0 0.9 0.7 0.0 0.9 0.0 0.4 0.2 0.0 7.7 3.7 0.1 0.2 0.2 1.0 0.5 0.0 0.0 1.3 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.7 18.1 15.0 21.7 16.4 12.8 12.4 11.7 11.1 4.0 CBLN3 ENSG00000139899 "Cerebellin 3 precursor" Q6UW01 14 24426532-24430954 "Predicted intracellular proteins, Predicted secreted proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 13 "brain: 105.2" "Cell line enhanced" "Detected in many" "ASC TERT1: 10.8;HDLM-2: 12.5;HSkMC: 18.6;Karpas-707: 14.0;U-266/70: 9.8" "Low cancer specificity" "Detected in all" "Region enriched" "Detected in all" 23 "cerebellum: 105.2" "Cell type enhanced" "Detected in some" "memory B-cell: 1.5;naive B-cell: 2.3" "Low lineage specificity" "Detected in single" "Region enriched" "Detected in some" 25 "cerebellum: 481.8" "Region enriched" "Detected in some" 48 "cerebellum: 583.0" HPA041266 Enhanced Supported Approved Nucleoplasm "Secreted in brain" Nucleoplasm "HPA041266: AB_10674430" "unprognostic (5.02e-2)" "unprognostic (3.26e-1)" "unprognostic (1.43e-3)" "prognostic unfavourable (4.22e-4)" "unprognostic (4.39e-4)" "unprognostic (5.39e-3)" "unprognostic (1.60e-2)" "unprognostic (1.92e-2)" "unprognostic (2.16e-2)" "unprognostic (9.76e-2)" "unprognostic (6.20e-2)" "unprognostic (2.71e-2)" "prognostic unfavourable (6.20e-6)" "unprognostic (2.75e-2)" "unprognostic (2.63e-1)" "unprognostic (1.72e-1)" "unprognostic (9.02e-2)" 2.1 7.7 1.2 4.5 1.3 0.0 1.2 105.2 1.7 1.8 1.1 1.9 1.0 0.6 1.3 4.8 1.0 1.2 3.1 1.6 1.0 1.1 1.2 1.4 1.3 7.9 1.3 1.4 3.3 1.0 1.0 1.3 1.7 4.6 1.2 0.7 1.7 1.6 1.6 1.4 1.6 1.3 1.3 2.0 7.4 1.4 1.6 1.1 1.1 1.2 1.5 5.3 1.9 1.3 2.3 0.3 0.1 0.8 0.0 0.3 0.0 1.1 1.0 0.5 1.9 4.9 10.8 0.3 4.1 8.5 1.6 2.1 0.5 2.0 1.8 0.9 2.6 0.3 0.6 2.2 1.1 12.5 0.4 0.0 3.4 0.8 2.7 0.3 0.7 18.6 1.0 2.1 1.7 1.4 0.5 14.0 2.1 0.6 0.0 0.5 0.1 1.1 0.0 0.0 1.3 1.0 0.4 0.7 0.4 0.3 0.1 0.5 0.6 0.4 6.5 6.0 1.2 2.4 0.2 9.8 2.3 1.9 0.3 0.8 1.0 0.0 0.0 0.1 0.0 0.8 0.3 1.5 0.1 0.1 0.0 2.3 0.2 0.0 0.1 0.0 0.1 0.3 0.0 0.0 1.2 1.3 105.2 1.7 1.0 1.1 1.3 1.4 4.6 1.1 CBLN4 "CBLNL1, dJ885A10.1" ENSG00000054803 "Cerebellin 4 precursor" Q9NTU7 20 55997440-56005472 "Plasma proteins, Predicted secreted proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 23.5;brain: 16.8;epididymis: 11.8" "Cell line enriched" "Detected in single" 49 "SH-SY5Y: 14.6" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA074497 Supported "Secreted in brain" 10000000 "HPA074497: " "unprognostic (3.61e-1)" "unprognostic (8.43e-3)" "unprognostic (2.43e-1)" "unprognostic (1.61e-2)" "unprognostic (1.99e-1)" "unprognostic (4.00e-1)" "unprognostic (3.25e-1)" "unprognostic (2.11e-1)" "unprognostic (1.42e-1)" "unprognostic (3.88e-1)" "unprognostic (9.63e-2)" "unprognostic (1.74e-1)" "unprognostic (1.40e-3)" "unprognostic (3.22e-4)" "unprognostic (7.50e-2)" "unprognostic (3.58e-2)" "unprognostic (1.79e-3)" 1.3 23.5 11.9 0.3 8.9 0.2 1.8 0.1 16.8 2.8 0.3 0.5 0.8 0.3 1.2 11.8 0.3 5.4 0.9 0.2 5.9 14.8 1.0 1.3 1.1 0.2 1.6 5.0 2.2 1.2 0.4 0.1 0.5 2.4 0.4 0.2 0.1 0.3 0.7 0.5 0.3 0.3 0.6 0.4 0.2 0.7 2.7 0.0 0.0 1.3 0.0 0.2 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.9 8.9 0.1 16.8 5.9 14.8 1.6 5.0 2.4 0.0 CCDC22 "CXorf37, JM1" ENSG00000101997 "Coiled-coil domain containing 22" O60826 X 49235467-49250526 "Disease related genes, Predicted intracellular proteins" "Protein transport, Transport, Ubl conjugation pathway" "Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000229, HPA000888" Uncertain Approved Approved Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "HPA000229: , HPA000888: AB_1078420" "unprognostic (1.24e-2)" "unprognostic (1.96e-2)" "unprognostic (1.98e-2)" "unprognostic (3.45e-1)" "unprognostic (1.36e-1)" "unprognostic (2.80e-2)" "prognostic unfavourable (2.17e-4)" "unprognostic (1.68e-2)" "unprognostic (2.62e-2)" "unprognostic (1.70e-1)" "unprognostic (4.57e-3)" "unprognostic (3.61e-2)" "unprognostic (4.99e-2)" "unprognostic (6.99e-2)" "unprognostic (2.57e-1)" "unprognostic (2.10e-2)" "unprognostic (1.40e-3)" 11.5 15.4 12.1 18.2 14.9 26.0 16.3 20.7 16.5 12.5 11.8 13.7 17.2 16.3 14.8 12.3 15.8 13.7 11.9 12.9 12.2 9.8 13.9 14.2 19.8 24.7 12.2 15.9 13.7 20.3 12.1 13.5 11.0 11.8 15.2 8.6 12.8 19.2 21.3 23.0 15.1 15.3 14.6 12.4 23.9 14.2 4.5 14.1 25.0 13.0 15.5 17.9 12.6 12.3 12.4 23.5 13.9 22.1 6.1 13.9 15.1 10.5 9.2 5.6 19.5 5.2 5.4 12.0 6.3 4.6 7.0 8.1 9.2 9.2 3.9 9.3 5.5 8.6 6.1 10.3 2.9 10.1 13.6 4.1 8.7 8.7 8.8 11.6 7.3 5.0 8.9 9.3 5.1 6.9 8.1 6.9 5.0 32.7 8.4 13.6 6.5 13.5 12.3 9.1 16.9 5.5 5.4 6.7 5.1 9.6 11.3 8.4 17.6 11.4 7.6 9.1 9.9 11.2 6.5 12.5 6.8 7.0 9.9 21.7 7.1 5.1 22.1 13.9 12.0 19.2 13.1 12.4 12.5 13.9 23.5 11.6 11.4 12.9 1.8 6.1 15.7 9.3 12.9 15.1 12.1 14.9 20.7 16.5 12.2 9.8 12.2 15.9 11.8 14.1 CCK ENSG00000187094 Cholecystokinin P06307 3 42257825-42266207 "Plasma proteins, Predicted secreted proteins" Hormone "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "brain: 95.1;intestine: 71.6" "Group enriched" "Detected in some" 7 "CAPAN-2: 8.7;RPTEC TERT1: 22.7" "Group enriched" "Detected in many" 5 "glioma: 4.0;pancreatic cancer: 1.8;prostate cancer: 3.5;stomach cancer: 1.0" "Group enriched" "Detected in many" 5 "amygdala: 59.0;basal ganglia: 29.8;cerebral cortex: 95.1;hippocampal formation: 35.8;olfactory region: 26.9" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Region enhanced" "Detected in all" "cerebral cortex: 565.3" "HPA045039, HPA069515" Enhanced Supported "Secreted to blood" "HPA045039: , HPA069515: " "unprognostic (3.36e-1)" "unprognostic (1.58e-1)" "unprognostic (1.92e-1)" "unprognostic (1.40e-3)" "unprognostic (1.04e-1)" "unprognostic (1.70e-1)" "unprognostic (2.39e-3)" "unprognostic (1.97e-2)" "unprognostic (3.91e-1)" "unprognostic (8.77e-2)" "unprognostic (1.35e-1)" "unprognostic (2.42e-1)" "unprognostic (1.37e-1)" "unprognostic (5.10e-2)" 0.9 1.1 59.0 1.1 29.8 0.8 0.9 0.2 95.1 0.8 11.3 1.4 0.0 71.6 0.8 0.8 0.9 0.9 0.9 0.9 35.8 10.8 0.8 0.9 1.1 0.8 8.0 26.9 0.8 1.1 0.8 4.1 9.4 1.3 13.5 0.9 0.0 0.8 1.0 0.8 0.9 10.5 1.0 1.3 0.8 1.7 1.7 0.5 0.0 0.8 0.0 0.8 0.8 0.2 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.2 0.7 0.0 0.0 0.0 0.0 8.7 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.1 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.9 22.7 0.1 0.2 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 59.0 29.8 0.2 95.1 35.8 10.8 8.0 26.9 1.3 0.5 CDC42EP4 "BORG4, CEP4, KAIA1777, MGC17125, MGC3740" ENSG00000179604 "CDC42 effector protein 4" Q9H3Q1 17 73283624-73312175 "Predicted intracellular proteins" "Cell shape" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "non-classical monocyte: 15.6" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA023335, HPA024797" Approved Supported Supported "Plasma membrane,Actin filaments,Microtubules" "Actin filaments, Microtubules" "Plasma membrane" "HPA023335: AB_10603783, HPA024797: AB_10600696" "unprognostic (8.76e-2)" "unprognostic (4.38e-3)" "unprognostic (1.49e-2)" "unprognostic (5.43e-3)" "unprognostic (6.29e-2)" "unprognostic (9.01e-3)" "unprognostic (2.44e-3)" "unprognostic (1.08e-1)" "unprognostic (8.00e-2)" "unprognostic (2.41e-1)" "unprognostic (4.16e-2)" "unprognostic (6.73e-2)" "unprognostic (3.97e-1)" "unprognostic (1.66e-1)" "unprognostic (1.54e-1)" "unprognostic (1.10e-1)" "unprognostic (1.94e-1)" 36.0 27.7 24.4 15.2 31.2 8.8 65.2 35.5 45.4 23.5 21.6 28.7 33.4 24.3 23.9 44.5 19.7 41.8 25.2 27.6 28.9 18.4 12.0 15.4 15.9 12.2 20.8 21.1 50.3 50.8 19.9 20.8 15.8 30.7 18.0 13.0 21.8 22.0 38.5 16.7 16.4 22.0 18.9 30.6 11.9 21.6 13.7 24.2 5.9 26.5 14.2 18.9 14.1 46.1 0.1 3.6 4.7 15.6 0.2 0.1 1.4 11.3 26.5 9.9 8.1 20.2 16.9 25.0 10.1 12.7 9.7 7.1 5.6 16.2 0.0 9.0 12.4 8.1 6.9 6.8 6.0 0.5 6.4 2.5 13.7 13.3 10.0 0.4 2.8 21.0 5.9 8.2 4.3 10.9 6.9 0.5 6.0 8.5 0.4 3.3 5.4 18.4 0.3 4.4 1.2 11.6 13.0 6.5 9.8 7.3 21.4 7.1 24.9 3.7 11.0 9.2 18.9 7.1 7.3 0.5 0.4 0.0 14.7 1.8 23.5 2.8 2.6 4.7 0.1 7.0 0.1 0.1 0.0 0.0 3.6 0.0 0.1 0.0 4.6 0.2 15.6 0.1 0.0 1.4 24.4 31.2 35.5 25.1 28.9 18.4 20.8 21.1 30.7 24.2 CDH15 "CDH14, CDH3" ENSG00000129910 "Cadherin 15" P55291 16 89171767-89195492 "Disease related genes, Predicted membrane proteins" "Cell adhesion" "Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "brain: 44.2;skeletal muscle: 60.3" "Cell line enriched" "Detected in some" 5 "RH-30: 56.6" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in some" 24 "cerebellum: 44.2" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in some" 7 "cerebellum: 17.6" "Region enriched" "Detected in many" 6 "cerebellum: 17.9" "HPA009139, HPA070961" Enhanced Supported Enhanced "Golgi apparatus,Plasma membrane" 390000 "Golgi apparatus, Plasma membrane" "HPA009139: AB_1078372, HPA070961: " "unprognostic (1.26e-1)" "unprognostic (7.70e-3)" "unprognostic (6.64e-3)" "unprognostic (2.81e-1)" "unprognostic (7.79e-3)" "unprognostic (2.70e-3)" "unprognostic (2.84e-3)" "unprognostic (4.37e-2)" "unprognostic (2.30e-3)" "unprognostic (7.66e-2)" "unprognostic (4.05e-2)" "unprognostic (1.73e-1)" "unprognostic (1.14e-7)" "unprognostic (3.09e-2)" "unprognostic (3.13e-1)" "unprognostic (5.50e-2)" "unprognostic (2.64e-2)" 0.8 0.2 0.0 0.1 0.0 0.1 0.1 44.2 0.2 0.7 0.1 0.0 0.0 0.2 0.1 2.8 0.6 0.1 0.1 0.1 0.0 0.0 0.2 0.8 0.2 0.1 0.0 0.0 0.1 0.9 0.1 0.0 0.8 1.8 0.5 0.1 0.0 0.3 0.2 60.3 0.1 0.1 0.1 0.3 0.6 0.1 0.3 0.0 0.0 0.1 6.5 0.3 0.1 0.0 0.0 0.8 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.2 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.1 12.0 0.0 0.0 0.0 0.0 0.1 0.0 56.6 0.1 0.0 0.0 0.3 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 44.2 0.1 0.0 0.0 0.0 0.0 1.8 0.0 CDH22 "C20orf25, dJ998H6.1" ENSG00000149654 "Cadherin 22" Q9UJ99 20 46173733-46308498 "Predicted membrane proteins" "Cell adhesion" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "brain: 55.8" "Cell line enriched" "Detected in single" 18 "SCLC-21H: 8.3" "Low cancer specificity" "Detected in some" "Region enhanced" "Detected in all" "cerebellum: 55.8" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA012164, HPA012715" Uncertain Supported "HPA012164: AB_1845902, HPA012715: " "unprognostic (2.41e-4)" "unprognostic (1.72e-2)" "unprognostic (3.10e-1)" "unprognostic (4.32e-3)" "unprognostic (3.39e-2)" "unprognostic (4.73e-1)" "unprognostic (4.32e-1)" "unprognostic (2.54e-2)" "unprognostic (5.54e-2)" "unprognostic (4.50e-4)" "unprognostic (2.62e-1)" "unprognostic (3.09e-1)" "unprognostic (7.26e-3)" "unprognostic (5.93e-2)" "unprognostic (1.79e-1)" "unprognostic (3.92e-2)" "unprognostic (9.83e-2)" 0.7 4.2 10.2 0.5 5.7 0.5 0.8 55.8 15.5 0.7 0.6 1.0 0.0 0.6 0.7 0.7 1.2 4.0 0.5 1.0 3.5 3.7 0.7 0.5 0.6 0.5 1.2 8.7 0.9 4.2 0.5 1.1 0.5 3.0 1.5 0.7 1.8 1.0 1.8 1.2 10.4 0.9 0.5 1.9 0.5 0.9 1.4 1.3 0.0 0.7 0.0 0.5 0.5 0.6 0.0 0.0 0.5 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.0 0.0 0.0 0.0 0.0 8.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 10.2 5.7 55.8 14.8 3.5 3.7 1.2 8.7 3.0 1.3 CHAT ENSG00000070748 "Choline O-acetyltransferase" P28329 10 49609095-49665104 "Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Neurotransmitter biosynthesis" "Acyltransferase, Transferase" "Congenital myasthenic syndrome, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "brain: 5.4;placenta: 10.4" "Cell line enriched" "Detected in some" 11 "NB-4: 15.5" "Not detected" "Not detected" "Region enriched" "Detected in single" 8 "basal ganglia: 5.4" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Region enhanced" "Detected in many" "basal ganglia: 18.4" "Group enriched" "Detected in many" 4 "basal ganglia: 7.7;pons and medulla: 8.1" "CAB002313, HPA048547, CAB079053" Supported Supported "CAB002313: AB_563661, CAB079053: , HPA048547: " "unprognostic (2.34e-2)" "unprognostic (6.10e-2)" "unprognostic (5.28e-2)" "unprognostic (6.96e-2)" "unprognostic (2.80e-2)" "unprognostic (3.98e-1)" "unprognostic (1.09e-1)" 0.2 0.0 0.2 0.3 5.4 0.0 0.2 0.2 0.2 0.2 0.6 0.2 0.2 1.6 0.2 0.5 0.2 0.0 0.2 0.2 0.2 0.6 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.9 0.0 0.2 10.4 0.2 0.2 0.2 0.2 0.2 0.3 0.2 0.2 1.1 0.2 0.4 0.2 0.0 0.5 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.6 1.0 0.3 0.2 0.6 1.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.5 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 1.0 15.5 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.7 0.0 0.1 0.0 0.7 0.1 0.0 0.1 0.1 0.3 0.1 0.0 0.1 0.0 0.1 0.0 1.3 0.0 0.0 0.2 0.3 0.4 0.1 0.5 0.3 1.0 0.4 0.1 0.6 0.5 0.3 0.0 0.6 0.1 1.0 0.2 0.0 0.2 5.4 0.2 0.2 0.2 0.6 0.2 0.2 0.2 0.2 CHGB "SCG1, SgI" ENSG00000089199 "Chromogranin B" P05060 20 5911430-5925361 "Plasma proteins, Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 424.9;pituitary gland: 177.5" "Group enriched" "Detected in some" 23 "SCLC-21H: 65.1;SH-SY5Y: 99.7" "Cancer enriched" "Detected in many" 6 "pancreatic cancer: 154.2" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "memory CD4 T-cell: 2.6;T-reg: 1.1" "Lineage enhanced" "Detected in single" "T-cells: 2.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008759, CAB009403, HPA012602" Enhanced Supported Enhanced Vesicles "Intracellular and membrane" 24000000 Vesicles "CAB009403: AB_2081255, HPA008759: AB_1846704, HPA012602: AB_1846706" "unprognostic (1.79e-3)" "unprognostic (7.72e-2)" "unprognostic (3.48e-1)" "unprognostic (2.90e-2)" "unprognostic (1.68e-2)" "prognostic unfavourable (1.89e-4)" "unprognostic (7.96e-3)" "unprognostic (2.86e-1)" "unprognostic (6.18e-3)" "unprognostic (7.93e-2)" "prognostic favourable (9.96e-4)" "unprognostic (8.56e-2)" "unprognostic (8.21e-2)" "unprognostic (1.56e-1)" "unprognostic (2.81e-2)" "unprognostic (2.73e-1)" "unprognostic (1.01e-2)" 3.4 424.9 8.2 1.4 10.2 0.8 1.0 82.5 16.4 0.8 3.0 2.1 1.2 7.7 0.9 1.3 0.8 2.5 0.8 7.6 20.7 15.4 1.7 0.7 1.0 1.1 7.2 9.1 3.0 17.0 0.8 177.5 0.8 51.8 5.6 2.5 0.7 0.9 1.2 2.1 0.9 4.4 0.9 2.3 0.8 19.7 2.4 0.8 0.0 1.9 0.4 0.9 0.8 0.1 0.0 0.6 0.0 0.0 0.0 2.6 0.2 0.0 1.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.2 0.0 0.7 0.0 0.2 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.1 3.5 0.0 0.0 0.0 0.0 0.0 0.0 65.1 99.7 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.5 0.0 0.1 0.4 0.1 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.0 0.6 0.0 0.2 0.0 0.0 0.0 0.0 0.0 1.1 0.2 8.2 10.2 82.5 16.4 20.7 15.4 7.2 9.1 51.8 0.8 CHRM1 ENSG00000168539 "Cholinergic receptor muscarinic 1" P11229 11 62908679-62921807 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "brain: 34.7;prostate: 28.2;salivary gland: 25.3" "Cell line enhanced" "Detected in some" "MCF7: 8.0;SK-BR-3: 4.0;T-47d: 2.6;WM-115: 1.4" "Cancer enriched" "Detected in some" 16 "prostate cancer: 27.9" "Group enriched" "Detected in many" 10 "amygdala: 13.2;basal ganglia: 22.0;cerebral cortex: 34.7;hippocampal formation: 14.2;olfactory region: 14.0" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 9 "amygdala: 74.1;basal ganglia: 65.6;cerebral cortex: 83.5;hippocampal formation: 100.4;olfactory region: 36.8" "HPA014101, CAB022366" Enhanced Supported Approved Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB022366: , HPA014101: AB_1854210" "unprognostic (3.19e-2)" "unprognostic (2.14e-1)" "unprognostic (2.25e-1)" "unprognostic (1.31e-2)" "unprognostic (7.94e-2)" "unprognostic (2.29e-1)" "unprognostic (1.16e-2)" "unprognostic (2.89e-2)" "unprognostic (1.91e-1)" "unprognostic (2.76e-1)" "unprognostic (2.08e-1)" "unprognostic (8.57e-4)" "unprognostic (4.88e-1)" "unprognostic (6.43e-2)" "unprognostic (1.75e-1)" 0.5 3.7 13.2 0.8 22.0 0.5 3.2 0.2 34.7 0.6 1.3 0.5 0.0 1.0 0.7 0.6 0.8 0.8 0.7 0.6 14.2 1.7 0.7 0.6 2.9 0.6 1.4 14.0 0.5 1.2 1.0 0.1 0.8 0.1 28.2 1.3 1.3 25.3 0.6 0.6 2.6 1.3 0.6 0.3 0.6 1.9 0.6 1.8 0.0 0.8 0.0 0.7 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.5 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 8.0 0.0 0.2 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 4.0 0.7 2.6 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.2 22.0 0.2 34.7 14.2 1.7 1.4 14.0 0.1 1.8 CNGA3 "ACHM2, CCNC1, CCNCa, CNCG3, CNG3" ENSG00000144191 "Cyclic nucleotide gated channel alpha 3" Q16281 2 98346155-98398601 "Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sensory transduction, Transport, Vision" "Ion channel, Ligand-gated ion channel" "Disease mutation, Leber congenital amaurosis" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "pituitary gland: 32.0" "Cell line enriched" "Detected in some" 7 "U-87 MG: 12.5" "Cancer enriched" "Detected in some" 9 "glioma: 7.9" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 6 "basal ganglia: 1.9;hypothalamus: 2.2" "Not detected" "Not detected" "HPA049378, CAB079025" Approved Approved "CAB079025: , HPA049378: " "unprognostic (2.34e-2)" "unprognostic (1.83e-2)" "unprognostic (4.96e-2)" "unprognostic (4.81e-2)" "unprognostic (1.13e-1)" "unprognostic (2.18e-1)" "unprognostic (4.17e-4)" "unprognostic (4.65e-2)" "unprognostic (1.86e-3)" "unprognostic (2.88e-1)" "unprognostic (3.85e-3)" "unprognostic (8.98e-2)" "unprognostic (5.90e-2)" "unprognostic (3.71e-2)" 0.1 0.0 0.3 1.4 0.7 0.0 0.7 0.1 2.9 0.1 6.1 2.4 0.1 2.8 0.1 0.1 4.6 0.8 0.4 0.1 1.2 4.0 0.1 0.1 0.2 0.1 0.8 0.4 0.1 1.5 0.0 32.0 0.1 4.9 0.1 3.2 1.2 0.2 0.5 0.1 0.0 4.0 2.2 4.3 0.1 3.0 1.1 0.3 0.1 0.1 0.1 0.1 1.6 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 1.7 0.0 0.0 0.0 0.0 12.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.7 0.1 1.5 1.2 4.0 0.8 0.4 4.9 0.3 CNP ENSG00000173786 "2',3'-cyclic nucleotide 3' phosphodiesterase" P09543 17 41966741-41977731 "Enzymes, Plasma proteins, Predicted intracellular proteins" "Hydrolase, RNA-binding" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 4 "brain: 211.7" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "plasmacytoid DC: 49.1" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002672, HPA023266, HPA023278, HPA023280, HPA023338" Enhanced Supported Enhanced Nucleoplasm,Cytosol 730000 Nucleoplasm Cytosol "CAB002672: , HPA023266: AB_1847058, HPA023278: AB_1847060, HPA023280: AB_1847061, HPA023338: AB_1847062" "unprognostic (2.17e-1)" "unprognostic (4.48e-2)" "unprognostic (3.85e-3)" "unprognostic (1.41e-1)" "unprognostic (3.09e-1)" "unprognostic (9.71e-2)" "unprognostic (2.58e-3)" "unprognostic (2.08e-1)" "unprognostic (2.23e-1)" "unprognostic (1.62e-1)" "unprognostic (5.76e-3)" "unprognostic (1.87e-1)" "unprognostic (2.99e-3)" "unprognostic (1.60e-1)" "unprognostic (1.55e-1)" "unprognostic (8.86e-2)" "unprognostic (1.10e-3)" 9.1 8.9 51.4 9.5 72.8 6.7 8.1 13.4 125.3 10.3 7.5 211.7 2.3 7.1 8.0 12.7 15.0 9.3 10.8 7.6 78.4 40.7 14.7 9.6 6.7 10.5 86.7 49.0 11.2 9.2 5.8 4.4 7.8 66.7 11.7 6.4 3.6 15.1 13.2 7.6 11.1 6.4 10.1 160.2 7.1 7.4 4.6 63.5 2.1 7.2 2.2 11.2 9.8 5.7 9.9 49.1 7.3 13.1 7.3 7.5 9.1 13.7 23.5 22.3 27.5 19.1 18.0 9.6 17.2 26.5 44.8 50.6 18.4 12.6 14.6 13.9 22.4 23.7 15.0 11.4 15.6 14.5 19.0 14.2 16.2 31.9 20.6 13.8 12.9 29.7 8.2 24.5 6.0 20.4 10.0 12.0 15.6 8.7 35.4 12.5 5.2 16.8 22.1 32.8 14.2 11.9 14.1 13.1 17.7 21.8 32.9 38.3 14.7 20.7 20.4 17.5 19.2 23.7 20.3 13.5 15.3 11.7 17.3 10.7 68.2 4.9 12.1 7.3 7.5 13.1 5.9 9.9 6.5 6.0 11.1 7.0 5.9 6.9 2.6 7.3 10.3 49.1 7.2 9.1 51.4 72.8 13.4 93.8 78.4 40.7 86.7 49.0 66.7 63.5 CPLX3 CPX-III ENSG00000213578 "Complexin 3" Q8WVH0 15 74826547-74831802 "Predicted intracellular proteins" "Exocytosis, Neurotransmitter transport, Sensory transduction, Transport, Vision" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 20.8;lymphoid tissue: 31.8;prostate: 56.4;retina: 32.8" "Cell line enhanced" "Detected in some" "Daudi: 5.5;Karpas-707: 4.8;SK-BR-3: 2.7;U-266/84: 3.1" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Low region specificity" "Detected in single" CAB079003 Supported "CAB079003: " 0.4 2.5 6.4 0.5 7.4 0.4 0.4 20.8 19.6 0.5 0.5 3.3 0.0 0.4 0.4 0.5 0.5 0.4 0.4 13.4 6.4 0.8 0.4 0.4 0.4 0.5 0.6 7.9 0.4 0.4 0.4 1.7 0.4 8.2 56.4 0.4 32.8 9.8 0.4 0.4 0.5 0.6 0.4 1.0 31.8 4.6 2.2 1.2 0.0 0.4 0.0 0.5 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 1.5 0.0 0.0 0.1 0.2 0.1 0.0 5.5 0.1 0.0 0.2 0.1 0.0 0.0 1.9 0.1 0.0 0.1 0.0 0.0 0.0 1.2 0.0 0.2 0.2 0.0 0.0 0.0 4.8 0.0 0.1 0.0 0.9 0.1 0.3 0.2 0.0 0.4 0.0 0.1 2.1 0.1 0.0 2.7 1.1 1.6 0.0 0.0 0.1 0.1 0.5 0.0 1.3 3.1 2.2 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.4 7.4 20.8 19.6 6.4 0.8 0.6 7.9 8.2 1.2 CRABP1 "CRABP, CRABP-I, CRABPI, RBP5" ENSG00000166426 "Cellular retinoic acid binding protein 1" P29762 15 78340324-78348230 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 40.1;retina: 73.2;thyroid gland: 80.6" "Group enriched" "Detected in some" 8 "AF22: 143.3;NTERA-2: 42.9" "Cancer enhanced" "Detected in many" "ovarian cancer: 117.2" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 13 "myeloid DC: 1.2" "Lineage enriched" "Detected in single" 13 "dendritic cells: 1.2" "Group enriched" "Detected in many" 5 "amygdala: 6.6;basal ganglia: 20.9;hypothalamus: 15.5;olfactory region: 15.7;pons and medulla: 7.8" "Low region specificity" "Detected in some" HPA017203 Enhanced Supported "HPA017203: AB_1846512" "unprognostic (1.23e-1)" "unprognostic (3.76e-3)" "unprognostic (1.46e-1)" "prognostic unfavourable (4.72e-4)" "unprognostic (2.01e-1)" "unprognostic (4.35e-2)" "unprognostic (1.05e-1)" "unprognostic (1.35e-1)" "unprognostic (2.45e-2)" "unprognostic (9.79e-2)" "unprognostic (1.21e-1)" "unprognostic (2.79e-2)" "unprognostic (9.37e-2)" "unprognostic (2.17e-1)" "unprognostic (1.07e-1)" "unprognostic (2.69e-1)" 0.7 1.3 6.3 1.8 25.6 0.6 24.8 2.8 12.4 1.2 1.9 3.3 0.3 0.9 1.5 1.9 0.7 0.5 1.2 0.7 1.1 21.9 4.2 0.5 0.8 0.6 16.9 4.5 0.7 0.7 0.5 6.3 7.0 40.1 1.0 1.3 73.2 0.6 24.8 0.5 12.3 2.3 1.3 7.3 21.1 1.9 0.6 2.4 0.4 80.6 2.4 1.0 0.7 0.4 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 143.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.7 0.1 0.0 0.9 0.0 0.0 1.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 7.6 0.0 42.9 0.1 0.0 0.0 0.0 0.0 0.2 12.0 8.1 0.0 0.0 0.0 0.2 4.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.3 25.6 2.8 12.4 1.1 21.9 16.9 4.5 40.1 2.4 CRB2 "FLJ16786, FLJ38464" ENSG00000148204 "Crumbs 2, cell polarity complex component" Q5IJ48 9 123356170-123380324 "Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" Gastrulation "Developmental protein" "Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 21.5" "Cell line enriched" "Detected in some" 7 "AF22: 26.8" "Group enriched" "Detected in some" 7 "glioma: 9.4;ovarian cancer: 5.6" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Low region specificity" "Detected in many" HPA043674 Approved Supported "Intracellular and membrane" 240000 "HPA043674: AB_10962974" "unprognostic (1.38e-2)" "unprognostic (2.39e-2)" "unprognostic (1.26e-1)" "unprognostic (2.83e-4)" "unprognostic (2.85e-2)" "unprognostic (1.14e-2)" "unprognostic (2.31e-1)" "unprognostic (3.69e-4)" "unprognostic (1.20e-1)" "unprognostic (7.28e-3)" "unprognostic (4.66e-3)" "unprognostic (3.09e-1)" "unprognostic (5.56e-5)" "unprognostic (1.31e-1)" "unprognostic (1.55e-1)" "unprognostic (4.38e-2)" "unprognostic (3.38e-1)" 1.3 0.6 6.8 1.9 8.7 1.3 1.0 3.0 16.2 0.5 2.4 21.5 0.0 0.9 2.4 0.9 0.7 3.4 0.5 0.6 9.7 3.7 5.7 0.5 0.6 2.4 7.3 17.4 0.9 0.5 0.5 1.3 0.7 7.4 0.6 1.7 5.1 0.6 0.6 0.5 1.0 1.0 1.3 9.5 1.8 1.1 1.1 7.7 0.0 0.6 0.0 2.3 0.7 0.2 0.3 0.0 0.7 0.0 0.0 0.2 0.0 0.0 0.1 26.8 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.4 0.1 0.3 0.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.1 0.0 0.4 0.0 0.0 3.6 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.6 0.8 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 6.8 8.7 3.0 8.2 9.7 3.7 7.3 17.4 7.4 7.7 CRHBP "CRF-BP, CRFBP" ENSG00000145708 "Corticotropin releasing hormone binding protein" P24387 5 76952713-76981158 "Plasma proteins, Predicted secreted proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 24.9;liver: 99.9" "Cell line enhanced" "Detected in some" "BJ hTERT+ SV40 Large T+: 4.9;BJ hTERT+ SV40 Large T+ RasG12V: 4.8;HBF TERT88: 8.7;U-698: 9.5;U-87 MG: 5.2;WM-115: 4.5" "Cancer enhanced" "Detected in some" "testis cancer: 2.5" "Region enhanced" "Detected in many" "hypothalamus: 24.9" "Cell type enriched" "Detected in single" 4 "neutrophil: 1.2" "Lineage enriched" "Detected in single" 4 "granulocytes: 1.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA036234, HPA046120" Approved Supported "Secreted to blood" 43000000 "HPA036234: , HPA046120: AB_10959760" "unprognostic (1.41e-1)" "unprognostic (2.00e-2)" "unprognostic (1.14e-1)" "unprognostic (1.78e-3)" "unprognostic (1.18e-1)" "unprognostic (1.65e-1)" "unprognostic (2.36e-3)" "unprognostic (4.44e-5)" "unprognostic (2.16e-1)" "unprognostic (7.08e-2)" "unprognostic (4.98e-4)" "unprognostic (1.09e-1)" "unprognostic (6.63e-5)" "unprognostic (2.76e-2)" "unprognostic (4.64e-1)" "unprognostic (1.74e-1)" "unprognostic (2.95e-2)" 8.4 5.6 3.5 0.4 5.4 1.2 2.6 0.0 7.8 1.6 0.3 3.2 1.8 0.4 1.2 0.7 0.2 0.9 0.5 3.2 4.0 24.9 16.1 99.9 0.3 0.4 2.7 5.4 0.8 0.2 0.4 0.0 18.1 1.8 0.6 0.3 1.5 0.6 1.9 0.5 0.2 0.3 0.8 2.2 13.9 0.3 0.5 1.2 0.0 1.9 0.9 0.4 0.5 0.2 0.0 0.0 1.2 0.1 0.0 0.2 0.8 0.0 0.0 0.6 0.0 0.1 0.1 0.0 0.0 0.1 4.9 4.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.7 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.7 0.0 0.0 2.9 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 2.5 0.0 0.0 0.0 9.5 5.2 0.0 4.5 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.8 3.5 5.4 0.0 7.8 4.0 24.9 2.7 5.4 1.8 1.2 CSK ENSG00000103653 "C-terminal Src kinase" P41240 15 74782057-74803198 "Enzymes, Plasma proteins, Predicted intracellular proteins" "Adaptive immunity, Immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 67.2" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011203, HPA026488, HPA028425" Approved Approved Approved Vesicles,Cytosol 1500000 "Vesicles, Cytosol" "CAB011203: AB_259070, HPA026488: AB_1847273, HPA028425: AB_10600899" "unprognostic (1.05e-1)" "prognostic favourable (5.14e-5)" "unprognostic (2.59e-3)" "prognostic favourable (8.22e-4)" "unprognostic (4.15e-2)" "unprognostic (4.11e-2)" "unprognostic (1.87e-1)" "unprognostic (2.96e-1)" "unprognostic (2.20e-1)" "unprognostic (1.31e-1)" "unprognostic (4.12e-2)" "unprognostic (4.61e-2)" "prognostic unfavourable (1.74e-4)" "prognostic favourable (1.07e-4)" "unprognostic (1.44e-1)" "unprognostic (1.01e-1)" "unprognostic (6.29e-2)" 9.3 8.0 9.5 39.3 11.0 19.9 12.6 18.7 13.4 12.1 13.5 11.8 7.3 16.1 13.9 6.4 33.3 10.6 11.2 14.0 9.8 8.5 8.0 20.9 15.6 67.2 11.1 7.4 10.5 6.7 6.6 10.4 8.8 12.2 9.8 8.9 9.8 13.2 7.0 8.7 14.9 26.2 8.5 10.9 62.7 13.1 8.1 10.6 62.7 8.1 9.5 47.4 17.4 13.2 35.6 22.8 49.6 46.8 16.3 30.7 19.9 12.7 18.0 8.8 14.5 8.4 6.5 7.6 8.6 8.2 16.3 11.6 16.4 11.8 57.1 11.4 7.7 13.3 18.5 17.3 4.6 27.6 22.8 48.3 6.6 16.5 11.7 25.2 61.6 9.2 8.5 11.6 10.4 12.3 13.9 19.9 9.7 21.5 18.1 14.9 10.9 12.9 20.1 7.6 41.6 7.5 28.4 14.7 10.2 11.1 23.4 14.8 16.1 37.2 10.6 19.8 10.4 15.5 14.8 10.7 21.5 58.3 10.2 48.2 13.3 20.7 19.7 49.6 23.4 42.4 20.0 29.4 20.3 23.1 22.8 35.6 15.7 18.4 39.1 16.3 46.8 13.2 30.7 19.9 9.5 11.0 18.7 13.4 9.8 8.5 11.1 7.4 12.2 10.6 CTBP2 ribeye ENSG00000175029 "C-terminal binding protein 2" P56545 10 124984317-125161170 "Plasma proteins, Predicted intracellular proteins" "Differentiation, Host-virus interaction, Transcription, Transcription regulation" "Oxidoreductase, Repressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA023559, HPA023564, CAB031916, HPA044971, CAB079018" Approved Approved Approved Cytosol Cytosol "CAB031916: AB_2086774, CAB079018: , HPA023559: AB_1847309, HPA023564: AB_1847310, HPA044971: " "unprognostic (8.69e-2)" "unprognostic (1.27e-2)" "unprognostic (4.14e-2)" "unprognostic (1.41e-2)" "unprognostic (6.84e-3)" "unprognostic (4.05e-3)" "unprognostic (3.63e-2)" "unprognostic (5.60e-3)" "unprognostic (1.46e-1)" "unprognostic (2.12e-1)" "unprognostic (3.24e-2)" "unprognostic (3.99e-3)" "prognostic favourable (1.70e-4)" "unprognostic (4.34e-2)" "unprognostic (1.48e-1)" "unprognostic (2.19e-2)" "unprognostic (1.62e-1)" 13.9 13.1 14.5 9.6 16.3 9.0 29.8 23.5 11.8 31.1 20.9 22.5 17.8 19.8 29.0 21.2 16.3 23.3 17.4 10.9 16.1 12.3 15.4 3.1 17.3 6.5 19.2 11.8 24.1 24.5 12.9 13.6 14.9 15.6 22.9 17.9 28.6 19.9 18.5 11.4 8.6 19.4 23.7 15.1 12.1 19.9 14.5 16.8 3.1 43.3 11.6 6.1 16.7 23.8 0.3 6.5 15.4 11.6 19.7 5.3 2.6 25.1 28.6 25.3 21.0 13.6 13.4 14.0 19.7 23.0 18.6 21.2 17.7 29.7 0.0 10.2 19.7 19.9 25.1 31.6 14.0 0.1 19.0 18.5 18.8 0.4 28.5 7.8 14.8 11.5 25.1 19.2 38.4 23.6 0.7 0.1 11.6 27.9 0.8 8.0 19.0 18.4 22.4 10.6 0.2 21.9 11.4 7.7 22.2 19.1 16.8 25.3 11.9 12.9 19.0 11.2 14.3 16.0 16.8 0.4 1.4 0.0 14.1 0.1 11.0 15.4 5.1 9.2 5.3 5.0 0.6 0.3 0.2 1.4 6.5 0.2 0.3 2.3 8.5 19.7 11.6 5.5 0.1 2.6 14.5 16.3 23.5 11.8 16.1 12.3 19.2 11.8 15.6 16.8 CYGB "HGB, STAP" ENSG00000161544 Cytoglobin Q8WWM9 17 76527356-76551175 "Predicted intracellular proteins, Transporters" "Oxygen transport, Transport" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in some" "ASC diff: 24.4;Hep G2: 18.6;HHSteC: 37.2;HSkMC: 30.3;SH-SY5Y: 40.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "naive B-cell: 4.4" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA017757, HPA061642" Approved Approved Supported "Nuclear speckles,Cytosol" "Nuclear speckles" Cytosol "HPA017757: AB_1847410, HPA061642: " "unprognostic (6.96e-2)" "unprognostic (1.39e-1)" "unprognostic (3.97e-2)" "prognostic favourable (2.55e-5)" "prognostic unfavourable (1.85e-4)" "unprognostic (3.36e-2)" "unprognostic (3.31e-3)" "unprognostic (2.01e-1)" "unprognostic (7.83e-2)" "unprognostic (1.42e-1)" "unprognostic (1.08e-2)" "unprognostic (4.14e-2)" "prognostic unfavourable (2.13e-4)" "unprognostic (3.34e-2)" "unprognostic (1.11e-2)" "unprognostic (2.49e-2)" "unprognostic (7.76e-2)" 48.1 16.1 6.2 9.5 8.3 1.1 34.4 10.9 11.6 13.3 19.0 1.5 8.4 15.2 8.8 8.4 12.5 8.8 24.1 43.4 4.2 11.2 6.9 13.6 17.8 9.5 6.3 5.5 11.2 7.6 8.5 5.0 10.0 17.7 22.8 7.0 23.7 10.4 9.4 17.1 8.2 17.8 17.6 3.5 8.0 13.1 9.3 2.2 1.1 22.0 11.4 3.4 35.1 41.5 4.4 0.4 2.4 0.3 2.5 1.3 0.5 0.0 0.3 0.6 0.1 24.4 7.2 8.2 0.2 0.6 0.1 0.2 0.0 0.1 0.0 7.9 0.7 0.2 0.0 10.5 0.0 0.0 0.0 0.1 0.1 18.6 37.2 0.0 0.0 30.3 2.3 0.8 0.8 0.1 0.0 0.0 0.3 0.2 0.0 0.1 0.1 0.4 0.1 0.1 0.0 0.1 0.0 0.2 40.6 0.0 0.0 0.8 0.0 0.2 0.0 1.0 0.5 0.1 0.0 0.4 0.0 0.1 0.0 0.1 3.1 0.0 0.3 0.4 0.5 0.2 0.3 3.4 0.4 0.2 0.4 4.4 0.7 1.3 2.4 2.5 0.2 0.0 0.5 0.5 6.2 8.3 10.9 11.6 4.2 11.2 6.3 5.5 17.7 2.2 DACT2 "bA503C24.7, C6orf116, DAPPER2" ENSG00000164488 "Dishevelled binding antagonist of beta catenin 2" Q5SW24 6 168292830-168319754 "Predicted intracellular proteins" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Group enriched" "Detected in many" 6 "brain: 14.2;placenta: 54.8" "Cell line enhanced" "Detected in some" "A549: 6.4;CACO-2: 5.1;EFO-21: 2.9;Hep G2: 2.9;hTCEpi: 3.5;NTERA-2: 4.6;SCLC-21H: 5.0" "Cancer enhanced" "Detected in many" "endometrial cancer: 14.1" "Region enriched" "Detected in many" 8 "basal ganglia: 14.2" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA030251, HPA030252" Approved Supported "HPA030251: AB_10611108, HPA030252: AB_10601993" "unprognostic (5.22e-6)" "unprognostic (3.13e-2)" "unprognostic (1.04e-2)" "prognostic favourable (1.07e-5)" "unprognostic (1.21e-1)" "unprognostic (1.41e-1)" "unprognostic (1.64e-2)" "unprognostic (1.08e-1)" "unprognostic (4.04e-1)" "unprognostic (1.31e-1)" "unprognostic (7.05e-3)" "unprognostic (2.48e-1)" "prognostic favourable (5.76e-5)" "unprognostic (1.51e-2)" "unprognostic (1.66e-2)" "unprognostic (2.03e-4)" "unprognostic (4.23e-2)" 1.0 1.3 0.5 0.4 14.2 0.0 0.4 1.5 1.4 2.3 1.1 1.2 1.0 0.9 3.7 2.2 0.7 2.2 2.9 2.7 0.9 0.5 2.2 2.4 2.0 0.4 1.1 0.9 0.9 1.6 0.0 0.4 54.8 1.7 6.1 0.4 1.6 5.3 0.5 0.4 5.6 0.8 0.8 0.7 0.4 0.5 1.0 0.7 0.9 0.4 0.4 0.8 1.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.4 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 5.1 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.8 0.0 0.0 0.0 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 4.6 0.0 0.0 0.0 0.0 0.0 0.0 5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 14.2 1.5 1.4 0.9 0.5 1.1 0.9 1.7 0.7 DAGLA "C11orf11, DAGLALPHA, KIAA0659, NSDDR" ENSG00000134780 "Diacylglycerol lipase alpha" Q9Y4D2 11 61680433-61747001 "Disease related genes, Predicted membrane proteins" "Lipid degradation, Lipid metabolism" Hydrolase "Neurodegeneration, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 22.0" "Cell line enhanced" "Detected in many" "CAPAN-2: 11.0;T-47d: 12.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "classical monocyte: 1.4;intermediate monocyte: 1.9;non-classical monocyte: 1.6" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA062497, CAB078793" Approved Supported "CAB078793: , HPA062497: " "unprognostic (2.53e-3)" "unprognostic (1.85e-1)" "unprognostic (1.26e-2)" "prognostic unfavourable (1.13e-7)" "unprognostic (1.23e-1)" "unprognostic (1.70e-1)" "unprognostic (1.14e-4)" "unprognostic (2.22e-2)" "unprognostic (2.29e-3)" "unprognostic (3.99e-3)" "unprognostic (1.55e-1)" "unprognostic (1.09e-1)" "unprognostic (1.11e-3)" "unprognostic (1.53e-1)" "unprognostic (1.52e-1)" "unprognostic (1.08e-1)" "unprognostic (1.14e-2)" 3.7 2.5 7.2 2.8 13.3 1.1 3.0 12.0 22.0 3.1 6.0 3.6 3.1 4.4 2.7 3.8 4.7 3.8 2.9 3.8 8.6 6.0 2.3 0.5 3.2 1.3 3.7 7.4 1.2 8.8 1.7 3.3 1.7 4.5 3.5 3.7 2.5 7.9 4.0 3.1 1.1 5.2 3.2 1.4 3.4 2.9 3.3 2.7 0.0 1.6 2.0 1.0 1.7 1.4 0.0 0.8 0.0 1.9 0.0 0.1 0.3 5.3 6.1 4.7 0.9 1.1 1.7 0.8 2.5 0.7 2.8 3.0 3.5 11.0 0.0 2.6 2.2 3.2 0.8 0.0 1.2 0.0 3.1 0.0 4.5 5.4 1.8 0.0 1.0 0.9 0.3 3.6 0.0 0.8 0.0 0.0 1.3 2.5 0.0 0.0 9.7 5.9 0.0 0.7 0.0 1.0 1.3 9.8 5.4 1.4 2.3 1.7 12.1 3.1 3.3 1.9 8.5 5.1 3.0 0.0 0.0 0.0 5.1 1.4 2.9 0.0 1.4 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.8 0.0 0.1 0.0 0.0 0.0 1.6 0.1 0.0 0.3 7.2 13.3 12.0 21.5 8.6 6.0 3.7 7.4 4.5 2.7 DBN1 D0S117E ENSG00000113758 "Drebrin 1" Q16643 5 177456608-177474401 "Plasma proteins, Predicted intracellular proteins" "Differentiation, Neurogenesis" "Actin-binding, Developmental protein" "Alzheimer disease, Amyloidosis, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "MAIT T-cell: 12.7" "Group enriched" "Detected in many" 8 "dendritic cells: 5.1;granulocytes: 6.0;T-cells: 12.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA051452, HPA056940" Enhanced Supported Supported "Plasma membrane,Actin filaments" 17000000 "Plasma membrane, Actin filaments" "HPA051452: AB_2681489, HPA056940: AB_2683279" "unprognostic (3.81e-2)" "unprognostic (6.60e-3)" "unprognostic (2.88e-2)" "unprognostic (7.57e-3)" "unprognostic (9.32e-2)" "unprognostic (5.68e-2)" "unprognostic (2.01e-3)" "unprognostic (4.29e-2)" "unprognostic (1.73e-2)" "unprognostic (7.92e-2)" "unprognostic (2.94e-2)" "unprognostic (3.64e-1)" "prognostic favourable (8.28e-4)" "unprognostic (1.53e-1)" "unprognostic (4.56e-2)" "unprognostic (1.05e-1)" "unprognostic (1.76e-3)" 21.4 9.0 21.7 15.0 42.4 5.4 13.5 12.0 46.0 25.7 21.7 8.8 8.7 8.6 37.4 15.0 19.2 16.2 21.5 13.9 24.2 20.9 15.1 2.7 12.1 7.3 11.9 22.1 20.2 13.2 9.1 17.1 6.7 20.3 14.9 5.8 9.3 24.8 23.0 21.3 12.7 10.0 29.5 8.6 7.8 17.0 14.4 9.4 19.8 20.0 11.0 4.4 20.6 12.0 0.2 5.1 6.0 0.9 0.1 12.7 1.5 2.9 10.1 33.8 58.9 8.0 12.7 10.5 36.1 9.3 21.2 17.8 34.9 10.6 0.0 25.8 28.0 4.7 14.9 26.2 10.0 0.8 12.9 19.6 13.2 14.5 28.5 7.3 3.6 16.6 6.9 23.7 7.1 34.9 9.0 4.7 15.4 4.2 20.1 11.2 48.9 22.7 60.2 36.6 5.9 15.8 4.2 39.8 54.1 11.8 5.2 20.0 14.4 7.6 53.9 23.7 32.2 5.2 16.7 1.1 0.5 31.6 9.9 6.9 14.5 6.0 0.9 0.7 9.2 0.5 12.7 0.1 0.2 6.6 1.4 0.2 0.3 4.5 2.5 0.1 0.4 5.1 0.0 1.5 21.7 42.4 12.0 40.8 24.2 20.9 11.9 22.1 20.3 9.4 DCX "DBCN, DC, LISX, SCLH, XLIS" ENSG00000077279 Doublecortin O43602 X 111293779-111412429 "Disease related genes, Predicted intracellular proteins" "Differentiation, Neurogenesis" "Developmental protein" "Disease mutation, Epilepsy, Lissencephaly" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 17.1;testis: 6.4" "Group enriched" "Detected in some" 8 "SCLC-21H: 33.8;SH-SY5Y: 13.9" "Cancer enriched" "Detected in some" 5 "glioma: 5.2" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in many" 9 "olfactory region: 90.9" "Region enriched" "Detected in all" 4 "olfactory region: 130.1" HPA036121 Enhanced Supported Approved Cytosol Cytosol "HPA036121: " "unprognostic (1.36e-2)" "unprognostic (1.99e-1)" "unprognostic (7.36e-2)" "unprognostic (4.00e-2)" "unprognostic (1.50e-1)" "unprognostic (2.24e-1)" "unprognostic (2.00e-2)" "unprognostic (7.18e-2)" "unprognostic (3.24e-2)" "unprognostic (2.33e-3)" "unprognostic (3.67e-1)" "unprognostic (4.90e-4)" "unprognostic (5.02e-3)" "unprognostic (1.27e-1)" "unprognostic (1.85e-1)" 0.8 1.1 7.0 0.7 9.2 0.7 3.2 0.7 17.1 0.7 0.6 0.9 0.0 0.7 4.1 3.6 0.6 0.6 0.8 0.7 4.2 5.4 0.5 0.5 0.6 0.7 2.5 6.7 0.6 0.8 0.5 1.0 0.6 3.7 0.5 0.8 0.0 2.2 0.6 0.5 0.7 0.7 0.6 3.0 0.6 1.2 6.4 2.3 0.0 0.6 0.0 0.5 0.6 0.3 0.3 0.4 0.6 0.2 0.7 0.4 0.0 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.5 0.0 0.0 0.0 33.8 13.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.2 0.2 0.2 0.1 0.4 0.3 0.3 0.2 0.1 0.3 0.3 0.3 0.6 0.7 0.0 0.4 0.1 0.0 7.0 9.2 0.7 10.8 4.2 5.4 2.5 6.7 3.7 2.3 DDX3X "DBX, DDX14, DDX3, HLP2" ENSG00000215301 "DEAD-box helicase 3, X-linked" O00571 X 41333284-41364472 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Apoptosis, Chromosome partition, Host-virus interaction, Immunity, Innate immunity, Ribosome biogenesis, Transcription, Transcription regulation, Translation regulation" "DNA-binding, Helicase, Hydrolase, RNA-binding" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001648, HPA005631, HPA059585" Supported Supported Approved Nucleoplasm,Cytosol 110000 Cytosol Nucleoplasm "HPA001648: AB_1078635, HPA005631: AB_1078633, HPA059585: " "unprognostic (2.42e-2)" "unprognostic (1.11e-1)" "unprognostic (8.01e-3)" "unprognostic (1.66e-1)" "unprognostic (8.12e-2)" "unprognostic (6.43e-2)" "unprognostic (1.17e-3)" "unprognostic (1.88e-1)" "unprognostic (9.80e-2)" "unprognostic (1.40e-1)" "unprognostic (3.25e-2)" "unprognostic (2.05e-1)" "unprognostic (1.51e-1)" "unprognostic (2.95e-1)" "unprognostic (4.77e-1)" "unprognostic (9.44e-2)" "unprognostic (2.93e-2)" 80.9 49.3 26.1 40.0 34.5 49.3 46.5 31.1 36.2 52.4 43.3 35.1 21.3 29.5 56.4 25.9 53.5 56.3 42.6 47.6 30.8 24.5 55.6 77.9 45.3 40.4 41.4 29.0 60.1 30.9 68.7 60.2 79.9 37.9 30.0 29.2 30.8 37.4 26.5 63.4 42.2 54.0 57.2 53.9 46.1 43.0 27.0 39.0 49.2 45.6 44.0 42.6 55.8 50.2 13.1 20.5 32.0 21.6 17.3 21.5 17.9 45.4 50.5 47.2 25.9 55.6 47.2 28.8 33.1 46.6 34.0 27.4 51.9 30.6 0.5 23.7 37.1 30.7 57.7 46.6 56.7 26.9 45.0 28.9 50.3 31.2 28.9 54.1 52.0 34.1 33.1 57.3 55.4 53.3 53.0 28.6 31.6 34.4 34.1 16.9 45.4 20.4 40.0 50.3 37.0 32.0 61.2 32.3 48.9 75.0 38.5 39.7 34.6 36.8 48.1 35.1 37.6 37.5 39.3 33.4 39.6 44.9 35.4 32.8 33.2 22.5 20.2 17.5 14.8 21.1 21.5 13.1 14.5 16.3 20.5 9.0 16.3 15.1 32.0 17.3 21.6 6.9 14.3 17.9 26.1 34.5 31.1 36.2 30.8 24.5 41.4 29.0 37.9 39.0 DDX3Y DBY ENSG00000067048 "DEAD-box helicase 3, Y-linked" O15523 Y 12904108-12920478 "Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "DNA-binding, Helicase, Hydrolase, RNA-binding" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "Daudi: 40.6;HEL: 41.4;U-266/84: 34.4;U-698: 30.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001648, HPA005631, HPA059583" Enhanced Supported Supported Nucleoplasm,Cytosol Cytosol Nucleoplasm "HPA001648: AB_1078635, HPA005631: AB_1078633, HPA059583: " "unprognostic (3.89e-2)" "unprognostic (1.70e-1)" "prognostic favourable (4.70e-5)" "unprognostic (6.50e-2)" "unprognostic (4.74e-2)" "unprognostic (2.22e-2)" "unprognostic (4.17e-2)" "unprognostic (3.37e-2)" "unprognostic (9.61e-2)" "unprognostic (2.58e-3)" "unprognostic (1.74e-1)" "unprognostic (2.66e-2)" "unprognostic (7.87e-2)" 12.0 10.5 4.9 29.5 14.1 46.1 8.7 17.0 16.3 0.4 24.4 12.6 31.5 7.6 0.4 29.7 12.2 0.4 14.2 10.8 5.6 7.1 8.9 26.5 20.0 17.7 5.7 0.0 0.4 14.5 0.4 12.2 14.0 20.2 26.7 15.8 15.1 20.4 32.6 17.7 8.4 16.0 40.7 6.2 34.3 8.9 41.9 0.0 26.9 10.8 21.4 19.3 14.4 0.0 6.1 8.8 6.5 7.1 6.5 8.4 3.8 0.1 7.5 0.0 0.0 0.0 0.0 5.5 18.6 13.3 9.8 12.1 0.0 0.0 40.6 0.0 18.3 0.0 0.0 0.0 17.3 10.2 0.0 41.4 0.0 12.2 9.7 0.0 0.0 10.3 11.6 0.0 0.0 0.0 0.0 0.0 11.6 0.0 16.0 0.0 7.4 0.0 0.0 4.9 7.4 10.5 11.2 12.2 0.0 0.0 0.0 13.6 0.0 9.7 13.3 15.3 0.0 0.0 12.2 21.9 34.4 30.2 1.8 0.0 0.0 1.6 6.2 5.7 8.4 7.1 7.7 6.1 6.4 7.1 8.8 5.9 7.8 6.5 6.5 6.5 4.6 2.5 5.7 3.8 4.9 14.1 17.0 16.3 5.6 7.1 5.7 0.0 20.2 0.0 DENND3 KIAA0870 ENSG00000105339 "DENN domain containing 3" A2RUS2 8 141117278-141195808 "Predicted intracellular proteins, Predicted membrane proteins" "Guanine-nucleotide releasing factor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 75.9" "Cell line enhanced" "Detected in many" "HDLM-2: 26.8;HeLa: 33.1;U-937: 24.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "eosinophil: 18.0;neutrophil: 22.2" "Lineage enriched" "Detected in many" 4 "granulocytes: 22.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA024491, HPA041668" Approved Approved Vesicles,Cytosol "Vesicles, Cytosol" "HPA024491: , HPA041668: " "unprognostic (2.27e-1)" "unprognostic (9.62e-2)" "unprognostic (9.47e-3)" "unprognostic (1.66e-1)" "unprognostic (6.96e-2)" "unprognostic (1.13e-1)" "unprognostic (1.53e-1)" "unprognostic (2.05e-1)" "unprognostic (1.55e-1)" "unprognostic (7.07e-3)" "unprognostic (2.71e-2)" "unprognostic (2.25e-2)" "unprognostic (7.74e-2)" "unprognostic (1.95e-1)" "unprognostic (2.02e-1)" "unprognostic (4.51e-2)" "unprognostic (5.42e-2)" 21.8 6.2 12.2 21.7 15.2 75.9 17.6 1.7 12.3 10.4 17.0 11.5 2.3 5.5 10.3 6.1 6.8 8.3 12.0 8.8 12.1 8.5 12.2 3.9 30.1 27.8 15.9 7.7 8.9 4.7 4.5 5.8 13.0 13.7 9.0 7.4 7.1 10.2 8.3 12.9 8.3 12.7 7.8 21.9 24.7 9.1 4.6 11.8 3.4 11.4 3.5 20.6 9.5 9.8 2.4 2.2 22.2 5.4 1.4 0.4 1.6 6.8 6.2 0.4 1.3 1.9 2.8 1.0 3.9 11.5 1.6 1.3 1.9 6.4 1.8 10.2 7.3 3.5 1.7 4.2 1.1 26.8 1.6 7.1 33.1 0.6 1.7 7.0 1.1 0.2 2.1 1.8 2.3 9.0 0.0 17.3 1.2 2.1 1.0 9.8 0.4 8.1 1.2 0.3 6.7 6.4 2.3 2.0 1.2 0.7 0.5 0.4 2.8 11.3 7.1 0.3 3.1 4.5 0.1 3.5 15.4 0.5 1.1 24.3 0.4 9.3 2.9 18.0 0.4 4.5 0.4 2.4 0.3 0.1 2.2 2.3 0.0 0.1 22.2 1.4 5.4 0.0 0.1 1.6 12.2 15.2 1.7 12.3 12.1 8.5 15.9 7.7 13.7 11.8 DGKB "DAGK2, DGK, DGK-BETA, KIAA0718" ENSG00000136267 "Diacylglycerol kinase beta" Q9Y6T7 7 14145049-14974777 "Enzymes, Plasma proteins, Predicted intracellular proteins" "Kinase, Transferase" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 37.7" "Cell line enhanced" "Detected in some" "AF22: 2.7;fHDF/TERT166: 5.5;hTEC/SVTERT24-B: 2.1;SCLC-21H: 2.8;SH-SY5Y: 2.1;U-266/70: 7.4" "Cancer enriched" "Detected in single" 11 "glioma: 1.7" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA020321 Supported "HPA020321: " "unprognostic (9.89e-2)" "unprognostic (9.72e-5)" "unprognostic (1.45e-1)" "unprognostic (2.88e-3)" "unprognostic (4.32e-2)" "unprognostic (3.37e-1)" "unprognostic (7.34e-2)" "unprognostic (5.91e-2)" "unprognostic (6.19e-2)" "unprognostic (8.87e-2)" "unprognostic (2.72e-2)" "unprognostic (1.18e-1)" "unprognostic (5.98e-2)" "unprognostic (2.37e-3)" "unprognostic (6.13e-2)" "unprognostic (1.33e-1)" "unprognostic (1.11e-4)" 1.1 5.2 11.5 1.1 37.7 0.8 0.8 1.3 34.0 4.9 1.6 1.4 0.0 0.9 6.1 0.9 1.6 2.7 1.3 1.4 10.5 4.3 2.6 1.1 0.8 0.8 2.2 11.3 0.8 0.9 0.8 1.8 0.7 4.8 1.1 1.7 0.0 0.9 0.9 1.2 0.9 1.2 3.1 3.5 0.8 0.8 0.9 7.9 0.0 0.9 0.0 0.8 1.5 0.6 0.7 0.6 1.3 0.3 0.6 0.5 0.1 0.1 0.0 2.7 0.1 0.0 0.2 0.1 0.0 1.2 0.0 0.3 0.2 0.0 0.1 0.0 5.5 0.2 0.0 0.0 0.2 0.0 0.0 0.3 0.3 0.1 0.0 0.1 0.1 0.0 0.0 2.1 0.0 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.6 0.0 0.1 0.0 0.4 0.0 0.0 2.8 2.1 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.9 0.0 0.0 7.4 0.0 0.0 0.1 0.1 0.1 0.7 0.3 0.3 0.5 0.2 0.4 0.3 0.5 0.2 0.1 0.7 0.5 0.4 1.3 0.6 0.2 0.6 0.2 0.1 11.5 37.7 1.3 19.1 10.5 4.3 2.2 11.3 4.8 7.9 DNAJC30 WBSCR18 ENSG00000176410 "DnaJ heat shock protein family (Hsp40) member C30" Q96LL9 7 73680969-73683453 "Predicted membrane proteins" "ATP synthesis" Chaperone "Williams-Beuren syndrome" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA017318 Uncertain Supported "HPA017318: AB_1858788" "unprognostic (1.86e-2)" "unprognostic (1.85e-1)" "unprognostic (2.16e-1)" "unprognostic (2.66e-1)" "prognostic unfavourable (1.12e-4)" "unprognostic (5.37e-2)" "unprognostic (1.50e-1)" "unprognostic (2.66e-2)" "unprognostic (4.53e-1)" "unprognostic (3.93e-2)" "unprognostic (2.85e-3)" "unprognostic (4.60e-2)" "prognostic favourable (4.91e-8)" "unprognostic (1.19e-1)" "unprognostic (1.82e-1)" "unprognostic (2.51e-1)" "unprognostic (1.20e-2)" 13.3 20.6 14.7 8.3 15.8 6.4 8.9 8.5 23.4 10.2 8.9 11.1 11.7 9.2 10.2 15.3 7.4 12.0 14.8 18.6 13.4 14.2 14.7 22.1 8.2 9.5 11.8 14.1 14.9 12.2 11.1 14.5 10.3 15.0 12.6 8.2 10.6 14.3 12.3 12.9 7.2 9.2 7.5 7.9 10.0 10.3 24.4 7.3 12.7 16.5 9.7 8.1 9.4 6.0 12.5 7.5 4.6 7.3 6.7 11.9 5.7 6.1 6.1 4.5 9.0 7.1 5.0 4.8 9.7 7.2 7.5 7.4 5.8 6.4 5.4 2.5 7.6 8.7 4.0 5.4 4.3 6.3 8.2 3.2 5.7 6.1 7.4 5.3 4.5 5.6 4.5 6.9 5.9 6.5 6.4 5.0 7.4 12.3 8.5 10.7 3.8 10.5 5.8 3.5 13.2 9.7 7.2 12.2 6.5 9.8 17.4 7.0 15.8 3.5 6.3 8.0 5.8 8.3 6.9 5.3 3.6 5.2 6.4 3.7 9.8 4.6 7.3 4.6 8.1 6.7 10.0 9.0 9.8 9.7 7.3 12.5 11.9 9.9 1.0 6.7 5.1 7.5 6.7 5.7 14.7 15.8 8.5 23.4 13.4 14.2 11.8 14.1 15.0 7.3 DPP6 "DPL1, DPPX" ENSG00000130226 "Dipeptidyl peptidase like 6" P42658 7 153887097-154894285 "Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters" "Disease mutation, Mental retardation, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 45.7;endometrium 1: 24.5;thyroid gland: 24.1" "Cell line enriched" "Detected in some" 9 "NTERA-2: 11.0" "Cancer enriched" "Detected in some" 11 "glioma: 12.1" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA050509 Enhanced Supported "HPA050509: " "unprognostic (1.29e-1)" "unprognostic (3.55e-2)" "unprognostic (5.68e-2)" "unprognostic (5.86e-2)" "unprognostic (1.53e-2)" "unprognostic (2.28e-1)" "unprognostic (2.73e-1)" "unprognostic (5.83e-4)" "unprognostic (1.55e-1)" "unprognostic (2.98e-1)" "unprognostic (7.45e-3)" "unprognostic (4.04e-3)" "unprognostic (2.94e-3)" "unprognostic (1.85e-4)" "unprognostic (1.05e-1)" "unprognostic (4.61e-3)" "unprognostic (6.11e-2)" 1.6 7.2 15.4 1.4 32.5 1.3 1.5 26.6 45.7 2.3 6.8 8.7 0.0 1.6 24.5 3.1 1.5 4.6 1.3 1.4 26.6 15.2 3.6 1.2 2.2 1.3 14.0 22.7 1.3 4.0 1.2 4.9 1.3 18.8 1.5 2.4 0.4 1.3 8.1 4.6 3.7 2.0 15.8 7.2 4.2 3.5 7.9 10.0 0.0 24.1 0.0 1.2 1.3 0.4 0.6 0.6 1.9 0.9 0.9 0.7 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.3 0.2 11.0 0.0 0.0 0.0 0.1 0.0 0.0 0.5 1.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.1 1.9 0.4 0.7 0.4 0.6 0.7 0.6 0.6 0.4 0.4 0.6 0.7 0.7 1.6 0.9 0.9 0.6 0.5 0.3 15.4 32.5 26.6 32.4 26.6 15.2 14.0 22.7 18.8 10.0 DRD1 ENSG00000184845 "Dopamine receptor D1" P21728 5 175440039-175444208 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 12 "brain: 34.5" "Cell line enriched" "Detected in some" 5 "RT4: 23.6" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in many" 5 "basal ganglia: 34.5" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in many" 9 "basal ganglia: 147.4" "Region enriched" "Detected in many" 13 "basal ganglia: 95.6" HPA013393 Supported "HPA013393: AB_1847833" "unprognostic (2.74e-2)" "unprognostic (6.36e-3)" "unprognostic (2.02e-1)" "unprognostic (1.07e-1)" "unprognostic (7.63e-3)" "unprognostic (1.28e-1)" "unprognostic (1.15e-6)" "unprognostic (6.69e-2)" "unprognostic (1.05e-1)" "unprognostic (1.24e-1)" "unprognostic (1.49e-1)" "unprognostic (2.74e-2)" "unprognostic (8.60e-4)" "unprognostic (5.86e-2)" "unprognostic (5.43e-1)" "unprognostic (6.00e-3)" "unprognostic (1.10e-2)" 0.7 1.5 1.9 0.2 34.5 0.0 0.1 0.1 12.0 0.7 0.7 0.4 0.0 0.5 0.4 0.7 0.7 0.6 1.1 0.3 1.0 0.6 0.7 2.6 1.8 0.1 0.5 1.6 0.3 0.0 0.0 0.1 2.5 0.3 2.7 0.9 2.1 0.1 1.2 0.1 0.1 0.3 0.4 0.1 0.4 0.4 0.1 6.8 0.1 0.1 0.0 0.4 1.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.6 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 34.5 0.1 5.3 1.0 0.6 0.5 1.6 0.3 6.8 DRD2 ENSG00000149295 "Dopamine receptor D2" P14416 11 113409615-113475691 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "adrenal gland: 17.3;brain: 52.0;pituitary gland: 51.6" "Cell line enriched" "Detected in some" 9 "SCLC-21H: 44.2" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in many" 5 "basal ganglia: 52.0" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in many" 10 "basal ganglia: 183.8" "Group enriched" "Detected in many" 9 "basal ganglia: 126.7;midbrain: 41.7" "HPA015139, HPA015691" Supported Supported "HPA015139: , HPA015691: AB_1847834" "unprognostic (8.49e-2)" "unprognostic (2.11e-1)" "unprognostic (1.69e-1)" "unprognostic (1.29e-4)" "unprognostic (2.32e-2)" "unprognostic (1.15e-1)" "unprognostic (1.97e-2)" "unprognostic (5.89e-2)" "unprognostic (4.40e-2)" "unprognostic (8.33e-4)" "unprognostic (1.10e-1)" "unprognostic (6.65e-3)" "unprognostic (2.29e-1)" "unprognostic (1.71e-1)" "unprognostic (4.82e-2)" "unprognostic (8.49e-3)" 0.6 17.3 0.9 0.5 52.0 0.2 2.1 0.2 3.3 1.3 0.6 1.5 0.0 0.3 2.3 0.4 0.9 2.1 0.6 0.5 0.3 4.1 0.3 0.2 0.6 0.2 9.9 0.2 0.3 0.4 0.3 51.6 0.2 2.4 1.5 0.9 3.9 5.1 1.7 1.7 0.3 0.5 3.2 0.2 0.2 0.5 1.6 9.5 0.0 0.2 0.0 0.3 0.3 0.3 0.0 0.0 0.2 0.0 0.0 0.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 5.0 0.0 0.8 0.0 0.5 0.0 0.0 0.0 1.5 0.2 0.0 0.0 0.5 0.0 0.0 4.7 0.0 0.0 0.0 44.2 5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.6 0.0 0.9 52.0 0.2 3.3 0.3 4.1 9.9 0.2 2.4 9.5 ECEL1 "DINE, XCE" ENSG00000171551 "Endothelin converting enzyme like 1" O95672 2 232479827-232487828 "Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Metalloprotease, Protease" "Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 28.6;ovary: 57.1" "Group enriched" "Detected in some" 6 "AN3-CA: 29.4;HeLa: 15.0" "Cancer enhanced" "Detected in many" "endometrial cancer: 12.9" "Region enriched" "Detected in many" 5 "hypothalamus: 28.6" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA067560, HPA069756, HPA077424" Approved Supported Approved "Nucleoplasm,Nuclear membrane,Nucleoli" Nucleoplasm "Nuclear membrane, Nucleoli" "HPA067560: , HPA069756: , HPA077424: " "unprognostic (1.21e-2)" "unprognostic (1.06e-2)" "unprognostic (4.39e-1)" "unprognostic (4.62e-3)" "unprognostic (2.80e-1)" "unprognostic (9.96e-4)" "unprognostic (7.56e-3)" "unprognostic (1.22e-1)" "unprognostic (9.89e-3)" "unprognostic (8.49e-2)" "unprognostic (1.54e-1)" "unprognostic (2.89e-1)" "unprognostic (1.24e-5)" "unprognostic (3.09e-2)" "unprognostic (3.68e-1)" "unprognostic (7.84e-2)" "unprognostic (5.45e-2)" 0.9 2.6 0.5 0.9 4.0 0.2 0.4 0.7 1.2 0.3 0.4 0.5 0.1 0.3 0.6 4.9 0.3 1.7 1.0 1.1 0.1 28.6 1.0 0.7 0.2 1.2 0.3 0.1 57.1 0.6 0.3 8.9 0.4 5.5 0.3 0.2 11.5 0.3 1.2 1.8 0.3 0.3 1.1 4.5 2.0 0.3 0.8 1.6 0.1 0.5 0.3 0.5 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 29.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.4 0.3 0.0 0.0 0.4 0.0 0.0 0.0 2.6 0.0 15.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 4.0 0.7 1.2 0.1 28.6 0.3 0.1 5.5 1.6 ECH1 HPXEL ENSG00000104823 "Enoyl-CoA hydratase 1" Q13011 19 38815422-38832005 "Predicted intracellular proteins" "Fatty acid metabolism, Lipid metabolism" Isomerase "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002907, HPA005835" Supported Supported Enhanced Mitochondria 5700000 Mitochondria "HPA002907: AB_1847964, HPA005835: AB_1847965" "unprognostic (1.91e-1)" "unprognostic (3.03e-2)" "unprognostic (3.64e-2)" "unprognostic (6.43e-2)" "unprognostic (5.73e-3)" "unprognostic (6.90e-2)" "unprognostic (1.28e-1)" "unprognostic (1.79e-1)" "unprognostic (2.43e-1)" "unprognostic (5.86e-2)" "unprognostic (2.24e-1)" "unprognostic (3.37e-1)" "unprognostic (7.01e-2)" "prognostic unfavourable (2.23e-4)" "unprognostic (3.54e-1)" "unprognostic (3.52e-1)" "unprognostic (1.74e-2)" 33.0 52.0 17.6 21.7 20.9 14.7 29.6 11.4 19.8 14.8 34.1 19.5 19.8 25.8 16.8 15.4 30.2 18.9 30.6 130.6 18.6 15.5 40.0 105.8 16.9 19.6 22.2 17.2 16.0 36.5 11.5 11.3 32.8 17.5 20.9 27.1 20.8 27.4 15.2 130.9 18.7 24.4 27.0 13.3 28.1 24.8 26.2 20.6 15.9 24.5 43.5 21.5 21.3 19.3 68.7 60.7 49.9 61.1 61.4 72.6 83.3 12.8 56.5 8.8 14.5 34.2 17.8 12.8 6.3 11.1 5.6 5.7 36.2 25.5 20.1 24.9 15.0 6.1 14.6 15.1 4.4 69.6 8.1 24.3 17.2 29.2 34.8 25.8 24.7 23.6 39.2 7.3 12.7 13.2 11.5 33.6 12.3 24.1 17.9 14.9 5.8 13.7 20.4 26.4 40.0 35.3 29.3 11.0 14.1 33.2 16.5 17.5 22.2 58.0 11.1 9.9 8.5 9.7 5.9 25.5 29.5 19.2 15.0 33.3 18.9 49.1 61.1 49.9 51.9 46.8 48.9 68.7 50.9 51.2 60.7 62.2 45.7 51.4 8.1 61.4 38.3 41.4 72.6 83.3 17.6 20.9 11.4 19.8 18.6 15.5 22.2 17.2 17.5 20.6 EFCAB12 C3orf25 ENSG00000172771 "EF-hand calcium binding domain 12" Q6NXP0 3 129401321-129428651 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 24.4;fallopian tube: 29.9;testis: 24.8" "Cell line enhanced" "Detected in some" "Hep G2: 4.6;RPTEC TERT1: 3.7;SCLC-21H: 2.9" "Low cancer specificity" "Detected in some" "Group enriched" "Detected in many" 4 "basal ganglia: 14.9;pons and medulla: 24.4" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Region enhanced" "Detected in many" "midbrain: 14.2" "HPA037694, HPA057532" Uncertain Supported Approved "Nucleoplasm,Nuclear bodies,Midbody ring" Nucleoplasm "Nuclear bodies, Midbody ring" "HPA037694: AB_10672605, HPA057532: " "unprognostic (2.06e-3)" "unprognostic (1.87e-2)" "unprognostic (2.96e-2)" "unprognostic (4.34e-3)" "unprognostic (1.81e-1)" "unprognostic (7.59e-4)" "unprognostic (2.37e-2)" "unprognostic (2.60e-1)" "unprognostic (1.13e-1)" "unprognostic (1.64e-1)" "unprognostic (1.81e-2)" "unprognostic (3.84e-1)" "unprognostic (1.20e-1)" "unprognostic (5.72e-2)" "unprognostic (2.27e-1)" "unprognostic (1.57e-2)" "unprognostic (4.59e-2)" 0.7 0.6 2.2 0.7 14.9 1.5 0.9 1.7 3.0 2.0 0.6 7.8 0.0 0.5 1.8 10.1 0.6 29.9 1.5 0.7 4.2 4.3 1.2 2.1 3.6 0.8 0.5 3.5 6.1 1.0 3.1 15.2 0.7 24.4 4.1 0.6 1.5 0.6 0.9 0.5 0.5 0.5 0.6 1.0 0.7 1.0 24.8 1.6 0.0 2.4 0.0 0.9 0.5 0.1 1.4 0.0 1.3 0.4 0.3 0.6 0.0 0.4 2.2 0.7 2.2 0.4 0.1 0.4 0.0 0.2 0.3 0.1 0.8 1.2 0.4 0.4 0.0 0.3 0.0 0.4 0.3 0.6 0.5 0.5 0.6 4.6 0.3 0.3 0.9 0.5 0.0 0.5 0.0 0.0 1.3 0.9 0.0 0.3 0.1 1.6 0.3 0.1 0.8 0.0 0.5 3.7 0.0 2.9 0.1 0.0 0.0 0.1 0.8 0.3 0.0 0.0 0.5 1.0 0.2 1.4 1.8 2.1 0.5 0.7 0.2 0.0 0.4 0.8 0.1 0.0 0.3 0.3 0.0 0.6 0.0 1.4 0.3 0.2 1.3 0.3 0.0 0.0 0.2 0.0 2.2 14.9 1.7 3.0 4.2 4.3 0.5 3.5 24.4 1.6 EFHC2 "FLJ22843, MRX74" ENSG00000183690 "EF-hand domain containing 2" Q5JST6 X 44147882-44343672 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 20.6;fallopian tube: 20.8" "Cell line enhanced" "Detected in some" "CAPAN-2: 5.1;HEL: 5.3;HMC-1: 17.6" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in all" "pons and medulla: 20.6" "Group enriched" "Detected in some" 5 "basophil: 14.1;NK-cell: 6.6" "Group enriched" "Detected in many" 5 "granulocytes: 14.1;NK-cells: 6.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA034492, HPA057359" Approved Supported Approved "Nucleoplasm,Nucleoli fibrillar center,Plasma membrane" "Nucleoplasm, Nucleoli fibrillar center" "Plasma membrane" "HPA034492: AB_10671227, HPA057359: " "unprognostic (1.93e-1)" "unprognostic (7.80e-3)" "unprognostic (7.35e-2)" "unprognostic (2.75e-1)" "unprognostic (6.83e-3)" "unprognostic (5.07e-2)" "unprognostic (4.29e-2)" "unprognostic (1.75e-2)" "unprognostic (3.50e-2)" "unprognostic (2.90e-2)" "unprognostic (3.88e-2)" "unprognostic (1.86e-2)" "unprognostic (7.89e-2)" "unprognostic (1.06e-1)" "unprognostic (6.13e-4)" "unprognostic (1.64e-3)" "unprognostic (4.97e-2)" 0.7 0.6 4.0 0.8 6.2 1.9 1.2 1.6 3.1 4.6 1.6 6.5 3.7 0.6 5.4 12.6 2.9 20.8 3.0 6.0 4.8 3.9 2.0 0.1 4.5 0.5 1.5 2.0 5.2 0.3 0.9 6.9 1.3 20.6 2.9 0.6 0.6 9.6 5.8 0.1 4.7 0.8 2.6 1.4 0.6 1.6 10.1 3.1 0.4 3.7 1.4 0.9 1.7 1.4 0.1 0.4 14.1 0.0 6.6 2.1 1.4 0.0 0.8 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 5.1 0.0 0.1 0.0 0.0 0.4 0.0 0.1 0.0 0.1 5.3 0.0 0.0 0.0 0.0 17.6 0.3 0.3 0.3 0.0 0.0 1.4 0.0 0.0 0.0 0.0 2.3 0.6 0.1 0.3 0.0 0.0 1.4 0.0 0.3 0.5 0.0 0.0 0.0 0.9 0.0 0.1 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0 14.1 0.0 0.0 2.1 0.0 0.8 0.1 0.8 0.1 0.4 0.1 0.7 1.0 1.9 6.6 0.0 0.0 0.0 1.4 4.0 6.2 1.6 3.1 4.8 3.9 1.5 2.0 20.6 3.1 EIF1AX "eIF-1A, eIF-4C, EIF1A, EIF4C" ENSG00000173674 "Eukaryotic translation initiation factor 1A, X-linked" P47813 X 20124518-20141844 "Predicted intracellular proteins" "Protein biosynthesis" "Initiation factor, RNA-binding" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA002561 Uncertain Supported Approved Cytosol Cytosol "HPA002561: AB_1078724" "unprognostic (1.91e-1)" "unprognostic (1.38e-1)" "unprognostic (1.04e-2)" "unprognostic (9.69e-2)" "unprognostic (1.43e-2)" "unprognostic (1.26e-3)" "unprognostic (7.13e-3)" "unprognostic (2.22e-1)" "unprognostic (8.28e-2)" "unprognostic (1.02e-3)" "unprognostic (2.82e-2)" "unprognostic (4.73e-2)" "unprognostic (8.66e-2)" "unprognostic (2.23e-3)" "unprognostic (7.81e-2)" "unprognostic (1.61e-1)" "unprognostic (1.52e-1)" 30.9 23.2 22.0 23.7 28.8 28.3 53.4 35.4 57.3 26.1 23.6 14.5 23.9 22.7 33.8 18.7 32.6 24.7 18.4 29.2 21.4 19.5 31.0 32.0 22.1 20.9 23.5 23.5 37.0 33.0 28.7 19.8 24.7 29.0 19.5 16.9 12.0 25.2 25.0 61.5 22.5 18.9 32.5 34.1 16.5 22.7 18.0 23.7 14.8 25.7 24.6 17.2 29.3 33.9 31.1 30.2 12.6 19.9 27.2 30.9 23.8 45.8 25.9 20.0 26.6 19.5 26.6 16.3 41.0 15.1 22.4 17.7 37.2 22.0 42.9 27.5 27.1 19.7 35.2 35.6 35.1 17.5 58.1 19.0 32.6 31.7 13.6 50.5 26.8 12.4 21.8 34.6 54.4 31.2 49.1 24.1 22.0 22.4 31.1 31.7 51.9 43.1 25.6 45.9 45.9 17.6 25.6 23.2 26.0 43.5 34.0 26.9 27.6 21.5 17.8 27.3 17.0 88.9 30.6 16.5 31.2 50.9 18.6 23.2 20.6 12.6 19.1 11.5 23.1 19.9 30.2 31.1 26.5 27.1 18.3 27.7 30.9 25.8 4.7 27.2 19.2 30.2 20.3 23.8 22.0 28.8 35.4 57.3 21.4 19.5 23.5 23.5 29.0 23.7 EIF1AY ENSG00000198692 "Eukaryotic translation initiation factor 1A, Y-linked" O14602 Y 20575725-20593154 "Predicted intracellular proteins" "Protein biosynthesis" "Initiation factor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 78.3;skeletal muscle: 124.6" "Cell line enhanced" "Detected in many" "Daudi: 37.3;HEL: 45.7;U-266/84: 32.3;U-698: 73.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" HPA002561 Uncertain Supported Approved Cytosol Cytosol "HPA002561: AB_1078724" "unprognostic (4.31e-2)" "unprognostic (3.74e-1)" "unprognostic (2.14e-3)" "unprognostic (2.68e-2)" "unprognostic (1.12e-2)" "unprognostic (2.89e-2)" "unprognostic (4.18e-2)" "unprognostic (2.17e-2)" "unprognostic (4.10e-2)" "unprognostic (8.53e-3)" "unprognostic (2.89e-1)" "unprognostic (6.03e-2)" 5.9 8.3 7.0 18.6 8.3 29.2 5.0 4.5 10.9 0.0 12.6 10.0 22.2 9.0 0.1 20.2 9.9 0.0 10.5 78.3 6.5 10.4 9.1 23.0 13.3 22.8 8.2 0.0 0.1 15.0 0.2 11.4 10.3 13.4 17.4 16.1 8.8 13.1 22.9 124.6 4.2 17.9 28.2 9.2 45.8 6.5 13.1 0.0 28.7 6.2 48.9 15.9 8.9 0.0 22.1 23.0 44.5 8.0 7.8 11.9 5.0 0.1 5.4 0.0 0.0 0.0 0.0 11.3 12.1 8.1 8.4 8.3 0.0 0.0 37.3 0.0 6.4 0.0 0.0 0.0 11.6 20.1 0.0 45.7 0.0 13.6 8.4 0.0 0.0 4.5 9.3 0.0 0.0 0.0 0.0 0.0 13.5 0.0 29.4 0.0 8.1 0.0 0.0 15.3 14.8 11.8 14.1 10.8 0.0 0.0 0.0 8.3 0.0 6.4 12.0 6.5 0.1 0.0 13.1 22.5 32.3 73.3 2.5 0.0 0.0 10.0 6.7 9.3 5.2 7.7 7.3 19.2 9.5 6.1 5.7 22.1 11.9 9.0 44.5 7.8 8.0 23.0 10.9 5.0 7.0 8.3 4.5 10.9 6.5 10.4 8.2 0.0 13.4 0.0 EMX2 ENSG00000170370 "Empty spiracles homeobox 2" Q04743 10 117542444-117549546 "Disease related genes, Predicted intracellular proteins, Transcription factors" "Developmental protein, DNA-binding" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ductus deferens: 46.8;epididymis: 53.9;seminal vesicle: 76.3" "Cell line enhanced" "Detected in some" "EFO-21: 16.8;fHDF/TERT166: 18.6;RPTEC TERT1: 18.7;RT4: 5.9" "Group enriched" "Detected in many" 13 "endometrial cancer: 40.8;ovarian cancer: 52.8;renal cancer: 18.6" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA003497, HPA065294" Enhanced Supported Approved Nucleoplasm Nucleoplasm "HPA003497: , HPA065294: " "unprognostic (1.53e-1)" "prognostic favourable (2.80e-4)" "unprognostic (7.21e-3)" "unprognostic (5.41e-3)" "unprognostic (1.69e-1)" "unprognostic (3.53e-2)" "unprognostic (1.34e-1)" "unprognostic (2.41e-1)" "unprognostic (7.33e-2)" "unprognostic (1.76e-1)" "unprognostic (2.77e-1)" "prognostic favourable (2.28e-13)" "unprognostic (3.65e-2)" "unprognostic (1.05e-1)" "unprognostic (4.17e-2)" "unprognostic (1.88e-2)" 4.6 0.5 11.5 0.6 10.3 0.5 1.4 0.5 12.5 23.5 0.7 7.3 46.8 0.5 40.5 53.9 0.7 25.4 1.2 0.6 14.7 2.1 25.5 0.5 0.5 0.7 1.8 10.4 5.7 0.5 0.6 1.1 0.6 2.5 1.9 0.5 3.4 1.3 76.3 5.1 4.7 0.5 22.6 0.6 0.5 0.5 3.6 6.2 0.0 0.5 1.2 0.7 4.2 2.4 0.7 0.5 2.4 0.9 1.0 0.7 0.1 0.0 0.0 0.0 1.8 0.0 0.2 0.1 1.3 0.0 0.0 0.0 0.0 0.0 0.0 16.8 18.6 0.1 0.4 0.0 0.0 0.0 1.8 0.5 0.1 0.1 0.0 0.1 0.1 3.6 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 3.9 0.1 18.7 5.9 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.1 1.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.5 0.6 0.5 0.6 0.7 0.4 0.4 0.4 0.4 0.7 0.6 0.5 1.1 1.0 0.9 0.5 0.6 0.1 11.5 10.3 0.5 12.5 14.7 2.1 1.8 10.4 2.5 6.2 ENO2 ENSG00000111674 "Enolase 2" P09104 12 6913745-6923698 "Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins" Glycolysis Lyase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 119.2" "Cell line enhanced" "Detected in many" "U-87 MG: 81.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "gdT-cell: 8.2;MAIT T-cell: 9.7;memory B-cell: 5.6;memory CD4 T-cell: 10.8;memory CD8 T-cell: 9.6;naive B-cell: 3.3;naive CD4 T-cell: 7.1;naive CD8 T-cell: 7.4;neutrophil: 6.2;T-reg: 5.5" "Group enriched" "Detected in many" 7 "B-cells: 5.6;granulocytes: 6.2;T-cells: 10.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000063, HPA068284, HPA068721, CAB073539, CAB079023" Enhanced Supported Supported "Plasma membrane,Cytosol" 89000000 "Plasma membrane, Cytosol" "CAB000063: AB_2099322, CAB073539: , CAB079023: , HPA068284: , HPA068721: " "unprognostic (8.96e-2)" "unprognostic (8.28e-2)" "prognostic unfavourable (6.96e-4)" "unprognostic (1.28e-1)" "unprognostic (7.95e-3)" "unprognostic (1.39e-2)" "prognostic unfavourable (5.15e-4)" "unprognostic (1.48e-1)" "unprognostic (9.43e-2)" "unprognostic (1.58e-1)" "unprognostic (1.98e-1)" "unprognostic (2.02e-2)" "prognostic unfavourable (7.89e-11)" "unprognostic (7.61e-2)" "unprognostic (3.06e-1)" "unprognostic (8.10e-3)" "unprognostic (1.24e-1)" 4.2 20.7 31.2 8.3 48.0 4.0 4.9 115.2 119.2 7.6 7.9 10.9 2.6 4.9 11.7 6.3 5.9 9.4 8.0 10.3 30.2 39.2 3.5 2.0 10.1 10.5 29.6 47.4 3.7 4.1 19.1 15.5 4.8 47.7 8.0 7.4 28.6 3.1 15.3 2.1 5.8 6.0 15.2 15.7 5.8 6.4 3.2 13.3 1.7 14.2 0.3 10.3 7.1 5.0 5.6 1.0 6.2 0.2 0.4 10.8 4.5 14.0 8.9 3.2 0.1 4.8 5.2 0.2 10.9 7.0 16.2 25.0 1.7 1.1 19.8 1.8 4.7 2.1 33.7 3.0 24.6 39.6 3.1 27.3 9.1 11.8 3.5 1.6 32.9 2.6 0.1 11.9 2.4 3.4 1.8 0.2 10.8 1.9 12.8 1.7 17.1 5.0 14.2 2.7 4.3 7.9 1.9 25.9 18.2 2.8 0.2 18.6 0.9 0.8 4.3 14.2 15.0 19.1 14.1 14.5 14.5 2.9 81.3 0.0 2.9 1.3 0.0 0.1 8.2 0.0 9.7 5.6 10.8 9.6 0.0 3.3 7.1 7.4 6.2 0.4 0.2 1.0 5.5 4.5 31.2 48.0 115.2 91.3 30.2 39.2 29.6 47.4 47.7 13.3 ETV1 ER81 ENSG00000006468 "ETS variant 1" P50549 7 13891228-13991425 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 90.0;salivary gland: 45.8" "Cell line enhanced" "Detected in many" "AN3-CA: 22.2;SCLC-21H: 26.3;U-87 MG: 51.9;WM-115: 25.6" "Cancer enhanced" "Detected in all" "glioma: 22.5" "Region enriched" "Detected in all" 8 "cerebellum: 90.0" "Cell type enriched" "Detected in single" 5 "T-reg: 3.1" "Lineage enriched" "Detected in single" 5 "T-cells: 3.1" "Low region specificity" "Detected in all" "Region enhanced" "Detected in all" "cerebellum: 418.9" "HPA068389, HPA077249" Supported Approved Nucleoplasm Nucleoplasm "HPA068389: , HPA077249: " "unprognostic (2.45e-1)" "unprognostic (1.01e-1)" "unprognostic (6.98e-2)" "unprognostic (1.04e-1)" "unprognostic (1.49e-2)" "unprognostic (2.13e-2)" "unprognostic (1.64e-7)" "unprognostic (7.08e-3)" "unprognostic (7.21e-2)" "unprognostic (2.36e-1)" "unprognostic (2.01e-1)" "unprognostic (3.02e-1)" "unprognostic (1.51e-3)" "unprognostic (2.21e-2)" "unprognostic (2.05e-1)" "unprognostic (1.05e-1)" "unprognostic (1.20e-2)" 2.5 12.4 8.1 1.1 11.7 0.2 4.4 90.0 35.2 1.4 2.4 3.1 0.1 1.2 2.4 1.3 1.5 1.1 9.2 18.0 7.0 4.5 2.1 2.0 14.9 0.7 4.5 6.9 1.0 1.6 11.4 7.4 1.9 8.3 3.1 2.4 0.9 45.8 7.1 0.9 1.5 1.9 2.0 3.5 4.5 1.7 4.5 2.9 0.3 6.5 0.9 4.7 1.8 1.3 0.0 0.0 0.0 0.6 0.0 3.1 0.2 0.0 1.6 11.7 22.2 4.1 12.2 0.0 1.0 3.9 0.6 2.6 0.0 5.3 0.0 1.2 1.8 0.1 0.4 1.2 1.4 0.3 0.5 0.6 1.0 0.0 2.4 3.8 1.5 3.6 0.0 7.6 0.6 5.0 3.4 0.1 4.7 0.0 0.0 0.0 17.5 11.8 0.0 7.1 0.9 7.9 0.1 26.3 5.1 0.0 0.4 6.3 0.4 0.1 2.7 2.3 0.7 4.5 4.3 4.0 1.2 0.0 51.9 0.2 25.6 0.0 0.2 0.0 0.1 0.6 0.3 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.1 0.2 8.1 11.7 90.0 10.9 7.0 4.5 4.5 6.9 8.3 2.9 FAM213B "C1orf93, MGC26818" ENSG00000157870 "Family with sequence similarity 213 member B" Q8TBF2 1 2586491-2591469 "Enzymes, Predicted intracellular proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Prostaglandin biosynthesis, Prostaglandin metabolism" Oxidoreductase "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "SK-BR-3: 26.3;U-2197: 22.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006403 Approved Approved "HPA006403: AB_1853870" "unprognostic (1.81e-2)" "unprognostic (2.25e-1)" "unprognostic (2.03e-1)" "unprognostic (2.83e-1)" "unprognostic (1.32e-1)" "unprognostic (1.52e-1)" "prognostic unfavourable (1.62e-4)" "unprognostic (1.20e-1)" "unprognostic (8.76e-2)" "unprognostic (3.09e-2)" "unprognostic (1.24e-3)" "unprognostic (2.76e-1)" "prognostic favourable (1.28e-4)" "unprognostic (5.22e-3)" "unprognostic (2.03e-1)" "unprognostic (7.91e-3)" "unprognostic (2.20e-2)" 6.0 9.1 14.7 5.7 14.9 3.8 4.6 7.4 20.0 7.9 15.4 6.2 5.2 22.0 4.5 6.7 5.7 10.5 23.7 3.2 15.0 15.5 7.4 3.5 6.0 5.8 11.7 11.0 7.1 4.6 4.4 4.3 8.4 10.7 5.7 7.4 9.0 5.3 7.7 1.8 6.1 20.2 4.8 6.5 7.4 11.7 3.3 4.7 5.4 5.2 0.9 5.2 6.3 3.5 2.1 2.2 1.5 2.3 7.5 6.3 3.2 7.6 4.2 4.3 4.8 2.1 2.4 0.6 6.9 2.9 6.5 2.9 3.0 9.0 1.9 7.0 4.4 6.4 3.8 4.8 2.2 5.8 2.0 4.8 3.3 4.8 5.0 2.7 1.3 3.5 2.5 4.5 1.7 9.2 6.4 3.0 6.5 5.5 6.2 1.1 5.2 16.3 6.8 6.4 5.0 6.8 3.9 5.8 9.6 5.9 26.3 7.9 4.6 1.0 13.3 5.7 6.6 22.5 2.6 2.8 4.3 1.4 5.3 9.1 1.1 1.5 2.0 1.1 3.8 2.3 6.3 2.1 4.2 4.1 2.2 1.5 3.5 5.4 1.5 7.5 2.0 1.0 5.6 3.2 14.7 14.9 7.4 20.0 15.0 15.5 11.7 11.0 10.7 4.7 FEV Pet-1 ENSG00000163497 "FEV, ETS transcription factor" Q99581 2 218981087-218985657 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 6.9;intestine: 7.0;pituitary gland: 5.4;stomach 1: 6.1" "Group enriched" "Detected in some" 6 "HMC-1: 18.7;SH-SY5Y: 23.9" "Group enriched" "Detected in some" 10 "pancreatic cancer: 3.0;prostate cancer: 9.9;stomach cancer: 2.4" "Region enhanced" "Detected in many" "pons and medulla: 6.9" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 13 "midbrain: 2.3;pons and medulla: 0.9" "Group enriched" "Detected in some" 34 "midbrain: 7.3;pons and medulla: 3.9" HPA067679 Supported Supported "Nuclear speckles" "Nuclear speckles" "HPA067679: " "unprognostic (4.58e-1)" "unprognostic (1.60e-1)" "unprognostic (7.21e-2)" "prognostic favourable (4.85e-4)" "unprognostic (2.87e-1)" "unprognostic (3.96e-1)" "unprognostic (1.52e-1)" "unprognostic (2.15e-1)" 0.1 4.1 0.0 1.2 3.5 0.0 0.0 0.0 2.6 0.0 2.0 0.7 0.0 7.0 0.1 0.0 0.0 0.1 0.0 0.0 1.1 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 4.2 0.0 5.4 0.0 6.9 4.0 3.2 0.0 0.0 0.0 0.0 0.0 5.4 0.0 0.1 0.0 6.1 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.8 0.0 0.0 0.0 0.0 18.7 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 23.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 2.6 1.1 0.2 0.2 0.0 6.9 1.0 FH fumarase ENSG00000091483 "Fumarate hydratase" P07954 1 241497603-241519761 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair, Tricarboxylic acid cycle" Lyase "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 93.4" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017785, HPA025770, HPA025948, HPA027341" Enhanced Supported Enhanced Mitochondria 2800000 Mitochondria "CAB017785: , HPA025770: AB_10599603, HPA025948: AB_10602177, HPA027341: AB_10601222" "unprognostic (1.03e-2)" "unprognostic (3.82e-2)" "unprognostic (9.46e-3)" "unprognostic (2.18e-1)" "unprognostic (2.10e-1)" "unprognostic (2.07e-1)" "unprognostic (2.28e-2)" "unprognostic (1.55e-1)" "unprognostic (5.14e-2)" "unprognostic (1.85e-2)" "unprognostic (1.27e-2)" "unprognostic (1.09e-1)" "prognostic favourable (2.76e-7)" "unprognostic (1.05e-1)" "unprognostic (1.05e-1)" "unprognostic (4.41e-2)" "unprognostic (1.24e-2)" 14.3 28.1 15.7 10.4 20.2 9.3 13.3 15.7 24.4 10.5 22.7 9.9 16.7 23.2 13.7 10.7 17.7 10.3 9.5 59.0 22.9 13.9 35.0 93.4 9.9 13.3 15.2 19.4 9.4 13.9 25.2 11.4 14.3 18.4 12.3 24.4 10.2 18.4 20.6 65.1 13.4 21.4 14.7 14.4 11.1 17.5 14.0 11.7 13.8 12.3 45.2 13.4 13.4 11.2 16.0 26.4 4.5 18.8 10.4 13.9 8.9 29.2 24.5 23.3 21.0 22.9 27.0 36.9 36.3 28.5 41.0 25.8 35.1 18.3 18.6 24.1 27.8 41.7 35.6 27.0 35.8 21.2 11.5 17.4 26.0 29.9 20.5 40.7 15.9 19.5 16.8 23.0 26.0 25.2 53.0 24.1 29.8 14.6 35.1 27.2 24.7 52.7 29.0 25.5 83.5 39.5 24.9 30.0 25.9 30.6 36.3 23.2 27.6 27.7 24.7 18.4 23.8 32.5 60.5 21.6 23.1 22.6 20.6 46.8 26.4 4.5 12.8 2.7 9.7 18.8 12.6 16.0 11.4 9.0 26.4 14.1 13.9 12.7 0.7 10.4 15.7 13.2 13.2 8.9 15.7 20.2 15.7 24.4 22.9 13.9 15.2 19.4 18.4 11.7 FKBP7 FKBP23 ENSG00000079150 "FK506 binding protein 7" Q9Y680 2 178463664-178478600 "Enzymes, Predicted intracellular proteins" "Isomerase, Rotamase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 51.9;ASC TERT1: 32.2;HSkMC: 21.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA008707 Approved Supported Supported "Endoplasmic reticulum" "Intracellular and membrane" "Endoplasmic reticulum" "HPA008707: AB_1848624" "unprognostic (1.33e-1)" "unprognostic (1.89e-2)" "unprognostic (1.43e-1)" "unprognostic (1.67e-1)" "unprognostic (5.61e-2)" "unprognostic (1.44e-1)" "unprognostic (1.25e-1)" "unprognostic (1.48e-1)" "unprognostic (1.34e-2)" "unprognostic (1.83e-2)" "unprognostic (6.05e-2)" "unprognostic (8.96e-3)" "prognostic unfavourable (4.61e-6)" "unprognostic (3.50e-3)" "unprognostic (1.34e-2)" "unprognostic (4.19e-3)" "unprognostic (1.10e-1)" 9.6 4.6 1.5 4.3 4.1 0.7 11.1 3.5 2.3 20.5 6.9 1.0 10.0 1.8 21.4 21.9 8.4 12.4 12.8 12.1 1.5 1.5 5.5 7.4 6.8 5.2 4.0 1.8 34.6 4.3 1.5 11.1 8.2 2.9 19.5 4.2 7.1 4.9 9.7 4.4 4.0 3.9 19.9 3.9 3.0 5.3 8.3 2.2 2.2 8.7 8.0 2.3 15.5 9.9 2.8 5.8 0.2 1.6 1.2 2.8 0.8 0.0 0.6 6.0 8.9 51.9 32.2 0.5 10.7 17.8 1.9 6.3 0.1 0.6 1.7 2.4 19.5 0.1 2.2 0.9 3.4 1.3 1.2 1.7 2.4 1.7 8.0 1.0 1.2 21.6 0.4 7.9 1.1 6.3 0.7 1.1 8.2 0.1 1.9 1.9 1.2 0.9 2.5 10.5 2.3 2.7 0.2 3.2 10.4 2.3 0.0 1.8 0.1 2.0 5.9 3.7 2.2 4.2 1.0 2.1 2.1 0.8 6.6 2.7 7.9 0.0 1.1 0.1 2.3 1.6 2.8 2.8 2.0 1.6 5.8 1.7 2.2 2.4 0.2 1.2 0.0 4.5 2.2 0.8 1.5 4.1 3.5 2.3 1.5 1.5 4.0 1.8 2.9 2.2 FLNA "ABP-280, FLN, FLN1, OPD1, OPD2" ENSG00000196924 "Filamin A" P21333 X 154348524-154374638 "Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters" "Cilium biogenesis/degradation" Actin-binding "Deafness, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "smooth muscle: 396.7;urinary bladder: 276.1" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000356, HPA000368, HPA001016, HPA001115, HPA002925" Enhanced Approved Enhanced "Plasma membrane,Actin filaments,Cytosol" 2900000000 "Plasma membrane, Actin filaments, Cytosol" "CAB000356: , HPA000368: , HPA001016: , HPA001115: AB_1078871, HPA002925: AB_1078869" "unprognostic (1.39e-1)" "unprognostic (9.40e-3)" "prognostic unfavourable (7.37e-4)" "unprognostic (3.68e-2)" "unprognostic (2.55e-1)" "unprognostic (6.05e-3)" "unprognostic (5.08e-2)" "unprognostic (1.08e-1)" "unprognostic (6.02e-2)" "unprognostic (1.30e-1)" "unprognostic (3.23e-2)" "unprognostic (9.58e-2)" "prognostic unfavourable (1.54e-6)" "unprognostic (5.49e-3)" "unprognostic (1.78e-1)" "unprognostic (1.62e-1)" "prognostic unfavourable (3.88e-4)" 42.8 8.8 2.9 46.4 3.9 22.9 30.7 2.0 5.2 106.5 204.2 6.3 86.0 13.1 158.9 54.4 140.2 79.9 121.0 18.8 3.2 2.2 17.2 5.5 29.1 21.1 3.4 5.9 77.4 7.3 1.6 4.8 20.0 9.4 129.3 13.4 19.0 12.6 98.8 13.7 15.0 50.2 396.7 3.6 25.5 82.7 29.9 2.9 12.1 11.7 16.3 15.1 276.1 64.5 6.3 13.1 7.1 19.7 5.9 22.6 24.1 87.2 67.8 23.9 30.8 20.9 27.7 39.4 58.4 65.1 53.6 47.7 43.9 16.2 7.5 151.6 90.7 50.1 21.5 51.2 15.1 30.8 7.5 24.2 88.7 15.2 38.5 28.6 31.8 26.5 12.4 79.8 31.9 39.8 6.8 52.3 38.3 20.0 13.6 9.9 25.2 45.1 13.7 21.7 6.7 20.8 18.2 5.3 12.1 48.8 7.9 39.3 7.6 9.0 95.2 61.2 59.0 62.0 107.6 32.8 19.2 15.2 56.9 19.2 61.2 4.1 11.5 7.1 22.6 15.2 14.3 6.3 10.5 18.7 13.1 3.0 4.0 9.1 2.6 5.9 19.7 1.7 12.8 24.1 2.9 3.9 2.0 5.2 3.2 2.2 3.4 5.9 9.4 2.9 FOXO1 "FKH1, FKHR, FOXO1A" ENSG00000150907 "Forkhead box O1" Q12778 13 40469953-40666597 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Apoptosis, Autophagy, Differentiation, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 85.9" "Cell line enhanced" "Detected in many" "ASC diff: 18.9;Daudi: 20.0;HSkMC: 25.2;U-698: 25.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001252, CAB022326" Approved Approved Supported Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB022326: , HPA001252: AB_1078906" "unprognostic (4.72e-2)" "unprognostic (1.81e-1)" "unprognostic (8.54e-2)" "unprognostic (4.35e-1)" "unprognostic (2.42e-1)" "unprognostic (2.52e-1)" "prognostic favourable (3.74e-4)" "unprognostic (6.35e-2)" "unprognostic (1.60e-1)" "unprognostic (8.65e-3)" "unprognostic (1.71e-1)" "unprognostic (1.31e-1)" "prognostic favourable (1.33e-5)" "unprognostic (1.93e-1)" "unprognostic (5.44e-1)" "unprognostic (9.09e-2)" "unprognostic (9.63e-2)" 41.6 6.9 7.0 18.4 11.2 8.0 35.5 2.3 5.0 21.4 13.4 8.4 7.7 3.5 27.4 9.8 9.5 17.2 13.3 9.9 7.8 3.9 8.3 25.6 15.3 22.4 8.3 3.9 46.0 12.2 3.8 6.2 9.5 6.5 7.9 6.8 5.7 7.5 9.3 85.9 12.3 7.6 18.6 9.7 10.8 7.4 12.3 9.0 9.4 13.1 9.0 15.6 14.4 16.2 6.1 0.5 2.8 1.6 1.1 7.1 1.0 0.3 0.6 5.6 0.1 18.9 3.7 5.4 0.8 1.1 0.2 0.1 1.4 1.3 20.0 3.7 0.5 4.8 4.4 2.4 0.3 9.1 4.6 0.0 0.6 4.4 9.0 0.1 0.5 25.2 16.4 0.1 3.1 14.2 0.3 6.4 1.4 0.7 0.0 0.2 8.2 1.4 14.2 6.5 1.5 10.5 2.5 1.2 0.3 0.7 3.8 0.8 0.6 0.5 8.3 0.1 1.1 0.0 0.5 3.6 1.3 25.9 0.5 0.9 2.6 0.9 0.8 0.5 1.5 1.0 2.3 3.2 3.9 2.2 0.5 6.1 7.1 5.3 2.8 1.1 1.6 0.0 5.5 1.0 7.0 11.2 2.3 5.0 7.8 3.9 8.3 3.9 6.5 9.0 FRMD4B "GRSP1, KIAA1013" ENSG00000114541 "FERM domain containing 4B" Q9Y2L6 3 69169990-69542583 "Plasma proteins, Predicted intracellular proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "CACO-2: 18.4;hTERT-HME1: 22.0;HUVEC TERT2: 23.9;TIME: 18.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA009705 Uncertain Supported 7400 "HPA009705: AB_1849147" "unprognostic (1.36e-1)" "unprognostic (2.92e-1)" "unprognostic (1.85e-1)" "unprognostic (1.17e-1)" "unprognostic (4.59e-2)" "unprognostic (9.73e-2)" "unprognostic (1.49e-1)" "unprognostic (2.02e-1)" "unprognostic (2.40e-2)" "unprognostic (2.32e-1)" "unprognostic (1.09e-2)" "unprognostic (8.23e-2)" "prognostic favourable (5.01e-4)" "unprognostic (1.49e-1)" "unprognostic (7.54e-2)" "unprognostic (2.79e-1)" "unprognostic (4.39e-3)" 10.0 3.7 10.0 7.8 32.0 9.3 11.1 2.3 16.6 17.4 8.4 47.9 3.3 5.9 7.8 9.7 25.9 9.2 13.3 11.6 14.9 8.1 11.6 23.7 16.7 9.3 27.1 11.1 7.7 5.8 1.5 4.8 16.9 21.2 12.0 8.9 11.5 23.8 6.8 2.8 22.1 8.2 7.0 21.3 20.0 10.0 2.8 30.2 9.4 27.4 10.2 8.4 7.9 15.0 1.4 11.0 8.3 18.9 2.4 9.9 4.5 3.0 0.8 4.9 0.1 0.1 0.7 5.4 0.2 0.7 0.4 0.4 18.4 5.3 0.3 1.7 0.2 12.0 1.9 14.1 0.6 1.0 1.4 7.8 0.6 1.0 0.3 2.0 4.1 0.7 16.5 0.5 22.0 23.9 0.7 2.7 1.4 3.4 0.2 0.4 2.6 3.5 12.8 1.2 0.5 7.2 2.1 5.4 7.0 0.8 5.8 15.2 2.1 3.1 18.7 0.2 2.0 0.2 0.7 0.2 0.1 0.4 0.1 6.1 6.2 8.3 18.9 1.5 1.4 9.2 5.0 1.1 4.6 1.9 10.8 1.4 1.4 1.3 4.9 2.4 1.5 11.0 9.9 4.5 10.0 32.0 2.3 16.6 14.9 8.1 27.1 11.1 21.2 30.2 FRMD6 "C14orf31, EX1, MGC17921, willin" ENSG00000139926 "FERM domain containing 6" Q96NE9 14 51489100-51730727 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BJ: 56.9;fHDF/TERT166: 119.2;U-138 MG: 48.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "basophil: 3.3;naive CD4 T-cell: 2.5" "Group enriched" "Detected in many" 5 "granulocytes: 3.3;T-cells: 2.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001297 Uncertain Supported Approved Mitochondria Mitochondria "HPA001297: AB_1078913" "unprognostic (1.30e-1)" "unprognostic (1.09e-1)" "unprognostic (1.84e-1)" "unprognostic (2.29e-1)" "unprognostic (2.64e-2)" "unprognostic (8.05e-2)" "unprognostic (8.19e-2)" "unprognostic (3.55e-3)" "unprognostic (1.28e-1)" "unprognostic (2.45e-2)" "prognostic unfavourable (2.66e-4)" "unprognostic (3.18e-2)" "prognostic unfavourable (1.28e-4)" "prognostic unfavourable (3.50e-4)" "unprognostic (1.18e-1)" "unprognostic (2.11e-2)" "unprognostic (1.20e-2)" 7.8 6.4 2.7 7.6 5.3 0.2 12.9 14.3 4.6 44.6 9.8 4.8 14.1 2.2 52.3 11.6 32.8 8.8 16.0 9.0 4.3 2.1 2.7 4.7 5.4 4.1 3.8 2.8 12.0 2.8 1.0 2.7 10.7 4.4 21.5 5.0 13.2 10.7 23.0 3.8 20.4 4.8 27.5 3.6 8.3 5.4 14.0 2.1 5.2 4.8 20.9 23.3 20.3 18.5 0.1 0.0 3.3 0.6 0.3 2.5 0.7 11.9 2.0 3.4 6.6 7.2 10.9 1.4 56.9 29.6 31.8 28.6 7.5 2.7 0.2 1.7 119.2 12.4 1.0 18.2 38.2 0.1 1.3 0.1 1.1 0.3 9.1 0.0 0.6 9.4 7.4 26.3 32.7 9.6 0.1 3.9 32.9 1.8 1.0 0.0 0.7 4.2 0.1 13.3 0.1 5.9 18.0 0.6 7.7 4.0 0.8 5.5 0.5 0.1 35.7 48.7 18.6 12.2 12.1 2.9 2.4 0.0 3.1 0.0 19.3 3.3 0.3 0.0 0.1 0.2 0.0 0.1 0.7 0.0 0.0 0.0 2.5 1.9 0.2 0.3 0.6 0.0 0.0 0.7 2.7 5.3 14.3 4.6 4.3 2.1 3.8 2.8 4.4 2.1 GABBR2 "GABABR2, GPR51, GPRC3B, HG20" ENSG00000136928 "Gamma-aminobutyric acid type B receptor subunit 2" O75899 9 98288082-98709197 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, Epilepsy, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 12 "brain: 52.7" "Cell line enhanced" "Detected in some" "BJ: 10.9;fHDF/TERT166: 5.4;HUVEC TERT2: 22.5;U-138 MG: 8.8" "Group enriched" "Detected in many" 10 "glioma: 7.2;thyroid cancer: 11.6;urothelial cancer: 3.9" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA013820, HPA031684, CAB079065" Enhanced Approved "CAB079065: , HPA013820: AB_1849364, HPA031684: " "unprognostic (2.00e-1)" "unprognostic (7.56e-2)" "unprognostic (3.75e-1)" "unprognostic (3.09e-5)" "unprognostic (2.52e-1)" "unprognostic (1.16e-1)" "unprognostic (2.81e-2)" "unprognostic (1.42e-1)" "unprognostic (2.66e-1)" "unprognostic (4.43e-2)" "unprognostic (1.43e-2)" "unprognostic (2.06e-1)" "unprognostic (1.76e-2)" "unprognostic (3.52e-2)" "unprognostic (1.91e-1)" "unprognostic (2.68e-2)" "unprognostic (3.45e-2)" 0.9 4.4 13.6 1.0 14.6 0.8 0.9 19.7 52.7 0.8 0.9 2.1 0.0 0.8 1.1 1.1 0.9 0.8 0.9 0.9 14.6 11.1 0.9 0.9 1.0 0.9 7.6 17.6 0.8 0.8 0.9 0.3 0.9 10.3 0.9 0.8 0.6 0.9 0.9 3.2 0.9 0.8 1.0 2.2 0.9 1.0 1.3 0.2 0.0 2.3 0.0 1.1 1.5 0.1 0.7 0.7 1.7 1.1 1.7 1.0 0.4 0.0 0.0 0.0 0.0 0.1 0.1 1.0 10.9 2.2 2.3 4.2 0.0 0.1 0.0 0.7 5.4 0.0 0.1 0.2 0.8 0.0 0.4 0.0 0.0 0.0 1.0 0.0 0.0 0.3 0.0 0.8 0.2 22.5 0.2 0.1 0.0 0.3 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.1 0.6 3.1 0.0 0.0 2.8 0.0 0.0 0.1 1.0 8.8 0.6 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.2 1.7 0.4 0.8 0.6 0.7 1.0 0.7 0.7 0.7 0.4 0.6 0.8 0.9 1.2 1.7 1.1 0.7 1.0 0.4 13.6 14.6 19.7 35.0 14.6 11.1 7.6 17.6 10.3 0.2 GABRA1 EJM5 ENSG00000022355 "Gamma-aminobutyric acid type A receptor alpha1 subunit" P14867 5 161847063-161899981 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 22 "brain: 58.6" "Cell line enhanced" "Detected in some" "HEL: 3.6;SCLC-21H: 1.1;U-2 OS: 1.5;U-87 MG: 2.3;WM-115: 1.2" "Cancer enriched" "Detected in single" 5 "glioma: 1.1" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022502, HPA055746" Enhanced Supported "CAB022502: , HPA055746: " "unprognostic (2.58e-2)" "unprognostic (4.78e-3)" "unprognostic (1.84e-1)" "unprognostic (3.31e-1)" "unprognostic (2.43e-1)" 1.0 2.6 8.5 1.0 21.9 1.0 1.0 35.2 58.6 1.0 1.0 1.8 0.0 1.1 1.0 1.0 1.0 1.0 1.0 1.0 10.5 8.8 1.0 1.0 1.0 1.0 6.7 22.0 1.0 1.0 1.0 0.1 1.0 7.4 1.2 1.0 0.2 1.0 1.1 1.0 1.0 1.0 1.0 1.3 1.1 1.5 1.1 0.0 0.0 1.0 0.0 1.3 1.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 3.6 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.9 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.1 0.0 0.1 0.0 0.0 2.3 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.5 21.9 35.2 49.8 10.5 8.8 6.7 22.0 7.4 0.0 GABRA2 ENSG00000151834 "Gamma-aminobutyric acid type A receptor alpha2 subunit" P47869 4 46248427-46475230 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 52.6" "Cell line enhanced" "Detected in some" "U-2 OS: 9.4;U-87 MG: 4.4;WM-115: 5.0" "Cancer enhanced" "Detected in some" "glioma: 0.8" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "basophil: 1.0" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB079061 Supported "Intracellular and membrane" "CAB079061: " "unprognostic (2.03e-2)" "unprognostic (2.77e-1)" "unprognostic (2.45e-4)" "unprognostic (6.87e-3)" "unprognostic (2.65e-1)" "unprognostic (2.08e-1)" "unprognostic (1.01e-1)" "unprognostic (4.09e-1)" "unprognostic (6.90e-3)" "unprognostic (8.83e-2)" "unprognostic (2.22e-5)" "unprognostic (1.75e-1)" "unprognostic (1.15e-1)" "unprognostic (2.67e-1)" "unprognostic (3.04e-2)" 2.2 1.3 38.5 1.4 34.4 1.2 1.9 10.4 52.6 1.7 4.5 4.9 0.0 2.0 1.4 11.7 1.7 1.0 1.6 1.0 38.9 7.7 8.8 1.4 1.0 1.4 3.7 31.0 1.9 1.0 0.9 0.6 1.5 10.5 1.0 3.5 0.0 1.2 1.9 1.0 1.3 7.7 1.3 6.9 2.3 1.6 1.5 7.1 0.0 1.1 0.0 1.4 1.2 0.8 0.2 0.3 1.0 0.1 0.1 0.1 0.0 0.5 0.5 0.1 0.6 0.0 0.0 0.5 0.3 0.0 0.0 0.0 2.1 0.6 0.2 0.5 0.0 0.8 0.0 0.0 0.1 0.5 0.5 0.1 0.7 0.2 0.8 0.1 0.2 0.0 0.0 0.2 0.2 0.0 0.8 0.2 0.0 0.4 0.0 0.3 0.9 0.1 0.0 0.6 0.4 0.1 0.6 0.2 0.0 0.1 0.3 0.0 0.3 0.4 0.1 0.5 9.4 0.5 0.1 0.7 1.2 0.2 4.4 0.4 5.0 1.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.9 0.1 0.1 0.3 0.0 0.0 38.5 34.4 10.4 31.4 38.9 7.7 3.7 31.0 10.5 7.1 GABRA3 ENSG00000011677 "Gamma-aminobutyric acid type A receptor alpha3 subunit" P34903 X 152166234-152451358 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "brain: 30.1" "Cell line enhanced" "Detected in some" "HMC-1: 7.8;Karpas-707: 13.2;PC-3: 7.6;U-2 OS: 6.5;U-266/70: 7.1;U-266/84: 11.7;U-87 MG: 7.7" "Cancer enriched" "Detected in many" 7 "testis cancer: 16.6" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "basophil: 1.5" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA000839 Approved Supported "HPA000839: AB_1078929" "unprognostic (9.63e-3)" "unprognostic (2.04e-1)" "unprognostic (2.02e-1)" "unprognostic (1.18e-2)" "unprognostic (7.07e-2)" "unprognostic (5.42e-2)" "unprognostic (2.34e-6)" "unprognostic (1.24e-1)" "unprognostic (2.70e-1)" "unprognostic (2.39e-2)" "unprognostic (2.63e-2)" "unprognostic (1.73e-1)" "unprognostic (7.29e-6)" "unprognostic (7.42e-3)" "unprognostic (6.20e-2)" "unprognostic (8.13e-2)" 0.7 0.7 7.7 0.6 15.2 0.7 0.7 1.3 30.1 2.2 0.8 3.3 0.0 0.8 1.2 0.8 1.3 0.7 0.7 0.7 10.9 15.9 0.7 0.7 0.7 0.7 4.7 10.5 0.6 0.7 0.6 0.9 5.2 6.2 0.8 0.8 0.4 0.7 1.8 0.8 1.1 0.9 0.8 2.1 0.7 0.7 1.8 1.1 0.0 0.7 0.0 0.9 1.8 0.4 0.0 0.1 1.5 0.3 0.3 0.2 0.0 0.0 0.8 0.0 0.0 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 4.0 0.0 0.0 0.0 7.8 0.0 0.0 0.0 0.0 0.0 1.3 13.2 0.0 0.0 0.0 0.0 2.4 7.6 0.0 0.0 0.0 0.0 0.0 0.2 4.8 0.0 4.9 0.4 0.1 1.2 0.0 5.0 6.5 0.3 1.4 7.1 11.7 0.0 7.7 0.0 4.9 1.5 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.3 0.3 0.1 0.2 0.0 7.7 15.2 1.3 28.4 10.9 15.9 4.7 10.5 6.2 1.1 GABRA5 ENSG00000186297 "Gamma-aminobutyric acid type A receptor alpha5 subunit" P31644 15 26866363-26949207 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 21 "brain: 52.6" "Group enriched" "Detected in some" 12 "A549: 25.8;HAP1: 8.9;NTERA-2: 10.7;U-2 OS: 9.3" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA077031, CAB079022" Supported Supported "Plasma membrane" "Plasma membrane" "CAB079022: , HPA077031: " "unprognostic (6.33e-2)" "unprognostic (8.94e-3)" "unprognostic (1.04e-1)" "unprognostic (2.50e-1)" "unprognostic (1.81e-1)" "unprognostic (3.75e-1)" "unprognostic (9.50e-3)" "unprognostic (2.57e-1)" "unprognostic (7.63e-2)" "unprognostic (8.50e-2)" "unprognostic (1.44e-2)" 0.8 0.8 12.0 0.8 48.2 0.8 0.8 0.1 52.6 0.8 0.8 0.8 0.0 0.8 0.8 0.7 2.5 0.8 1.5 0.9 20.9 6.0 0.9 0.8 0.8 0.8 2.3 15.2 0.7 0.7 0.7 0.1 0.8 1.0 1.0 0.7 0.0 0.7 0.9 0.7 0.8 0.7 1.4 0.3 0.8 1.1 1.4 2.0 1.3 0.9 0.0 1.1 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 25.8 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.5 0.0 8.9 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 10.7 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 9.3 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.0 48.2 0.1 26.0 20.9 6.0 2.3 15.2 1.0 2.0 GABRG2 ENSG00000113327 "Gamma-aminobutyric acid type A receptor gamma2 subunit" P18507 5 162000057-162162977 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 47.1" "Cell line enhanced" "Detected in many" "CACO-2: 10.7;Karpas-707: 8.5;RPMI-8226: 10.3;U-266/70: 17.9;U-266/84: 14.1" "Cancer enhanced" "Detected in single" "glioma: 1.4" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 7.3" "Group enriched" "Detected in many" 5 "B-cells: 2.9;granulocytes: 7.3;T-cells: 3.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB079060 Supported "CAB079060: " "unprognostic (2.88e-2)" "unprognostic (1.56e-2)" "unprognostic (6.31e-3)" "unprognostic (3.07e-3)" "unprognostic (1.52e-1)" 1.1 5.7 9.7 1.2 28.8 3.3 0.9 21.7 47.1 0.7 1.5 1.1 0.0 2.2 1.2 1.3 1.3 1.3 3.8 1.6 10.6 19.6 1.0 1.2 1.9 1.2 7.5 19.1 1.5 1.0 0.8 5.3 2.9 17.6 1.0 1.3 0.6 1.3 0.8 1.2 3.3 1.9 1.6 2.6 1.2 3.3 1.7 1.8 0.0 1.8 0.0 1.3 1.5 0.3 2.9 0.7 7.3 0.3 0.9 3.2 0.2 3.6 1.7 2.0 0.3 0.0 0.0 2.1 0.6 0.0 0.0 0.0 10.7 4.7 0.7 5.3 0.0 1.6 1.2 0.0 0.0 0.8 1.1 0.0 2.1 1.3 0.0 0.2 0.5 0.3 0.0 0.0 0.0 0.0 1.8 8.5 0.0 2.5 0.4 0.1 6.1 2.9 0.4 0.1 10.3 0.0 3.4 0.9 0.8 0.3 0.6 3.4 5.7 5.7 0.2 0.3 4.5 0.3 0.5 17.9 14.1 0.5 0.2 0.4 0.4 7.3 0.3 0.6 0.4 0.3 2.7 2.9 0.7 0.6 0.0 2.5 3.2 0.7 1.6 0.9 0.2 0.7 0.6 0.2 9.7 28.8 21.7 38.1 10.6 19.6 7.5 19.1 17.6 1.8 GAD1 GAD ENSG00000128683 "Glutamate decarboxylase 1" Q99259 2 170813213-170861151 "Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Neurotransmitter biosynthesis" "Decarboxylase, Lyase" "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 53.9" "Cell line enhanced" "Detected in many" "HaCaT: 10.5;HEL: 34.2" "Cancer enhanced" "Detected in many" "endometrial cancer: 4.4" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Region enriched" "Detected in all" 4 "olfactory region: 888.9" "CAB004415, HPA031949, HPA058412, CAB078176" Enhanced Supported Approved Vesicles Vesicles "CAB004415: AB_627650, CAB078176: , HPA031949: , HPA058412: " "unprognostic (1.28e-1)" "prognostic favourable (7.31e-4)" "unprognostic (1.87e-2)" "prognostic favourable (8.61e-4)" "unprognostic (1.12e-1)" "unprognostic (3.05e-1)" "unprognostic (4.97e-7)" "unprognostic (1.51e-1)" "unprognostic (7.72e-2)" "unprognostic (4.27e-4)" "unprognostic (6.75e-2)" "unprognostic (9.18e-3)" "unprognostic (6.90e-5)" "unprognostic (2.93e-2)" "unprognostic (6.57e-2)" "unprognostic (1.56e-2)" "unprognostic (3.08e-3)" 1.2 2.0 14.5 0.9 28.1 3.7 1.0 10.6 53.9 1.8 1.0 3.1 0.0 1.0 2.6 5.5 1.2 1.1 1.0 1.0 10.8 24.4 6.0 1.0 1.1 1.1 8.6 17.5 1.1 1.1 9.5 2.8 1.4 6.0 1.8 1.0 1.3 1.0 1.3 0.9 1.0 1.1 1.0 2.6 1.0 1.0 4.0 3.4 0.0 1.1 0.0 1.2 1.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.7 0.3 0.0 3.7 0.0 0.0 0.0 0.2 0.0 1.4 0.9 2.5 3.5 0.0 0.5 0.2 10.5 1.2 0.3 0.8 1.4 7.2 34.2 3.0 0.1 0.0 0.1 0.6 0.0 3.1 0.0 1.2 0.0 8.8 0.1 0.4 0.8 0.0 0.0 4.2 3.7 0.5 2.5 0.2 4.6 4.9 3.6 1.1 6.5 0.0 1.8 0.1 0.0 0.0 6.4 0.9 1.3 3.7 0.0 0.0 0.0 6.2 1.7 8.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.5 28.1 10.6 36.7 10.8 24.4 8.6 17.5 6.0 3.4 GAL "GAL-GMAP, GALN, GLNN, GMAP" ENSG00000069482 "Galanin and GMAP prepropeptide" P22466 11 68683779-68691175 "Disease related genes, Plasma proteins, Predicted secreted proteins" "Hormone, Neuropeptide" "Disease mutation, Epilepsy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 8 "pituitary gland: 149.9" "Cell line enhanced" "Detected in some" "CACO-2: 46.9;HEK 293: 21.9;K-562: 24.3;NB-4: 86.7;SH-SY5Y: 35.0" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in some" 8 "hypothalamus: 18.8" "Cell type enriched" "Detected in single" 15 "intermediate monocyte: 1.5" "Lineage enriched" "Detected in single" 15 "monocytes: 1.5" "Region enhanced" "Detected in many" "hypothalamus: 111.6" "Low region specificity" "Detected in all" "HPA049864, CAB079779" Enhanced Supported Supported "Golgi apparatus,Vesicles" "Secreted to blood" 60030 "Golgi apparatus" Vesicles "CAB079779: , HPA049864: " "unprognostic (8.56e-2)" "unprognostic (1.45e-2)" "unprognostic (7.50e-2)" "prognostic unfavourable (1.22e-4)" "unprognostic (2.70e-1)" "unprognostic (2.27e-2)" "unprognostic (8.07e-3)" "prognostic unfavourable (8.17e-4)" "unprognostic (5.98e-2)" "unprognostic (1.07e-2)" "unprognostic (8.84e-2)" "unprognostic (7.42e-2)" "unprognostic (1.20e-1)" "unprognostic (8.85e-2)" "unprognostic (7.88e-2)" "unprognostic (5.38e-2)" "unprognostic (3.24e-2)" 2.8 0.2 0.1 14.8 0.5 0.4 4.5 0.6 2.0 0.2 6.0 0.1 0.4 1.7 0.2 0.7 0.7 0.2 0.3 0.6 1.3 18.8 0.3 0.2 0.2 0.1 0.2 0.6 0.2 2.9 0.0 149.9 0.9 2.2 0.7 4.1 0.6 0.5 1.8 0.3 4.5 2.2 9.7 0.3 0.2 1.5 0.5 0.4 0.7 0.2 0.4 0.3 1.5 0.3 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 1.9 0.2 0.0 0.0 0.0 4.4 6.6 0.0 0.1 0.0 46.9 1.7 0.0 2.4 0.2 0.0 0.0 0.0 0.0 0.0 21.9 1.1 14.1 0.0 0.2 0.6 0.0 0.3 0.7 0.0 0.0 1.1 24.3 0.0 0.0 13.3 0.0 86.7 11.2 4.2 0.0 0.0 8.9 0.1 0.0 9.1 35.0 4.6 0.2 0.0 0.2 10.2 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.6 0.7 1.3 18.8 0.2 0.6 2.2 0.4 GAP43 "B-50, PP46" ENSG00000172020 "Growth associated protein 43" P17677 3 115623324-115721490 "Plasma proteins, Predicted intracellular proteins, Transporters" "Differentiation, Growth regulation, Neurogenesis" "Calmodulin-binding, Developmental protein" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 25 "brain: 132.7" "Cell line enhanced" "Detected in some" "AF22: 16.4;NTERA-2: 34.8;SCLC-21H: 22.4;SH-SY5Y: 16.8;U-87 MG: 7.8" "Cancer enriched" "Detected in many" 43 "glioma: 245.6" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 10 "naive CD8 T-cell: 1.7" "Lineage enriched" "Detected in single" 17 "T-cells: 1.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004417, HPA013392, HPA015600, CAB078783" Enhanced Supported Enhanced "Plasma membrane" "Plasma membrane" "CAB004417: AB_627660, CAB078783: AB_2620096, HPA013392: AB_1849468, HPA015600: AB_1849466" "unprognostic (1.24e-1)" "unprognostic (1.31e-1)" "unprognostic (1.15e-2)" "unprognostic (5.72e-5)" "unprognostic (7.44e-3)" "unprognostic (2.19e-2)" "unprognostic (3.97e-3)" "unprognostic (3.15e-3)" "unprognostic (6.08e-4)" "unprognostic (3.33e-1)" "unprognostic (2.17e-2)" "unprognostic (1.62e-1)" "unprognostic (5.35e-8)" "unprognostic (1.15e-1)" "unprognostic (1.09e-1)" "unprognostic (2.78e-2)" "unprognostic (1.29e-3)" 1.8 5.0 48.8 5.2 38.3 1.4 1.9 31.2 132.7 1.6 4.1 4.3 0.0 2.7 1.5 1.5 1.9 1.5 3.8 3.6 29.0 56.6 1.4 1.4 1.5 1.5 30.6 42.2 1.4 1.8 1.4 1.5 2.2 25.7 1.7 4.0 0.8 2.2 1.5 1.4 1.4 4.3 3.6 6.1 1.4 1.5 1.6 5.7 0.0 1.5 0.0 1.6 1.7 0.2 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 16.4 0.0 0.0 0.0 0.0 0.4 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 3.7 0.0 0.0 0.0 0.0 34.8 0.0 0.0 0.0 0.0 0.0 0.0 22.4 16.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 7.8 0.0 0.7 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 48.8 38.3 31.2 75.7 29.0 56.6 30.6 42.2 25.7 5.7 GFAP FLJ45472 ENSG00000131095 "Glial fibrillary acidic protein" P14136 17 44903161-44916937 "Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Disease mutation, Leukodystrophy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 61 "brain: 595.5" "Cell line enhanced" "Detected in many" "U-87 MG: 9.5" "Cancer enriched" "Detected in some" 368 "glioma: 2468.0" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 9.8" "Group enriched" "Detected in many" 5 "granulocytes: 9.8;NK-cells: 2.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000039, HPA056030, HPA063513" Enhanced Supported Supported "Intermediate filaments" 220000000 "Intermediate filaments" "CAB000039: AB_10013382, HPA056030: , HPA063513: " "unprognostic (1.79e-2)" "unprognostic (2.74e-1)" "unprognostic (9.83e-2)" "unprognostic (2.12e-5)" "unprognostic (4.08e-1)" "unprognostic (5.09e-1)" "unprognostic (1.26e-1)" "unprognostic (6.53e-2)" "unprognostic (6.57e-3)" "unprognostic (7.35e-2)" "unprognostic (5.86e-2)" "unprognostic (1.24e-1)" "unprognostic (7.63e-2)" "unprognostic (2.75e-5)" "unprognostic (1.49e-1)" "unprognostic (1.66e-1)" "unprognostic (1.64e-1)" 3.0 2.9 122.2 3.2 105.4 5.8 3.0 33.9 595.5 2.7 3.0 171.0 0.0 2.8 2.9 3.0 3.6 3.2 3.1 4.0 143.0 175.1 3.0 2.8 3.0 3.1 227.0 67.3 3.0 3.0 3.4 1.3 2.8 212.7 3.0 2.9 0.0 3.1 2.9 3.2 3.3 2.8 2.9 482.0 3.0 3.0 2.9 119.0 0.0 3.0 0.0 2.9 3.4 0.0 1.1 0.8 9.8 1.2 2.9 0.8 0.3 1.7 1.1 2.0 3.8 0.0 0.8 0.5 1.7 2.0 2.4 2.0 2.1 2.4 3.5 3.1 0.9 4.3 2.2 0.7 3.0 4.3 1.9 2.8 2.9 1.4 0.1 0.8 4.2 0.2 1.3 1.7 0.0 0.0 1.3 8.3 0.6 2.2 2.9 4.1 2.7 5.2 1.2 1.2 2.8 1.1 1.5 2.7 2.9 0.5 3.4 0.3 2.2 2.2 1.2 2.1 1.6 1.9 2.5 1.2 2.3 2.7 9.5 3.4 3.3 1.9 1.2 0.5 0.5 1.1 0.4 0.4 0.5 0.7 0.3 1.1 0.6 0.8 9.8 2.9 0.7 0.8 0.4 0.3 122.2 105.4 33.9 69.4 143.0 175.1 227.0 67.3 212.7 119.0 GJA1 "CX43, GJAL, ODD, ODDD, ODOD, SDTY3" ENSG00000152661 "Gap junction protein alpha 1" P17302 6 121435692-121449727 "Cancer-related genes, Disease related genes, Predicted membrane proteins" "Cancer-related genes, Cataract, Disease mutation, Hypotrichosis, Palmoplantar keratoderma" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BJ hTERT+: 48.8;HUVEC TERT2: 61.6;NTERA-2: 62.7;TIME: 45.3;U-87 MG: 61.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010753, HPA035097, HPA047551, HPA069245" Enhanced Supported Supported "Nucleoplasm,Vesicles,Cell Junctions" "Vesicles, Cell Junctions" Nucleoplasm "CAB010753: AB_476857, HPA035097: , HPA047551: , HPA069245: " "unprognostic (3.37e-2)" "unprognostic (3.41e-3)" "unprognostic (2.95e-1)" "unprognostic (4.18e-2)" "unprognostic (1.48e-2)" "unprognostic (1.67e-2)" "unprognostic (1.27e-1)" "unprognostic (6.78e-2)" "unprognostic (2.89e-2)" "unprognostic (1.56e-1)" "unprognostic (5.47e-2)" "unprognostic (1.00e-1)" "unprognostic (4.88e-2)" "prognostic unfavourable (4.99e-5)" "unprognostic (2.39e-1)" "unprognostic (1.29e-1)" "unprognostic (3.00e-3)" 19.7 65.2 78.6 5.5 69.7 0.4 14.2 32.4 44.4 64.5 4.0 23.8 6.1 4.2 23.5 5.5 17.3 7.8 23.0 36.0 87.3 25.5 3.6 2.5 15.2 4.4 42.9 39.9 10.5 4.5 94.7 5.7 63.8 53.7 20.0 4.8 26.3 7.1 35.7 3.4 86.3 4.4 25.6 38.7 1.1 6.4 8.3 64.3 0.5 38.9 9.9 7.6 14.8 32.2 0.5 0.5 0.4 0.5 0.0 0.4 0.0 0.0 7.2 32.1 0.0 17.5 10.9 0.0 24.0 48.8 8.1 19.8 0.1 0.0 0.0 2.7 9.3 3.1 0.8 14.7 26.4 0.0 8.8 0.3 2.9 0.0 21.9 0.0 0.0 29.0 15.9 29.6 10.7 61.6 0.0 0.7 1.6 1.3 0.0 12.9 62.7 8.0 0.0 0.0 0.6 32.4 3.5 0.0 0.5 0.0 0.0 0.0 2.5 0.0 45.3 25.0 6.9 21.1 15.5 0.0 0.0 0.0 61.0 0.0 3.5 0.4 0.5 0.0 0.2 0.0 0.2 0.0 0.3 0.0 0.2 0.5 0.4 0.4 0.0 0.0 0.1 0.5 0.1 0.0 78.6 69.7 32.4 42.8 87.3 25.5 42.9 39.9 53.7 64.3 GKAP1 "FKSG21, GKAP42" ENSG00000165113 "G kinase anchoring protein 1" Q5VSY0 9 83739421-83829516 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "testis: 98.8" "Cell line enhanced" "Detected in many" "U-266/84: 22.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA035117, HPA035118, HPA066173" Enhanced Supported Approved "Centriolar satellite,Cytosol" "Centriolar satellite, Cytosol" "HPA035117: , HPA035118: AB_10671100, HPA066173: AB_2732740" "unprognostic (1.91e-1)" "unprognostic (2.94e-2)" "unprognostic (1.12e-1)" "unprognostic (1.16e-1)" "unprognostic (9.62e-2)" "unprognostic (2.50e-1)" "unprognostic (2.52e-3)" "unprognostic (7.66e-3)" "unprognostic (3.04e-1)" "unprognostic (1.86e-2)" "prognostic favourable (6.96e-5)" "unprognostic (4.18e-1)" "prognostic favourable (1.05e-6)" "unprognostic (9.73e-2)" "unprognostic (1.38e-2)" "unprognostic (2.06e-1)" "unprognostic (6.24e-3)" 4.4 4.2 6.0 2.8 6.1 2.5 9.2 15.6 6.1 4.7 5.0 4.1 6.6 3.0 5.5 4.5 3.2 3.9 3.4 9.0 6.1 6.8 4.2 5.1 2.9 2.6 6.5 3.1 7.0 5.2 6.2 7.9 2.0 6.1 6.6 2.7 3.2 4.2 5.9 25.0 1.7 3.0 8.1 8.0 2.4 3.5 98.8 7.2 8.4 8.1 5.2 2.7 6.0 14.7 1.9 0.6 3.0 0.8 5.3 1.9 0.1 4.8 6.0 4.4 5.8 0.6 0.0 6.2 1.9 1.5 3.0 3.1 0.8 2.7 7.5 1.9 0.8 1.0 4.3 0.5 5.1 8.9 3.9 4.3 3.0 4.3 6.5 2.0 0.4 0.2 3.5 1.5 1.6 2.7 3.5 6.3 0.9 4.5 10.5 6.9 3.6 3.0 7.4 9.9 2.6 3.1 0.8 14.7 8.7 4.3 2.0 3.4 0.8 4.1 0.9 1.0 7.1 0.7 3.3 10.3 22.6 2.9 2.2 1.4 1.2 3.0 0.8 0.6 1.4 0.0 1.3 1.7 1.3 1.5 0.6 1.9 1.0 1.9 2.5 5.3 0.3 0.3 1.5 0.1 6.0 6.1 15.6 6.1 6.1 6.8 6.5 3.1 6.1 7.2 GLRA1 STHE ENSG00000145888 "Glycine receptor alpha 1" P23415 5 151822513-151924842 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 10 "brain: 31.7" "Cell line enhanced" "Detected in single" "HeLa: 1.3" "Not detected" "Not detected" "Region enriched" "Detected in many" 10 "pons and medulla: 31.7" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 4 "hypothalamus: 11.0;midbrain: 18.1;pons and medulla: 27.6" "Region enhanced" "Detected in many" "pons and medulla: 54.9" "HPA016502, CAB079042" Uncertain Supported "CAB079042: , HPA016502: AB_1849819" "unprognostic (3.17e-1)" "unprognostic (2.47e-1)" "unprognostic (3.85e-7)" "unprognostic (8.24e-2)" "unprognostic (9.45e-3)" 0.3 3.2 1.2 0.1 0.7 0.2 0.1 3.2 0.9 0.1 0.2 0.0 0.0 0.5 0.1 0.1 0.1 0.1 0.1 0.3 0.1 2.7 0.2 0.1 0.1 0.1 2.7 0.0 0.1 2.2 0.1 0.1 0.2 31.7 0.1 0.1 1.6 0.1 0.1 0.6 0.1 0.1 0.1 12.6 0.1 0.1 0.2 0.0 0.0 0.2 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.8 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 1.3 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.3 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.7 3.2 0.9 0.1 2.7 2.7 0.0 31.7 0.0 GMFB GMF ENSG00000197045 "Glia maturation factor beta" P60983 14 54474484-54489196 "Plasma proteins, Predicted intracellular proteins" "Growth factor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 54.4" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA002954 Approved Approved Approved "Nucleoplasm,Nuclear bodies,Cytosol" 1000000 "Nucleoplasm, Cytosol" "Nuclear bodies" "HPA002954: AB_1078997" "unprognostic (7.93e-2)" "unprognostic (7.69e-3)" "unprognostic (4.81e-3)" "unprognostic (2.99e-2)" "unprognostic (1.12e-2)" "unprognostic (2.06e-2)" "prognostic unfavourable (2.21e-4)" "unprognostic (1.48e-2)" "unprognostic (1.90e-1)" "unprognostic (1.03e-1)" "unprognostic (1.11e-1)" "unprognostic (4.29e-2)" "prognostic favourable (9.48e-5)" "unprognostic (1.80e-1)" "unprognostic (2.82e-1)" "unprognostic (1.23e-1)" "unprognostic (9.09e-2)" 14.2 13.2 37.9 12.9 26.7 14.2 15.3 25.1 41.6 11.8 19.8 23.9 6.1 19.1 11.6 8.5 9.3 8.4 9.7 9.6 36.7 30.1 19.9 14.7 13.8 13.3 36.9 28.3 9.8 7.3 10.1 13.6 17.9 25.6 9.0 20.7 6.6 7.0 8.0 4.1 7.8 17.5 10.5 54.4 10.1 10.7 6.2 21.7 6.4 12.8 6.1 13.5 10.0 7.4 9.1 12.8 16.4 14.5 9.0 8.8 6.8 30.4 12.3 24.7 18.0 26.7 33.4 18.5 31.2 23.0 22.7 28.4 14.2 27.0 28.0 14.8 30.7 11.3 24.9 21.6 36.0 10.1 8.6 14.0 13.9 13.1 22.8 19.5 12.3 25.3 20.3 19.7 19.5 20.4 10.2 9.9 35.9 15.1 11.9 7.6 15.9 13.1 12.1 29.0 8.1 29.0 29.0 14.7 22.8 21.7 18.5 23.6 20.4 15.5 16.1 33.0 25.1 16.7 19.3 3.5 6.2 17.5 27.8 12.1 20.8 8.7 11.0 9.2 6.1 13.5 8.5 7.6 7.2 6.0 12.8 9.1 7.8 8.2 16.4 9.0 14.5 5.2 8.8 6.8 37.9 26.7 25.1 33.5 36.7 30.1 36.9 28.3 25.6 21.7 GMFG ENSG00000130755 "Glia maturation factor gamma" O60234 19 39328353-39342372 "Plasma proteins, Predicted intracellular proteins" "Growth factor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 5 "blood: 276.5;bone marrow: 80.9;lymphoid tissue: 109.5" "Cell line enhanced" "Detected in some" "HMC-1: 77.0;Karpas-707: 59.8;NB-4: 43.6;REH: 49.0;THP-1: 76.8;U-937: 52.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA002954 Uncertain Approved Approved "Nucleoplasm,Nuclear bodies,Cytosol" 1500000 "Nucleoplasm, Cytosol" "Nuclear bodies" "HPA002954: AB_1078997" "unprognostic (1.22e-2)" "prognostic favourable (7.35e-4)" "unprognostic (2.37e-2)" "unprognostic (1.21e-3)" "unprognostic (9.93e-2)" "unprognostic (2.14e-2)" "unprognostic (1.19e-1)" "unprognostic (4.84e-2)" "unprognostic (1.00e-1)" "unprognostic (2.09e-1)" "unprognostic (3.09e-1)" "unprognostic (1.15e-1)" "prognostic unfavourable (9.11e-6)" "unprognostic (3.01e-1)" "unprognostic (8.76e-3)" "unprognostic (1.06e-1)" "unprognostic (5.27e-3)" 22.6 6.1 7.3 29.6 7.4 80.9 16.8 2.2 4.8 6.0 8.8 4.0 1.7 5.3 4.4 9.4 6.4 7.3 8.7 7.5 6.0 4.9 9.4 9.7 28.5 42.2 8.6 2.3 4.7 3.6 1.1 3.1 18.0 5.8 6.1 7.9 4.9 8.1 2.3 5.4 4.2 17.8 6.8 8.2 86.0 5.9 2.9 5.6 109.5 9.8 7.0 37.1 11.1 7.5 39.1 57.2 276.5 79.4 41.6 88.0 106.7 0.1 0.0 0.2 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 3.8 33.5 0.3 0.0 0.2 0.0 0.1 0.1 11.3 0.0 36.5 0.0 0.5 0.6 39.0 77.0 0.1 0.0 0.0 0.1 2.0 1.3 59.8 0.3 0.0 35.5 43.6 0.0 0.0 49.0 0.4 21.9 0.0 5.2 0.1 0.0 0.1 0.2 0.2 0.1 76.8 20.0 0.0 0.4 0.1 0.1 3.4 11.6 38.3 0.2 52.7 0.3 185.2 79.4 178.1 37.7 72.3 40.0 39.1 56.7 46.6 57.2 35.0 55.9 46.4 276.5 41.6 78.9 22.2 88.0 106.7 7.3 7.4 2.2 4.8 6.0 4.9 8.6 2.3 5.8 5.6 GNG12 ENSG00000172380 "G protein subunit gamma 12" Q9UBI6 1 67701466-67833467 "Predicted intracellular proteins, RAS pathway related proteins" Transducer "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA057790, HPA062208" Enhanced Supported Approved Mitochondria Mitochondria "HPA057790: , HPA062208: " "unprognostic (5.18e-2)" "unprognostic (1.76e-3)" "unprognostic (4.46e-3)" "unprognostic (7.77e-2)" "unprognostic (1.06e-1)" "unprognostic (4.71e-2)" "unprognostic (5.29e-2)" "unprognostic (5.84e-3)" "unprognostic (5.50e-2)" "unprognostic (3.41e-2)" "unprognostic (4.46e-3)" "unprognostic (8.13e-2)" "unprognostic (4.12e-3)" "unprognostic (2.33e-2)" "unprognostic (9.33e-2)" "unprognostic (7.78e-2)" "unprognostic (2.14e-3)" 28.7 23.8 10.3 13.8 9.4 0.0 49.4 5.1 7.7 28.3 34.5 10.9 16.6 40.1 41.5 20.7 34.0 21.2 27.2 14.2 11.8 9.3 36.1 15.4 16.4 12.4 9.1 6.3 24.9 16.0 23.9 17.1 40.1 14.3 21.4 22.2 14.6 16.4 19.3 9.0 33.0 86.2 51.8 22.9 17.5 19.5 11.6 9.6 3.6 23.1 20.5 16.5 31.5 26.7 0.0 0.0 0.0 0.0 0.7 0.0 0.0 9.8 9.3 9.9 5.3 42.3 36.8 10.2 30.7 40.2 27.2 24.5 4.3 9.8 0.0 13.1 43.0 7.4 6.2 25.2 47.9 0.0 4.7 0.1 8.3 0.0 16.9 0.0 0.5 22.0 15.1 28.9 38.5 42.6 0.5 0.0 29.8 1.6 0.0 0.0 7.5 11.6 0.0 20.5 0.1 26.1 8.9 2.2 4.6 21.3 8.9 41.2 4.5 0.1 54.7 31.6 20.6 56.8 18.9 0.5 0.0 0.0 20.0 1.1 42.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 10.3 9.4 5.1 7.7 11.8 9.3 9.1 6.3 14.3 9.6 GNG2 ENSG00000186469 "G protein subunit gamma 2" P59768 14 51826195-51979342 "Predicted intracellular proteins, RAS pathway related proteins" Transducer "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 68.4;brain: 50.5;testis: 55.7" "Cell line enhanced" "Detected in many" "AF22: 20.5;fHDF/TERT166: 36.3;MOLT-4: 28.2;SH-SY5Y: 23.9;WM-115: 65.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003534, CAB018380" Uncertain Supported Approved "Vesicles,Plasma membrane" "Plasma membrane" Vesicles "CAB018380: AB_631547, HPA003534: AB_1079004" "unprognostic (6.11e-2)" "unprognostic (5.78e-3)" "unprognostic (2.06e-3)" "unprognostic (6.55e-2)" "unprognostic (1.33e-1)" "unprognostic (4.01e-2)" "unprognostic (1.18e-1)" "unprognostic (1.03e-1)" "unprognostic (5.72e-2)" "unprognostic (1.24e-1)" "prognostic favourable (1.64e-4)" "unprognostic (8.47e-2)" "prognostic unfavourable (3.90e-6)" "unprognostic (9.82e-2)" "unprognostic (1.29e-1)" "unprognostic (1.08e-1)" "unprognostic (3.59e-2)" 22.0 10.4 50.5 17.4 18.5 25.0 11.7 4.9 46.1 5.9 13.0 5.2 1.6 6.8 5.7 4.7 6.5 3.5 7.9 6.6 30.9 50.3 4.0 5.6 8.5 19.4 10.7 20.7 7.1 3.3 1.6 12.2 8.6 8.9 6.6 9.1 8.3 4.5 4.4 2.3 3.5 9.9 8.8 8.5 41.2 7.3 55.7 2.5 39.6 3.9 4.3 19.5 8.5 4.0 8.0 13.9 68.4 34.9 5.0 36.5 27.6 0.0 0.8 20.5 12.8 3.1 4.1 0.3 3.3 4.2 1.6 1.3 1.6 0.0 0.0 0.4 36.3 0.0 2.7 0.0 1.1 9.2 0.3 0.0 0.2 0.0 1.6 1.8 0.1 6.8 0.0 1.6 0.1 0.0 0.0 1.7 10.4 0.0 28.2 3.0 10.9 2.5 10.0 1.6 0.5 1.7 0.0 3.0 23.9 0.0 0.0 8.8 0.0 0.0 0.0 5.0 0.8 0.1 2.5 0.0 0.0 1.4 4.1 10.0 65.4 68.4 13.5 36.0 36.5 23.3 24.6 8.0 20.3 29.7 13.9 7.3 12.9 22.8 39.9 5.0 34.9 6.0 28.8 27.6 50.5 18.5 4.9 44.2 30.9 50.3 10.7 20.7 8.9 2.5 GNG7 FLJ00058 ENSG00000176533 "G protein subunit gamma 7" O60262 19 2511219-2702709 "Predicted intracellular proteins, RAS pathway related proteins" Transducer "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "brain: 115.9" "Cell line enhanced" "Detected in some" "Daudi: 10.3;REH: 30.3;SK-MEL-30: 14.0;U-266/70: 29.2;U-266/84: 13.4" "Cancer enhanced" "Detected in all" "glioma: 21.9" "Region enriched" "Detected in all" 5 "basal ganglia: 115.9" "Group enriched" "Detected in many" 4 "memory B-cell: 23.9;naive B-cell: 20.5;plasmacytoid DC: 19.9" "Group enriched" "Detected in many" 4 "B-cells: 23.9;dendritic cells: 19.9" "Region enriched" "Detected in many" 6 "basal ganglia: 1142.7" "Region enriched" "Detected in all" 6 "basal ganglia: 484.6" HPA057790 Supported Supported "HPA057790: " "unprognostic (3.97e-3)" "unprognostic (1.16e-4)" "unprognostic (4.92e-2)" "unprognostic (2.72e-1)" "unprognostic (2.79e-1)" "unprognostic (8.42e-4)" "prognostic favourable (3.05e-4)" "prognostic favourable (1.35e-5)" "unprognostic (1.27e-2)" "unprognostic (4.95e-2)" "prognostic favourable (3.71e-4)" "unprognostic (1.27e-1)" "prognostic favourable (0.00e+0)" "unprognostic (6.96e-2)" "unprognostic (1.46e-1)" "unprognostic (6.36e-2)" "unprognostic (4.96e-2)" 3.1 4.8 19.8 4.5 115.9 5.4 4.1 9.7 28.2 2.6 3.8 23.4 0.8 4.7 4.8 4.9 11.1 6.5 3.3 22.5 20.3 11.4 6.0 2.2 3.0 8.0 20.0 10.0 10.0 7.2 5.4 4.6 1.4 20.9 7.1 3.0 12.2 22.8 5.7 2.9 1.7 4.9 3.4 28.5 11.0 5.8 5.5 22.0 0.1 3.7 0.4 8.2 3.4 1.4 23.9 19.9 5.0 0.6 0.0 0.5 1.3 0.1 0.0 1.5 3.3 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.3 10.3 0.5 0.1 0.1 1.6 0.0 0.0 0.0 1.4 0.2 0.0 1.2 0.7 0.0 6.1 0.2 0.2 0.0 0.1 0.0 0.1 6.7 0.0 1.0 0.2 0.6 1.2 0.6 30.3 0.0 2.7 0.1 0.0 0.0 4.4 0.0 0.0 14.0 0.2 2.6 0.0 0.0 1.5 0.1 0.1 29.2 13.4 2.2 0.1 3.2 7.7 1.1 0.6 3.2 0.1 0.2 0.4 23.9 0.2 0.1 2.5 20.5 0.5 0.3 5.0 0.0 0.0 19.9 0.0 1.3 19.8 115.9 9.7 20.0 20.3 11.4 20.0 10.0 20.9 22.0 GOLGA5 "golgin-84, GOLIM5, ret-II, rfg5" ENSG00000066455 "Golgin A5" Q8TBA6 14 92794231-92839963 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000992, HPA063876" Enhanced Supported Supported "Golgi apparatus" "Golgi apparatus" "HPA000992: AB_1079009, HPA063876: AB_2685140" "unprognostic (2.06e-1)" "unprognostic (1.76e-1)" "unprognostic (1.57e-1)" "unprognostic (2.64e-1)" "unprognostic (1.73e-1)" "unprognostic (2.77e-2)" "unprognostic (1.68e-1)" "unprognostic (3.15e-1)" "unprognostic (1.78e-1)" "unprognostic (5.02e-2)" "unprognostic (1.15e-2)" "unprognostic (2.83e-2)" "unprognostic (7.67e-2)" "unprognostic (6.44e-2)" "unprognostic (1.76e-1)" "unprognostic (1.06e-2)" "unprognostic (2.49e-2)" 20.8 20.3 16.8 15.7 17.3 6.5 24.4 11.6 17.5 24.9 20.4 17.2 25.5 16.5 18.2 41.7 21.2 15.3 17.5 18.3 17.5 15.6 21.5 51.0 16.6 18.2 18.6 14.6 18.9 26.8 23.6 27.2 44.4 16.4 23.4 23.7 12.7 24.3 30.2 20.6 18.9 25.6 18.9 19.4 16.9 23.0 23.5 17.6 13.5 24.8 17.8 16.4 20.7 15.8 9.7 9.7 22.2 12.7 8.1 12.4 6.3 12.6 11.6 10.5 9.6 22.1 30.0 18.1 17.5 32.3 17.1 20.2 8.5 17.4 8.2 14.4 27.8 13.3 9.3 14.3 23.3 10.0 4.4 7.7 5.8 11.4 25.7 9.0 13.0 23.0 26.0 12.0 24.9 16.8 6.8 11.1 18.7 23.4 6.9 7.8 6.5 12.5 5.4 15.5 8.2 17.4 15.4 7.5 10.6 15.9 12.0 17.8 20.6 10.0 13.9 9.8 6.5 12.7 8.7 13.6 10.5 7.2 22.6 7.2 16.4 9.1 9.8 22.2 10.9 12.7 12.3 9.7 11.1 11.1 9.7 9.2 9.9 8.6 8.7 8.1 10.8 9.1 12.4 6.3 16.8 17.3 11.6 17.5 17.5 15.6 18.6 14.6 16.4 17.6 GPR151 "GALR4, PGR7" ENSG00000173250 "G protein-coupled receptor 151" Q8TDV0 5 146513103-146516190 "G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Group enriched" "Detected in some" 7 "blood: 1.5;brain: 2.8" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "naive B-cell: 1.5" "Low lineage specificity" "Detected in single" "Region enriched" "Detected in single" 19 "thalamus: 36.8" "Region enriched" "Detected in single" 7 "thalamus: 4.6" HPA065728 Supported "HPA065728: " "unprognostic (2.09e-1)" "unprognostic (2.30e-1)" "unprognostic (1.14e-1)" "unprognostic (1.32e-2)" 0.0 0.1 0.4 0.0 0.5 0.1 0.0 0.0 2.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 2.8 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.5 0.2 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.3 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.8 0.3 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.5 0.0 0.0 0.3 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.6 0.1 0.1 0.1 0.4 0.4 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.2 1.5 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 GPR17 ENSG00000144230 "G protein-coupled receptor 17" Q13304 2 127645864-127652639 "G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "brain: 43.8" "Cell line enhanced" "Detected in some" "HeLa: 4.5;REH: 7.5;TIME: 7.4;U-2 OS: 3.1;U-2197: 3.5;U-251 MG: 4.4" "Cancer enriched" "Detected in some" 32 "glioma: 16.5" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 11 "naive B-cell: 4.0" "Lineage enriched" "Detected in single" 11 "B-cells: 4.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA029766 Enhanced Supported Approved Vesicles Vesicles "HPA029766: AB_10612114" "unprognostic (8.10e-2)" "unprognostic (1.73e-1)" "unprognostic (2.61e-1)" "unprognostic (1.42e-2)" "unprognostic (1.54e-1)" "unprognostic (5.19e-2)" "unprognostic (2.77e-5)" "unprognostic (8.40e-3)" "unprognostic (2.92e-1)" "unprognostic (3.25e-2)" "unprognostic (1.61e-3)" "unprognostic (6.60e-2)" "unprognostic (2.11e-3)" "unprognostic (3.33e-2)" "unprognostic (2.19e-1)" "unprognostic (2.04e-1)" "unprognostic (1.31e-1)" 7.0 2.2 23.7 6.8 21.3 0.8 5.4 4.1 25.6 2.4 16.4 43.8 0.0 3.3 11.2 3.3 5.0 4.0 4.3 12.5 20.6 1.2 2.3 1.6 9.3 2.4 9.1 9.9 1.4 4.6 0.5 0.4 2.7 18.8 3.9 0.8 0.1 1.7 0.5 13.1 6.7 3.8 0.5 6.3 12.6 5.0 1.8 22.6 0.0 2.8 0.0 0.5 6.1 3.9 4.0 0.3 0.1 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.3 0.3 0.6 0.0 0.0 1.6 0.2 0.0 0.0 0.0 0.8 0.0 0.0 0.0 4.5 0.8 0.2 0.0 0.0 0.0 0.0 0.6 0.0 0.1 0.0 0.3 0.0 0.0 0.6 0.2 0.1 0.2 7.5 0.2 0.0 0.0 0.0 0.0 0.3 0.2 0.3 0.0 0.3 0.0 7.4 0.0 3.1 3.5 4.4 0.2 0.0 0.0 0.1 0.1 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.3 4.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 23.7 21.3 4.1 25.6 20.6 1.2 9.1 9.9 18.8 22.6 GPR88 ENSG00000181656 "G protein-coupled receptor 88" Q9GZN0 1 100538137-100542018 "Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Mental retardation" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in some" 5 "brain: 62.7" "Group enriched" "Detected in some" 8 "HSkMC: 4.8;SCLC-21H: 5.9" "Cancer enriched" "Detected in some" 9 "liver cancer: 12.0" "Group enriched" "Detected in many" 7 "basal ganglia: 62.7;thalamus: 32.8" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in many" 11 "basal ganglia: 643.5" "Region enriched" "Detected in some" 35 "basal ganglia: 223.4" HPA007488 Approved "HPA007488: " "unprognostic (1.65e-1)" "unprognostic (1.50e-1)" "unprognostic (8.30e-2)" "unprognostic (8.37e-3)" "unprognostic (5.41e-1)" "unprognostic (5.63e-2)" "unprognostic (1.82e-1)" "unprognostic (1.28e-1)" "unprognostic (1.03e-2)" "unprognostic (7.76e-2)" "unprognostic (8.23e-3)" "unprognostic (2.45e-1)" "unprognostic (3.93e-4)" "unprognostic (1.85e-2)" "unprognostic (5.56e-2)" "unprognostic (4.41e-1)" "unprognostic (1.35e-2)" 0.7 0.6 1.2 0.5 62.7 0.2 10.9 0.0 6.8 0.1 0.3 0.8 0.0 0.6 0.2 0.2 0.2 0.1 0.2 0.4 0.9 0.8 0.3 13.1 0.2 0.3 0.7 1.1 3.8 0.1 4.6 0.5 0.2 7.0 0.6 0.5 0.3 0.7 0.1 0.3 0.1 0.5 0.3 0.5 13.7 0.4 0.2 32.8 0.0 0.1 0.0 0.2 0.2 0.0 0.0 0.4 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 4.8 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.0 5.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 62.7 0.0 6.8 0.9 0.8 0.7 1.1 7.0 32.8 GRM1 "GPRC1A, mGlu1, MGLUR1, PPP1R85" ENSG00000152822 "Glutamate metabotropic receptor 1" Q13255 6 146027646-146437598 "Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, Neurodegeneration, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "brain: 39.9" "Cell line enhanced" "Detected in some" "AF22: 1.6;HeLa: 1.4;Karpas-707: 1.5" "Not detected" "Not detected" "Region enhanced" "Detected in many" "cerebellum: 39.9" "Cell type enriched" "Detected in single" 4 "NK-cell: 1.1" "Lineage enriched" "Detected in single" 4 "NK-cells: 1.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA015701 Approved Supported Approved Vesicles Vesicles "HPA015701: AB_1853917" "unprognostic (1.04e-2)" "unprognostic (7.33e-2)" "unprognostic (3.73e-3)" "unprognostic (9.77e-3)" "unprognostic (6.75e-2)" "unprognostic (2.13e-1)" "unprognostic (1.09e-1)" "unprognostic (5.78e-2)" "unprognostic (4.31e-2)" "unprognostic (2.93e-2)" "unprognostic (9.48e-3)" "unprognostic (7.92e-2)" "unprognostic (1.84e-2)" "unprognostic (1.03e-1)" "unprognostic (3.50e-2)" "unprognostic (8.33e-3)" "unprognostic (9.76e-2)" 0.5 0.5 6.6 0.4 6.0 0.4 0.5 39.9 13.0 0.5 0.5 0.9 0.0 0.4 0.5 0.7 0.5 0.7 0.5 7.7 6.0 2.7 2.7 0.5 0.6 0.5 2.6 4.1 0.5 0.5 0.4 0.2 0.5 3.6 0.5 0.4 2.6 0.5 0.8 0.4 0.5 0.5 0.5 1.0 0.6 0.5 1.3 0.9 0.0 0.8 0.0 0.4 0.5 0.1 0.0 0.0 0.2 0.0 1.1 0.0 0.0 0.0 0.1 1.6 0.2 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.5 0.2 0.2 0.0 0.0 0.0 0.2 0.1 0.0 0.4 1.4 0.0 0.2 0.0 0.0 0.5 0.0 0.0 0.0 0.7 0.0 1.5 0.1 0.0 0.0 0.4 0.2 0.8 0.0 0.0 0.0 0.1 0.0 1.1 0.6 0.1 0.1 0.5 0.0 0.5 0.1 0.1 0.1 0.7 0.2 0.2 0.1 0.1 0.5 0.8 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.1 0.0 0.0 0.0 0.0 6.6 6.0 39.9 10.5 6.0 2.7 2.6 4.1 3.6 0.9 GRM2 "GPRC1B, mGlu2, MGLUR2" ENSG00000164082 "Glutamate metabotropic receptor 2" Q14416 3 51707070-51718613 "G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 7 "brain: 13.2" "Cell line enriched" "Detected in some" 6 "SCLC-21H: 11.7" "Cancer enhanced" "Detected in single" "testis cancer: 1.3" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA027868, HPA065166" Approved Supported "HPA027868: , HPA065166: " "unprognostic (1.01e-1)" "unprognostic (8.61e-4)" "unprognostic (7.66e-2)" "unprognostic (7.29e-3)" "unprognostic (1.98e-1)" "unprognostic (3.68e-2)" "unprognostic (7.10e-2)" "unprognostic (1.27e-1)" "unprognostic (1.39e-2)" "unprognostic (2.05e-1)" "unprognostic (4.45e-1)" "unprognostic (1.74e-1)" "unprognostic (1.37e-2)" "unprognostic (1.35e-1)" "unprognostic (1.82e-1)" "unprognostic (2.93e-2)" "unprognostic (1.19e-2)" 0.8 0.6 4.6 0.8 6.3 1.6 0.7 3.8 13.2 0.6 0.6 0.4 0.0 0.6 0.8 0.4 0.5 0.5 0.4 0.9 3.0 3.1 0.5 0.5 0.6 0.7 1.2 7.0 0.5 0.4 0.4 0.4 0.6 8.3 0.7 0.5 0.6 0.8 0.6 1.8 1.3 0.5 0.6 0.5 1.1 0.5 1.3 0.2 0.0 0.5 0.0 0.5 1.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 11.7 0.4 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.2 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.6 6.3 3.8 13.2 3.0 3.1 1.2 7.0 8.3 0.2 HAPLN1 CRTL1 ENSG00000145681 "Hyaluronan and proteoglycan link protein 1" P10915 5 83637805-83721613 "Predicted secreted proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "placenta: 41.8" "Group enriched" "Detected in some" 37 "PC-3: 44.7;TIME: 28.2;U-2 OS: 46.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019105, HPA019482, HPA025238" Enhanced Approved Supported Vesicles "Secreted to extracellular matrix" Vesicles "HPA019105: AB_1850496, HPA019482: AB_1850498, HPA025238: " "unprognostic (5.74e-4)" "unprognostic (2.94e-2)" "unprognostic (6.58e-3)" "unprognostic (2.30e-2)" "unprognostic (1.30e-1)" "unprognostic (2.76e-3)" "unprognostic (6.01e-4)" "unprognostic (2.52e-2)" "unprognostic (1.70e-1)" "unprognostic (9.04e-3)" "unprognostic (1.31e-1)" "unprognostic (2.28e-2)" "prognostic unfavourable (4.81e-9)" "unprognostic (6.87e-2)" "unprognostic (2.04e-1)" "unprognostic (8.62e-2)" "unprognostic (3.91e-2)" 0.1 0.0 5.4 1.5 3.9 0.0 0.1 0.6 4.7 0.1 4.7 0.1 0.1 3.8 0.5 0.1 1.2 0.0 0.5 1.8 3.4 1.3 0.4 0.1 0.9 0.1 1.7 0.7 0.2 0.2 0.0 0.1 41.8 1.5 4.9 5.8 1.5 0.9 0.1 0.1 0.5 9.3 0.3 0.6 0.1 2.4 0.1 0.1 0.1 0.3 0.5 0.3 0.9 0.1 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 1.0 44.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 28.2 0.0 46.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 5.4 3.9 0.6 4.4 3.4 1.3 1.7 0.7 1.5 0.1 HCRT "OX, PPOX" ENSG00000161610 "Hypocretin neuropeptide precursor" O43612 17 42184060-42185452 "Disease related genes, Predicted secreted proteins" Neuropeptide "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 31 "brain: 84.3" "Cell line enhanced" "Detected in some" "HDLM-2: 1.9;Karpas-707: 1.0;RPMI-8226: 3.6" "Cancer enhanced" "Detected in single" "glioma: 0.5" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 4 "B-cells: 2.7;granulocytes: 2.3;T-cells: 2.2" "Region enriched" "Detected in some" 5 "hypothalamus: 110.5" "Region enriched" "Detected in single" 56 "hypothalamus: 152.0" "HPA064801, CAB079778" Enhanced Supported "Secreted to blood" "CAB079778: , HPA064801: " "unprognostic (3.34e-2)" "unprognostic (7.76e-5)" "unprognostic (3.21e-2)" "unprognostic (3.01e-2)" "unprognostic (2.20e-2)" "unprognostic (1.41e-1)" "unprognostic (1.23e-1)" 0.9 0.0 0.0 1.1 0.2 0.9 0.0 0.0 0.7 0.0 0.5 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 84.3 0.4 0.0 0.0 0.4 0.1 0.3 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.3 0.1 0.3 0.0 0.0 0.0 0.0 2.7 0.4 2.3 0.5 0.4 2.2 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.9 0.9 0.8 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.6 1.0 0.0 0.0 0.8 0.8 0.4 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.9 0.2 0.7 0.8 0.2 0.0 0.1 0.0 2.3 0.5 0.0 1.2 0.4 2.2 1.5 0.9 1.6 0.4 2.7 1.4 1.3 0.1 0.4 0.2 0.3 0.5 0.1 HOMER1 "HOMER-1B, SYN47, Ves-1" ENSG00000152413 "Homer scaffolding protein 1" Q86YM7 5 79372636-79514217 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 28.9;skeletal muscle: 28.0" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004437, HPA036521, HPA036522" Enhanced Supported Approved Cytosol Cytosol "CAB004437: AB_627742, HPA036521: AB_2675170, HPA036522: AB_2675171" "unprognostic (2.80e-1)" "unprognostic (5.30e-2)" "unprognostic (4.00e-2)" "unprognostic (5.79e-2)" "unprognostic (8.83e-2)" "unprognostic (6.40e-2)" "unprognostic (2.00e-3)" "unprognostic (2.41e-3)" "unprognostic (2.22e-1)" "unprognostic (3.79e-1)" "unprognostic (3.07e-3)" "unprognostic (3.98e-1)" "unprognostic (7.35e-2)" "unprognostic (9.30e-2)" "unprognostic (1.72e-1)" "unprognostic (2.83e-2)" "unprognostic (2.86e-3)" 3.0 1.6 11.3 2.4 19.7 0.6 2.7 8.4 28.9 4.4 1.6 1.2 0.0 1.0 6.8 4.5 4.7 2.5 6.9 19.1 8.5 4.2 5.9 2.0 5.1 1.3 2.9 13.3 4.7 2.4 4.5 3.6 5.3 5.3 2.0 1.3 2.1 1.9 2.1 28.0 2.6 1.2 4.7 2.2 1.1 2.1 5.1 3.5 1.7 14.4 4.8 1.7 5.0 2.2 2.0 0.6 0.2 0.0 0.4 2.3 0.5 8.4 5.9 8.8 14.0 3.4 2.2 20.4 5.4 4.3 5.5 5.9 9.2 6.0 0.1 16.5 4.6 4.6 10.9 14.6 9.5 1.2 8.6 10.2 2.5 9.1 5.5 4.7 3.3 3.6 9.5 4.9 13.8 2.5 12.4 5.6 7.1 11.9 20.0 3.3 14.9 5.0 13.1 14.5 12.9 5.8 13.2 9.0 5.4 10.2 7.3 5.4 10.0 4.2 0.4 4.1 10.3 4.9 9.5 2.7 6.1 5.0 11.6 1.9 7.8 0.0 0.0 0.1 2.3 0.0 1.3 2.0 0.9 0.7 0.0 1.6 0.5 1.7 0.2 0.4 0.0 0.6 0.0 0.5 11.3 19.7 8.4 18.8 8.5 4.2 2.9 13.3 5.3 3.5 HOMER2 "CPD, Cupidin, DFNA68, HOMER-2, HOMER-2A, HOMER-2B, Vesl-2" ENSG00000103942 "Homer scaffolding protein 2" Q9NSB8 15 82836946-82986153 "Disease related genes, Predicted intracellular proteins" Hearing "Deafness, Disease mutation, Non-syndromic deafness" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "pancreas: 80.9" "Cell line enhanced" "Detected in many" "HAP1: 21.1;Karpas-707: 37.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "myeloid DC: 4.1" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA040134, CAB079014" Uncertain Supported Supported Cytosol Cytosol "CAB079014: , HPA040134: AB_10795272" "unprognostic (7.34e-2)" "unprognostic (3.58e-2)" "unprognostic (5.75e-4)" "unprognostic (3.31e-3)" "unprognostic (4.85e-2)" "unprognostic (1.24e-1)" "unprognostic (1.04e-2)" "unprognostic (7.13e-3)" "unprognostic (2.69e-1)" "unprognostic (1.40e-1)" "unprognostic (1.02e-1)" "unprognostic (2.75e-1)" "unprognostic (8.16e-4)" "unprognostic (2.30e-1)" "unprognostic (3.21e-2)" "unprognostic (1.26e-1)" "unprognostic (4.45e-3)" 0.7 2.9 3.9 0.5 3.8 1.6 9.9 5.1 6.5 8.9 1.4 4.6 2.7 3.2 3.4 13.0 8.0 9.6 12.9 12.5 5.0 3.1 2.8 19.4 2.5 1.0 2.5 4.2 1.7 80.9 2.7 4.5 0.4 13.2 21.8 0.6 12.7 34.5 2.0 36.0 15.9 0.6 0.7 5.4 2.3 17.8 2.3 2.0 0.2 13.4 14.2 5.0 0.8 4.3 1.4 4.1 1.6 0.6 0.4 1.1 1.0 6.4 2.7 2.9 7.6 0.0 0.0 0.4 0.4 0.0 0.7 0.2 0.5 4.6 0.0 3.6 3.3 3.6 21.1 9.9 0.5 17.5 13.4 4.1 0.1 3.2 0.2 0.1 13.3 0.7 15.2 0.2 0.8 0.0 0.1 37.4 2.8 18.8 1.2 0.4 4.6 2.0 0.8 4.6 2.2 10.2 7.9 20.7 5.3 7.4 5.7 6.9 6.9 1.4 0.1 7.0 13.0 0.5 5.9 4.8 2.2 0.7 11.9 0.1 2.5 0.3 0.6 1.5 0.4 0.5 0.3 0.7 0.8 0.2 4.1 1.4 0.6 0.4 1.6 0.4 0.3 1.8 1.1 1.0 3.9 3.8 5.1 6.5 5.0 3.1 2.5 4.2 13.2 2.0 HOMER3 HOMER-3 ENSG00000051128 "Homer scaffolding protein 3" Q9NSC5 19 18929201-18941261 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 64.8" "Cell line enhanced" "Detected in many" "NB-4: 61.2;THP-1: 73.6;U-266/84: 63.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "classical monocyte: 14.7" "Group enriched" "Detected in many" 4 "granulocytes: 5.1;monocytes: 14.7" "Region enriched" "Detected in many" 6 "cerebellum: 212.2" "Low region specificity" "Detected in all" "CAB032656, HPA040999, CAB079015" Enhanced Supported Supported "Plasma membrane,Cytosol,Cytoplasmic bodies" Cytosol "Plasma membrane, Cytoplasmic bodies" "CAB032656: AB_2120801, CAB079015: , HPA040999: " "unprognostic (3.41e-2)" "unprognostic (1.71e-1)" "prognostic unfavourable (4.24e-5)" "unprognostic (1.19e-1)" "unprognostic (2.06e-1)" "unprognostic (1.11e-1)" "prognostic unfavourable (4.93e-5)" "unprognostic (1.07e-1)" "unprognostic (8.88e-2)" "unprognostic (5.78e-2)" "unprognostic (1.28e-1)" "unprognostic (2.10e-2)" "unprognostic (5.99e-2)" "unprognostic (3.76e-2)" "unprognostic (2.33e-1)" "unprognostic (1.41e-1)" "unprognostic (4.11e-2)" 11.4 8.3 11.1 6.5 16.0 12.4 31.0 42.3 12.2 8.7 6.7 17.6 2.1 4.9 8.2 5.2 7.6 4.8 10.9 11.9 15.8 9.0 21.2 4.1 7.0 5.5 19.4 7.2 8.2 5.3 13.6 2.4 9.7 15.5 8.1 4.5 15.4 8.4 7.0 49.2 10.9 5.5 7.6 24.2 64.8 6.5 3.4 14.6 2.2 19.6 7.8 3.3 12.3 16.8 2.4 1.2 5.1 14.7 0.0 0.7 3.6 19.3 5.0 9.6 7.9 8.9 9.0 4.7 19.2 17.0 19.3 9.8 2.5 7.4 0.1 9.1 21.5 12.1 3.3 24.9 10.8 0.6 2.0 0.0 1.6 4.7 8.3 3.7 0.3 7.3 16.1 10.7 14.5 23.4 0.5 5.1 14.0 5.2 0.3 61.2 4.9 20.7 9.5 2.9 9.0 6.9 5.0 0.0 8.1 4.7 5.6 13.5 2.5 73.6 18.6 17.2 7.7 20.7 23.0 49.9 63.2 16.1 27.1 47.3 12.4 0.1 14.7 2.6 0.1 5.1 0.0 2.4 0.7 0.3 1.2 1.7 0.1 0.0 5.1 0.0 1.4 0.2 0.7 3.6 11.1 16.0 42.3 12.2 15.8 9.0 19.4 7.2 15.5 14.6 HPF1 "C4orf27, FLJ20534" ENSG00000056050 "Histone PARylation factor 1" Q9NWY4 4 169729465-169757953 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA043467 Uncertain Approved Approved "Microtubules,Cytokinetic bridge,Cytosol" Cytosol "Microtubules, Cytokinetic bridge" "HPA043467: AB_10793949" "unprognostic (1.09e-1)" "unprognostic (1.15e-2)" "unprognostic (1.72e-2)" "unprognostic (1.47e-1)" "unprognostic (2.70e-1)" "unprognostic (1.09e-1)" "unprognostic (8.68e-3)" "unprognostic (2.74e-2)" "prognostic unfavourable (5.63e-4)" "prognostic favourable (7.47e-4)" "unprognostic (6.34e-2)" "unprognostic (4.55e-1)" "unprognostic (3.06e-1)" "unprognostic (2.26e-1)" "unprognostic (1.32e-1)" "unprognostic (5.51e-2)" "unprognostic (1.09e-1)" 16.5 18.6 27.3 14.9 26.3 13.7 20.9 22.9 31.7 17.6 17.5 17.6 10.0 11.5 23.2 25.2 17.2 16.9 12.7 20.9 27.3 24.0 17.5 20.8 13.5 18.0 24.9 22.6 23.1 13.1 13.9 22.9 16.0 33.4 17.4 17.6 15.1 12.2 16.0 17.4 18.6 11.3 24.2 23.8 16.4 14.0 12.9 19.8 20.8 18.5 14.9 19.3 19.0 14.8 13.6 15.6 12.8 14.1 14.9 22.2 13.3 12.4 7.9 27.6 14.4 16.9 20.9 11.7 22.7 22.5 28.3 30.1 5.3 13.5 6.5 6.1 14.7 5.6 18.9 16.5 30.0 20.4 12.9 21.2 11.6 7.5 11.9 17.9 7.8 13.5 16.8 18.2 5.6 24.5 15.9 25.5 24.6 10.1 37.5 15.6 11.2 10.3 16.6 13.1 7.8 16.1 8.2 6.6 24.6 15.0 6.6 20.5 13.0 16.1 11.8 9.7 15.4 22.6 20.2 12.2 18.1 19.4 26.8 17.5 15.4 8.9 12.3 12.8 18.5 14.1 21.9 13.6 21.5 22.2 15.6 11.1 21.2 21.7 3.3 14.9 13.1 10.7 22.0 13.3 27.3 26.3 22.9 31.7 27.3 24.0 24.9 22.6 33.4 19.8 HSPA2 ENSG00000126803 "Heat shock protein family A (Hsp70) member 2" P54652 14 64535905-64546173 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Differentiation, Spermatogenesis, Stress response" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 87.0;skeletal muscle: 90.5" "Cell line enhanced" "Detected in many" "A549: 24.6;BEWO: 38.4;BJ hTERT+: 32.8;SCLC-21H: 34.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000798, HPA052504" Enhanced Supported Approved Nucleoplasm,Vesicles 77000000 Vesicles Nucleoplasm "HPA000798: AB_1079090, HPA052504: " "prognostic favourable (1.78e-4)" "unprognostic (1.72e-1)" "unprognostic (2.73e-1)" "unprognostic (1.08e-2)" "unprognostic (3.78e-2)" "unprognostic (2.90e-2)" "unprognostic (7.11e-2)" "prognostic unfavourable (9.11e-4)" "unprognostic (1.31e-1)" "unprognostic (3.14e-2)" "unprognostic (2.09e-1)" "unprognostic (2.60e-1)" "unprognostic (5.31e-2)" "unprognostic (1.14e-1)" "unprognostic (1.90e-1)" "unprognostic (8.36e-2)" "unprognostic (1.25e-1)" 5.2 3.3 21.1 5.2 45.3 1.5 5.2 3.7 37.6 3.3 23.3 87.0 0.1 4.4 13.8 12.8 25.2 7.2 4.2 22.8 33.2 18.7 26.6 2.6 4.5 3.2 71.0 20.6 2.4 3.8 7.5 4.3 37.6 37.7 3.8 6.9 3.5 10.2 4.0 90.5 14.8 7.8 17.9 83.8 8.5 5.7 58.8 65.2 0.0 2.3 8.2 3.9 12.4 4.0 0.7 0.3 2.4 0.6 0.9 3.7 0.5 9.6 24.6 3.8 0.0 2.7 0.2 38.4 13.9 32.8 5.6 9.2 0.9 17.4 2.4 5.6 15.1 11.0 0.0 0.7 3.4 1.3 1.9 0.0 1.4 0.0 2.7 0.0 3.3 1.2 0.5 0.8 0.0 0.3 0.0 2.0 2.7 4.3 0.1 0.1 2.8 3.0 1.9 0.0 0.0 8.6 1.5 34.1 1.9 0.6 1.2 0.0 0.9 1.0 0.5 0.1 0.0 1.2 0.0 2.5 0.0 0.0 3.1 0.0 3.7 0.9 0.2 0.1 1.8 0.4 0.1 0.7 1.7 0.8 0.0 0.5 0.6 0.6 2.4 0.9 0.6 0.3 3.7 0.5 21.1 45.3 3.7 28.3 33.2 18.7 71.0 20.6 37.7 65.2 IGDCC4 "LOC57722, NOPE" ENSG00000103742 "Immunoglobulin superfamily DCC subclass member 4" Q8TDY8 15 65381464-65423072 "Plasma proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 14.1" "Cell line enhanced" "Detected in some" "A549: 5.0;AF22: 10.2;CAPAN-2: 8.9;EFO-21: 5.1;HSkMC: 5.7;NTERA-2: 7.6" "Cancer enhanced" "Detected in many" "glioma: 6.9" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008510, HPA008576" Approved Approved Approved Nucleoplasm,Cytosol 34000000 "Nucleoplasm, Cytosol" "HPA008510: , HPA008576: AB_1079496" "unprognostic (1.16e-1)" "unprognostic (9.38e-2)" "unprognostic (1.92e-2)" "unprognostic (1.20e-2)" "unprognostic (1.58e-1)" "unprognostic (1.77e-2)" "unprognostic (2.75e-3)" "unprognostic (9.94e-2)" "unprognostic (4.18e-2)" "unprognostic (3.65e-2)" "unprognostic (3.29e-2)" "unprognostic (6.36e-2)" "unprognostic (1.83e-8)" "unprognostic (3.30e-2)" "unprognostic (4.54e-2)" "unprognostic (2.33e-1)" "unprognostic (5.32e-3)" 1.7 6.2 8.3 3.7 5.0 0.2 1.3 2.0 4.9 6.1 1.4 8.0 0.0 1.0 2.3 7.2 2.6 2.9 6.7 2.2 6.2 4.1 0.6 0.3 0.7 1.1 5.6 3.1 13.3 0.7 0.2 2.4 8.2 6.1 0.9 1.2 1.6 1.5 1.3 14.1 1.5 1.7 3.1 5.0 0.5 1.9 2.5 6.5 0.0 4.6 4.0 1.5 4.7 5.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.0 10.2 0.0 0.0 1.1 0.1 0.4 0.0 0.0 0.4 0.6 8.9 0.0 5.1 0.4 0.0 2.5 0.0 0.1 0.0 0.6 0.0 0.0 0.2 0.4 0.0 0.0 5.7 0.0 0.5 0.0 0.0 0.5 0.0 1.8 0.0 0.0 0.8 7.6 0.0 0.0 2.5 0.0 3.6 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.0 4.1 2.6 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.3 5.0 2.0 3.9 6.2 4.1 5.6 3.1 6.1 6.5 IGFBP5 ENSG00000115461 "Insulin like growth factor binding protein 5" P24593 2 216672105-216695525 "Plasma proteins, Predicted secreted proteins" "Growth factor binding" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ovary: 245.3" "Cell line enhanced" "Detected in many" "BJ: 77.9;BJ hTERT+: 207.2;T-47d: 50.4;U-138 MG: 68.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA059827, HPA070407" Supported Approved "Nuclear bodies,Golgi apparatus,Vesicles" "Secreted to blood" 109650000 330000000 "Golgi apparatus, Vesicles" "Nuclear bodies" "HPA059827: , HPA070407: " "unprognostic (7.69e-2)" "unprognostic (2.56e-1)" "unprognostic (1.02e-1)" "prognostic unfavourable (1.78e-4)" "unprognostic (4.58e-2)" "unprognostic (3.47e-1)" "unprognostic (2.04e-1)" "unprognostic (1.76e-1)" "unprognostic (1.32e-1)" "unprognostic (9.58e-2)" "unprognostic (1.12e-1)" "unprognostic (2.41e-2)" "unprognostic (4.04e-2)" "unprognostic (9.62e-3)" "unprognostic (1.55e-1)" "unprognostic (3.28e-2)" "unprognostic (1.91e-3)" 47.3 23.4 6.2 19.2 6.3 0.1 41.3 3.6 6.5 191.7 23.1 19.7 15.8 3.9 94.6 91.0 30.0 96.9 21.4 16.9 8.2 2.4 34.8 7.8 9.3 14.5 12.1 7.4 245.3 3.5 6.5 37.7 32.7 7.0 31.4 7.9 188.5 12.0 15.1 47.0 13.5 14.2 71.8 7.4 7.6 36.9 51.7 12.0 1.5 130.1 34.5 17.6 28.8 45.2 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 20.1 0.0 23.2 0.7 0.0 77.9 207.2 10.4 1.0 0.0 0.0 0.0 0.3 0.2 0.0 2.4 0.0 0.5 0.0 0.7 20.0 0.4 0.0 10.1 0.0 0.1 3.2 0.0 1.4 0.0 0.0 0.0 0.0 0.0 6.4 0.0 0.1 0.2 0.3 0.0 0.0 0.1 6.7 23.1 1.3 0.8 1.3 9.6 0.0 50.4 0.0 7.5 68.7 4.2 10.4 3.7 0.0 0.0 0.0 0.1 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 6.2 6.3 3.6 6.5 8.2 2.4 12.1 7.4 7.0 12.0 INA "NEF5, NF-66" ENSG00000148798 "Internexin neuronal intermediate filament protein alpha" Q16352 10 103277163-103290351 "Predicted intracellular proteins" "Differentiation, Neurogenesis" "Developmental protein" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 65.4" "Cell line enhanced" "Detected in some" "NTERA-2: 20.6;SCLC-21H: 40.5;SH-SY5Y: 23.0;SiHa: 27.4" "Cancer enhanced" "Detected in many" "testis cancer: 18.2" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002059, HPA007572, HPA008057" Enhanced Supported Approved "Intermediate filaments" "Intermediate filaments" "CAB002059: AB_442031, HPA007572: , HPA008057: AB_1851833" "unprognostic (1.77e-1)" "unprognostic (2.50e-2)" "unprognostic (9.54e-2)" "unprognostic (5.49e-3)" "unprognostic (3.91e-1)" "unprognostic (1.45e-3)" "unprognostic (1.31e-1)" "unprognostic (2.29e-2)" "unprognostic (2.08e-2)" "unprognostic (1.98e-1)" "unprognostic (8.09e-3)" "unprognostic (3.07e-2)" "unprognostic (1.78e-3)" "unprognostic (1.66e-1)" "unprognostic (1.90e-1)" "unprognostic (1.50e-1)" "unprognostic (1.07e-1)" 1.5 15.7 16.6 2.6 21.3 1.3 1.3 26.9 65.2 1.3 2.7 2.3 0.0 2.0 1.3 1.4 1.9 1.3 1.5 1.3 13.2 34.0 1.3 1.4 1.5 1.4 27.2 17.7 1.3 3.6 1.3 12.8 1.5 65.4 1.5 2.8 5.5 1.3 1.4 1.3 2.2 2.5 2.2 7.9 1.3 2.6 4.1 3.3 0.0 1.5 0.0 1.5 2.9 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.6 4.6 0.0 0.0 0.0 7.5 5.1 1.2 1.2 0.1 0.0 0.0 0.0 2.1 0.3 0.7 4.2 0.0 0.3 9.2 1.9 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.0 0.0 5.0 0.0 20.6 0.0 0.0 0.0 0.0 3.2 0.0 40.5 23.0 27.4 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 1.3 1.1 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.6 21.3 26.9 42.0 13.2 34.0 27.2 17.7 65.4 3.3 IPO7 "Imp7, RANBP7" ENSG00000205339 "Importin 7" O95373 11 9384622-9448126 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters" "Host-virus interaction, Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019002, HPA056590" Approved Approved Supported Nucleoplasm,Cytosol 26000 "Nucleoplasm, Cytosol" "HPA019002: AB_1856059, HPA056590: " "unprognostic (1.92e-1)" "prognostic unfavourable (4.98e-4)" "unprognostic (9.50e-2)" "unprognostic (1.27e-1)" "unprognostic (3.68e-1)" "unprognostic (1.60e-2)" "prognostic unfavourable (6.57e-4)" "unprognostic (1.19e-2)" "unprognostic (7.60e-2)" "unprognostic (2.12e-1)" "prognostic unfavourable (8.38e-6)" "unprognostic (3.06e-1)" "unprognostic (1.55e-1)" "unprognostic (1.13e-1)" "unprognostic (8.08e-2)" "unprognostic (2.17e-1)" "unprognostic (3.90e-3)" 23.9 20.6 21.8 18.6 24.4 12.3 36.0 24.1 30.6 24.3 27.4 14.4 19.3 17.0 25.7 19.3 29.0 20.3 20.3 37.7 22.8 23.4 26.5 24.7 22.0 23.2 23.3 17.4 23.4 25.9 33.1 19.1 26.5 24.8 24.4 22.1 12.0 21.4 22.4 88.2 17.1 16.1 53.4 25.7 16.6 21.5 9.7 16.8 20.8 34.3 28.5 20.9 43.7 33.9 3.8 5.8 1.3 6.3 6.9 5.4 1.6 37.3 29.2 34.4 27.3 34.9 45.1 27.6 45.5 29.3 33.7 36.5 25.3 34.4 35.1 16.6 35.0 29.4 48.8 35.3 56.3 16.7 40.3 29.0 33.2 25.3 21.8 44.3 22.1 28.8 38.3 22.1 52.2 39.7 43.4 21.1 43.8 15.2 26.7 21.7 33.9 34.0 28.1 54.2 15.8 27.8 35.3 13.7 26.9 20.3 40.3 32.8 18.5 22.3 31.1 41.5 28.6 42.7 48.6 6.1 23.4 24.2 27.2 23.9 22.5 0.1 2.5 0.6 2.7 4.8 5.4 3.8 3.1 3.9 5.8 3.1 3.9 3.2 1.3 6.9 6.3 2.7 2.8 1.6 21.8 24.4 24.1 30.6 22.8 23.4 23.3 17.4 24.8 16.8 IQCB1 "KIAA0036, NPHP5, SLSN5" ENSG00000173226 "IQ motif containing B1" Q15051 3 121769763-121835079 "Disease related genes, Predicted intracellular proteins" "Cilium biogenesis/degradation" Calmodulin-binding "Ciliopathy, Leber congenital amaurosis, Nephronophthisis, Senior-Loken syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-698: 47.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA042028 Approved Approved Supported "Microtubules,Cytokinetic bridge,Mitotic spindle" "Microtubules, Cytokinetic bridge, Mitotic spindle" "HPA042028: " "unprognostic (3.82e-2)" "prognostic favourable (1.77e-4)" "unprognostic (2.16e-1)" "unprognostic (4.10e-2)" "unprognostic (1.24e-2)" "unprognostic (1.69e-2)" "prognostic unfavourable (3.08e-5)" "prognostic favourable (3.67e-4)" "unprognostic (1.42e-1)" "unprognostic (1.87e-1)" "unprognostic (1.70e-1)" "unprognostic (6.78e-3)" "unprognostic (1.50e-3)" "unprognostic (2.59e-3)" "unprognostic (2.75e-1)" "unprognostic (1.67e-1)" "unprognostic (4.75e-3)" 11.5 10.8 9.9 25.1 12.6 16.6 21.9 14.7 16.8 14.4 11.8 8.8 16.9 11.0 14.7 19.4 13.1 15.9 11.5 10.4 10.1 10.1 10.6 9.0 15.0 20.6 12.5 14.5 19.8 22.7 13.9 20.7 12.1 12.4 16.2 15.6 10.9 14.4 30.2 11.4 14.2 14.0 14.6 11.4 19.3 11.2 40.1 12.5 16.2 11.4 9.5 23.0 16.7 14.1 18.9 7.6 8.9 10.4 8.6 10.0 4.9 13.7 3.7 18.4 20.7 3.0 4.5 21.6 6.6 4.0 7.4 9.0 12.7 6.7 27.9 9.2 3.7 10.6 11.3 5.3 11.1 5.4 9.1 18.5 7.3 10.4 7.7 22.9 5.6 2.8 10.2 5.1 11.5 5.6 11.0 10.4 8.3 6.9 14.9 16.2 15.5 6.8 14.8 8.8 8.9 4.3 6.1 9.9 8.0 6.3 4.5 11.4 4.0 17.9 4.7 7.1 8.5 3.4 8.5 25.2 16.0 47.4 6.8 10.5 6.4 2.5 5.2 8.9 6.3 9.9 9.0 18.9 8.3 7.6 7.6 17.5 10.0 6.3 2.1 8.6 10.4 7.2 8.7 4.9 9.9 12.6 14.7 16.8 10.1 10.1 12.5 14.5 12.4 12.5 ITPKA "IP3-3KA, IP3KA" ENSG00000137825 "Inositol-trisphosphate 3-kinase A" P23677 15 41493393-41503551 "Enzymes, Predicted intracellular proteins" "Calmodulin-binding, Kinase, Transferase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "brain: 28.8;intestine: 19.8;stomach 1: 10.7" "Cell line enhanced" "Detected in many" "Hep G2: 22.7" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in many" 5 "amygdala: 12.3;basal ganglia: 21.2;cerebral cortex: 28.8;hippocampal formation: 10.4;olfactory region: 8.2" "Cell type enriched" "Detected in single" 8 "MAIT T-cell: 4.7" "Lineage enriched" "Detected in single" 13 "T-cells: 4.7" "Group enriched" "Detected in many" 13 "amygdala: 120.1;basal ganglia: 97.6;cerebellum: 62.9;cerebral cortex: 164.4;hippocampal formation: 162.9" "Group enriched" "Detected in many" 7 "amygdala: 12.1;basal ganglia: 40.8;cerebral cortex: 32.2;hippocampal formation: 28.6" HPA040454 Enhanced Approved Approved Vesicles Vesicles "HPA040454: AB_10672897" "unprognostic (5.91e-2)" "unprognostic (2.16e-3)" "unprognostic (4.19e-1)" "unprognostic (3.57e-3)" "prognostic unfavourable (6.77e-4)" "unprognostic (2.25e-2)" "unprognostic (2.69e-2)" "unprognostic (1.01e-1)" "unprognostic (3.58e-1)" "unprognostic (1.28e-1)" "unprognostic (1.21e-1)" "unprognostic (2.06e-1)" "prognostic unfavourable (3.76e-9)" "unprognostic (2.15e-1)" "unprognostic (2.87e-1)" "unprognostic (1.12e-3)" "unprognostic (2.10e-2)" 0.4 3.0 12.3 1.1 21.2 0.8 0.4 3.0 28.8 0.6 8.5 0.3 0.0 19.8 0.6 0.5 0.4 0.6 0.6 0.7 10.4 0.9 0.4 0.8 0.4 0.4 1.6 8.2 0.6 2.5 1.7 0.0 0.7 0.3 0.8 3.4 0.0 2.1 0.8 1.4 0.4 19.7 0.7 0.2 0.4 10.7 3.5 0.6 0.0 0.4 0.0 0.4 0.4 0.2 0.0 0.0 0.0 0.0 0.3 4.7 0.0 4.8 1.3 0.2 5.6 0.0 1.8 10.2 3.0 2.4 2.0 2.1 11.2 0.2 0.0 2.5 0.2 0.5 2.4 0.2 0.1 4.5 3.0 6.8 3.0 22.7 9.2 2.3 0.3 0.1 0.1 1.9 0.6 0.1 8.6 1.3 0.7 3.2 0.2 4.4 0.6 4.0 1.1 1.0 0.4 0.2 0.3 0.5 1.1 2.2 0.0 0.2 0.6 3.4 0.2 4.9 5.1 5.5 8.1 0.7 7.1 0.0 9.1 9.0 1.6 0.0 0.0 0.0 0.3 0.0 4.7 0.0 0.3 0.5 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 12.3 21.2 3.0 28.8 10.4 0.9 1.6 8.2 0.3 0.6 KCNIP4 "CALP, KCHIP4, MGC44947" ENSG00000185774 "Potassium voltage-gated channel interacting protein 4" Q6PIL6 4 20728616-21948799 "Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 38.9" "Cell line enhanced" "Detected in many" "RPTEC TERT1: 9.9;SCLC-21H: 7.7" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA022862, HPA066717" Supported Approved Vesicles Vesicles "HPA022862: AB_1852654, HPA066717: " "unprognostic (8.08e-2)" "unprognostic (1.05e-1)" "unprognostic (7.36e-2)" "unprognostic (4.14e-2)" "unprognostic (9.26e-2)" "unprognostic (1.49e-1)" "unprognostic (2.53e-1)" "unprognostic (2.99e-2)" "unprognostic (1.18e-1)" "unprognostic (1.86e-1)" "unprognostic (1.25e-1)" "unprognostic (2.13e-1)" "unprognostic (3.11e-1)" "unprognostic (1.03e-2)" "unprognostic (2.69e-1)" "unprognostic (4.59e-2)" "unprognostic (2.10e-2)" 1.1 3.6 15.8 2.2 28.3 1.0 0.9 22.4 38.9 15.0 4.2 1.8 0.0 2.4 9.6 1.1 5.6 3.9 2.6 1.8 11.9 16.2 7.8 0.7 1.1 1.1 11.6 19.3 1.9 1.0 0.5 5.1 1.8 16.9 1.0 5.2 3.5 1.4 0.8 1.3 2.3 5.5 7.8 3.9 1.1 1.3 1.3 3.5 0.0 8.9 0.0 0.5 2.7 1.1 0.3 0.7 0.0 0.7 0.8 0.7 0.3 1.7 1.5 2.1 2.1 0.0 0.0 1.1 1.3 0.0 0.0 0.0 1.9 1.6 3.3 1.4 0.5 0.9 0.0 0.1 0.0 0.4 2.3 1.2 2.5 1.1 0.0 3.2 0.5 0.0 0.7 0.0 1.4 0.6 2.0 1.1 0.0 0.6 2.7 1.9 2.8 1.4 0.8 4.1 1.3 9.9 0.9 7.7 4.6 1.4 1.7 2.1 0.9 1.2 2.1 1.1 1.5 2.3 3.1 1.0 0.1 1.2 3.6 2.7 1.7 0.0 0.3 0.0 0.2 0.7 0.7 0.2 0.1 0.2 0.7 0.3 0.5 0.5 0.0 0.8 0.5 0.3 0.2 0.3 15.8 28.3 22.4 33.0 11.9 16.2 11.6 19.3 16.9 3.5 KCNMB4 ENSG00000135643 "Potassium calcium-activated channel subfamily M regulatory beta subunit 4" Q86W47 12 70366276-70434292 "FDA approved drug targets, Predicted membrane proteins" "Ion transport, Transport" "Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "adrenal gland: 24.4;brain: 37.7" "Cell line enhanced" "Detected in many" "NTERA-2: 9.0;RH-30: 9.7;RT4: 10.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "naive CD8 T-cell: 2.8" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA072287 Enhanced Approved Approved Cytosol Cytosol "HPA072287: " "unprognostic (3.90e-1)" "unprognostic (1.72e-2)" "unprognostic (2.69e-2)" "unprognostic (2.62e-2)" "unprognostic (6.98e-2)" "unprognostic (1.13e-3)" "unprognostic (1.85e-1)" "unprognostic (2.48e-2)" "unprognostic (3.50e-1)" "unprognostic (2.95e-2)" "unprognostic (3.75e-1)" "unprognostic (2.47e-2)" "unprognostic (2.19e-2)" "unprognostic (1.96e-1)" "unprognostic (1.78e-1)" "unprognostic (4.62e-2)" "unprognostic (1.05e-2)" 4.4 24.4 19.8 2.6 24.6 1.3 2.6 13.8 37.7 3.5 5.0 28.4 1.0 2.5 3.2 2.8 2.6 3.3 3.2 5.9 25.9 10.4 5.8 1.8 4.6 2.8 28.6 19.3 5.4 1.5 1.3 1.4 4.9 11.6 2.9 2.9 2.0 3.8 4.5 4.2 4.9 3.0 2.8 15.2 2.8 1.8 3.8 26.0 0.8 3.3 0.0 2.6 2.4 2.1 1.7 0.6 0.3 0.3 0.2 2.8 0.5 0.0 0.4 5.7 3.2 0.3 0.3 0.6 0.7 1.0 0.3 0.9 0.2 2.1 2.8 0.3 0.0 0.1 6.2 0.9 0.2 1.3 3.5 1.4 1.3 3.2 0.0 0.1 0.1 1.7 0.1 0.0 0.0 0.2 0.0 0.0 1.1 0.8 2.0 0.5 9.0 6.5 2.9 9.7 0.2 0.3 10.6 2.8 3.5 0.9 1.1 0.1 3.2 0.1 0.1 0.4 1.5 0.1 0.4 2.0 0.0 2.8 0.5 0.0 0.9 0.3 0.3 0.0 0.3 0.3 0.3 0.6 0.6 0.6 0.6 1.7 2.2 2.8 0.3 0.2 0.1 0.2 0.6 0.5 19.8 24.6 13.8 19.1 25.9 10.4 28.6 19.3 11.6 26.0 KCTD12 "C13orf2, KIAA1778, PFET1" ENSG00000178695 "Potassium channel tetramerization domain containing 12" Q96CX2 13 76880166-76886390 "Plasma proteins, Predicted intracellular proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 30.2;HUVEC TERT2: 60.0;TIME: 48.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "classical monocyte: 6.4;myeloid DC: 5.9" "Group enriched" "Detected in many" 17 "dendritic cells: 5.9;granulocytes: 1.6;monocytes: 6.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA056987, HPA077376" Supported Approved Mitochondria 19000000 Mitochondria "HPA056987: , HPA077376: " "unprognostic (6.42e-2)" "unprognostic (2.67e-1)" "unprognostic (5.13e-1)" "unprognostic (1.04e-3)" "unprognostic (5.82e-2)" "unprognostic (3.98e-2)" "unprognostic (2.02e-1)" "unprognostic (1.32e-3)" "unprognostic (1.35e-2)" "unprognostic (1.90e-1)" "unprognostic (9.83e-3)" "unprognostic (1.23e-1)" "prognostic favourable (1.14e-4)" "unprognostic (2.11e-2)" "unprognostic (1.65e-2)" "unprognostic (1.07e-1)" "unprognostic (9.25e-2)" 29.6 7.5 12.1 14.3 17.9 2.1 24.7 11.7 9.4 13.1 10.3 10.3 5.1 5.5 14.2 9.2 10.7 21.6 15.1 10.3 10.5 8.2 8.5 6.4 17.2 21.5 17.0 5.9 13.6 6.8 8.2 6.6 22.9 13.8 9.9 11.7 13.8 8.4 4.9 11.2 7.7 8.4 17.9 14.0 21.3 8.3 10.0 13.5 3.1 8.4 5.8 8.4 11.0 15.0 0.0 5.9 1.6 6.4 0.0 0.2 1.4 0.4 0.3 4.0 0.0 30.2 14.4 1.1 1.7 0.4 1.1 1.5 0.1 0.0 0.0 1.0 4.8 14.0 1.7 17.2 0.9 0.3 9.2 0.0 10.4 0.0 1.3 4.6 0.0 5.8 5.7 0.7 13.1 60.0 0.0 0.0 14.1 0.3 2.1 0.0 2.0 2.0 0.1 1.9 5.0 4.6 0.0 1.1 2.1 4.5 0.1 0.6 0.2 3.1 48.2 0.7 1.3 0.1 3.6 0.7 0.1 0.0 11.4 1.0 4.2 0.0 6.4 1.1 0.0 4.1 0.0 0.0 0.1 0.0 5.9 0.0 0.1 0.2 1.6 0.0 2.3 3.0 0.0 1.4 12.1 17.9 11.7 7.5 10.5 8.2 17.0 5.9 13.8 13.5 KIAA0319 NMIG ENSG00000137261 KIAA0319 Q5VV43 6 24544104-24646155 "Disease related genes, Predicted membrane proteins, Predicted secreted proteins" Neurogenesis "Developmental protein" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "brain: 23.5" "Cell line enhanced" "Detected in some" "A-431: 3.6;A549: 4.1;HDLM-2: 4.8;SCLC-21H: 7.8;U-266/84: 6.3" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 9 "memory B-cell: 1.4;neutrophil: 5.0" "Group enriched" "Detected in many" 32 "B-cells: 1.4;granulocytes: 5.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA015607, HPA076313" Enhanced Supported Approved Vesicles "Secreted in brain" Vesicles "HPA015607: AB_1852299, HPA076313: " "unprognostic (1.64e-1)" "unprognostic (2.81e-2)" "unprognostic (1.21e-1)" "unprognostic (1.31e-1)" "unprognostic (1.08e-1)" "unprognostic (1.77e-1)" "unprognostic (1.72e-2)" "unprognostic (4.65e-2)" "unprognostic (9.70e-2)" "unprognostic (2.21e-5)" "unprognostic (7.88e-4)" "unprognostic (9.53e-4)" "unprognostic (1.44e-6)" "unprognostic (1.20e-1)" "unprognostic (6.97e-2)" "unprognostic (3.13e-1)" "unprognostic (3.41e-2)" 0.9 1.9 9.9 1.3 10.2 0.9 1.1 10.7 23.5 0.9 1.6 4.0 0.0 0.9 0.9 0.9 0.8 4.8 1.4 0.8 9.7 7.7 0.9 0.8 2.2 0.9 5.8 12.1 0.8 3.0 0.8 3.8 1.1 10.2 1.7 1.7 0.0 0.8 0.9 0.8 2.4 1.1 1.1 1.4 1.1 3.2 3.5 2.3 0.0 0.8 0.0 1.1 0.9 0.1 1.4 0.0 5.0 0.0 0.0 0.0 0.0 3.6 4.1 0.2 2.6 0.0 0.0 0.1 0.0 0.1 0.1 0.3 0.2 1.5 1.1 2.0 0.0 1.7 0.7 0.0 0.0 4.8 1.8 0.0 3.5 0.2 0.0 0.0 0.9 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.0 1.2 0.1 0.0 0.5 0.3 0.2 0.0 0.8 0.1 0.2 7.8 0.5 0.1 2.2 0.0 0.8 0.0 0.0 0.0 0.6 0.4 0.7 0.6 6.3 0.3 1.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.3 0.0 0.0 5.0 0.0 0.0 0.0 0.0 0.0 9.9 10.2 10.7 14.9 9.7 7.7 5.8 12.1 10.2 2.3 KIT "C-Kit, CD117, PBT, SCFR" ENSG00000157404 "KIT proto-oncogene receptor tyrosine kinase" P10721 4 54657918-54740715 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "breast: 65.5" "Group enriched" "Detected in some" 13 "HEL: 47.7;HMC-1: 100.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "basophil: 12.7;eosinophil: 10.0;NK-cell: 9.7" "Group enriched" "Detected in many" 6 "granulocytes: 12.7;NK-cells: 9.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003288, HPA004471, CAB068253, CAB072867, HPA073252" Enhanced Supported Supported "Plasma membrane" 48000000 "Plasma membrane" "CAB003288: AB_2335702, CAB068253: , CAB072867: , HPA004471: AB_1078431, HPA073252: " "unprognostic (1.55e-2)" "unprognostic (1.91e-1)" "unprognostic (4.04e-2)" "unprognostic (8.19e-2)" "unprognostic (3.96e-2)" "unprognostic (2.18e-2)" "unprognostic (2.33e-2)" "unprognostic (1.97e-2)" "unprognostic (3.60e-2)" "unprognostic (1.64e-1)" "unprognostic (2.20e-1)" "unprognostic (1.92e-2)" "prognostic favourable (5.63e-4)" "unprognostic (1.34e-3)" "unprognostic (1.87e-1)" "unprognostic (1.29e-2)" "unprognostic (2.30e-1)" 8.1 1.6 9.5 6.6 11.8 3.7 65.5 18.3 12.0 12.1 10.3 6.5 10.2 5.8 8.9 4.2 9.9 2.5 15.5 2.4 36.0 4.4 9.4 1.1 13.8 3.8 3.6 6.0 28.5 2.1 1.3 2.3 6.2 5.7 9.6 10.4 20.7 12.9 6.9 1.3 14.6 8.9 10.2 3.9 3.2 12.8 4.0 4.5 0.4 28.9 4.3 4.9 9.8 12.5 0.0 1.8 12.7 0.9 9.7 1.9 0.1 0.0 0.0 0.7 0.0 0.1 0.0 0.0 0.6 0.9 2.5 3.2 0.0 0.0 0.0 0.0 1.4 0.0 0.5 0.0 2.1 0.0 1.1 47.7 0.0 0.0 0.0 0.0 100.2 0.0 0.0 0.0 0.0 5.6 0.6 0.1 0.0 0.0 0.2 0.4 1.3 0.0 0.1 0.0 0.0 0.0 4.7 1.2 0.4 0.0 0.0 0.0 0.0 0.5 0.0 0.1 0.0 1.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 12.7 0.0 10.0 0.1 0.0 1.9 0.0 0.3 0.7 1.8 0.0 0.0 0.0 0.8 9.7 0.9 0.0 0.0 0.1 9.5 11.8 18.3 12.0 36.0 4.4 3.6 6.0 5.7 4.5 LEPR "CD295, OBR" ENSG00000116678 "Leptin receptor" P48357 1 65420652-65641559 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" Receptor "Cancer-related genes, FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 82.8" "Cell line enhanced" "Detected in many" "K-562: 46.1;RPTEC TERT1: 22.3" "Cancer enriched" "Detected in many" 7 "liver cancer: 13.1" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 6.9" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in some" HPA030899 Approved Supported "Secreted to blood" 8235000 8300000 "HPA030899: AB_10610003" "unprognostic (1.59e-2)" "unprognostic (1.09e-3)" "unprognostic (3.09e-1)" "unprognostic (8.95e-2)" "unprognostic (2.32e-1)" "unprognostic (2.64e-1)" "unprognostic (2.58e-1)" "unprognostic (2.30e-1)" "unprognostic (1.78e-1)" "unprognostic (6.59e-3)" "unprognostic (1.79e-1)" "unprognostic (2.41e-1)" "unprognostic (7.53e-2)" "unprognostic (1.11e-1)" "unprognostic (2.27e-1)" "unprognostic (3.49e-2)" "unprognostic (1.73e-1)" 15.9 5.5 3.8 3.7 4.3 3.3 23.5 2.5 3.9 15.0 9.2 5.6 5.4 3.2 20.6 7.3 10.9 11.7 10.1 9.2 4.3 4.9 14.6 82.8 20.3 9.0 4.9 3.3 18.4 16.7 3.9 13.1 12.8 8.2 10.8 4.1 18.1 12.0 5.7 5.6 10.2 7.3 12.9 7.0 6.4 11.9 6.6 3.1 1.9 13.1 11.2 6.9 13.6 8.6 0.6 1.8 6.9 1.9 1.1 2.3 1.8 1.3 0.8 1.1 1.2 5.0 4.6 3.8 5.9 3.4 2.0 1.9 0.6 3.2 0.5 4.4 7.4 1.1 0.9 5.1 5.5 6.9 1.5 7.7 3.5 0.1 3.0 0.5 0.6 13.0 3.0 1.2 4.6 5.8 46.1 0.9 9.5 0.3 0.6 0.1 1.8 0.1 0.1 0.9 0.3 22.3 0.6 0.7 11.3 1.4 0.6 1.6 2.1 2.0 2.2 2.1 4.3 0.4 3.2 1.3 0.8 0.2 4.4 2.2 2.0 6.9 1.9 2.8 1.3 1.5 1.3 0.6 1.1 1.1 1.8 0.3 0.9 1.5 1.1 1.1 1.7 1.2 2.3 1.8 3.8 4.3 2.5 3.9 4.3 4.9 4.9 3.3 8.2 3.1 LHX2 "hLhx2, LH-2" ENSG00000106689 "LIM homeobox 2" P50458 9 124001670-124033301 "Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "brain: 44.7;retina: 17.0" "Cell line enhanced" "Detected in many" "AN3-CA: 15.8;HAP1: 15.7;HeLa: 10.9;NTERA-2: 19.6;U-138 MG: 10.3" "Group enriched" "Detected in many" 5 "cervical cancer: 3.2;glioma: 10.7;melanoma: 3.5" "Group enriched" "Detected in many" 6 "amygdala: 30.7;basal ganglia: 20.5;cerebral cortex: 26.6;hippocampal formation: 23.6;olfactory region: 16.1" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "amygdala: 41.7;basal ganglia: 25.3;cerebral cortex: 46.8;hippocampal formation: 47.4;olfactory region: 19.7" "Group enriched" "Detected in many" 6 "amygdala: 55.6;basal ganglia: 46.4;cerebral cortex: 70.9;hippocampal formation: 73.5;olfactory region: 35.5" HPA000838 Supported Approved Nucleoplasm Nucleoplasm "HPA000838: " "unprognostic (3.60e-3)" "prognostic favourable (9.52e-4)" "unprognostic (3.52e-1)" "unprognostic (9.97e-2)" "unprognostic (1.29e-1)" "unprognostic (1.12e-2)" "unprognostic (6.37e-3)" "unprognostic (1.07e-1)" "unprognostic (4.59e-2)" "unprognostic (3.24e-1)" "unprognostic (2.96e-1)" "unprognostic (1.32e-2)" "unprognostic (4.66e-15)" "unprognostic (1.72e-1)" "unprognostic (2.92e-1)" "unprognostic (2.46e-2)" "unprognostic (1.77e-1)" 0.9 1.0 30.7 1.1 20.5 0.9 1.1 0.0 44.7 0.8 0.9 4.7 0.0 1.0 0.8 0.8 0.8 0.8 1.0 0.8 23.6 2.4 0.8 6.1 0.9 1.1 1.5 16.1 1.1 0.8 0.8 4.6 5.1 0.0 0.8 1.1 17.0 1.1 0.8 0.8 2.2 0.9 0.8 0.2 0.9 0.9 4.0 4.2 0.0 0.8 0.0 1.1 0.9 0.0 0.0 0.0 0.5 0.1 0.0 0.1 0.0 0.0 4.9 0.1 15.8 0.0 0.2 1.6 0.4 0.2 1.2 0.1 4.9 0.0 0.1 2.1 0.9 0.1 15.7 0.0 0.6 0.0 3.4 0.0 10.9 0.2 1.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 7.9 0.0 0.1 19.6 4.6 4.2 0.0 0.0 0.0 0.0 6.4 0.0 4.0 0.0 0.0 5.6 2.0 0.0 10.3 0.4 2.9 0.7 0.2 3.2 0.0 0.6 2.2 1.2 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.5 0.0 0.0 0.0 0.1 0.0 30.7 20.5 0.0 26.6 23.6 2.4 1.5 16.1 0.0 4.2 LIAS LAS ENSG00000121897 "Lipoic acid synthetase" O43766 4 39458587-39485109 "Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" Transferase "Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA018842, HPA019076" Approved Supported Approved Nucleoplasm,Mitochondria,Cytosol Mitochondria "Nucleoplasm, Cytosol" "HPA018842: AB_1852864, HPA019076: AB_1852866" "unprognostic (3.61e-1)" "unprognostic (1.89e-1)" "unprognostic (8.44e-2)" "unprognostic (2.33e-1)" "unprognostic (4.87e-2)" "unprognostic (1.49e-1)" "unprognostic (8.31e-2)" "unprognostic (1.57e-1)" "unprognostic (4.19e-2)" "unprognostic (3.68e-2)" "unprognostic (2.46e-3)" "unprognostic (3.80e-2)" "prognostic favourable (4.11e-7)" "unprognostic (9.41e-3)" "unprognostic (2.35e-1)" "unprognostic (5.45e-2)" "unprognostic (6.98e-2)" 9.8 12.9 9.9 7.0 12.7 10.2 11.3 10.2 13.3 7.0 10.7 12.9 8.1 10.4 9.1 10.7 11.6 11.9 7.4 14.0 10.6 10.6 15.7 15.5 5.7 9.0 12.3 10.5 19.2 12.4 10.0 11.5 6.8 15.7 8.2 12.4 9.0 7.8 7.0 42.7 8.8 9.9 13.6 12.4 8.9 9.9 20.1 13.2 8.7 8.8 13.5 8.3 10.0 7.9 9.6 5.8 3.7 7.1 6.9 16.7 4.3 3.9 3.0 4.0 3.7 8.3 8.1 3.4 4.6 2.5 4.3 2.9 5.0 5.5 14.4 5.3 1.7 3.5 11.1 6.3 5.7 1.6 2.8 6.0 1.6 5.0 7.6 13.1 3.9 7.8 10.4 5.0 16.0 4.9 14.3 3.6 5.2 2.5 7.3 16.8 5.2 10.0 6.4 10.7 8.7 5.1 2.1 4.3 3.7 2.6 3.5 14.8 3.9 6.0 1.8 3.4 7.6 4.5 10.6 7.0 10.6 10.1 5.3 15.3 2.9 2.0 6.2 3.7 6.1 7.1 12.6 9.6 8.3 8.0 5.8 8.5 16.7 11.5 3.3 6.9 5.1 5.4 5.2 4.3 9.9 12.7 10.2 13.3 10.6 10.6 12.3 10.5 15.7 13.2 LPCAT2 "AGPAT11, AYTL1, FLJ20481, LysoPAFAT" ENSG00000087253 "Lysophosphatidylcholine acyltransferase 2" Q7L5N7 16 55508998-55586670 "Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Lipid biosynthesis, Lipid metabolism, Phospholipid biosynthesis, Phospholipid metabolism" "Acyltransferase, Transferase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "CAPAN-2: 33.5;HaCaT: 25.7;HL-60: 28.7;HMC-1: 47.8;WM-115: 34.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 28.8;eosinophil: 49.4" "Lineage enriched" "Detected in many" 5 "granulocytes: 49.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007891, HPA008433" Enhanced Supported Supported "Endoplasmic reticulum,Lipid droplets" "Endoplasmic reticulum" "Lipid droplets" "HPA007891: AB_1845223, HPA008433: " "unprognostic (1.43e-1)" "unprognostic (2.44e-2)" "prognostic favourable (3.43e-4)" "prognostic favourable (8.03e-6)" "unprognostic (2.91e-1)" "unprognostic (9.65e-3)" "unprognostic (8.12e-3)" "unprognostic (3.26e-3)" "unprognostic (1.67e-1)" "unprognostic (7.97e-2)" "unprognostic (3.18e-3)" "unprognostic (9.16e-2)" "unprognostic (1.93e-1)" "unprognostic (2.33e-1)" "unprognostic (4.15e-2)" "unprognostic (1.96e-1)" "unprognostic (3.53e-2)" 10.5 7.5 10.5 8.0 16.2 43.5 9.9 1.7 7.5 11.0 5.2 18.2 36.5 4.3 17.0 21.5 7.2 8.5 6.2 5.7 9.6 6.3 6.7 2.4 7.4 10.3 18.6 3.1 11.0 3.8 12.7 1.9 9.0 16.1 8.2 5.5 5.1 7.7 33.2 3.0 10.2 5.4 8.9 30.7 8.9 5.3 4.6 14.9 0.9 49.0 5.2 2.6 8.5 8.5 0.0 5.4 49.4 9.3 0.0 0.0 1.4 9.4 1.2 1.0 0.1 3.3 1.2 1.7 4.0 3.9 2.0 2.0 2.1 33.5 0.0 13.8 5.7 25.7 0.6 5.5 3.2 2.5 2.8 9.6 3.1 4.9 1.2 28.7 47.8 0.6 5.6 2.2 1.8 15.4 0.4 0.1 3.3 0.6 0.0 11.6 1.5 0.1 2.9 1.1 1.4 1.9 3.7 0.6 7.4 7.7 3.1 5.6 1.3 7.3 17.3 0.3 0.0 2.0 2.7 0.1 0.0 0.0 0.8 14.0 34.0 28.8 4.5 49.4 0.0 6.9 0.0 0.0 0.0 0.0 5.4 0.0 0.0 0.0 12.1 0.0 9.3 0.1 0.0 1.4 10.5 16.2 1.7 7.5 9.6 6.3 18.6 3.1 16.1 14.9 LPO SPO ENSG00000167419 Lactoperoxidase P22079 17 58218548-58268518 "Enzymes, Predicted intracellular proteins, Predicted secreted proteins" "Hydrogen peroxide" "Antimicrobial, Oxidoreductase, Peroxidase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 262 "salivary gland: 345.7" "Cell line enriched" "Detected in some" 9 "THP-1: 14.1" "Not detected" "Not detected" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA028688 Enhanced Supported "Secreted to digestive system" "HPA028688: AB_10601909" "unprognostic (2.74e-1)" "unprognostic (5.12e-2)" "unprognostic (4.14e-3)" "unprognostic (1.56e-3)" "unprognostic (2.41e-2)" "unprognostic (9.71e-2)" "unprognostic (2.06e-2)" "unprognostic (1.53e-1)" "unprognostic (2.40e-2)" "unprognostic (6.27e-3)" "unprognostic (6.32e-2)" "unprognostic (2.56e-1)" "unprognostic (0.00e+0)" "unprognostic (3.41e-2)" "unprognostic (3.15e-1)" "unprognostic (2.72e-2)" "unprognostic (1.22e-1)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 345.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.3 1.2 0.0 0.0 1.2 0.8 1.3 0.7 0.8 0.9 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.6 0.0 0.0 0.0 0.0 0.1 0.0 0.1 1.1 0.0 0.0 0.0 0.0 0.0 14.1 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 1.0 1.5 0.0 0.9 0.7 0.4 0.6 0.3 0.5 0.9 0.7 0.6 0.2 1.2 0.6 0.9 1.3 0.8 0.3 0.8 0.4 0.4 0.0 0.0 0.0 0.1 0.1 0.0 0.8 0.0 0.0 0.0 LRPAP1 "A2MRAP, HBP44, RAP" ENSG00000163956 "LDL receptor related protein associated protein 1" P30533 4 3506376-3532559 "Disease related genes, Predicted intracellular proteins" Heparin-binding "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008001, CAB025518" Enhanced Supported Supported "Endoplasmic reticulum" "Intracellular and membrane" "Endoplasmic reticulum" "CAB025518: , HPA008001: AB_1853292" "unprognostic (3.20e-3)" "unprognostic (7.01e-2)" "unprognostic (2.30e-1)" "unprognostic (2.22e-2)" "unprognostic (1.37e-2)" "unprognostic (9.61e-2)" "unprognostic (1.01e-2)" "unprognostic (3.89e-3)" "unprognostic (8.58e-2)" "unprognostic (6.12e-2)" "unprognostic (2.14e-3)" "unprognostic (2.19e-1)" "prognostic favourable (4.67e-11)" "unprognostic (6.25e-2)" "unprognostic (1.56e-1)" "unprognostic (2.58e-1)" "unprognostic (5.61e-2)" 9.4 11.3 13.7 8.7 34.4 17.4 8.5 11.4 22.1 10.1 9.3 9.1 15.5 10.6 11.1 16.7 7.2 10.5 11.2 28.1 11.6 13.1 17.7 16.5 10.8 9.9 10.6 14.5 13.2 28.8 20.0 18.1 35.2 9.9 11.2 7.6 11.5 23.0 18.9 12.5 10.9 10.3 8.4 7.2 10.9 10.7 10.9 12.0 4.8 11.6 6.9 6.5 8.6 8.0 6.2 8.8 37.7 15.9 7.3 7.1 15.1 4.2 8.9 6.5 9.5 9.2 4.8 14.0 7.0 7.9 6.3 5.1 17.6 8.6 2.3 7.4 6.7 6.9 4.1 7.4 3.7 1.8 9.7 3.2 8.9 11.6 5.7 5.2 15.0 6.1 5.8 5.0 2.7 7.8 5.6 8.8 5.5 6.9 3.3 19.9 5.4 9.4 4.5 5.0 8.4 6.8 9.7 5.9 5.2 8.6 3.5 9.1 7.6 9.6 6.3 6.1 5.7 4.7 9.0 4.9 3.2 3.2 7.3 15.4 8.3 11.2 15.9 37.7 6.5 12.5 5.6 6.2 6.0 6.1 8.8 5.9 6.7 6.1 13.3 7.3 11.4 6.6 7.1 15.1 13.7 34.4 11.4 22.1 11.6 13.1 10.6 14.5 9.9 12.0 LUZP2 ENSG00000187398 "Leucine zipper protein 2" Q86TE4 11 24496970-25082631 "Predicted intracellular proteins, Predicted secreted proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "adrenal gland: 11.1;brain: 32.7" "Group enriched" "Detected in some" 4 "HaCaT: 14.3;HAP1: 7.1" "Group enriched" "Detected in some" 7 "glioma: 3.5;prostate cancer: 4.5" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 1.9" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "HPA039007, HPA046161" Enhanced Supported Approved "Nucleoplasm,Plasma membrane,Cytosol" "Secreted in brain" "Nucleoplasm, Cytosol" "Plasma membrane" "HPA039007: , HPA046161: " "unprognostic (4.49e-2)" "unprognostic (2.74e-2)" "unprognostic (8.63e-2)" "unprognostic (3.50e-1)" "unprognostic (5.22e-3)" "unprognostic (3.38e-1)" "unprognostic (4.88e-2)" "unprognostic (5.67e-4)" "unprognostic (2.40e-1)" "unprognostic (5.66e-2)" "unprognostic (6.16e-3)" "unprognostic (4.09e-2)" "unprognostic (5.18e-3)" "unprognostic (9.41e-3)" "unprognostic (4.18e-2)" "unprognostic (2.17e-1)" "unprognostic (9.64e-2)" 1.2 11.1 14.5 0.9 10.8 0.9 1.6 2.6 32.7 0.9 2.1 5.9 0.0 0.9 1.0 0.8 0.9 0.8 1.0 1.0 10.3 13.8 1.0 2.3 1.1 0.8 13.7 5.6 0.8 0.8 0.7 1.9 0.8 26.7 4.5 1.7 0.0 1.0 0.9 0.8 0.9 1.1 1.2 30.0 0.9 0.9 1.6 14.5 0.0 0.8 0.9 0.8 1.6 0.3 0.5 0.4 1.9 0.3 0.3 0.3 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 14.3 7.1 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.6 0.3 0.0 0.2 0.2 0.0 1.5 0.1 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.1 1.5 0.3 0.4 0.2 0.1 0.2 0.2 0.1 0.3 0.1 0.5 0.3 0.2 1.9 0.3 0.2 0.4 0.1 0.0 14.5 10.8 2.6 9.3 10.3 13.8 13.7 5.6 26.7 14.5 MAP1B "MAP5, PPP1R102" ENSG00000131711 "Microtubule associated protein 1B" P46821 5 72107234-72209570 "Plasma proteins, Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 102.5" "Cell line enhanced" "Detected in many" "TIME: 64.1" "Cancer enriched" "Detected in all" 5 "glioma: 48.1" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009792, HPA022275" Enhanced Supported Enhanced Cytosol 140000 Cytosol "CAB009792: AB_2137420, HPA022275: AB_1853944" "unprognostic (9.96e-2)" "unprognostic (3.97e-2)" "unprognostic (1.57e-2)" "unprognostic (3.70e-1)" "unprognostic (4.67e-3)" "unprognostic (2.98e-2)" "unprognostic (1.74e-1)" "unprognostic (1.73e-1)" "unprognostic (1.42e-1)" "unprognostic (7.00e-2)" "unprognostic (4.78e-3)" "unprognostic (1.32e-1)" "unprognostic (1.52e-2)" "unprognostic (1.13e-2)" "unprognostic (1.90e-1)" "unprognostic (1.75e-2)" "prognostic unfavourable (8.22e-5)" 20.3 18.1 27.5 10.2 39.6 1.6 9.3 52.3 101.9 15.3 6.1 21.6 3.5 3.2 9.2 9.8 12.8 7.7 10.7 17.1 37.6 40.7 4.4 3.3 3.7 3.2 42.4 42.5 7.8 4.5 3.0 7.0 9.5 102.5 19.0 6.2 9.4 7.6 24.0 3.6 10.2 3.9 22.9 45.7 2.4 7.2 11.0 11.3 0.0 5.7 0.1 2.6 13.4 5.9 0.2 0.4 0.6 0.0 0.0 0.3 2.1 0.3 12.1 30.5 11.0 19.0 33.3 0.0 6.5 5.0 6.6 7.9 0.1 0.4 0.0 15.7 24.1 0.1 16.6 0.6 10.0 0.0 2.4 1.3 4.3 3.9 10.1 0.0 1.0 33.4 2.1 26.6 9.9 20.6 1.9 0.0 11.2 0.1 0.0 0.0 8.2 3.9 0.1 3.6 0.0 0.5 0.0 19.7 13.6 6.4 0.0 3.3 0.0 1.2 64.1 21.0 9.9 15.3 29.4 1.4 0.0 0.0 22.7 0.0 16.3 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.1 0.2 0.0 0.2 0.1 0.2 0.6 0.0 0.0 0.4 0.2 2.1 27.5 39.6 52.3 59.1 37.6 40.7 42.4 42.5 102.5 11.3 MAP2 "MAP2A, MAP2B, MAP2C" ENSG00000078018 "Microtubule associated protein 2" P11137 2 209424058-209734118 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Calmodulin-binding "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 8 "brain: 122.3" "Cell line enhanced" "Detected in some" "AF22: 74.6;NTERA-2: 26.7;SCLC-21H: 37.5;SH-SY5Y: 21.0" "Cancer enhanced" "Detected in many" "glioma: 30.4" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 13 "memory B-cell: 2.6;naive B-cell: 3.4" "Lineage enriched" "Detected in single" 15 "B-cells: 3.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001984, HPA008273, HPA012828" Enhanced Supported "CAB001984: , HPA008273: AB_1853945, HPA012828: AB_1853946" "unprognostic (2.47e-2)" "unprognostic (2.81e-1)" "unprognostic (2.58e-2)" "prognostic unfavourable (1.98e-6)" "unprognostic (2.29e-2)" "unprognostic (1.79e-1)" "unprognostic (1.13e-2)" "unprognostic (6.06e-2)" "unprognostic (1.31e-1)" "unprognostic (9.84e-2)" "unprognostic (1.09e-2)" "unprognostic (1.60e-1)" "unprognostic (1.23e-1)" "unprognostic (2.69e-3)" "unprognostic (2.54e-1)" "unprognostic (7.28e-2)" "unprognostic (4.10e-5)" 4.6 9.2 62.1 2.1 63.1 1.5 4.9 24.7 122.3 4.4 2.5 3.8 0.0 2.0 2.9 4.0 5.6 2.8 6.3 6.2 73.6 53.8 3.9 3.7 9.3 2.4 31.0 48.8 6.4 8.2 12.5 14.7 1.9 35.4 6.5 2.5 7.6 4.9 4.7 2.2 12.1 2.0 3.2 19.9 2.4 2.6 5.4 11.4 0.0 12.2 0.4 2.9 2.8 1.5 3.4 0.1 0.0 0.0 0.0 0.2 0.3 0.6 0.1 74.6 0.0 1.0 0.5 0.0 0.4 0.5 0.1 0.5 0.0 4.0 0.0 0.4 0.9 1.0 5.7 0.4 0.2 0.0 0.3 0.2 2.3 0.0 9.4 0.0 0.0 0.8 2.4 0.0 1.4 1.9 0.0 0.7 0.0 0.2 0.0 0.0 26.7 0.1 0.0 0.1 0.0 0.9 0.0 37.5 21.0 1.5 0.2 0.9 2.0 0.0 0.0 0.0 0.4 0.0 1.0 0.5 0.0 0.0 3.9 0.0 11.1 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.1 0.0 0.0 3.4 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.3 62.1 63.1 24.7 79.6 73.6 53.8 31.0 48.8 35.4 11.4 MAP6D1 "FLJ12748, SL21" ENSG00000180834 "MAP6 domain containing 1" Q9H9H5 3 183815876-183825594 "Predicted intracellular proteins" Calmodulin-binding "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "brain: 48.1;skeletal muscle: 33.5" "Cell line enriched" "Detected in many" 5 "T-47d: 38.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "memory CD8 T-cell: 2.7" "Lineage enriched" "Detected in single" 5 "T-cells: 2.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA037991 Enhanced Supported Approved Cytosol Cytosol "HPA037991: AB_10672503" "unprognostic (9.23e-3)" "unprognostic (2.70e-1)" "unprognostic (1.65e-1)" "unprognostic (1.27e-3)" "unprognostic (1.32e-1)" "unprognostic (3.67e-2)" "unprognostic (1.21e-1)" "unprognostic (1.13e-1)" "unprognostic (2.42e-1)" "unprognostic (1.28e-2)" "unprognostic (5.36e-2)" "prognostic unfavourable (3.37e-4)" "unprognostic (8.81e-12)" "unprognostic (1.08e-1)" "unprognostic (2.96e-3)" "unprognostic (1.86e-1)" "unprognostic (5.72e-2)" 1.1 1.2 11.8 1.5 16.0 1.1 2.0 30.9 32.1 1.5 1.4 48.1 0.0 1.9 1.4 2.0 1.1 1.5 1.3 1.9 18.8 9.2 1.2 1.3 1.4 1.7 24.7 8.7 1.7 6.0 1.8 0.5 1.3 18.4 2.7 1.4 0.0 1.6 2.0 33.5 4.6 1.5 1.4 37.7 1.5 1.2 1.3 20.4 2.2 1.1 0.0 1.4 1.1 0.2 0.5 0.3 0.2 0.2 0.0 2.7 0.3 1.8 1.3 2.1 0.4 0.5 0.7 1.6 2.3 0.4 4.5 3.0 1.8 0.1 0.2 3.0 3.5 1.4 4.4 1.1 3.0 1.3 6.6 0.2 0.0 0.0 1.3 2.4 0.8 0.3 0.3 1.1 0.4 0.9 0.3 0.0 0.6 8.2 5.7 3.3 2.0 3.8 2.8 3.3 0.0 0.2 0.0 7.0 1.3 1.7 1.3 2.4 38.9 2.3 0.4 1.0 1.6 1.6 3.5 1.4 0.8 1.1 0.3 0.4 0.2 0.0 0.2 0.2 0.0 0.0 0.0 0.5 0.5 2.7 0.3 0.0 0.0 0.9 0.0 0.0 0.1 0.2 0.0 0.3 11.8 16.0 30.9 19.9 18.8 9.2 24.7 8.7 18.4 20.4 MAPK6 "ERK3, HsT17250, p97MAPK, PRKM6" ENSG00000069956 "Mitogen-activated protein kinase 6" Q16659 15 51952106-52067372 "Enzymes, Predicted intracellular proteins" "Cell cycle" "Kinase, Serine/threonine-protein kinase, Transferase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005184, HPA030262" Approved Supported Enhanced Cytosol Cytosol "CAB005184: AB_2140298, HPA030262: AB_10601868" "unprognostic (6.61e-2)" "unprognostic (1.75e-2)" "unprognostic (5.05e-2)" "unprognostic (3.40e-3)" "unprognostic (2.72e-1)" "unprognostic (5.52e-2)" "unprognostic (6.13e-2)" "unprognostic (2.32e-3)" "unprognostic (3.99e-2)" "unprognostic (8.54e-2)" "unprognostic (3.68e-2)" "unprognostic (3.90e-2)" "unprognostic (3.27e-3)" "unprognostic (2.03e-1)" "unprognostic (1.72e-1)" "unprognostic (3.07e-2)" "unprognostic (2.31e-2)" 11.8 7.4 14.4 10.9 23.2 25.6 13.7 33.0 24.5 16.3 18.7 12.5 9.3 16.3 15.9 13.3 32.3 8.2 17.0 9.1 13.3 15.9 14.4 32.6 12.6 9.4 13.1 16.8 11.5 8.5 12.2 15.3 13.9 23.8 10.5 18.1 9.5 17.9 11.4 27.1 24.0 26.2 17.8 14.2 9.2 15.7 25.7 13.0 11.7 13.4 22.7 12.4 18.9 22.4 4.9 4.2 3.0 4.5 6.5 7.9 3.6 8.7 11.8 23.3 8.9 7.2 11.9 17.0 12.5 12.6 11.6 13.7 14.1 5.3 12.6 8.8 16.0 12.4 17.9 23.9 15.9 7.7 5.6 18.8 7.0 22.3 17.4 14.0 40.2 12.7 43.9 14.0 36.4 10.9 24.3 21.5 14.7 19.7 9.8 11.0 8.2 5.7 8.6 15.0 20.2 11.1 36.9 11.4 10.8 10.1 8.2 18.3 7.5 20.9 10.8 13.9 15.0 9.0 16.7 11.2 32.9 15.6 17.2 20.6 17.0 3.0 4.5 1.2 3.8 4.3 4.7 4.9 5.6 4.3 4.2 2.6 5.4 3.8 0.6 6.5 2.8 1.9 7.9 3.6 14.4 23.2 33.0 24.3 13.3 15.9 13.1 16.8 23.8 13.0 MARS "CMT2U, MetRS, SPG70" ENSG00000166986 "Methionyl-tRNA synthetase" P56192 12 57475445-57517569 "Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Protein biosynthesis" "Aminoacyl-tRNA synthetase, Ligase, RNA-binding, tRNA-binding" "Charcot-Marie-Tooth disease, Disease mutation, Neurodegeneration, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "RH-30: 116.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004125, CAB017097" Supported Approved Enhanced Cytosol 21000 Cytosol "CAB017097: , HPA004125: AB_1079312" "prognostic unfavourable (1.73e-4)" "unprognostic (2.21e-1)" "unprognostic (1.56e-1)" "unprognostic (1.09e-1)" "unprognostic (1.57e-2)" "unprognostic (4.90e-3)" "prognostic unfavourable (4.55e-7)" "unprognostic (8.47e-2)" "unprognostic (1.73e-1)" "unprognostic (4.03e-2)" "unprognostic (2.85e-2)" "unprognostic (3.77e-2)" "prognostic unfavourable (1.59e-4)" "unprognostic (1.13e-2)" "unprognostic (1.96e-1)" "unprognostic (1.13e-1)" "unprognostic (2.06e-2)" 23.8 26.7 35.1 27.3 29.1 23.0 19.8 25.1 36.0 17.4 23.9 23.1 23.9 17.3 23.3 36.3 29.5 17.9 16.1 25.0 28.0 29.5 20.5 45.9 24.3 25.1 40.1 25.5 25.8 48.3 35.7 34.0 22.2 30.9 25.6 24.7 19.8 26.0 30.0 24.5 18.4 20.1 33.7 30.7 30.7 31.3 29.6 30.9 21.4 26.9 22.3 34.3 24.3 27.9 12.9 29.3 19.0 27.0 14.1 18.9 15.5 16.5 23.0 15.4 26.7 17.3 10.5 28.4 23.7 27.8 25.1 26.9 24.7 18.4 29.1 15.7 28.7 18.8 35.1 30.6 26.3 25.2 15.2 20.5 8.6 13.9 38.5 30.9 23.6 15.3 47.6 28.7 74.4 17.9 31.7 62.4 17.4 22.9 27.6 23.3 29.1 25.4 24.0 116.3 30.1 18.9 13.0 20.6 20.9 12.3 18.9 32.8 25.0 40.5 13.2 9.1 26.9 13.1 14.0 57.2 57.8 35.1 22.3 23.5 31.0 12.1 14.6 19.0 18.9 27.0 17.2 12.9 12.9 17.1 29.3 7.7 11.1 15.2 7.2 14.1 21.8 28.4 13.1 15.5 35.1 29.1 25.1 36.0 28.0 29.5 40.1 25.5 30.9 30.9 MBP ENSG00000197971 "Myelin basic protein" P02686 18 76978827-77133683 "Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Autoimmune encephalomyelitis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 43 "brain: 1297.7" "Cell line enhanced" "Detected in many" "HL-60: 28.4;SK-MEL-30: 59.1" "Group enriched" "Detected in all" 9 "glioma: 47.5;melanoma: 20.8" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002300, HPA049222, HPA064368" Enhanced Supported Approved "Plasma membrane" "Plasma membrane" "CAB002300: AB_563893, HPA049222: , HPA064368: " "unprognostic (9.36e-2)" "unprognostic (7.60e-2)" "unprognostic (1.28e-2)" "unprognostic (1.22e-1)" "unprognostic (6.93e-2)" "unprognostic (2.81e-1)" "unprognostic (1.14e-1)" "unprognostic (3.31e-1)" "unprognostic (9.87e-2)" "unprognostic (2.90e-2)" "unprognostic (5.25e-2)" "unprognostic (1.95e-1)" "prognostic favourable (4.48e-12)" "unprognostic (2.90e-1)" "unprognostic (5.99e-2)" "unprognostic (1.33e-1)" "unprognostic (6.03e-2)" 4.0 3.4 271.6 6.1 244.9 10.1 4.5 28.7 418.9 5.6 5.5 487.7 0.0 5.9 4.4 3.6 6.4 9.0 5.7 6.8 355.0 247.6 6.2 5.9 6.2 7.1 645.5 43.4 3.7 6.8 16.4 0.7 2.7 242.9 4.5 5.6 0.4 5.0 4.9 29.9 7.9 6.2 3.8 1297.7 7.6 5.1 2.9 224.3 0.0 6.8 0.0 7.7 6.0 0.6 3.4 6.8 23.7 4.7 15.4 17.1 5.6 7.4 6.5 0.0 0.2 11.0 16.4 2.6 0.1 0.2 0.2 0.1 0.9 11.5 4.6 1.3 0.5 14.7 1.1 6.5 0.2 17.8 1.6 2.9 1.1 1.5 6.9 28.4 19.8 2.3 5.5 5.9 9.1 1.9 0.0 1.0 0.0 0.9 1.1 14.6 0.6 5.2 0.4 0.1 10.2 10.4 10.1 0.5 0.1 0.9 0.0 59.1 0.2 17.4 0.0 0.0 0.1 0.0 0.8 0.0 0.1 4.9 1.7 18.0 0.7 11.0 4.7 17.8 13.2 4.6 8.0 3.4 9.4 17.1 5.3 3.3 5.7 10.5 23.7 15.4 4.4 6.8 7.9 5.6 271.6 244.9 28.7 127.7 355.0 247.6 645.5 43.4 242.9 224.3 MCC ENSG00000171444 "Mutated in colorectal cancers" P23508 5 113022099-113488830 "Predicted intracellular proteins" "Wnt signaling pathway" "Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ovary: 49.4" "Cell line enhanced" "Detected in many" "HBEC3-KT: 27.7;hTCEpi: 18.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "plasmacytoid DC: 6.3" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA037390, HPA037391" Approved Approved Supported "Nucleoplasm,Cytosol,Cytoplasmic bodies" "Nucleoplasm, Cytosol" "Cytoplasmic bodies" "HPA037390: AB_2675451, HPA037391: AB_10671248" "unprognostic (6.60e-2)" "unprognostic (1.23e-1)" "unprognostic (1.44e-1)" "unprognostic (1.23e-1)" "unprognostic (8.40e-2)" "unprognostic (1.06e-1)" "unprognostic (1.20e-1)" "unprognostic (5.21e-2)" "unprognostic (9.59e-2)" "unprognostic (8.02e-3)" "unprognostic (1.56e-1)" "unprognostic (1.74e-1)" "prognostic favourable (6.19e-4)" "unprognostic (1.70e-3)" "unprognostic (3.34e-1)" "unprognostic (2.47e-2)" "unprognostic (2.90e-1)" 7.1 2.3 6.9 3.2 6.1 0.5 7.8 11.4 8.1 11.8 3.2 3.4 5.9 1.7 12.5 4.7 9.1 7.4 4.4 8.4 9.2 5.0 3.9 12.7 4.6 3.0 7.6 5.1 49.4 4.5 28.9 5.2 7.1 7.8 7.7 2.4 15.1 6.7 9.5 5.0 13.9 2.6 9.1 5.8 3.4 3.6 6.5 5.2 1.3 3.2 6.1 4.3 9.3 11.8 0.2 6.3 1.3 0.2 0.1 1.6 0.1 0.4 0.1 7.0 0.6 6.1 5.7 7.8 1.1 3.1 1.3 1.6 0.2 6.4 0.0 7.5 0.5 8.6 4.3 27.7 0.6 2.2 2.6 0.0 2.4 1.8 1.8 0.3 0.1 7.6 18.6 3.5 13.2 8.2 0.0 10.5 2.9 0.6 0.1 0.1 3.8 0.5 0.1 6.1 1.9 0.1 17.3 3.1 6.7 5.7 0.0 15.2 2.3 0.0 9.8 4.8 4.5 7.5 2.1 3.0 0.0 0.0 12.9 0.0 5.1 0.0 0.2 0.1 0.5 0.2 1.6 0.2 0.5 0.6 0.0 0.2 0.4 0.5 1.3 0.1 0.1 6.3 1.5 0.1 6.9 6.1 11.4 8.1 9.2 5.0 7.6 5.1 7.8 5.2 MROH1 "HEATR7A, KIAA1833" ENSG00000179832 "Maestro heat like repeat family member 1" Q8NDA8 8 144148016-144261940 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA024287, HPA044465" Approved Supported Approved Nucleoplasm Nucleoplasm "HPA024287: , HPA044465: AB_10960985" "unprognostic (1.25e-1)" "unprognostic (4.85e-2)" "unprognostic (1.38e-1)" "prognostic favourable (6.74e-4)" "unprognostic (2.97e-2)" "unprognostic (2.42e-2)" "unprognostic (2.46e-1)" "unprognostic (4.17e-1)" "unprognostic (1.17e-1)" "unprognostic (1.48e-2)" "unprognostic (6.64e-2)" "unprognostic (1.92e-1)" "prognostic favourable (3.65e-6)" "unprognostic (1.61e-3)" "unprognostic (1.97e-1)" "unprognostic (1.68e-1)" "unprognostic (1.48e-2)" 5.7 7.5 11.9 7.6 10.0 19.7 6.1 17.8 16.0 6.0 8.5 4.5 13.0 16.7 5.4 7.3 9.2 6.8 7.0 5.4 7.0 6.0 8.3 5.8 9.4 8.1 5.2 11.7 5.1 17.3 5.4 11.1 8.3 10.3 9.0 4.5 6.9 14.3 9.8 5.2 13.4 14.3 6.5 3.9 11.5 14.0 7.5 5.0 5.2 33.3 3.9 7.5 8.5 6.6 1.9 5.5 4.4 9.5 1.1 5.6 2.8 9.7 4.0 0.5 3.9 1.9 2.0 17.7 4.3 3.0 2.4 3.3 6.8 17.6 5.2 6.3 2.4 9.4 0.6 6.6 1.1 2.9 5.6 6.2 11.7 6.1 4.8 2.7 6.6 3.8 6.9 3.8 5.6 3.4 2.5 2.3 2.7 20.8 4.7 5.8 1.5 19.1 6.2 1.3 5.3 3.5 19.3 4.5 3.9 10.8 10.4 3.2 7.7 3.8 8.5 4.9 9.3 9.9 3.5 4.1 2.0 5.5 9.7 8.4 2.9 4.4 7.4 1.9 2.4 9.5 1.9 1.1 2.1 2.5 5.5 1.9 2.0 1.4 1.5 1.1 7.9 1.7 5.6 2.8 11.9 10.0 17.8 16.0 7.0 6.0 5.2 11.7 10.3 5.0 MTSS1 "KIAA0429, MIM, MIMA, MIMB" ENSG00000170873 "MTSS1, I-BAR domain containing" O43312 8 124550790-124728429 "Plasma proteins, Predicted intracellular proteins" Actin-binding "Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 20.7;HDLM-2: 23.8;HEL: 81.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "non-classical monocyte: 44.8" "Group enriched" "Detected in many" 4 "B-cells: 16.1;monocytes: 44.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019613, HPA064003, HPA075540" Approved Supported Uncertain "Plasma membrane,Cytosol" 10000 "Plasma membrane, Cytosol" "HPA019613: , HPA064003: , HPA075540: " "unprognostic (1.70e-1)" "unprognostic (4.13e-2)" "unprognostic (9.50e-2)" "unprognostic (1.38e-1)" "unprognostic (3.87e-2)" "unprognostic (7.02e-2)" "unprognostic (4.24e-2)" "unprognostic (1.26e-2)" "unprognostic (2.18e-1)" "unprognostic (2.50e-1)" "unprognostic (8.12e-2)" "unprognostic (1.48e-1)" "prognostic favourable (2.11e-7)" "unprognostic (6.74e-2)" "unprognostic (1.04e-1)" "unprognostic (2.41e-1)" "unprognostic (8.92e-3)" 18.7 27.3 14.0 9.2 16.3 8.5 12.4 36.0 19.1 8.1 8.2 32.1 1.7 5.0 5.6 15.8 32.4 8.9 7.0 13.4 13.5 13.6 18.2 51.5 12.0 12.1 18.1 10.3 8.2 21.0 2.6 10.5 25.3 16.9 7.9 7.0 19.8 10.2 5.3 16.5 21.3 5.0 7.2 20.9 23.9 9.0 15.8 20.0 8.2 4.1 12.1 12.2 9.7 13.7 16.1 3.3 0.6 44.8 0.6 6.9 6.8 0.9 0.2 12.9 0.3 20.7 10.7 0.0 0.5 3.5 0.2 0.1 1.2 0.1 0.4 1.3 0.0 0.2 0.1 7.1 0.2 23.8 0.4 81.4 0.2 6.4 4.7 0.0 8.7 17.0 16.5 3.9 10.3 7.8 0.1 0.1 1.4 0.6 0.2 1.0 0.5 0.1 0.1 0.0 0.1 2.9 2.8 9.3 0.8 2.0 1.9 6.6 0.3 0.2 4.0 0.7 0.4 0.0 0.2 0.2 0.2 1.4 7.5 0.2 2.7 0.6 3.9 0.0 6.9 25.6 0.8 13.2 1.5 2.6 3.3 16.1 0.7 2.1 0.6 0.6 44.8 0.0 0.1 6.8 14.0 16.3 36.0 16.7 13.5 13.6 18.1 10.3 16.9 20.0 MTX2 ENSG00000128654 "Metaxin 2" O75431 2 176269395-176338025 "Predicted intracellular proteins" "Protein transport, Transport" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA031550, HPA031551, HPA031552" Approved Approved Supported Nucleoli,Mitochondria "Intracellular and membrane" Mitochondria Nucleoli "HPA031550: AB_10599733, HPA031551: AB_10601442, HPA031552: AB_10794616" "unprognostic (2.61e-1)" "unprognostic (9.86e-2)" "unprognostic (6.54e-2)" "prognostic unfavourable (5.06e-4)" "unprognostic (1.92e-2)" "unprognostic (1.62e-2)" "unprognostic (1.05e-2)" "unprognostic (1.29e-1)" "unprognostic (2.87e-2)" "unprognostic (3.97e-2)" "unprognostic (1.80e-2)" "unprognostic (8.30e-2)" "unprognostic (1.22e-1)" "unprognostic (2.03e-1)" "unprognostic (9.92e-2)" "unprognostic (3.15e-2)" "unprognostic (1.33e-2)" 13.2 26.4 21.3 12.0 22.3 5.5 18.8 15.0 44.9 13.0 20.7 18.5 16.6 15.4 15.5 27.9 22.2 20.0 12.0 33.6 23.6 26.3 31.5 20.2 10.6 8.9 21.5 16.5 13.2 16.4 23.7 25.7 17.3 21.8 18.9 24.6 16.3 24.7 16.5 45.0 12.5 14.8 17.6 25.7 9.4 14.6 40.6 14.0 10.2 14.7 19.8 13.6 14.4 13.6 16.2 12.1 4.7 12.6 15.1 13.4 7.9 17.8 10.6 21.6 13.2 14.5 16.8 20.8 19.3 18.1 17.7 20.7 18.2 19.5 22.9 32.7 17.0 12.1 23.5 23.7 24.4 22.7 17.0 21.8 13.4 32.1 23.0 33.7 7.4 18.7 29.6 18.5 32.0 25.2 28.9 17.8 20.8 16.3 11.8 34.3 20.6 16.8 0.0 15.7 20.4 50.2 32.5 30.9 26.5 16.1 21.5 39.7 12.0 22.0 22.1 17.7 15.7 18.5 20.1 20.0 20.8 27.4 22.0 17.0 21.4 4.7 7.7 3.2 8.5 12.6 11.5 16.2 10.9 9.6 12.1 11.4 13.2 13.4 0.0 15.1 10.9 9.8 13.4 7.9 21.3 22.3 15.0 44.9 23.6 26.3 21.5 16.5 21.8 14.0 MX1 "IFI-78K, MxA" ENSG00000157601 "MX dynamin like GTPase 1" P20591 21 41420304-41459214 "Predicted intracellular proteins" "Antiviral defense, Immunity, Innate immunity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in some" "BJ hTERT+ SV40 Large T+: 117.5;BJ hTERT+ SV40 Large T+ RasG12V: 105.8;Karpas-707: 27.1;SK-MEL-30: 35.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA030917, HPA030918, HPA049724" Approved Approved Supported "Nuclear membrane,Cytosol" "Nuclear membrane, Cytosol" "HPA030917: AB_10602010, HPA030918: , HPA049724: AB_2680862" "unprognostic (3.62e-1)" "unprognostic (6.84e-2)" "unprognostic (3.41e-2)" "unprognostic (2.55e-2)" "unprognostic (3.97e-1)" "unprognostic (2.27e-1)" "unprognostic (1.35e-3)" "unprognostic (5.86e-2)" "unprognostic (1.77e-1)" "unprognostic (3.50e-2)" "unprognostic (1.03e-2)" "unprognostic (6.88e-2)" "prognostic unfavourable (1.57e-4)" "unprognostic (9.95e-2)" "unprognostic (8.10e-2)" "unprognostic (3.24e-1)" "unprognostic (1.81e-1)" 19.3 7.5 8.6 19.8 22.5 25.7 11.6 3.1 15.5 14.4 12.8 9.4 4.7 14.7 13.2 19.3 19.2 12.4 19.0 8.1 12.4 16.2 20.8 11.9 28.4 17.3 14.3 11.4 16.3 7.2 7.5 16.2 9.7 20.5 7.2 5.4 15.9 54.0 8.4 3.7 5.7 15.4 11.3 13.1 34.5 16.2 5.2 4.8 33.7 16.9 14.5 20.7 15.6 11.5 22.8 25.0 36.5 27.0 9.2 29.5 17.0 2.3 0.0 0.1 0.2 0.1 1.0 0.0 0.1 3.7 117.5 105.8 0.7 4.9 0.0 1.0 0.4 0.3 0.1 0.1 2.3 0.7 0.1 0.2 0.4 0.3 1.1 0.1 0.1 1.0 0.3 7.0 0.2 0.4 0.0 27.1 0.0 0.2 2.0 0.4 0.4 1.1 2.0 0.0 3.7 0.5 1.5 0.2 0.1 0.1 0.2 35.4 1.6 0.9 0.2 0.1 0.1 0.0 0.1 6.0 5.6 0.2 0.1 0.4 0.3 13.7 24.0 14.0 10.9 27.0 14.6 22.8 16.0 12.7 16.9 20.1 14.5 10.7 36.5 9.2 22.0 25.0 29.5 17.0 8.6 22.5 3.1 15.5 12.4 16.2 14.3 11.4 20.5 4.8 NCAM2 "MGC51008, NCAM21" ENSG00000154654 "Neural cell adhesion molecule 2" O15394 21 20998315-21543329 "Plasma proteins, Predicted membrane proteins" "Cell adhesion" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 15.9;brain: 52.7" "Cell line enriched" "Detected in some" 4 "T-47d: 44.1" "Cancer enhanced" "Detected in some" "glioma: 5.5" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA030900, HPA030901" Enhanced Supported Supported "Nuclear bodies,Plasma membrane" 100000000 "Nuclear bodies, Plasma membrane" "HPA030900: AB_10602037, HPA030901: " "unprognostic (9.70e-2)" "unprognostic (1.08e-1)" "unprognostic (1.47e-1)" "unprognostic (2.54e-2)" "unprognostic (1.85e-1)" "unprognostic (1.81e-1)" "unprognostic (1.37e-2)" "unprognostic (3.01e-2)" "unprognostic (5.90e-2)" "unprognostic (1.62e-1)" "unprognostic (1.31e-1)" "unprognostic (5.61e-1)" "unprognostic (3.07e-4)" "unprognostic (2.47e-4)" "unprognostic (1.62e-1)" "unprognostic (8.05e-2)" "unprognostic (1.35e-3)" 2.0 15.9 25.8 2.0 22.3 1.1 3.1 7.0 52.7 3.3 2.1 14.7 0.0 1.3 2.3 1.8 1.7 1.8 2.6 3.1 18.7 13.9 1.3 9.1 4.4 1.2 21.6 19.4 1.4 1.3 1.1 1.0 1.7 17.9 2.2 2.4 0.5 1.8 2.3 1.5 2.0 1.9 2.7 17.3 2.0 1.3 8.3 26.6 0.0 1.5 0.0 1.3 1.4 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 2.3 2.3 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.6 0.0 0.2 0.6 0.0 1.1 0.0 0.0 5.6 0.0 1.7 0.0 0.0 5.1 1.1 0.1 7.1 0.1 0.0 0.2 0.0 0.5 0.0 2.1 0.0 0.0 0.0 2.6 0.0 0.3 0.3 44.1 3.3 0.0 0.6 0.4 0.0 0.0 0.3 0.0 0.0 1.2 0.0 10.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 25.8 22.3 7.0 22.4 18.7 13.9 21.6 19.4 17.9 26.6 NCDN "NCDN-1, NCDN-2" ENSG00000020129 Neurochondrin Q9UBB6 1 35557473-35567274 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 12 "brain: 144.3" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA023676 Enhanced Supported Supported Cytosol Cytosol "HPA023676: AB_1854325" "unprognostic (1.15e-1)" "unprognostic (7.11e-2)" "unprognostic (1.08e-1)" "unprognostic (6.05e-2)" "unprognostic (6.12e-3)" "unprognostic (2.39e-1)" "prognostic unfavourable (1.91e-5)" "unprognostic (4.66e-2)" "unprognostic (1.41e-1)" "unprognostic (4.36e-2)" "prognostic favourable (3.73e-4)" "unprognostic (5.91e-3)" "unprognostic (5.34e-3)" "unprognostic (5.88e-3)" "unprognostic (2.87e-1)" "unprognostic (3.24e-2)" "unprognostic (2.23e-2)" 5.2 11.3 33.4 6.0 144.3 3.4 3.6 28.7 104.9 9.9 3.5 8.7 1.2 3.9 6.2 4.8 4.5 8.1 6.5 12.0 45.4 25.0 4.0 2.5 4.5 5.9 15.8 32.3 9.2 6.1 6.2 5.5 4.7 26.4 7.1 2.9 3.6 6.7 8.0 5.3 5.6 3.2 6.5 10.7 5.0 4.7 5.8 15.6 0.8 6.5 0.6 4.6 6.0 2.4 5.9 2.7 0.8 4.5 3.0 6.5 5.5 8.7 10.6 8.9 14.0 12.9 16.0 6.1 11.6 12.1 12.2 9.8 10.6 13.0 10.0 11.3 10.7 13.5 8.7 14.1 4.5 9.7 18.0 12.4 15.6 5.4 17.9 11.2 14.3 15.3 11.8 21.6 8.7 6.5 13.4 16.0 9.9 15.7 10.2 7.2 39.9 18.7 8.4 4.9 12.9 8.2 9.8 11.1 16.0 13.2 12.2 16.3 11.7 7.4 8.8 15.6 11.2 11.4 15.8 22.6 15.9 7.4 19.4 18.0 14.2 0.0 4.5 0.8 3.1 2.6 3.8 5.9 4.8 4.8 2.7 2.7 6.5 5.3 0.7 3.0 4.2 1.6 2.7 5.5 33.4 144.3 28.7 61.4 45.4 25.0 15.8 32.3 26.4 15.6 NCS1 "FREQ, NCS-1" ENSG00000107130 "Neuronal calcium sensor 1" P62166 9 130172578-130237304 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 76.8" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 1.2;MAIT T-cell: 1.2" "Lineage enriched" "Detected in single" 13 "T-cells: 1.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB018587, HPA019713" Enhanced Supported Enhanced "Plasma membrane" "Plasma membrane" "CAB018587: AB_649907, HPA019713: AB_1854404" "prognostic unfavourable (5.40e-4)" "unprognostic (1.57e-1)" "unprognostic (4.64e-3)" "prognostic unfavourable (8.69e-4)" "unprognostic (1.29e-1)" "unprognostic (9.23e-2)" "prognostic unfavourable (1.11e-4)" "unprognostic (1.61e-3)" "unprognostic (4.27e-1)" "unprognostic (1.21e-2)" "unprognostic (8.45e-2)" "unprognostic (1.58e-1)" "unprognostic (3.71e-3)" "unprognostic (8.59e-2)" "unprognostic (1.69e-1)" "prognostic unfavourable (8.25e-4)" "unprognostic (1.65e-1)" 5.8 12.6 76.8 7.9 56.6 4.6 2.8 18.6 66.2 7.7 20.1 6.4 5.0 3.6 12.6 4.1 24.9 13.5 8.7 4.6 74.3 25.7 8.7 1.6 2.5 1.6 20.6 28.1 4.6 3.5 1.5 2.7 1.6 17.7 14.9 6.8 4.2 5.3 41.6 0.9 10.0 4.3 34.3 6.8 1.1 5.1 2.2 7.1 0.0 20.1 0.7 2.7 16.4 4.6 0.0 0.0 0.0 0.0 0.0 1.2 0.1 7.7 15.8 8.2 16.4 5.1 11.6 3.9 20.0 9.3 15.4 10.3 7.5 4.0 0.0 7.3 25.2 14.0 13.3 17.5 6.9 22.9 4.0 0.0 10.5 8.0 7.9 0.6 9.7 13.4 8.9 17.4 11.0 14.5 5.6 0.1 22.2 22.2 1.4 7.7 12.5 6.7 0.0 25.9 5.3 15.0 4.9 21.7 20.4 12.3 5.9 11.8 11.0 4.9 11.4 29.9 24.3 23.9 25.6 0.0 0.0 0.0 34.9 2.2 32.2 0.0 0.0 0.0 1.2 0.0 1.2 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 76.8 56.6 18.6 59.9 74.3 25.7 20.6 28.1 17.7 7.1 NECAB1 EFCBP1 ENSG00000123119 "N-terminal EF-hand calcium binding protein 1" Q8N987 8 90791550-90959408 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "brain: 56.4" "Cell line enhanced" "Detected in many" "HEL: 6.1;MOLT-4: 6.4;U-266/70: 6.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA023252, HPA023629, HPA025963, HPA031262, CAB068208, CAB068209, CAB068210" Enhanced Supported Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB068208: , CAB068209: , CAB068210: , HPA023252: AB_1848013, HPA023629: AB_1848014, HPA025963: AB_1848015, HPA031262: AB_2673815" "unprognostic (8.09e-3)" "unprognostic (3.78e-1)" "unprognostic (8.17e-3)" "unprognostic (5.96e-5)" "unprognostic (2.51e-1)" "unprognostic (1.30e-1)" "unprognostic (3.83e-3)" "unprognostic (8.38e-2)" "unprognostic (1.78e-3)" "unprognostic (2.60e-1)" "unprognostic (2.25e-2)" "unprognostic (2.57e-2)" "unprognostic (2.19e-3)" "unprognostic (4.45e-3)" "unprognostic (1.68e-2)" "unprognostic (2.42e-3)" "unprognostic (5.39e-3)" 2.7 4.9 19.7 2.0 27.3 3.2 1.5 0.5 56.4 1.4 3.7 12.1 0.3 1.7 4.1 4.4 3.6 1.6 3.1 10.9 19.5 9.8 3.4 1.1 6.8 1.4 16.0 30.7 3.8 1.3 1.9 1.9 2.8 10.8 2.6 1.1 4.1 2.5 2.0 1.3 1.9 1.8 1.3 18.7 2.4 2.1 5.2 17.4 0.0 2.9 0.0 1.0 4.2 1.2 0.5 1.8 0.3 0.0 0.7 0.9 0.2 0.2 0.1 2.3 0.4 0.0 0.1 0.1 2.5 0.1 0.0 0.0 0.0 0.7 0.1 0.2 0.0 0.0 1.0 0.0 0.1 0.0 4.7 6.1 2.0 0.0 0.0 0.0 0.2 0.7 0.0 0.0 0.1 0.0 4.1 4.4 0.0 4.9 6.4 3.1 0.9 0.1 0.0 4.0 0.0 0.0 0.0 4.1 4.4 0.1 0.0 2.1 0.0 0.2 1.5 3.9 3.8 0.0 1.6 6.1 3.7 3.2 3.8 0.0 1.8 0.0 0.0 0.1 0.6 0.0 0.4 0.2 0.4 0.6 0.1 0.5 0.6 0.9 0.3 0.7 0.0 1.8 0.9 0.2 19.7 27.3 0.5 37.1 19.5 9.8 16.0 30.7 10.8 17.4 NECAB2 EFCBP2 ENSG00000103154 "N-terminal EF-hand calcium binding protein 2" Q7Z6G3 16 83968632-84002776 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 30.6;brain: 42.5;kidney: 12.4;liver: 15.1" "Cell line enhanced" "Detected in some" "AF22: 7.5;SCLC-21H: 28.6;U-87 MG: 10.1" "Cancer enhanced" "Detected in many" "liver cancer: 7.2" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 68 "neutrophil: 30.6" "Lineage enriched" "Detected in single" 68 "granulocytes: 30.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA013998, HPA014144, CAB068211" Enhanced Supported "CAB068211: , HPA013998: AB_1848016, HPA014144: AB_1848017" "unprognostic (5.27e-2)" "unprognostic (1.14e-1)" "unprognostic (5.50e-2)" "unprognostic (3.48e-5)" "unprognostic (3.45e-2)" "unprognostic (4.20e-2)" "unprognostic (6.74e-2)" "unprognostic (8.79e-2)" "unprognostic (4.15e-1)" "unprognostic (2.59e-1)" "unprognostic (5.75e-3)" "unprognostic (2.14e-2)" "prognostic unfavourable (1.58e-4)" "unprognostic (8.89e-3)" "unprognostic (3.48e-1)" "unprognostic (8.61e-3)" "unprognostic (3.75e-2)" 1.8 1.1 34.1 1.3 42.5 1.3 0.9 0.2 35.2 0.7 1.1 2.2 0.0 1.9 2.2 0.9 0.7 0.7 1.3 1.0 9.5 21.7 12.4 15.1 1.0 0.8 5.0 14.0 0.7 2.1 1.6 3.3 0.9 7.4 0.8 0.9 0.1 0.6 0.8 0.5 0.7 1.7 1.2 1.9 1.1 2.8 5.4 5.9 0.0 0.8 0.0 0.5 1.1 0.0 0.0 0.0 30.6 0.4 0.0 0.0 0.0 0.1 3.7 7.5 0.0 0.0 1.0 0.1 0.1 0.1 0.1 0.0 0.2 0.2 0.0 1.2 0.1 0.0 1.3 0.0 0.0 0.0 2.1 0.0 0.0 0.3 0.1 0.0 1.2 0.4 0.1 0.2 0.2 0.1 0.1 0.1 0.0 4.3 0.0 0.0 3.9 0.5 0.0 0.0 0.4 0.0 0.0 28.6 1.2 0.0 0.1 2.2 3.8 1.3 0.2 0.1 2.2 0.3 0.0 0.1 0.0 0.0 10.1 0.4 0.2 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 30.6 0.0 0.0 0.0 0.0 0.0 34.1 42.5 0.2 21.2 9.5 21.7 5.0 14.0 7.4 5.9 NEFL "CMT1F, CMT2E, NF68, NFL, PPP1R110" ENSG00000277586 "Neurofilament light" P07196 8 24950955-24957110 "Disease related genes, Predicted intracellular proteins" "Charcot-Marie-Tooth disease, Disease mutation, Neurodegeneration, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 7 "brain: 95.1" "Group enriched" "Detected in some" 5 "HEK 293: 112.2;PC-3: 30.1" "Cancer enhanced" "Detected in many" "renal cancer: 24.0" "Cell type enriched" "Detected in some" 5 "memory CD4 T-cell: 13.7" "Lineage enriched" "Detected in single" 138 "T-cells: 13.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA014850, HPA015021" Enhanced Supported Approved "Nuclear speckles,Intermediate filaments" "Nuclear speckles" "Intermediate filaments" "HPA014850: AB_1854397, HPA015021: " "unprognostic (7.63e-2)" "unprognostic (1.36e-2)" "unprognostic (9.53e-2)" "unprognostic (6.81e-2)" "unprognostic (2.82e-2)" "unprognostic (6.69e-2)" "unprognostic (3.69e-2)" "unprognostic (3.78e-3)" "unprognostic (3.06e-1)" "unprognostic (1.60e-1)" "unprognostic (1.46e-2)" "unprognostic (1.94e-1)" "prognostic unfavourable (4.91e-4)" "unprognostic (5.76e-3)" "unprognostic (7.88e-2)" "unprognostic (3.97e-3)" "unprognostic (3.17e-3)" 0.7 12.0 10.3 1.4 20.1 0.6 0.6 2.3 92.1 1.8 1.8 3.0 0.0 1.0 0.7 0.8 3.8 0.7 0.6 0.6 14.1 3.5 0.6 0.6 0.7 0.0 23.8 0.7 0.7 0.6 0.0 0.6 95.1 1.6 1.5 5.0 0.6 9.5 0.6 0.7 1.7 1.2 18.0 0.7 1.1 1.6 2.1 0.0 1.0 0.0 0.8 0.6 0.0 0.0 0.0 0.0 0.0 0.0 13.7 2.1 0.0 0.1 14.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.1 0.0 0.1 0.0 0.0 112.2 0.0 0.0 0.0 4.9 0.0 0.1 1.8 0.4 0.0 0.3 0.0 0.0 0.0 0.4 0.0 0.0 0.0 3.8 30.1 0.0 0.0 0.0 6.9 1.0 6.2 6.4 2.6 0.0 0.4 0.0 0.0 0.0 0.6 7.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 13.7 1.5 0.0 0.0 3.0 0.1 0.0 0.0 0.0 0.0 0.2 2.1 NPAS1 "bHLHe11, MOP5, PASD5" ENSG00000130751 "Neuronal PAS domain protein 1" Q99742 19 47019820-47045775 "Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in some" "brain: 14.2;skin 1: 10.5;stomach 1: 8.0" "Cell line enhanced" "Detected in many" "BJ: 8.7;Daudi: 8.9;HEK 293: 9.8;HMC-1: 8.1;NB-4: 15.6;U-266/84: 9.5" "Cancer enhanced" "Detected in many" "testis cancer: 5.1" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in single" "memory B-cell: 2.2" "Lineage enhanced" "Detected in single" "B-cells: 2.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA043364, HPA072259" Approved Approved Nucleoplasm Nucleoplasm "HPA043364: , HPA072259: " "unprognostic (2.34e-3)" "unprognostic (6.25e-2)" "unprognostic (7.32e-4)" "unprognostic (1.38e-1)" "unprognostic (6.24e-2)" "unprognostic (2.46e-2)" "unprognostic (2.76e-3)" "unprognostic (2.21e-2)" "unprognostic (1.09e-1)" "unprognostic (3.75e-1)" "unprognostic (5.91e-2)" "unprognostic (2.64e-1)" "unprognostic (2.14e-8)" "unprognostic (8.82e-2)" "unprognostic (2.07e-1)" "unprognostic (1.06e-1)" "unprognostic (4.20e-2)" 0.6 0.6 9.5 1.3 4.1 0.9 1.3 0.4 14.2 0.4 0.9 0.4 0.0 0.5 0.6 0.4 0.8 1.2 0.5 0.9 9.0 5.2 1.2 0.8 0.9 1.7 3.0 4.1 0.4 1.5 0.7 1.1 0.8 5.1 0.6 0.5 3.4 0.7 0.5 0.5 10.5 0.4 0.7 0.8 3.9 8.0 0.8 0.2 0.0 0.6 0.0 1.3 0.5 0.4 2.2 0.0 0.0 0.0 0.0 0.6 0.0 0.1 2.1 0.2 0.4 0.2 0.1 0.0 8.7 0.2 0.1 0.4 0.6 0.5 8.9 2.0 7.0 0.2 1.8 0.2 0.1 0.6 9.8 0.7 0.8 2.1 0.0 4.7 8.1 0.8 0.3 0.0 0.1 0.2 3.0 0.7 1.1 0.7 0.3 15.6 2.1 1.5 0.8 0.3 0.7 0.5 0.5 0.7 0.6 0.7 0.3 2.0 1.9 1.5 0.1 0.1 0.9 0.1 0.2 4.9 9.5 1.9 1.1 0.9 6.4 0.0 0.0 0.0 0.3 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 9.5 4.1 0.4 14.2 9.0 5.2 3.0 4.1 5.1 0.2 NPAS2 "bHLHe9, MOP4, PASD4" ENSG00000170485 "Neuronal PAS domain protein 2" Q99743 2 100820152-100996829 "Predicted intracellular proteins, Transcription factors" "Biological rhythms, DNA damage, Transcription, Transcription regulation" "Activator, DNA-binding" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A549: 24.1;PC-3: 36.4;RT4: 29.3;U-87 MG: 26.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "naive CD4 T-cell: 2.0;naive CD8 T-cell: 1.3" "Lineage enriched" "Detected in single" 21 "T-cells: 2.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA019674 Uncertain Supported Approved Nucleoplasm Nucleoplasm "HPA019674: AB_10601275" "unprognostic (2.74e-1)" "unprognostic (8.89e-2)" "unprognostic (4.66e-2)" "unprognostic (5.06e-3)" "unprognostic (4.39e-2)" "unprognostic (3.05e-1)" "prognostic unfavourable (2.07e-4)" "unprognostic (5.47e-3)" "unprognostic (4.48e-1)" "unprognostic (1.56e-1)" "unprognostic (1.59e-3)" "unprognostic (2.13e-1)" "prognostic unfavourable (3.55e-7)" "unprognostic (7.03e-2)" "unprognostic (6.58e-2)" "unprognostic (7.71e-3)" "unprognostic (1.34e-3)" 6.6 11.5 16.8 8.2 24.8 1.2 10.1 7.6 23.0 11.9 14.4 4.3 1.3 26.7 8.8 4.9 32.4 8.2 13.6 27.3 15.3 6.8 15.9 14.1 5.3 3.6 6.2 14.1 3.3 32.5 1.7 12.7 14.2 10.3 12.2 15.1 6.5 23.7 7.0 12.7 18.5 20.2 17.9 11.0 5.7 19.1 9.9 8.5 0.5 6.3 6.0 13.4 22.4 14.4 0.0 0.0 0.0 0.0 0.0 2.0 0.0 4.2 24.1 0.0 0.2 23.8 10.4 3.5 7.9 23.9 3.3 7.1 0.4 1.9 0.0 9.6 1.3 0.2 3.5 5.9 3.4 0.3 1.4 0.0 4.3 11.0 11.3 0.0 1.0 8.7 9.6 8.0 12.9 13.5 0.1 0.0 2.6 8.6 1.6 0.2 0.4 36.4 0.1 0.5 0.2 17.0 29.3 0.0 0.4 0.0 1.4 17.9 0.2 0.2 5.1 2.4 3.3 4.8 3.4 0.0 0.0 0.0 26.1 0.0 4.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.7 0.0 0.0 0.0 2.0 1.3 0.0 0.0 0.0 0.0 1.3 0.0 16.8 24.8 7.6 23.0 15.3 6.8 6.2 14.1 10.3 8.5 NPY PYY4 ENSG00000122585 "Neuropeptide Y" P01303 7 24284163-24291865 "Plasma proteins, Predicted secreted proteins" Neuropeptide "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "adrenal gland: 50.5;brain: 63.6;prostate: 131.2" "Cell line enriched" "Detected in some" 36 "SH-SY5Y: 121.1" "Cancer enriched" "Detected in many" 187 "prostate cancer: 1214.9" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB016733, CAB034368, HPA036636, HPA044572, HPA056798" Supported Supported Enhanced "Golgi apparatus" "Secreted to blood" 30733800 "Golgi apparatus" "CAB016733: , CAB034368: AB_2298657, HPA036636: , HPA044572: , HPA056798: " "unprognostic (2.00e-1)" "prognostic unfavourable (5.78e-4)" "unprognostic (4.15e-1)" "unprognostic (3.76e-2)" "unprognostic (1.59e-2)" "unprognostic (1.87e-1)" "unprognostic (6.30e-2)" "unprognostic (1.24e-2)" "unprognostic (1.78e-1)" "unprognostic (2.52e-1)" 1.6 50.5 27.2 5.5 63.6 2.8 1.0 0.1 55.9 1.0 1.8 2.8 1.4 4.7 1.1 1.1 2.5 1.0 1.4 1.0 11.9 20.6 1.1 1.0 1.1 1.0 2.6 18.3 1.0 4.0 1.0 0.5 1.0 1.9 131.2 1.7 0.0 1.0 14.7 1.0 1.0 5.0 1.4 1.4 1.0 1.7 1.3 13.9 0.0 1.1 0.0 1.0 3.9 4.5 0.5 0.0 0.0 0.0 0.0 0.7 0.4 0.0 0.0 0.4 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.0 3.4 0.0 0.1 0.0 0.0 0.1 121.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 27.2 63.6 0.1 31.2 11.9 20.6 2.6 18.3 1.9 13.9 NUCB2 NEFA ENSG00000070081 "Nucleobindin 2" 11 17208153-17349980 "Predicted intracellular proteins, Predicted secreted proteins" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "salivary gland: 160.3" "Cell line enhanced" "Detected in all" "HL-60: 187.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA008395, CAB015931, CAB079781" Approved Supported Enhanced "Golgi apparatus" "Secreted to blood" 1245000 "Golgi apparatus" "CAB015931: , CAB079781: AB_2313672, HPA008395: AB_1854683" "unprognostic (2.49e-1)" "unprognostic (1.75e-2)" "unprognostic (1.39e-1)" "prognostic favourable (8.27e-6)" "unprognostic (5.24e-3)" "unprognostic (2.51e-1)" "unprognostic (3.96e-3)" "unprognostic (3.66e-3)" "unprognostic (1.81e-1)" "prognostic favourable (1.98e-4)" "unprognostic (1.46e-2)" "unprognostic (3.38e-2)" "prognostic unfavourable (3.94e-5)" "unprognostic (2.39e-1)" "unprognostic (1.61e-1)" "unprognostic (4.78e-2)" "unprognostic (8.02e-3)" 10.2 13.9 9.5 7.5 13.1 66.4 17.9 13.5 7.5 18.3 7.8 3.8 79.5 6.6 11.4 59.6 29.7 13.7 7.3 25.0 7.5 10.9 10.8 51.1 12.5 13.5 8.5 7.6 15.4 92.8 58.9 69.7 35.8 10.3 13.4 8.3 5.8 160.3 104.9 7.2 4.2 6.8 11.3 9.4 9.8 11.4 18.7 6.1 86.1 22.7 17.7 10.4 12.1 11.0 3.7 71.7 28.8 7.6 45.2 49.5 20.1 12.1 5.1 5.6 17.1 12.8 17.6 6.9 27.2 39.6 12.2 21.7 5.0 2.8 18.7 6.8 25.8 5.2 3.5 6.9 19.1 12.9 8.0 13.8 6.4 8.6 37.0 187.4 25.4 7.6 9.2 8.8 21.5 14.9 11.9 38.0 12.0 10.7 66.0 67.8 1.3 5.3 24.4 13.8 1.5 5.4 3.8 6.7 3.8 11.9 12.0 6.0 9.8 51.0 13.3 13.0 12.0 39.2 11.5 7.5 4.0 10.4 15.0 66.2 11.1 28.8 7.6 27.6 17.1 5.0 22.3 3.7 16.3 31.5 6.9 2.4 46.0 49.5 7.0 45.2 4.0 71.7 7.0 20.1 9.5 13.1 13.5 7.5 7.5 10.9 8.5 7.6 10.3 6.1 OGFOD1 "FLJ10826, KIAA1612, TPA1" ENSG00000087263 "2-oxoglutarate and iron dependent oxygenase domain containing 1" Q8N543 16 56451490-56479100 "Predicted intracellular proteins" "Dioxygenase, Oxidoreductase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 56.1" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003215, HPA003722" Approved Approved Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA003215: AB_1078881, HPA003722: " "unprognostic (1.13e-1)" "unprognostic (4.52e-2)" "unprognostic (3.80e-3)" "unprognostic (2.86e-2)" "unprognostic (2.48e-3)" "prognostic unfavourable (6.65e-4)" "prognostic unfavourable (7.02e-4)" "unprognostic (5.51e-2)" "unprognostic (6.87e-2)" "unprognostic (3.36e-2)" "unprognostic (1.58e-2)" "unprognostic (4.59e-2)" "unprognostic (7.49e-2)" "unprognostic (7.20e-2)" "unprognostic (6.11e-2)" "unprognostic (1.25e-1)" "unprognostic (1.84e-2)" 8.8 13.4 10.0 8.0 11.6 3.3 9.4 10.3 14.3 10.8 7.0 12.4 6.0 7.4 9.5 8.4 18.1 10.1 7.8 12.9 7.7 11.1 12.9 13.9 7.5 7.5 9.1 10.4 10.2 6.5 13.7 13.1 8.3 15.6 8.0 8.9 8.5 8.4 10.0 56.1 8.8 5.8 15.1 11.1 8.6 7.4 8.2 6.2 10.6 9.3 12.6 13.0 9.6 8.3 7.8 7.5 11.8 8.9 8.7 12.1 6.5 11.1 13.2 13.0 16.1 14.7 17.8 12.2 18.2 14.7 25.9 18.8 16.1 8.2 20.4 9.3 14.5 16.1 27.5 12.4 29.3 6.3 14.8 14.8 11.5 16.5 11.3 16.0 17.5 11.8 14.1 19.2 16.0 21.0 20.6 3.9 21.8 7.2 12.7 9.2 22.0 22.8 23.8 19.9 23.8 11.6 8.0 10.4 11.6 22.5 14.6 12.2 13.3 13.3 13.6 14.4 11.5 11.1 16.0 8.0 15.5 30.1 11.5 11.6 11.4 11.8 4.7 4.8 8.8 6.3 11.9 7.8 11.2 10.4 7.1 6.1 12.1 10.0 1.7 8.7 8.9 7.5 9.3 6.5 10.0 11.6 10.3 14.3 7.7 11.1 9.1 10.4 15.6 6.2 OPRM1 MOR1 ENSG00000112038 "Opioid receptor mu 1" P35372 6 154010496-154246867 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "brain: 37.9" "Cell line enriched" "Detected in single" 24 "SH-SY5Y: 12.8" "Not detected" "Not detected" "Region enhanced" "Detected in many" "cerebellum: 37.9" "Cell type enhanced" "Detected in single" "neutrophil: 2.1" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA014509, HPA067435" Enhanced Supported "HPA014509: AB_1854801, HPA067435: " "unprognostic (7.34e-2)" "unprognostic (6.91e-2)" 0.5 3.4 7.0 0.6 17.5 1.8 0.9 37.9 7.6 0.5 0.6 0.8 0.0 0.6 0.7 1.4 3.7 0.5 1.0 0.5 2.6 2.3 0.5 0.5 0.5 0.9 0.6 9.3 0.8 0.7 0.4 0.6 0.5 5.2 0.7 0.4 0.0 0.6 0.2 0.9 1.8 0.5 0.3 1.9 0.6 1.0 8.0 0.5 0.0 1.0 0.0 0.3 0.5 0.5 0.5 0.2 2.1 0.1 0.1 0.7 0.0 0.1 0.0 0.2 0.4 0.0 0.2 0.2 0.2 0.0 0.1 0.0 0.2 0.4 0.4 0.1 0.0 0.3 0.3 0.2 0.1 0.2 0.1 0.1 0.4 0.1 0.0 0.3 0.5 0.1 0.5 0.0 0.1 0.1 0.1 0.3 0.3 0.2 0.1 0.0 0.1 0.0 0.2 0.2 0.0 0.1 0.1 0.3 12.8 0.0 0.0 0.3 0.3 0.1 0.3 0.4 0.1 0.3 0.1 0.4 0.2 0.1 0.3 0.1 0.0 0.2 0.1 0.6 0.6 0.0 0.7 0.2 0.3 0.5 0.1 0.5 0.4 0.1 2.1 0.1 0.0 0.2 0.3 0.0 7.0 17.5 37.9 7.6 2.6 2.3 0.6 9.3 5.2 0.5 OSBPL9 ENSG00000117859 "Oxysterol binding protein like 9" Q96SU4 1 51577179-51798427 "Plasma proteins, Predicted intracellular proteins" "Lipid transport, Transport" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA027378, HPA027397" Supported Approved Supported "Golgi apparatus,Vesicles" "Golgi apparatus" Vesicles "HPA027378: AB_1854816, HPA027397: AB_1854817" "unprognostic (5.99e-2)" "unprognostic (1.93e-2)" "unprognostic (1.22e-2)" "unprognostic (2.43e-3)" "unprognostic (3.11e-1)" "unprognostic (6.72e-2)" "unprognostic (2.85e-2)" "unprognostic (2.47e-1)" "unprognostic (4.17e-3)" "unprognostic (1.58e-1)" "unprognostic (8.36e-3)" "unprognostic (8.61e-2)" "unprognostic (3.64e-2)" "unprognostic (7.53e-3)" "unprognostic (2.55e-1)" "unprognostic (4.95e-2)" "unprognostic (3.37e-1)" 35.7 28.8 12.6 19.0 20.7 20.3 27.4 30.3 17.6 29.4 15.4 29.8 20.0 13.1 36.3 29.7 18.8 19.4 15.0 27.2 13.5 16.1 35.4 52.6 25.7 18.2 25.1 14.0 29.4 26.9 43.2 27.6 20.8 22.2 37.1 16.6 29.9 18.2 22.4 55.6 15.2 16.4 25.3 28.2 22.5 22.5 20.0 24.8 19.4 28.2 18.5 24.6 27.7 31.6 23.4 19.9 28.7 13.6 12.8 23.2 12.6 21.7 11.2 22.8 5.0 16.3 8.1 40.8 11.2 18.8 18.1 21.6 16.3 16.4 31.8 19.6 12.3 10.1 19.2 19.4 25.8 22.6 14.1 25.1 21.9 33.5 15.8 25.8 13.0 16.3 18.8 20.4 13.5 23.8 47.5 10.4 10.1 15.5 7.4 28.0 31.0 5.2 18.7 33.1 33.7 24.2 17.0 11.3 15.0 9.5 26.1 31.0 12.6 26.0 14.3 5.2 17.4 6.5 19.9 25.4 16.1 37.1 12.8 12.0 8.0 28.7 13.6 25.0 16.1 11.4 23.2 23.4 16.0 16.6 19.9 16.4 17.1 18.1 15.9 12.8 8.6 15.7 15.3 12.6 12.6 20.7 30.3 17.6 13.5 16.1 25.1 14.0 22.2 24.8 OTP ENSG00000171540 "Orthopedia homeobox" Q5XKR4 5 77628712-77639688 "Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 10 "brain: 16.2" "Cell line enhanced" "Detected in some" "HDLM-2: 3.2;SCLC-21H: 1.5;THP-1: 1.5" "Cancer enriched" "Detected in single" 6 "glioma: 1.2" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in some" 7 "hypothalamus: 23.4" "Region enhanced" "Detected in some" "hypothalamus: 24.0" HPA059342 Enhanced Supported "HPA059342: " "unprognostic (1.00e-1)" "unprognostic (2.40e-2)" "unprognostic (6.25e-2)" "unprognostic (8.06e-3)" "unprognostic (1.16e-1)" "unprognostic (7.77e-2)" "unprognostic (7.77e-2)" "unprognostic (2.39e-2)" "unprognostic (9.66e-2)" "unprognostic (4.64e-2)" "unprognostic (7.76e-14)" "unprognostic (3.38e-2)" "unprognostic (1.84e-1)" "unprognostic (9.49e-3)" 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 16.2 0.0 0.0 1.5 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.8 0.1 0.3 0.1 0.0 0.2 0.0 0.0 0.0 0.0 1.5 0.0 0.3 0.0 0.0 0.1 1.5 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 OTUB1 "FLJ20113, FLJ40710" ENSG00000167770 "OTU deubiquitinase, ubiquitin aldehyde binding 1" Q96FW1 11 63985853-64001811 "Enzymes, Plasma proteins, Predicted intracellular proteins" "Adaptive immunity, DNA damage, DNA repair, Immunity, Ubl conjugation pathway" "Hydrolase, Protease, Thiol protease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA039176, CAB072836" Approved Supported Approved Nucleoplasm,Cytosol 630000 "Nucleoplasm, Cytosol" "CAB072836: , HPA039176: AB_10674980" "unprognostic (2.50e-1)" "unprognostic (5.70e-3)" "unprognostic (3.93e-2)" "unprognostic (1.63e-1)" "unprognostic (2.78e-1)" "prognostic unfavourable (3.05e-4)" "unprognostic (1.85e-3)" "unprognostic (1.34e-2)" "unprognostic (2.45e-1)" "unprognostic (1.27e-2)" "unprognostic (3.04e-1)" "unprognostic (1.34e-1)" "unprognostic (1.33e-3)" "unprognostic (6.76e-2)" "unprognostic (1.42e-1)" "unprognostic (4.84e-2)" "unprognostic (1.82e-1)" 19.8 24.7 41.9 24.1 61.6 32.6 20.8 41.8 101.9 24.3 25.0 31.9 22.3 24.7 21.9 23.6 37.8 34.5 21.6 31.6 46.9 37.8 27.2 27.6 23.0 31.9 33.1 45.4 23.4 23.0 26.0 21.6 30.7 60.4 23.8 24.1 24.2 30.4 27.7 26.7 36.9 26.0 23.1 26.7 25.7 23.9 22.1 21.2 27.8 29.9 24.5 32.8 27.1 22.9 46.0 60.8 56.1 71.3 44.8 64.5 78.2 30.5 55.2 30.5 26.9 20.6 22.8 23.4 18.4 27.4 41.0 30.3 37.0 29.3 16.3 35.0 29.5 38.2 39.3 45.8 25.5 18.8 30.5 27.1 33.1 46.8 28.9 26.9 29.8 24.2 29.8 31.3 20.0 38.6 18.9 18.5 27.5 62.8 29.3 35.6 35.7 26.3 24.1 11.9 27.8 42.6 44.7 23.1 33.3 20.8 32.0 33.6 49.6 23.8 27.9 21.9 21.3 29.3 24.1 21.8 13.7 23.3 28.3 17.5 20.9 55.1 56.3 54.3 53.1 71.3 41.4 46.0 49.1 48.6 60.8 41.9 38.4 42.6 56.1 44.8 60.9 42.1 64.5 78.2 41.9 61.6 41.8 101.9 46.9 37.8 33.1 45.4 60.4 21.2 OTUD6B "CGI-77, DUBA5" ENSG00000155100 "OTU domain containing 6B" Q8N6M0 8 91070196-91087095 "Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Ubl conjugation pathway" "Hydrolase, Protease, Thiol protease" "Disease mutation, Epilepsy, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA024046, HPA024503, HPA024772" Approved Approved Approved "Nucleoplasm,Golgi apparatus,Cytosol" "Nucleoplasm, Golgi apparatus, Cytosol" "HPA024046: AB_10600925, HPA024503: AB_1854845, HPA024772: AB_1854846" "prognostic unfavourable (7.50e-4)" "unprognostic (1.28e-1)" "unprognostic (1.45e-1)" "unprognostic (4.78e-3)" "unprognostic (4.91e-2)" "unprognostic (1.49e-1)" "unprognostic (1.52e-2)" "unprognostic (1.16e-3)" "unprognostic (2.17e-1)" "unprognostic (5.51e-2)" "unprognostic (1.27e-2)" "unprognostic (8.61e-3)" "unprognostic (1.87e-2)" "unprognostic (1.96e-1)" "unprognostic (4.53e-1)" "unprognostic (8.78e-2)" "unprognostic (5.71e-2)" 11.4 11.3 14.6 14.1 18.2 8.9 13.2 13.8 19.6 12.3 11.3 9.9 10.3 9.2 12.1 9.0 13.2 9.1 8.6 14.0 14.9 13.7 11.0 10.5 10.0 13.8 18.5 15.5 12.5 9.9 11.2 14.4 14.9 16.2 11.6 11.3 6.0 9.5 14.8 35.3 11.2 9.1 12.4 19.9 11.3 8.8 11.9 17.4 13.9 11.8 11.0 11.9 11.9 14.0 7.2 12.9 8.8 7.8 7.8 6.8 2.9 16.0 9.3 8.3 6.2 3.7 2.8 8.7 12.7 4.8 11.9 7.7 7.9 10.1 17.1 6.2 6.7 5.5 17.2 10.4 18.5 13.7 10.5 23.2 9.6 6.0 8.0 11.8 12.3 4.7 5.0 9.6 22.7 9.6 23.2 10.7 10.1 8.7 19.8 7.7 4.5 18.4 8.9 8.0 15.2 9.3 11.6 2.0 7.5 1.2 28.3 12.3 14.5 5.7 9.8 7.1 10.7 10.8 12.1 10.7 20.4 25.0 10.4 14.8 13.6 8.8 6.5 4.3 5.9 7.8 6.8 7.2 4.8 5.7 8.1 6.8 6.7 5.9 0.9 7.8 5.8 12.9 3.6 2.9 14.6 18.2 13.8 19.6 14.9 13.7 18.5 15.5 16.2 17.4 OXT "OT, OT-NPI, OXT-NPI" ENSG00000101405 "Oxytocin/neurophysin I prepropeptide" P01178 20 3071620-3072517 "Plasma proteins, Predicted secreted proteins" Hormone "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 10 "brain: 232.0" "Group enriched" "Detected in some" 4 "CACO-2: 5.1;HL-60: 1.3;HMC-1: 3.7;PC-3: 2.6" "Cancer enriched" "Detected in some" 5 "testis cancer: 12.1" "Region enriched" "Detected in some" 59 "hypothalamus: 232.0" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Region enriched" "Detected in some" 5 "hypothalamus: 210.0" "Group enriched" "Detected in some" 878 "basal ganglia: 840.1;hypothalamus: 2453.1" HPA071892 Supported Supported "Secreted to blood" 1501000 "HPA071892: " "unprognostic (7.45e-3)" "unprognostic (1.99e-2)" "unprognostic (2.66e-2)" "unprognostic (2.28e-1)" "unprognostic (2.62e-1)" "unprognostic (3.82e-2)" "unprognostic (8.22e-2)" "unprognostic (8.36e-2)" "unprognostic (6.02e-2)" "unprognostic (3.05e-2)" "unprognostic (6.65e-2)" "unprognostic (6.18e-1)" "unprognostic (3.81e-1)" "unprognostic (3.36e-2)" "unprognostic (1.95e-1)" "unprognostic (1.81e-1)" "unprognostic (1.10e-1)" 5.0 0.2 0.0 0.1 3.9 0.2 0.2 0.0 0.3 0.1 0.0 0.4 0.0 2.6 0.0 3.8 0.0 0.0 0.0 0.0 0.1 232.0 1.6 24.0 0.2 0.2 0.0 0.0 0.2 0.0 0.0 1.8 0.6 0.2 0.2 0.0 0.0 0.4 0.2 0.2 0.2 2.4 0.0 0.0 0.2 0.2 1.5 0.0 0.2 0.0 0.0 0.0 0.0 0.0 3.7 1.5 6.3 0.4 0.4 3.6 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.5 0.0 0.0 0.0 5.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.3 6.3 0.8 0.4 1.0 3.7 1.7 1.1 0.9 3.6 3.2 3.6 1.1 0.4 0.0 1.5 2.4 0.9 0.0 3.9 0.0 0.3 0.1 232.0 0.0 0.0 0.2 0.0 PACSIN3 SDPIII ENSG00000165912 "Protein kinase C and casein kinase substrate in neurons 3" Q9UKS6 11 47177525-47186443 "Plasma proteins, Predicted intracellular proteins" Endocytosis "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "heart muscle: 40.6;skeletal muscle: 121.6;tongue: 44.6" "Cell line enhanced" "Detected in many" "T-47d: 41.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA039480, HPA043904" Approved Approved Supported "Plasma membrane,Cytosol" Cytosol "Plasma membrane" "HPA039480: AB_2676531, HPA043904: AB_2678725" "unprognostic (1.75e-1)" "unprognostic (1.11e-1)" "unprognostic (1.73e-2)" "unprognostic (3.10e-2)" "unprognostic (1.21e-1)" "unprognostic (6.89e-2)" "unprognostic (4.66e-2)" "unprognostic (8.17e-2)" "unprognostic (2.85e-1)" "prognostic favourable (2.09e-4)" "unprognostic (3.86e-3)" "unprognostic (1.26e-1)" "unprognostic (2.75e-2)" "unprognostic (9.72e-2)" "unprognostic (1.92e-1)" "unprognostic (1.29e-1)" "unprognostic (4.76e-2)" 4.1 17.0 3.9 2.2 5.7 0.4 4.3 3.5 4.7 6.5 8.5 8.6 7.1 1.6 6.7 7.6 12.6 4.8 5.8 40.6 4.0 2.4 2.9 10.0 3.9 0.8 7.6 3.6 6.3 14.6 4.8 1.0 8.0 4.4 8.6 1.1 4.6 11.3 6.7 121.6 11.9 1.9 7.4 8.3 1.5 6.0 1.6 6.5 0.3 8.5 44.6 7.1 6.4 5.7 0.0 0.1 0.0 0.9 0.0 0.2 0.9 16.4 8.3 3.8 16.6 3.3 3.3 18.6 5.1 7.4 10.8 6.1 12.3 2.3 0.1 1.6 2.8 27.1 7.6 12.5 4.3 2.5 12.9 2.5 31.3 28.2 6.5 0.5 2.6 9.3 16.8 5.7 9.1 4.8 5.4 0.2 4.4 32.6 0.3 12.1 4.7 16.6 10.1 14.4 2.6 4.5 15.6 0.1 13.0 8.1 5.8 7.6 41.0 2.2 2.3 18.9 19.0 2.4 14.1 2.8 1.3 1.5 6.1 5.7 9.7 0.0 0.3 0.0 0.0 0.9 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 3.9 5.7 3.5 4.7 4.0 2.4 7.6 3.6 4.4 6.5 PAK1 ENSG00000149269 "P21 (RAC1) activated kinase 1" Q13153 11 77321707-77474635 "Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Apoptosis, Exocytosis" "Allosteric enzyme, Kinase, Serine/threonine-protein kinase, Transferase" "Disease mutation, Epilepsy, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 70.0;brain: 71.4" "Cell line enhanced" "Detected in many" "U-266/70: 51.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 9 "classical monocyte: 29.3;eosinophil: 45.0;intermediate monocyte: 28.7;myeloid DC: 42.3;neutrophil: 70.0;non-classical monocyte: 30.4" "Group enriched" "Detected in all" 11 "dendritic cells: 42.3;granulocytes: 70.0;monocytes: 30.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003565, CAB005312" Enhanced Supported Supported "Plasma membrane,Cytosol" 200000 "Plasma membrane, Cytosol" "CAB005312: AB_2160720, HPA003565: AB_1854935" "unprognostic (1.15e-2)" "unprognostic (3.23e-2)" "prognostic favourable (5.87e-4)" "unprognostic (1.30e-1)" "prognostic unfavourable (1.15e-4)" "unprognostic (6.62e-2)" "unprognostic (8.19e-3)" "unprognostic (4.84e-2)" "unprognostic (1.05e-1)" "unprognostic (1.22e-3)" "unprognostic (1.86e-2)" "unprognostic (2.76e-1)" "unprognostic (1.02e-1)" "unprognostic (6.91e-2)" "unprognostic (1.57e-1)" "unprognostic (4.00e-3)" "unprognostic (1.52e-2)" 5.4 6.0 30.5 13.8 39.5 22.9 7.8 49.1 71.4 9.8 18.2 8.4 2.3 18.2 9.1 13.3 9.9 9.8 13.2 5.3 19.0 16.9 11.3 6.0 6.9 7.5 12.8 40.6 10.4 9.2 11.8 10.8 11.9 39.2 12.2 20.2 5.4 10.4 8.8 34.0 6.7 18.9 11.6 7.8 11.7 17.1 11.1 6.6 7.6 17.7 3.9 9.4 10.5 10.4 2.7 42.3 70.0 30.4 4.3 2.4 12.2 11.8 8.0 17.4 7.8 7.1 11.9 13.9 13.6 9.7 12.9 15.2 11.4 15.9 10.6 5.0 11.7 6.1 12.1 14.4 20.4 12.2 9.8 11.2 5.4 0.7 4.7 18.9 16.6 8.8 8.7 15.1 22.5 3.0 7.4 18.7 23.4 0.8 12.0 8.7 25.7 6.9 18.5 22.5 0.4 3.3 9.9 7.5 7.4 7.3 3.1 5.7 13.9 8.6 0.2 8.6 14.9 45.9 11.3 51.4 26.4 7.0 7.2 12.6 9.3 0.3 29.3 45.0 1.9 28.7 1.5 2.7 1.4 1.8 42.3 1.9 1.3 2.4 70.0 4.3 30.4 3.6 1.1 12.2 30.5 39.5 49.1 71.4 19.0 16.9 12.8 40.6 39.2 6.6 PARP1 "ADPRT, PARP, PPOL" ENSG00000143799 "Poly(ADP-ribose) polymerase 1" P09874 1 226360691-226408079 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, Transcription, Transcription regulation" "DNA-binding, Glycosyltransferase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000147, CAB003839, CAB003840, HPA045168, CAB075726, CAB075727" Supported Supported Enhanced Nucleoplasm 39000 Nucleoplasm "CAB000147: AB_430876, CAB003839: AB_365493, CAB003840: AB_562187, CAB075726: , CAB075727: , HPA045168: " "unprognostic (2.02e-1)" "unprognostic (9.40e-2)" "unprognostic (7.44e-3)" "unprognostic (1.32e-1)" "unprognostic (4.29e-1)" "unprognostic (9.22e-2)" "prognostic unfavourable (3.40e-4)" "unprognostic (2.20e-1)" "unprognostic (3.62e-2)" "unprognostic (1.39e-1)" "unprognostic (2.13e-1)" "unprognostic (1.66e-1)" "prognostic unfavourable (1.35e-5)" "unprognostic (2.38e-2)" "unprognostic (1.82e-1)" "unprognostic (3.14e-2)" "unprognostic (2.64e-1)" 17.3 16.6 31.2 35.7 31.2 14.3 15.3 21.1 29.2 14.3 21.8 37.4 10.3 15.0 18.2 13.0 18.1 15.0 10.8 24.2 27.8 21.9 13.4 24.8 14.1 56.3 40.7 21.8 14.6 28.1 62.6 22.9 28.7 30.4 22.0 19.2 16.3 17.0 24.7 47.3 11.7 19.6 25.5 49.1 32.7 15.9 22.5 34.8 29.5 14.5 16.5 70.2 19.9 13.7 53.0 16.5 9.0 17.5 11.1 21.8 11.5 28.5 15.3 42.6 30.1 11.2 9.2 24.3 18.9 16.9 25.8 21.2 24.3 14.0 83.2 28.3 11.5 21.5 58.5 18.6 22.7 34.9 81.7 32.2 20.4 15.9 6.7 53.4 15.6 9.1 7.4 20.7 14.7 20.0 51.2 42.5 13.3 13.6 17.1 19.3 78.4 30.4 51.8 73.0 76.9 12.1 20.4 42.9 37.6 24.6 27.6 15.5 23.2 33.5 15.2 13.7 22.7 18.5 35.4 17.3 29.0 71.5 11.4 18.1 30.7 9.0 6.7 6.9 18.3 11.3 21.6 46.8 19.4 18.0 14.3 53.0 15.2 16.4 1.0 11.1 17.5 16.5 21.8 11.5 31.2 31.2 21.1 28.4 27.8 21.9 40.7 21.8 30.4 34.8 PAX5 BSAP ENSG00000196092 "Paired box 5" Q02548 9 36833275-37034185 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Spermatogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 21.6;lymphoid tissue: 33.4" "Group enriched" "Detected in some" 8 "Daudi: 21.0;REH: 61.0;U-698: 27.6" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in single" 5 "midbrain: 1.6" "Group enriched" "Detected in some" 209 "memory B-cell: 20.1;naive B-cell: 21.6" "Lineage enriched" "Detected in single" 216 "B-cells: 21.6" "Region enriched" "Detected in single" 11 "midbrain: 4.7" "Group enriched" "Detected in some" 6 "hippocampal formation: 3.8;midbrain: 10.8;pons and medulla: 3.2" "CAB026269, CAB026869, HPA056394, HPA068498" Enhanced Supported Approved Nucleoplasm,Vesicles,Cytosol Nucleoplasm "Vesicles, Cytosol" "CAB026269: , CAB026869: , HPA056394: , HPA068498: " "unprognostic (4.69e-4)" "unprognostic (3.83e-1)" "unprognostic (9.13e-2)" "unprognostic (1.42e-1)" "unprognostic (2.65e-2)" "unprognostic (1.15e-1)" "unprognostic (2.09e-2)" "unprognostic (2.95e-2)" "unprognostic (2.48e-1)" "unprognostic (2.00e-2)" "unprognostic (1.03e-1)" "unprognostic (2.46e-2)" "unprognostic (1.11e-3)" "unprognostic (3.15e-1)" "unprognostic (8.96e-2)" "unprognostic (6.03e-2)" "unprognostic (1.01e-1)" 0.4 0.2 0.2 33.4 0.2 5.5 0.2 0.2 0.2 0.2 0.7 0.1 0.0 0.0 0.2 0.0 0.7 0.2 0.4 0.2 0.2 0.3 0.5 0.3 0.3 23.2 1.6 0.0 0.2 0.2 0.0 0.5 0.1 0.2 0.3 0.3 0.4 2.5 0.0 0.6 0.2 8.7 0.0 0.3 16.5 0.7 0.9 0.0 2.3 0.4 0.2 30.1 1.3 0.2 21.6 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 21.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.6 0.1 61.0 0.1 0.1 0.0 0.0 4.3 1.0 0.0 0.2 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 27.6 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 20.1 0.0 0.0 0.0 21.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.2 0.2 0.2 0.2 0.3 1.6 0.0 0.2 0.0 PAX6 "AN, AN2, D11S812E, WAGR" ENSG00000007372 "Paired box 6" P26367 11 31784779-31818062 "Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Differentiation, Transcription, Transcription regulation" "Developmental protein, DNA-binding, Repressor" "Disease mutation, Peters anomaly" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 78.3;retina: 29.4" "Cell line enhanced" "Detected in some" "AF22: 11.6;AN3-CA: 15.0;HEK 293: 14.1;HeLa: 11.0;U-251 MG: 12.3" "Cancer enhanced" "Detected in some" "glioma: 2.5" "Region enriched" "Detected in all" 5 "cerebellum: 78.3" "Cell type enhanced" "Detected in some" "basophil: 1.6" "Low lineage specificity" "Detected in single" "Group enriched" "Detected in many" 5 "cerebellum: 61.0;olfactory region: 41.2" "Low region specificity" "Detected in all" "HPA030775, CAB034143" Enhanced Supported Enhanced Nucleoplasm Nucleoplasm "CAB034143: AB_1127044, HPA030775: AB_10601243" "unprognostic (2.89e-1)" "unprognostic (2.98e-2)" "unprognostic (8.34e-2)" "unprognostic (3.85e-2)" "unprognostic (4.42e-2)" "unprognostic (7.82e-2)" "unprognostic (2.76e-1)" "unprognostic (1.91e-1)" "unprognostic (4.24e-3)" "unprognostic (1.68e-1)" "unprognostic (1.20e-2)" "unprognostic (3.91e-1)" "unprognostic (8.96e-2)" "unprognostic (1.32e-1)" "unprognostic (1.76e-1)" "unprognostic (1.57e-1)" "unprognostic (3.42e-3)" 0.8 2.0 12.6 0.8 10.4 1.1 1.0 78.3 23.5 0.8 1.1 9.3 0.0 3.5 0.8 1.8 0.8 0.8 0.8 0.8 16.0 3.7 0.9 0.9 0.7 0.9 3.9 9.1 0.8 15.8 0.8 4.6 0.8 10.8 0.8 1.4 29.4 0.8 0.9 1.9 1.6 2.0 0.8 16.1 0.8 19.4 2.8 9.8 0.0 0.8 0.0 1.0 1.1 0.3 0.2 0.2 1.6 0.4 0.4 0.5 0.1 0.0 0.2 11.6 15.0 3.7 5.0 4.5 0.0 0.0 0.1 0.0 0.9 2.7 0.1 4.8 1.6 0.3 1.3 0.0 0.2 0.0 14.1 6.6 11.0 6.2 0.0 0.3 0.0 0.0 0.5 0.1 0.3 0.0 5.3 0.0 0.2 0.0 2.7 0.4 0.2 7.6 0.0 5.5 0.1 0.6 0.4 0.5 0.0 0.3 0.1 0.0 3.4 0.0 0.0 3.9 0.3 0.0 12.3 0.0 0.1 0.0 6.2 0.0 0.0 1.6 0.0 0.1 0.0 0.1 0.5 0.0 0.1 0.0 0.2 0.2 0.2 0.3 1.0 0.4 0.4 0.2 0.1 0.1 12.6 10.4 78.3 12.2 16.0 3.7 3.9 9.1 10.8 9.8 PBK "CT84, FLJ14385, Nori-3, SPK, TOPK" ENSG00000168078 "PDZ binding kinase" Q96KB5 8 27809620-27838095 "Enzymes, Plasma proteins, Predicted intracellular proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "lymphoid tissue: 19.4;testis: 67.9" "Cell line enhanced" "Detected in many" "A-431: 60.7" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "NK-cell: 2.1;T-reg: 1.6" "Group enriched" "Detected in many" 10 "NK-cells: 2.1;T-cells: 1.6" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "HPA005753, HPA050656" Enhanced Supported Approved Cytosol Cytosol "HPA005753: AB_1855018, HPA050656: AB_2681205" "unprognostic (7.17e-2)" "unprognostic (7.21e-3)" "unprognostic (1.04e-3)" "unprognostic (2.77e-2)" "unprognostic (1.50e-1)" "unprognostic (1.27e-1)" "prognostic unfavourable (8.29e-5)" "unprognostic (3.65e-3)" "unprognostic (7.38e-2)" "unprognostic (2.88e-3)" "prognostic unfavourable (6.56e-4)" "unprognostic (1.20e-1)" "prognostic unfavourable (1.18e-12)" "unprognostic (9.61e-2)" "unprognostic (1.86e-1)" "unprognostic (8.30e-2)" "unprognostic (8.68e-2)" 0.6 0.8 0.2 7.7 0.3 3.3 1.3 0.3 0.4 1.1 3.8 0.3 0.2 3.7 0.4 0.6 6.2 0.3 0.8 3.3 0.3 0.2 0.7 0.9 1.2 5.4 0.3 0.2 0.4 0.4 0.0 0.2 2.2 0.3 0.4 4.6 0.2 1.1 0.2 0.4 1.9 3.6 0.9 0.6 1.7 1.7 67.9 0.2 19.4 0.3 4.7 5.3 0.7 1.9 0.1 0.0 0.0 0.0 2.1 1.6 0.5 60.7 19.8 19.5 12.3 1.9 3.4 8.2 27.9 13.3 28.8 24.3 6.9 11.3 32.4 9.9 10.7 16.1 18.7 9.4 31.6 7.9 10.2 7.8 14.1 10.0 0.1 5.0 11.6 0.9 7.7 13.3 7.1 14.5 11.4 21.8 33.9 6.9 19.2 5.9 3.5 17.2 12.0 27.2 8.7 10.8 9.4 7.7 12.1 10.4 12.2 15.6 12.9 7.7 8.4 18.9 45.6 23.9 29.6 3.1 8.6 15.0 11.5 8.9 40.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 1.3 0.0 0.1 0.0 0.1 0.0 2.1 0.0 0.0 1.6 0.5 0.2 0.3 0.3 0.4 0.3 0.2 0.3 0.2 0.3 0.2 PCDH15 "CDHR15, DFNB23, USH1F" ENSG00000150275 "Protocadherin related 15" Q96QU1 10 53802771-55627942 "Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Hearing" "Deafness, Disease mutation, Non-syndromic deafness, Retinitis pigmentosa, Usher syndrome" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "adrenal gland: 27.4;retina: 25.1" "Cell line enhanced" "Detected in some" "HDLM-2: 2.1;HUVEC TERT2: 1.7;U-2 OS: 2.7;U-266/70: 8.1" "Cancer enriched" "Detected in single" 9 "glioma: 0.7" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA074437 Supported "Intracellular and membrane" "HPA074437: " "unprognostic (1.38e-1)" "unprognostic (3.39e-1)" "unprognostic (8.15e-5)" "unprognostic (3.07e-3)" "unprognostic (2.79e-1)" "unprognostic (9.15e-4)" "unprognostic (2.02e-1)" "unprognostic (3.89e-2)" "unprognostic (1.12e-3)" "unprognostic (1.31e-3)" "unprognostic (1.19e-1)" "unprognostic (1.34e-1)" "unprognostic (3.27e-1)" "unprognostic (7.66e-3)" 0.7 27.4 9.7 0.9 7.4 0.6 0.5 4.3 10.9 0.7 0.7 5.6 0.0 0.8 0.6 1.1 0.6 0.6 0.6 0.9 10.5 5.8 11.0 0.5 3.7 1.8 6.0 3.2 0.5 0.5 0.4 6.9 0.7 8.7 0.7 0.5 25.1 0.6 0.5 0.4 0.5 0.8 0.5 5.7 1.3 0.9 4.4 7.9 0.0 0.6 0.0 1.2 1.5 0.3 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.1 0.6 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 1.7 0.2 0.2 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.5 1.5 0.0 0.0 0.0 0.1 0.0 0.0 1.5 2.7 0.0 0.0 8.1 0.8 0.0 1.2 0.0 0.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 9.7 7.4 4.3 7.1 10.5 5.8 6.0 3.2 8.7 7.9 PCLO "ACZ, DKFZp779G1236, KIAA0559" ENSG00000186472 "Piccolo presynaptic cytomatrix protein" Q9Y6V0 7 82754013-83162930 "Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Neurodegeneration "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 50.3" "Group enriched" "Detected in some" 28 "REH: 61.0;U-2 OS: 70.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA015858, HPA029579, CAB079012" Approved Supported Approved "Nuclear speckles,Plasma membrane" "Nuclear speckles, Plasma membrane" "CAB079012: , HPA015858: AB_1855071, HPA029579: AB_10602044" "unprognostic (1.32e-2)" "unprognostic (1.99e-1)" "unprognostic (9.33e-2)" "unprognostic (1.31e-1)" "unprognostic (2.08e-2)" "unprognostic (1.52e-1)" "unprognostic (4.49e-3)" "unprognostic (6.14e-2)" "unprognostic (4.61e-2)" "unprognostic (1.82e-1)" "unprognostic (3.00e-1)" "unprognostic (1.56e-1)" "unprognostic (4.79e-6)" "unprognostic (5.15e-2)" "unprognostic (2.42e-2)" "unprognostic (1.36e-5)" "unprognostic (6.62e-5)" 3.1 7.9 8.8 0.8 26.3 0.4 4.7 50.3 19.4 3.2 3.9 1.6 0.4 2.9 1.0 7.3 2.3 2.0 1.9 2.2 9.8 5.7 8.2 0.6 1.8 0.6 4.6 12.6 1.9 4.0 11.4 19.2 1.0 9.1 4.9 3.5 3.6 2.5 5.0 0.6 2.6 2.4 0.7 5.3 1.1 2.9 4.5 4.4 0.0 8.4 0.0 0.8 1.0 2.5 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.3 0.4 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.2 0.0 0.1 0.0 0.0 0.2 0.1 1.3 0.5 0.5 0.0 0.1 0.0 0.2 0.0 0.0 0.2 0.0 0.1 0.4 0.0 2.3 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.4 1.1 61.0 1.0 0.0 0.4 0.2 1.1 0.8 0.0 0.6 0.1 0.7 0.1 0.0 0.0 70.0 0.3 0.1 0.0 0.0 0.1 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 8.8 26.3 50.3 19.4 9.8 5.7 4.6 12.6 9.1 4.4 PCP4 PEP-19 ENSG00000183036 "Purkinje cell protein 4" P48539 21 39867317-39929397 "Predicted intracellular proteins" Calmodulin-binding "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 177.9;seminal vesicle: 234.5" "Cell line enhanced" "Detected in some" "RPMI-8226: 56.4;SK-BR-3: 9.5;T-47d: 17.6" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in all" 5 "basal ganglia: 177.9" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005792 Enhanced Supported Approved "Nucleoplasm,Nucleoli fibrillar center" "Nucleoplasm, Nucleoli fibrillar center" "HPA005792: AB_1855086" "unprognostic (6.82e-2)" "prognostic favourable (9.76e-4)" "unprognostic (5.26e-2)" "unprognostic (1.56e-1)" "unprognostic (4.03e-2)" "unprognostic (2.94e-1)" "unprognostic (2.87e-2)" "unprognostic (1.07e-1)" "unprognostic (1.04e-1)" "unprognostic (3.95e-3)" "unprognostic (2.63e-1)" "prognostic favourable (1.85e-7)" "unprognostic (9.00e-2)" "unprognostic (2.99e-3)" "unprognostic (1.10e-1)" "unprognostic (1.07e-2)" 2.1 11.0 5.6 1.4 177.9 1.0 2.6 15.8 15.8 39.3 10.6 11.4 50.8 1.9 11.4 65.7 38.4 2.9 1.7 1.7 8.3 14.0 9.7 1.0 1.1 1.0 11.6 3.7 1.2 2.1 3.4 1.0 1.3 20.0 60.9 6.9 49.0 1.7 234.5 1.0 1.4 1.5 93.5 3.7 1.5 1.1 1.2 37.5 0.0 39.2 0.0 1.2 65.6 12.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.5 0.5 0.0 0.0 0.0 56.4 0.0 0.0 0.1 0.1 0.0 9.5 0.0 17.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.6 177.9 15.8 15.8 8.3 14.0 11.6 3.7 20.0 37.5 PCP4L1 IQM1 ENSG00000248485 "Purkinje cell protein 4 like 1" A6NKN8 1 161258727-161285450 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "No human protein/transcript evidence" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 67.7;urinary bladder: 33.2" "Group enriched" "Detected in some" 6 "RT4: 15.7;T-47d: 10.3" "Group enriched" "Detected in many" 6 "cervical cancer: 12.4;head and neck cancer: 5.1;lung cancer: 13.6;testis cancer: 18.9;urothelial cancer: 21.8" "Group enriched" "Detected in all" 5 "basal ganglia: 67.7;cerebral cortex: 17.9;pons and medulla: 30.8" "Cell type enhanced" "Detected in single" "T-reg: 3.1" "Lineage enhanced" "Detected in single" "T-cells: 3.1" "Low region specificity" "Detected in all" HPA052833 Enhanced Supported Approved Nucleoplasm,Mitochondria "Nucleoplasm, Mitochondria" "HPA052833: " "unprognostic (1.81e-2)" "unprognostic (9.39e-2)" "unprognostic (5.25e-2)" "unprognostic (2.07e-1)" "unprognostic (3.03e-2)" "unprognostic (1.87e-2)" "unprognostic (2.51e-1)" "prognostic favourable (8.10e-5)" "unprognostic (2.39e-1)" "unprognostic (1.92e-1)" "unprognostic (4.93e-2)" "unprognostic (7.37e-2)" "unprognostic (3.63e-5)" "unprognostic (4.81e-2)" "unprognostic (1.25e-1)" "unprognostic (2.09e-1)" "unprognostic (6.15e-2)" 3.2 1.0 5.7 1.3 67.7 0.6 2.2 4.4 28.9 4.3 4.3 1.4 1.5 2.2 2.2 3.3 16.5 2.1 3.9 1.3 3.9 6.3 1.0 4.3 5.0 0.7 7.8 4.6 2.6 0.5 0.6 21.9 0.9 30.8 5.5 3.2 5.9 1.2 17.8 1.0 2.8 3.3 6.8 7.5 0.8 1.2 2.3 5.3 0.0 1.0 0.0 3.0 33.2 4.1 0.0 0.7 0.0 0.0 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 1.9 0.0 0.0 0.0 0.0 0.0 2.1 0.4 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.3 0.0 0.1 0.0 0.1 0.0 15.7 2.2 0.0 0.0 0.3 0.0 10.3 0.4 0.2 0.0 0.0 0.0 0.0 0.9 1.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.1 0.0 5.7 67.7 4.4 17.9 3.9 6.3 7.8 4.6 30.8 5.3 PCSK1N "BigLEN, PEN, proSAAS, SAAS, SCG8, SgVIII" ENSG00000102109 "Proprotein convertase subtilisin/kexin type 1 inhibitor" Q9UHG2 X 48831094-48835633 "Predicted secreted proteins" Neuropeptide "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 74.9;kidney: 72.9;pituitary gland: 127.7" "Cell line enhanced" "Detected in some" "HEK 293: 19.6;PC-3: 49.6;SCLC-21H: 19.7;SH-SY5Y: 18.2;SiHa: 17.2;U-266/84: 22.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "MAIT T-cell: 3.0;memory CD4 T-cell: 6.5;memory CD8 T-cell: 6.3;naive CD4 T-cell: 2.7;naive CD8 T-cell: 8.2;T-reg: 2.1" "Lineage enriched" "Detected in single" 77 "T-cells: 8.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003925, HPA064734" Enhanced Supported Approved Vesicles "Secreted to blood" 5300000 Vesicles "HPA003925: AB_1079582, HPA064734: AB_2685339" "unprognostic (2.44e-3)" "unprognostic (5.86e-2)" "unprognostic (1.94e-1)" "prognostic unfavourable (1.15e-4)" "unprognostic (3.36e-1)" "unprognostic (4.76e-3)" "unprognostic (1.49e-2)" "unprognostic (3.34e-1)" "unprognostic (5.63e-2)" "unprognostic (3.55e-1)" "unprognostic (1.50e-3)" "unprognostic (2.79e-3)" "prognostic favourable (1.36e-4)" "unprognostic (3.34e-2)" "unprognostic (2.91e-2)" "unprognostic (1.91e-1)" "unprognostic (2.14e-1)" 4.1 27.5 49.1 2.6 72.7 2.1 2.2 15.6 70.3 3.2 9.8 10.8 1.5 12.4 4.4 10.9 2.1 2.3 2.8 2.7 38.5 74.9 72.9 2.1 2.6 2.2 33.5 29.0 2.2 20.0 12.4 127.7 2.3 32.9 4.6 2.7 6.6 2.8 3.1 2.2 2.8 8.5 2.7 18.3 2.4 26.0 3.8 9.8 0.0 2.2 0.0 2.1 2.1 0.5 0.1 0.0 0.0 0.0 0.0 8.2 0.8 0.0 1.8 0.0 5.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 1.7 0.0 0.0 3.5 0.0 0.2 0.0 0.3 0.0 0.0 19.6 0.0 0.0 2.9 0.0 0.0 1.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.1 2.7 49.6 0.0 0.0 0.1 0.4 0.0 19.7 18.2 17.2 0.0 1.4 0.0 0.0 0.0 0.0 7.6 0.0 1.6 4.5 22.9 0.0 0.1 0.0 0.5 0.0 0.0 0.0 1.1 0.0 3.0 0.0 6.5 6.3 0.0 0.1 2.7 8.2 0.0 0.0 0.0 0.0 2.1 0.8 49.1 72.7 15.6 70.3 38.5 74.9 33.5 29.0 32.9 9.8 PDYN "ADCA, PENKB, SCA23" ENSG00000101327 Prodynorphin P01213 20 1978757-1994285 "Disease related genes, Potential drug targets, Predicted secreted proteins, Transporters" "Endorphin, Neuropeptide, Neurotransmitter, Opioid peptide" "Disease mutation, Neurodegeneration, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 17 "brain: 55.9" "Cell line enhanced" "Detected in some" "AF22: 1.5;NTERA-2: 2.8;THP-1: 2.6" "Group enriched" "Detected in some" 29 "glioma: 2.6;ovarian cancer: 1.6" "Region enriched" "Detected in many" 4 "basal ganglia: 55.9" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 4 "basal ganglia: 150.7;hypothalamus: 70.9" "Region enhanced" "Detected in many" "basal ganglia: 131.1" "HPA053342, CAB079777" Enhanced Supported "Secreted in brain" "CAB079777: , HPA053342: " "unprognostic (7.00e-2)" "unprognostic (1.07e-1)" "unprognostic (1.40e-1)" "unprognostic (3.73e-2)" 0.4 0.4 13.2 0.4 55.9 0.4 0.4 0.0 40.3 0.4 0.4 1.2 0.0 0.4 0.4 0.4 0.4 0.4 0.4 0.4 5.0 3.9 0.4 0.4 0.4 0.4 0.7 3.7 0.4 0.4 0.4 0.0 0.4 0.2 0.4 0.4 0.0 0.4 0.4 0.4 0.6 0.4 0.4 2.2 0.4 0.4 3.2 1.1 0.0 0.5 0.0 0.4 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.2 55.9 0.0 3.8 5.0 3.9 0.7 3.7 0.2 1.1 PGD ENSG00000142657 "Phosphogluconate dehydrogenase" P52209 1 10398592-10420144 "Enzymes, Plasma proteins, Predicted intracellular proteins" "Gluconate utilization, Pentose shunt" Oxidoreductase "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 115.1;esophagus: 123.8" "Cell line enhanced" "Detected in all" "A549: 177.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 4 "basophil: 98.6;classical monocyte: 32.0;eosinophil: 115.1;neutrophil: 38.4" "Group enriched" "Detected in all" 5 "granulocytes: 115.1;monocytes: 32.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA031314, HPA031315" Enhanced Supported Approved "Intermediate filaments,Cytosol" 59000000 "Intermediate filaments, Cytosol" "HPA031314: AB_10610278, HPA031315: AB_2673825" "unprognostic (4.65e-2)" "unprognostic (2.58e-1)" "unprognostic (8.65e-2)" "unprognostic (9.80e-2)" "unprognostic (1.31e-2)" "unprognostic (2.28e-1)" "prognostic unfavourable (3.98e-4)" "unprognostic (1.90e-2)" "unprognostic (2.83e-1)" "unprognostic (1.40e-2)" "unprognostic (4.92e-1)" "unprognostic (1.36e-1)" "unprognostic (1.37e-3)" "unprognostic (1.43e-1)" "unprognostic (1.49e-1)" "unprognostic (2.43e-3)" "unprognostic (1.14e-1)" 29.8 12.7 10.9 14.2 11.8 85.5 23.7 8.0 19.1 16.0 14.1 13.8 8.1 22.9 6.3 12.5 123.8 8.4 24.9 14.3 10.3 12.1 15.4 23.2 25.6 34.9 12.4 11.4 14.3 8.3 16.2 10.8 17.0 19.3 7.9 12.9 19.7 31.8 6.8 8.5 10.6 25.3 9.5 12.6 27.6 13.4 27.0 7.4 16.8 21.2 68.8 49.9 14.8 26.1 3.9 15.9 115.1 32.0 2.0 3.0 19.0 22.6 177.4 44.2 47.5 67.3 41.7 9.6 15.3 27.2 21.2 29.1 26.0 26.1 22.2 18.9 15.7 19.2 32.3 27.5 14.3 15.3 28.2 30.0 31.9 54.6 20.5 49.6 33.4 29.7 13.8 33.5 8.3 50.1 40.1 19.7 27.2 25.7 40.9 24.8 26.6 15.6 31.8 40.6 40.9 29.7 12.2 23.8 20.8 13.1 20.8 18.1 22.9 42.6 46.9 11.2 20.0 13.3 16.9 14.9 27.3 39.9 24.5 53.9 10.1 98.6 32.0 115.1 2.6 15.3 3.0 3.9 2.5 2.4 15.9 2.3 2.4 2.6 38.4 2.0 10.9 11.4 2.4 19.0 10.9 11.8 8.0 19.1 10.3 12.1 12.4 11.4 19.3 7.4 PMCH MCH ENSG00000183395 "Pro-melanin concentrating hormone" P20382 12 102196459-102197845 "Predicted secreted proteins" "Differentiation, Spermatogenesis" "Developmental protein, Hormone, Neuropeptide" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 11 "brain: 124.8" "Cell line enriched" "Detected in some" 8 "HDLM-2: 30.6" "Cancer enhanced" "Detected in single" "endometrial cancer: 0.8" "Region enriched" "Detected in some" 27 "hypothalamus: 124.8" "Cell type enriched" "Detected in some" 8 "T-reg: 11.3" "Lineage enriched" "Detected in single" 81 "T-cells: 11.3" "Group enriched" "Detected in some" 131 "hypothalamus: 737.6;thalamus: 373.6" "Region enriched" "Detected in single" 30 "hypothalamus: 98.6" "HPA046055, HPA061884" Enhanced Supported "Secreted to blood" 274240 "HPA046055: AB_2679517, HPA061884: AB_2684632" "unprognostic (3.23e-3)" "unprognostic (8.04e-2)" "unprognostic (3.96e-4)" "unprognostic (2.09e-2)" "unprognostic (1.75e-1)" "unprognostic (7.73e-2)" "unprognostic (4.31e-3)" "unprognostic (1.43e-2)" "unprognostic (3.18e-3)" "unprognostic (4.51e-2)" "unprognostic (1.21e-1)" "unprognostic (2.16e-6)" "unprognostic (1.17e-2)" "unprognostic (1.93e-1)" "unprognostic (5.10e-2)" "unprognostic (3.53e-2)" 0.1 0.0 0.3 2.1 2.0 2.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.5 1.1 1.0 0.0 0.2 0.6 0.8 124.8 0.1 0.1 0.2 6.4 0.4 0.1 0.1 0.1 0.0 1.4 0.2 4.5 0.2 0.0 0.1 0.2 0.1 0.1 0.9 0.1 0.1 0.9 1.1 2.0 0.2 0.7 1.0 0.1 0.1 1.7 0.2 0.1 0.0 0.0 0.0 0.0 0.1 11.3 0.0 0.3 0.1 0.3 0.3 0.0 0.0 0.6 0.4 0.0 0.0 0.0 0.0 0.2 0.2 0.2 0.0 0.2 0.0 0.0 0.0 30.6 0.1 0.5 0.6 0.3 0.0 1.0 0.4 0.0 0.0 0.0 0.0 3.7 0.7 0.1 0.0 0.0 0.6 1.0 0.5 1.2 0.3 0.6 1.2 0.0 0.2 0.3 0.4 0.4 0.6 0.1 0.2 0.1 0.4 0.4 0.4 0.1 0.5 0.1 0.5 0.4 0.4 0.8 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 11.3 0.0 0.3 2.0 0.1 0.1 0.8 124.8 0.4 0.1 4.5 0.7 POU3F2 "BRN2, OCT7, OTF7, POUF3" ENSG00000184486 "POU class 3 homeobox 2" P20265 6 98834592-98839470 "Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Transcription, Transcription regulation" "Activator, DNA-binding" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 23 "brain: 28.0" "Cell line enhanced" "Detected in some" "AF22: 51.0;SK-MEL-30: 7.0;U-251 MG: 15.6;WM-115: 13.5" "Cancer enriched" "Detected in some" 11 "glioma: 16.9" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA047081, HPA056261" Approved Supported Nucleoplasm Nucleoplasm "HPA047081: , HPA056261: " "unprognostic (5.94e-4)" "unprognostic (7.80e-2)" "unprognostic (3.07e-3)" "unprognostic (1.83e-1)" "unprognostic (3.57e-1)" "unprognostic (1.38e-1)" "unprognostic (1.17e-3)" "unprognostic (1.84e-1)" "unprognostic (1.16e-1)" "unprognostic (1.60e-1)" "unprognostic (1.63e-3)" "unprognostic (4.77e-1)" "unprognostic (9.38e-11)" "unprognostic (4.77e-2)" "unprognostic (2.84e-2)" "unprognostic (8.47e-3)" "unprognostic (4.04e-1)" 0.9 1.0 9.0 0.9 10.8 0.9 0.9 3.4 28.0 0.9 0.9 10.3 0.0 0.9 0.9 0.9 0.9 0.9 0.9 0.9 9.8 7.1 0.9 0.9 0.9 0.9 10.7 6.8 0.9 0.9 0.9 0.0 0.9 9.7 0.9 0.9 0.0 0.9 0.9 0.9 1.0 0.9 0.9 8.4 0.9 0.9 1.2 9.0 0.0 0.9 0.0 0.9 0.9 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 51.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.4 0.0 0.2 2.2 1.6 0.4 0.0 0.0 0.0 2.8 1.4 0.0 0.0 7.0 0.4 0.0 0.0 0.3 0.0 0.1 15.6 0.0 0.0 0.0 0.0 0.0 13.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 9.0 10.8 3.4 12.5 9.8 7.1 10.7 6.8 9.7 9.0 POU4F1 "BRN3A, RDC-1" ENSG00000152192 "POU class 4 homeobox 1" Q01851 13 78598362-78603560 "Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in some" 4 "brain: 25.3" "Cell line enhanced" "Detected in some" "HEK 293: 10.9;HEL: 11.5;REH: 8.1;RH-30: 13.9;SCLC-21H: 13.3;U-266/70: 12.5" "Low cancer specificity" "Detected in single" "Region enriched" "Detected in many" 23 "pons and medulla: 25.3" "Cell type enriched" "Detected in single" 8 "plasmacytoid DC: 1.1" "Lineage enriched" "Detected in single" 8 "dendritic cells: 1.1" "Group enriched" "Detected in some" 14 "midbrain: 3.0;pons and medulla: 2.2;thalamus: 2.4" "Group enriched" "Detected in some" 25 "midbrain: 3.1;pons and medulla: 7.4;thalamus: 2.5" HPA068024 Enhanced Approved "HPA068024: " "unprognostic (6.70e-2)" "unprognostic (2.38e-1)" "unprognostic (1.27e-4)" "unprognostic (1.03e-1)" "unprognostic (1.25e-2)" "unprognostic (1.05e-3)" "unprognostic (1.32e-1)" "unprognostic (6.30e-2)" "unprognostic (6.00e-2)" "unprognostic (1.70e-2)" "unprognostic (9.17e-2)" "unprognostic (8.98e-2)" "unprognostic (9.95e-2)" "unprognostic (1.53e-1)" "unprognostic (4.75e-3)" 0.1 0.0 1.1 2.3 1.0 1.2 1.0 0.2 0.4 0.1 0.1 0.0 0.0 0.4 0.0 0.2 0.2 0.0 0.0 0.2 1.0 1.0 0.0 0.5 0.1 2.3 0.7 0.0 0.0 0.1 0.1 0.0 0.9 25.3 0.0 0.3 6.3 0.2 0.0 1.8 0.4 0.3 0.0 2.5 0.3 0.3 4.4 0.4 2.7 0.0 0.2 3.5 0.3 0.1 0.1 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 2.0 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 3.9 0.0 0.0 0.0 10.9 11.5 0.0 1.4 0.0 5.7 3.4 0.0 0.1 0.0 0.0 0.0 2.3 0.0 0.5 0.0 0.8 1.0 0.0 0.0 8.1 13.9 0.0 0.0 0.0 13.3 0.1 0.0 0.0 0.5 0.0 1.1 0.1 0.0 0.0 0.2 0.0 12.5 3.7 0.0 0.0 6.2 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 1.1 1.0 0.2 0.4 1.0 1.0 0.7 0.0 25.3 0.4 PPP1R1B "DARPP-32, FLJ20940" ENSG00000131771 "Protein phosphatase 1 regulatory inhibitor subunit 1B" Q9UD71 17 39626740-39636626 "Predicted intracellular proteins" "Protein phosphatase inhibitor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 173.9;salivary gland: 105.3" "Cell line enhanced" "Detected in some" "ASC diff: 5.5;CAPAN-2: 8.7;HSkMC: 23.1;SCLC-21H: 19.3" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in all" 4 "basal ganglia: 173.9" "Cell type enriched" "Detected in single" 37 "eosinophil: 3.6" "Lineage enriched" "Detected in single" 37 "granulocytes: 3.6" "Region enriched" "Detected in many" 8 "basal ganglia: 1113.7" "Region enriched" "Detected in all" 21 "basal ganglia: 1698.9" "CAB004026, HPA048630, HPA061142" Approved Approved "CAB004026: AB_2169007, HPA048630: , HPA061142: " "unprognostic (2.71e-1)" "unprognostic (4.09e-2)" "unprognostic (6.91e-3)" "unprognostic (2.42e-1)" "unprognostic (3.01e-1)" "unprognostic (7.69e-2)" "unprognostic (6.00e-3)" "unprognostic (2.76e-2)" "unprognostic (1.75e-2)" "unprognostic (6.13e-2)" "unprognostic (6.07e-2)" "unprognostic (2.04e-1)" "unprognostic (1.27e-1)" "unprognostic (2.67e-2)" "unprognostic (2.50e-2)" "unprognostic (2.52e-3)" "unprognostic (1.55e-1)" 26.2 10.0 25.6 5.8 173.9 0.6 23.3 14.6 24.1 7.4 64.1 16.2 39.4 25.7 1.8 2.2 1.9 9.4 4.6 0.7 17.3 11.2 2.0 0.5 5.1 0.5 21.9 22.2 2.6 19.1 0.6 1.7 0.5 17.9 19.9 63.3 6.9 105.3 49.6 0.5 5.7 20.9 4.1 12.4 0.5 13.6 4.6 40.0 0.0 0.5 0.3 0.8 3.6 1.5 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.5 3.3 0.1 0.0 0.0 0.0 0.0 0.0 8.7 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.6 0.6 0.0 0.0 0.4 0.0 0.0 19.3 0.4 0.0 1.0 0.0 0.4 0.7 0.0 0.0 1.2 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 25.6 173.9 14.6 24.1 17.3 11.2 21.9 22.2 17.9 40.0 PRKCA PKCA ENSG00000154229 "Protein kinase C alpha" P17252 17 66302636-66810743 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Angiogenesis, Apoptosis, Cell adhesion" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "U-87 MG: 53.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 17 "dendritic cells: 1.4;monocytes: 2.7;T-cells: 4.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003844, HPA006563, HPA006564, CAB016290" Enhanced Approved Enhanced "Plasma membrane,Cytosol" 1900000 Cytosol "Plasma membrane" "CAB003844: AB_562331, CAB016290: AB_628141, HPA006563: AB_1079626, HPA006564: AB_1079625" "unprognostic (3.06e-1)" "unprognostic (3.56e-2)" "unprognostic (1.38e-2)" "unprognostic (1.01e-1)" "unprognostic (1.53e-1)" "unprognostic (7.41e-3)" "unprognostic (7.43e-2)" "unprognostic (6.86e-3)" "unprognostic (4.93e-2)" "unprognostic (1.50e-1)" "unprognostic (2.09e-1)" "unprognostic (2.24e-2)" "unprognostic (5.50e-2)" "unprognostic (2.46e-1)" "unprognostic (1.83e-1)" "unprognostic (1.35e-3)" "unprognostic (8.77e-2)" 4.0 19.6 26.5 9.0 22.8 2.5 3.0 10.8 33.9 7.0 13.8 19.0 3.5 14.6 14.8 6.7 4.7 6.1 10.8 5.8 31.6 15.6 16.7 6.5 6.0 8.4 18.7 15.6 20.4 5.5 1.7 6.0 6.5 17.6 17.2 11.2 7.0 3.1 22.3 6.6 3.8 12.7 13.7 15.0 7.9 7.9 3.7 14.4 0.4 4.5 1.3 5.9 9.5 9.5 0.0 1.4 0.1 2.7 0.1 4.0 1.0 2.3 12.3 2.5 2.6 6.2 15.9 0.3 13.3 8.7 9.6 8.2 1.4 1.5 3.1 3.6 21.4 0.3 1.3 1.5 20.9 5.1 3.0 0.0 7.3 6.4 8.5 3.8 20.9 6.9 0.6 12.0 10.3 8.2 8.0 0.0 14.8 0.7 7.7 2.3 1.0 6.6 1.4 18.8 0.0 3.4 2.0 1.5 8.5 4.4 2.5 0.1 0.3 5.4 24.5 16.7 9.7 10.4 8.3 0.0 0.0 0.3 53.0 0.0 8.2 0.1 0.6 0.0 0.5 0.8 1.5 0.0 2.5 1.2 1.1 0.0 4.0 2.3 0.0 0.1 2.7 1.4 0.5 1.0 26.5 22.8 10.8 28.2 31.6 15.6 18.7 15.6 17.6 14.4 PRKCE ENSG00000171132 "Protein kinase C epsilon" Q02156 2 45651345-46187990 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Cell adhesion, Cell cycle, Cell division, Immunity" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 36.5" "Cell line enhanced" "Detected in many" "REH: 19.1;TIME: 19.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive B-cell: 5.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001948, HPA044496, HPA054252" Enhanced Supported Approved Vesicles Vesicles "CAB001948: , HPA044496: , HPA054252: " "unprognostic (1.10e-1)" "unprognostic (1.78e-1)" "unprognostic (2.27e-1)" "prognostic unfavourable (2.42e-4)" "unprognostic (9.61e-2)" "unprognostic (5.70e-2)" "unprognostic (1.51e-1)" "prognostic favourable (9.62e-4)" "unprognostic (3.05e-1)" "unprognostic (6.72e-2)" "unprognostic (7.49e-3)" "unprognostic (9.99e-2)" "prognostic favourable (2.63e-7)" "unprognostic (1.21e-1)" "unprognostic (7.11e-2)" "unprognostic (6.43e-3)" "unprognostic (2.23e-2)" 5.5 7.4 15.3 7.2 14.2 9.3 8.1 28.8 36.5 6.6 5.5 3.8 5.9 3.6 5.6 4.6 4.7 7.6 4.7 7.7 22.5 10.0 12.8 15.5 17.5 6.9 6.0 15.0 4.1 4.2 16.3 6.0 10.4 9.1 3.6 4.7 3.7 3.6 8.6 7.2 3.0 3.7 6.2 4.4 4.9 4.4 7.2 3.7 1.5 6.5 1.2 5.4 5.0 6.5 5.5 2.2 1.7 1.4 0.9 1.3 0.6 5.3 2.0 2.8 2.8 4.3 5.1 2.3 3.8 6.8 3.2 3.4 0.5 5.3 8.1 3.6 3.9 1.3 1.8 2.0 4.5 4.8 3.4 0.0 1.4 1.1 4.9 0.6 2.9 4.5 2.2 4.7 3.4 11.6 1.1 1.9 3.6 2.7 2.6 0.3 1.0 1.0 19.1 13.5 8.6 2.9 3.7 2.0 4.3 1.7 5.7 12.3 4.6 1.9 19.2 6.2 6.5 4.5 3.7 0.0 0.0 6.8 5.1 4.5 6.2 0.0 1.2 1.7 1.0 0.4 1.1 3.6 0.7 0.7 2.2 5.5 1.3 0.4 0.4 0.9 1.4 0.9 0.0 0.6 15.3 14.2 28.8 33.2 22.5 10.0 6.0 15.0 9.1 3.7 PTHLH "HHM, PLP, PTHR, PTHRP" ENSG00000087494 "Parathyroid hormone like hormone" P12272 12 27958084-27972705 "Cancer-related genes, Disease related genes, Predicted secreted proteins" Hormone "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 45.6" "Group enriched" "Detected in some" 4 "HaCaT: 63.2;HBEC3-KT: 78.1" "Cancer enhanced" "Detected in many" "head and neck cancer: 64.0" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 7 "T-reg: 3.0" "Lineage enriched" "Detected in single" 30 "T-cells: 3.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA035982 Approved Approved Supported "Nucleoplasm,Golgi apparatus,Cytosol" "Secreted in other tissues" "Nucleoplasm, Cytosol" "Golgi apparatus" "HPA035982: AB_10794631" "unprognostic (1.67e-1)" "unprognostic (5.26e-3)" "unprognostic (1.31e-1)" "unprognostic (4.41e-2)" "unprognostic (2.11e-1)" "unprognostic (1.13e-1)" "prognostic unfavourable (3.37e-4)" "unprognostic (1.60e-2)" "unprognostic (1.18e-1)" "unprognostic (5.16e-2)" "unprognostic (4.09e-3)" "unprognostic (3.84e-1)" "prognostic unfavourable (1.82e-9)" "unprognostic (2.01e-2)" "unprognostic (1.34e-1)" "unprognostic (5.23e-3)" "unprognostic (7.87e-3)" 2.9 1.0 6.5 3.5 5.3 0.0 20.2 1.4 8.7 11.0 2.3 1.4 2.1 2.4 11.2 2.0 17.0 1.2 45.6 4.0 4.3 3.5 0.4 0.2 1.3 1.1 1.4 4.3 2.6 1.7 0.7 2.3 3.6 3.1 5.5 1.8 2.4 5.3 2.6 0.7 1.5 1.6 13.4 0.8 3.6 1.9 1.3 1.0 0.1 1.4 15.8 3.4 8.0 12.3 0.0 0.0 0.0 0.0 0.0 3.0 0.1 0.3 2.1 0.0 0.0 0.6 0.6 0.0 0.0 0.2 0.1 0.2 0.0 1.7 0.0 0.1 0.5 63.2 0.2 78.1 0.0 1.5 0.3 0.1 0.4 0.0 0.1 0.0 0.1 0.0 4.3 2.0 7.7 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.3 3.6 0.0 0.3 0.1 7.6 0.0 0.0 0.0 3.5 0.0 0.4 0.1 0.0 1.2 0.3 1.9 1.1 16.6 1.0 0.0 2.5 1.6 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.1 6.5 5.3 1.4 6.2 4.3 3.5 1.4 4.3 3.1 1.0 QKI QK3 ENSG00000112531 "QKI, KH domain containing RNA binding" Q96PU8 6 163414000-163578596 "Cancer-related genes, Predicted intracellular proteins" "Differentiation, mRNA processing, mRNA splicing, mRNA transport, Translation regulation, Transport" "Developmental protein, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 100.3" "Cell line enhanced" "Detected in all" "AF22: 64.0" "Cancer enriched" "Detected in all" 6 "glioma: 42.0" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019123, CAB022602" Enhanced Supported Supported Nucleoplasm Nucleoplasm "CAB022602: , HPA019123: AB_1855980" "unprognostic (2.42e-1)" "unprognostic (5.81e-2)" "unprognostic (1.31e-1)" "unprognostic (1.06e-2)" "unprognostic (8.57e-2)" "unprognostic (1.65e-1)" "prognostic unfavourable (1.27e-4)" "unprognostic (1.34e-1)" "unprognostic (7.06e-2)" "unprognostic (1.76e-3)" "unprognostic (1.08e-1)" "unprognostic (5.15e-2)" "prognostic unfavourable (2.31e-5)" "prognostic unfavourable (3.69e-4)" "unprognostic (1.16e-1)" "unprognostic (3.86e-1)" "unprognostic (4.09e-2)" 32.4 12.4 37.5 16.2 63.5 27.1 14.6 15.1 100.3 14.9 12.2 83.9 3.7 4.0 14.7 4.9 16.0 12.3 15.7 64.0 43.7 18.1 11.1 18.4 24.9 11.4 72.5 31.9 18.4 7.6 7.8 4.7 23.4 46.5 7.9 8.4 7.1 10.2 11.1 59.9 12.4 7.1 21.1 68.8 16.9 8.9 20.5 74.3 5.0 10.4 10.8 11.4 15.8 17.7 1.7 7.3 10.8 8.4 7.4 3.8 1.3 4.2 18.0 64.0 21.3 19.4 21.6 14.9 11.6 27.5 19.1 23.1 12.2 3.9 5.2 9.7 29.1 6.4 33.9 12.1 31.0 10.4 10.9 20.4 9.9 13.6 23.7 10.8 6.3 25.2 5.0 20.4 32.5 26.3 29.8 12.3 12.3 8.1 7.2 2.3 8.2 9.1 11.1 39.9 10.3 10.5 13.5 1.2 7.4 12.4 6.8 5.1 2.6 17.7 26.7 13.2 11.2 14.2 21.3 7.8 9.5 6.3 11.4 9.6 31.0 3.4 8.4 3.8 2.3 5.4 3.8 1.4 1.6 2.0 4.3 1.7 1.5 2.5 10.8 7.4 5.5 7.3 1.1 1.3 37.5 63.5 15.1 41.4 43.7 18.1 72.5 31.9 46.5 74.3 RAB3A ENSG00000105649 "RAB3A, member RAS oncogene family" P20336 19 18196784-18204074 "Predicted intracellular proteins" "Exocytosis, Protein transport, Transport" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 7 "brain: 114.7" "Cell line enhanced" "Detected in many" "PC-3: 13.5;SCLC-21H: 24.7;SH-SY5Y: 11.8;U-2197: 17.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003160, CAB009949, CAB078998" Enhanced Supported Approved Nucleoplasm,Centrosome,Cytosol Nucleoplasm "Centrosome, Cytosol" "CAB009949: AB_632292, CAB078998: , HPA003160: AB_1079731" "unprognostic (1.82e-1)" "unprognostic (2.22e-1)" "unprognostic (6.80e-3)" "prognostic unfavourable (3.17e-4)" "unprognostic (1.21e-1)" "unprognostic (1.88e-1)" "unprognostic (1.36e-1)" "unprognostic (1.40e-3)" "unprognostic (1.85e-1)" "unprognostic (1.64e-1)" "unprognostic (4.46e-3)" "unprognostic (1.13e-1)" "prognostic favourable (6.14e-7)" "unprognostic (1.23e-1)" "unprognostic (1.88e-1)" "unprognostic (1.85e-2)" "unprognostic (6.14e-2)" 2.3 13.0 32.3 2.6 50.5 2.0 2.0 39.1 114.7 2.8 3.1 6.3 0.0 3.6 2.7 2.6 2.4 3.2 2.8 17.0 40.8 32.7 4.1 2.2 2.5 2.4 31.5 35.6 8.0 2.3 5.0 7.5 2.4 38.2 3.8 2.8 5.8 4.2 4.4 7.5 2.5 3.0 2.9 7.0 2.5 2.5 2.2 4.8 0.0 2.9 0.1 2.1 2.9 0.7 4.6 6.0 5.1 3.0 0.7 4.2 2.6 0.9 1.0 2.3 3.2 3.8 1.0 1.4 2.0 1.2 1.4 1.9 0.9 0.5 3.3 2.2 1.6 2.7 10.7 1.3 0.7 0.7 3.4 1.3 3.9 3.7 0.9 2.2 4.1 3.1 1.3 0.8 0.4 0.4 0.7 1.1 1.3 3.2 5.0 0.6 1.9 13.5 3.5 0.2 2.8 1.5 0.5 24.7 11.8 1.0 4.3 2.3 0.9 0.4 0.4 1.2 0.9 17.1 1.1 2.1 4.5 0.8 3.2 1.7 1.1 0.0 3.0 3.8 3.0 2.2 4.0 4.6 3.2 3.0 6.0 2.2 4.1 4.2 5.1 0.7 2.7 5.5 1.8 2.6 32.3 50.5 39.1 95.0 40.8 32.7 31.5 35.6 38.2 4.8 RABGGTB ENSG00000137955 "Rab geranylgeranyltransferase beta subunit" P53611 1 75786197-75795079 "Enzymes, Predicted intracellular proteins" "Prenyltransferase, Transferase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA026585, HPA027167, HPA030793" Approved Supported Approved Vesicles Vesicles "HPA026585: AB_1856026, HPA027167: AB_1856027, HPA030793: " "unprognostic (4.83e-2)" "unprognostic (3.04e-1)" "unprognostic (2.09e-2)" "unprognostic (2.45e-2)" "unprognostic (9.02e-2)" "unprognostic (3.52e-2)" "prognostic unfavourable (9.80e-5)" "unprognostic (9.62e-3)" "unprognostic (2.93e-1)" "unprognostic (1.93e-1)" "unprognostic (2.23e-1)" "unprognostic (6.95e-2)" "prognostic unfavourable (1.12e-5)" "unprognostic (6.05e-2)" "unprognostic (1.56e-1)" "unprognostic (6.77e-2)" "unprognostic (3.89e-1)" 19.4 31.8 20.2 25.3 20.1 8.7 23.5 25.8 24.2 19.4 18.8 16.8 14.8 18.6 20.9 14.1 15.7 15.6 12.0 27.2 19.1 20.4 40.7 35.8 17.4 13.1 26.3 14.8 18.5 33.2 12.3 26.4 17.3 20.5 15.6 16.2 13.7 25.0 15.8 33.5 9.5 14.5 13.1 29.4 19.0 14.3 11.9 18.0 21.3 17.3 21.6 34.4 12.4 13.3 10.6 12.8 7.6 11.5 6.3 10.7 4.4 17.0 9.7 17.7 6.9 22.3 25.7 10.3 23.3 17.4 22.4 17.9 22.1 4.2 14.4 23.9 12.9 10.6 43.3 18.8 31.6 14.8 11.6 12.4 16.4 37.2 27.6 16.6 7.6 17.1 42.6 20.0 23.1 18.2 20.7 15.0 25.1 7.4 14.0 19.8 14.1 16.7 11.5 26.2 6.6 17.1 9.4 9.6 9.3 5.3 30.1 54.2 5.9 17.0 17.6 14.2 16.1 33.2 44.6 10.1 29.5 10.3 16.4 13.5 6.2 7.6 7.7 4.5 8.8 11.5 10.3 10.6 8.9 8.1 12.8 7.1 10.5 10.7 1.3 6.3 8.0 12.0 8.0 4.4 20.2 20.1 25.8 24.2 19.1 20.4 26.3 14.8 20.5 18.0 RAD18 RNF73 ENSG00000070950 "RAD18, E3 ubiquitin protein ligase" Q9NS91 3 8775402-8963773 "Enzymes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, Ubl conjugation pathway" "DNA-binding, Transferase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA006716, HPA006724, HPA008752" Supported Approved Enhanced "Nucleoplasm,Nuclear bodies" "Nuclear bodies" Nucleoplasm "HPA006716: , HPA006724: , HPA008752: AB_2668129" "unprognostic (1.26e-1)" "unprognostic (1.07e-1)" "unprognostic (4.45e-2)" "unprognostic (1.25e-3)" "unprognostic (2.73e-2)" "unprognostic (6.15e-2)" "prognostic unfavourable (1.12e-4)" "unprognostic (2.01e-1)" "unprognostic (9.76e-2)" "unprognostic (1.17e-1)" "unprognostic (2.02e-2)" "prognostic unfavourable (3.73e-4)" "prognostic unfavourable (3.65e-5)" "unprognostic (1.97e-2)" "unprognostic (1.51e-1)" "unprognostic (7.92e-2)" "unprognostic (1.89e-2)" 6.2 5.7 7.4 5.6 12.7 7.9 9.5 16.4 11.4 5.5 6.6 3.9 5.4 17.7 6.5 3.7 7.6 4.9 5.6 4.4 4.7 3.3 4.3 5.7 5.9 7.6 8.4 6.9 7.1 4.2 3.4 6.9 6.9 5.7 7.4 9.0 3.5 7.5 3.5 3.7 8.5 10.5 6.0 7.8 8.5 5.1 9.5 9.8 16.6 6.7 4.7 7.5 6.1 6.8 3.7 6.3 8.7 3.0 4.3 5.5 1.5 9.7 9.3 7.8 4.6 1.9 4.2 9.5 15.5 5.3 15.0 10.3 8.4 6.3 12.1 3.0 8.8 3.4 8.2 8.0 15.3 7.4 10.3 10.3 9.3 5.0 1.2 13.5 8.9 1.5 2.9 14.8 10.1 4.8 10.9 12.0 13.0 11.3 13.7 9.6 10.8 17.1 10.9 8.6 9.5 4.3 7.5 3.2 7.4 6.9 6.6 5.0 6.9 6.0 4.0 12.4 6.8 10.6 13.2 6.1 9.3 26.3 9.2 15.0 9.1 7.4 2.7 8.7 3.0 3.0 5.5 3.7 4.0 5.2 3.4 3.7 4.3 3.2 1.2 4.3 1.8 6.3 5.0 1.5 7.4 12.7 16.4 11.4 4.7 3.3 8.4 6.9 5.7 9.8 RAP1GAP "KIAA0474, RAP1GA1, RAP1GAP1, RAP1GAPII" ENSG00000076864 "RAP1 GTPase activating protein" P47736 1 21596215-21669363 "Predicted intracellular proteins" "GTPase activation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 89.3;thyroid gland: 72.5" "Cell line enhanced" "Detected in many" "A549: 24.0;Hep G2: 11.2;K-562: 14.8;SCLC-21H: 27.8;SK-BR-3: 14.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 11 "neutrophil: 1.1" "Lineage enriched" "Detected in single" 11 "granulocytes: 1.1" "Low region specificity" "Detected in all" "Region enriched" "Detected in all" 4 "basal ganglia: 286.1" "HPA001922, CAB003851" Enhanced Supported Approved Cytosol Cytosol "CAB003851: AB_562338, HPA001922: AB_1079743" "unprognostic (1.17e-2)" "unprognostic (4.33e-2)" "unprognostic (7.84e-2)" "unprognostic (2.45e-2)" "unprognostic (4.52e-2)" "unprognostic (1.21e-1)" "prognostic unfavourable (5.85e-4)" "unprognostic (8.33e-2)" "unprognostic (1.52e-2)" "unprognostic (2.35e-1)" "unprognostic (3.43e-2)" "unprognostic (1.35e-2)" "prognostic favourable (1.12e-6)" "unprognostic (1.11e-1)" "unprognostic (9.85e-3)" "unprognostic (4.86e-3)" "unprognostic (3.64e-2)" 0.9 38.2 30.2 1.9 89.3 1.1 3.1 27.1 40.1 4.7 10.5 5.7 0.0 6.9 1.7 1.8 2.9 3.0 13.4 2.7 17.8 12.9 33.2 10.3 7.8 1.2 8.6 20.6 1.6 49.3 7.1 8.2 5.8 14.6 7.4 9.4 2.4 43.9 1.2 0.7 2.1 11.6 1.1 3.2 0.9 28.4 2.1 14.2 0.0 72.5 0.9 1.6 2.5 0.5 0.0 0.0 1.1 0.0 0.0 0.0 0.3 3.1 24.0 0.2 1.9 0.0 0.0 0.4 0.0 0.0 0.0 0.0 2.2 3.3 0.0 2.4 0.1 4.1 2.3 0.1 0.0 0.5 1.2 1.1 2.3 11.2 0.4 0.0 3.5 0.1 1.6 0.0 0.0 0.0 14.8 0.6 0.0 7.9 3.8 0.3 1.5 3.7 2.2 0.6 0.5 5.5 1.7 27.8 5.0 4.0 14.5 4.6 1.4 2.7 0.0 0.0 1.7 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.3 30.2 89.3 27.1 30.4 17.8 12.9 8.6 20.6 14.6 14.2 RBFOX3 "FOX-3, HRNBP3, NeuN" ENSG00000167281 "RNA binding fox-1 homolog 3" A6NFN3 17 79089345-79516148 "Predicted intracellular proteins" "mRNA processing, mRNA splicing" RNA-binding "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 60.4;seminal vesicle: 21.5" "Group enriched" "Detected in some" 6 "A549: 12.9;NTERA-2: 11.7;SCLC-21H: 18.7;U-2 OS: 8.8" "Cancer enhanced" "Detected in some" "prostate cancer: 1.1" "Region enhanced" "Detected in all" "cerebellum: 60.4" "Cell type enhanced" "Detected in single" "gdT-cell: 1.4" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA030790, CAB078782" Enhanced Supported Supported Nucleoplasm Nucleoplasm "CAB078782: , HPA030790: AB_10602305" "unprognostic (2.84e-1)" "unprognostic (1.88e-1)" "unprognostic (4.10e-2)" "unprognostic (9.23e-3)" "unprognostic (8.85e-2)" "unprognostic (2.34e-1)" "unprognostic (1.69e-1)" "unprognostic (1.09e-1)" "unprognostic (7.72e-2)" "unprognostic (1.50e-1)" "unprognostic (2.19e-1)" "unprognostic (1.04e-1)" "unprognostic (3.22e-15)" "unprognostic (8.92e-3)" "unprognostic (1.92e-1)" "unprognostic (1.61e-1)" "unprognostic (1.88e-1)" 0.5 1.0 10.2 0.6 23.5 0.6 0.2 60.4 33.2 0.5 15.2 0.3 0.2 1.5 9.3 3.0 8.3 1.0 0.3 0.3 8.6 3.3 0.4 0.2 0.3 0.4 1.8 3.5 0.3 0.5 0.2 0.9 0.3 5.5 13.2 2.2 0.2 0.2 21.5 0.3 0.3 1.3 8.1 2.3 0.4 0.5 7.2 5.6 0.2 0.3 0.2 0.2 15.2 1.0 0.7 0.2 0.0 0.7 0.0 1.4 0.2 0.0 12.9 0.2 0.2 0.0 0.0 0.3 0.4 0.0 0.0 0.0 0.2 0.1 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 2.1 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 11.7 0.2 0.2 0.5 0.0 0.0 0.0 18.7 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 8.8 0.5 0.0 0.7 0.0 0.3 0.4 0.3 0.0 0.0 0.7 0.0 1.4 0.3 0.0 0.7 0.1 0.4 0.2 0.7 0.4 0.9 0.0 0.0 0.0 0.1 0.0 0.2 10.2 23.5 60.4 19.5 8.6 3.3 1.8 3.5 5.5 5.6 RCN2 "E6BP, ERC-55, ERC55, TCBP49" ENSG00000117906 "Reticulocalbin 2" Q14257 15 76931619-76954392 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "epididymis: 147.5" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA030694, HPA030695" Enhanced Supported Enhanced "Endoplasmic reticulum" "Intracellular and membrane" 41000 "Endoplasmic reticulum" "HPA030694: AB_2673573, HPA030695: AB_2673574" "unprognostic (1.69e-2)" "unprognostic (1.79e-1)" "unprognostic (1.92e-2)" "unprognostic (3.45e-2)" "unprognostic (2.42e-1)" "unprognostic (8.71e-2)" "prognostic unfavourable (7.36e-5)" "unprognostic (1.74e-1)" "unprognostic (2.20e-2)" "unprognostic (4.61e-3)" "unprognostic (1.39e-1)" "unprognostic (1.98e-1)" "unprognostic (1.70e-2)" "unprognostic (2.11e-2)" "unprognostic (2.99e-1)" "unprognostic (1.15e-1)" "unprognostic (3.67e-2)" 13.8 14.7 29.9 12.1 32.6 9.9 16.8 25.1 37.5 16.8 15.0 17.3 28.1 10.4 20.6 147.5 14.9 25.0 15.3 17.3 29.5 41.5 22.6 9.3 13.5 12.5 27.2 29.5 18.8 11.0 28.4 17.8 27.7 24.6 19.6 17.2 15.5 12.0 21.9 22.7 10.6 11.0 18.2 18.5 12.4 13.8 48.2 14.8 14.8 22.1 17.0 14.3 17.8 13.3 15.9 12.0 9.8 7.2 14.1 19.0 11.5 20.4 14.5 64.8 30.5 28.0 32.0 40.5 24.4 33.3 31.8 26.6 17.9 17.6 12.8 35.4 26.5 31.3 49.0 21.0 40.7 9.8 38.2 6.3 21.2 29.6 33.5 22.8 9.8 28.9 29.1 15.6 20.2 33.5 15.9 12.8 33.1 13.1 22.5 15.7 49.3 16.2 23.8 42.7 8.1 20.9 27.5 37.1 37.0 39.9 22.4 46.4 21.8 25.3 17.9 37.6 30.4 23.9 50.1 18.4 56.6 15.2 21.4 19.2 34.0 4.5 4.8 9.8 14.8 4.4 17.2 14.8 15.7 19.0 10.2 15.9 17.8 17.2 2.6 14.1 7.2 12.0 10.9 11.5 29.9 32.6 25.1 37.5 29.5 41.5 27.2 29.5 24.6 14.8 RET "CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51" ENSG00000165731 "Ret proto-oncogene" P07949 10 43077027-43130351 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Hirschsprung disease, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "parathyroid gland: 63.9" "Cell line enhanced" "Detected in some" "MCF7: 17.6;NB-4: 11.6;SH-SY5Y: 89.7;THP-1: 26.8" "Cancer enhanced" "Detected in many" "breast cancer: 11.0" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "non-classical monocyte: 6.7" "Group enriched" "Detected in many" 13 "dendritic cells: 2.1;monocytes: 6.7" "Low region specificity" "Detected in many" "Region enriched" "Detected in many" 6 "midbrain: 95.5" "CAB002581, HPA008356, HPA008495" Approved Supported Approved "Golgi apparatus,Plasma membrane,Cytosol" 260000 "Golgi apparatus, Cytosol" "Plasma membrane" "CAB002581: AB_563673, HPA008356: AB_1847232, HPA008495: " "unprognostic (7.94e-2)" "unprognostic (3.68e-2)" "unprognostic (4.49e-1)" "prognostic unfavourable (5.02e-4)" "unprognostic (1.15e-1)" "unprognostic (9.13e-4)" "unprognostic (1.27e-2)" "unprognostic (3.62e-2)" "unprognostic (2.86e-1)" "unprognostic (2.01e-1)" "unprognostic (1.54e-3)" "unprognostic (4.43e-1)" "unprognostic (9.35e-5)" "unprognostic (1.64e-3)" "unprognostic (8.28e-2)" "unprognostic (3.67e-3)" "unprognostic (2.02e-2)" 1.8 15.2 1.1 1.8 1.3 0.7 1.2 4.1 9.0 1.9 3.1 0.9 1.1 1.5 0.9 0.6 1.2 0.7 1.0 1.2 1.5 5.8 1.0 11.7 0.7 0.8 17.5 1.2 0.8 1.3 63.9 6.3 0.8 16.8 2.2 1.5 2.8 13.6 2.0 4.5 1.1 2.6 1.1 2.8 0.6 2.1 2.0 0.0 0.1 0.8 5.1 0.6 1.9 1.4 0.2 2.1 0.0 6.7 0.0 0.3 0.4 0.0 0.1 0.0 0.5 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 17.6 0.0 11.6 2.1 0.0 0.0 0.0 0.0 0.0 0.0 1.3 89.7 0.0 0.0 0.0 1.2 26.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.8 0.0 0.2 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 6.7 2.1 0.3 0.4 1.1 1.3 4.1 9.0 1.5 5.8 17.5 1.2 16.8 0.0 RGS10 ENSG00000148908 "Regulator of G protein signaling 10" O43665 10 119499828-119542708 "Predicted intracellular proteins" "GTPase activation, Signal transduction inhibitor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 77.9;lymphoid tissue: 96.9" "Cell line enhanced" "Detected in many" "HMC-1: 92.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004559, HPA021305, HPA058485" Enhanced Supported Supported "Nucleoplasm,Plasma membrane" 1400000 "Nucleoplasm, Plasma membrane" "CAB004559: AB_628216, HPA021305: AB_1856225, HPA058485: " "unprognostic (1.64e-2)" "prognostic favourable (6.81e-4)" "unprognostic (7.98e-2)" "prognostic favourable (6.32e-4)" "unprognostic (5.21e-2)" "unprognostic (6.19e-2)" "unprognostic (4.32e-3)" "unprognostic (6.35e-2)" "unprognostic (9.90e-3)" "unprognostic (1.10e-1)" "unprognostic (1.42e-2)" "unprognostic (1.30e-1)" "prognostic unfavourable (4.20e-10)" "unprognostic (2.50e-1)" "unprognostic (9.20e-2)" "unprognostic (7.70e-2)" "unprognostic (7.92e-3)" 9.6 7.7 11.9 28.2 12.1 23.6 15.4 2.8 12.4 25.8 44.0 17.0 5.3 12.5 15.3 13.1 21.9 10.8 18.8 11.7 12.0 10.5 8.3 3.9 13.5 47.6 17.4 6.7 10.3 3.9 0.8 6.6 16.9 10.5 17.8 18.9 6.4 18.1 8.2 13.2 9.3 23.1 19.1 28.5 18.7 12.8 3.7 11.1 96.9 14.7 11.1 34.3 17.9 20.0 6.9 40.2 20.5 26.3 7.6 77.9 63.0 29.6 5.5 0.4 52.1 7.5 48.1 4.9 13.8 21.0 8.4 13.5 1.7 7.1 12.7 7.4 10.7 6.6 7.7 8.4 22.2 6.2 8.9 34.0 1.6 4.0 12.0 6.9 92.5 18.7 11.2 16.2 15.1 15.9 8.7 10.3 9.6 13.4 40.2 24.0 2.4 15.0 7.8 0.0 4.7 4.3 6.9 2.1 1.7 2.6 34.0 48.7 6.5 12.3 20.9 4.8 4.1 6.8 11.8 0.5 7.9 4.6 1.4 30.2 2.1 20.5 21.5 0.2 15.0 26.3 15.7 6.9 32.5 25.8 40.2 3.6 77.9 58.5 9.9 7.6 21.6 23.9 35.0 63.0 11.9 12.1 2.8 12.4 12.0 10.5 17.4 6.7 10.5 11.1 RGS5 ENSG00000143248 "Regulator of G protein signaling 5" O15539 1 163111121-163321791 "Predicted intracellular proteins" "Signal transduction inhibitor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in some" 44 "HUVEC TERT2: 90.9;SH-SY5Y: 301.8" "Cancer enhanced" "Detected in all" "renal cancer: 226.3" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001821 Supported "HPA001821: AB_1079806" "unprognostic (3.75e-1)" "unprognostic (3.93e-3)" "unprognostic (2.31e-1)" "unprognostic (6.91e-2)" "unprognostic (2.50e-2)" "unprognostic (1.32e-3)" "unprognostic (1.65e-2)" "unprognostic (7.38e-2)" "unprognostic (3.54e-3)" "unprognostic (2.19e-1)" "unprognostic (1.53e-2)" "unprognostic (1.48e-1)" "prognostic unfavourable (9.17e-4)" "unprognostic (3.81e-3)" "unprognostic (7.05e-2)" "unprognostic (6.08e-2)" "unprognostic (1.41e-1)" 38.3 96.6 23.8 16.1 42.1 0.5 18.4 11.9 28.6 62.6 28.5 11.6 20.8 19.5 23.3 19.8 28.1 22.7 43.5 67.8 28.3 22.0 32.4 10.3 24.9 9.2 37.9 20.8 15.5 9.3 19.5 18.3 6.3 41.7 34.4 13.8 59.3 8.8 59.9 37.1 6.8 48.6 83.1 19.7 5.7 27.3 13.4 20.8 4.1 53.6 35.0 11.7 77.5 20.7 2.2 0.4 0.5 0.5 0.6 2.3 0.5 0.0 0.0 4.4 0.5 0.0 0.2 0.1 0.0 0.3 0.1 0.1 0.3 0.1 0.0 0.6 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 90.9 0.0 0.0 0.3 0.0 0.0 0.1 2.7 0.1 0.0 0.0 0.2 0.0 0.0 0.3 301.8 0.0 0.0 0.1 0.0 0.0 0.3 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.2 0.0 0.2 0.0 0.4 0.4 2.3 2.2 2.1 1.0 0.4 1.2 2.1 2.0 0.5 0.6 0.5 0.2 1.1 0.5 23.8 42.1 11.9 28.6 28.3 22.0 37.9 20.8 41.7 20.8 RGS9 "MGC111763, MGC26458, PERRS, RGS9L" ENSG00000108370 "Regulator of G protein signaling 9" O75916 17 65100812-65227703 "Disease related genes, Plasma proteins, Predicted intracellular proteins" "Sensory transduction, Vision" "Signal transduction inhibitor" "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 47.3" "Group enriched" "Detected in some" 8 "HDLM-2: 22.9;HEL: 9.3" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in all" 6 "basal ganglia: 47.3" "Group enriched" "Detected in many" 6 "gdT-cell: 11.0;MAIT T-cell: 2.8;memory CD8 T-cell: 7.4;naive CD8 T-cell: 3.6;NK-cell: 3.7" "Group enriched" "Detected in many" 74 "NK-cells: 3.7;T-cells: 11.0" "Region enriched" "Detected in many" 9 "basal ganglia: 222.4" "Region enriched" "Detected in many" 9 "basal ganglia: 79.8" "HPA013550, HPA014137" Enhanced Supported Approved Nucleoplasm,Vesicles "Nucleoplasm, Vesicles" "HPA013550: , HPA014137: " "unprognostic (4.43e-3)" "unprognostic (7.49e-3)" "unprognostic (5.12e-2)" "unprognostic (3.09e-5)" "unprognostic (1.07e-1)" "unprognostic (1.14e-1)" "unprognostic (3.17e-1)" "unprognostic (1.93e-1)" "unprognostic (1.20e-1)" "unprognostic (4.88e-2)" "prognostic favourable (1.35e-4)" "unprognostic (1.07e-1)" "unprognostic (5.07e-2)" "unprognostic (4.94e-2)" "unprognostic (3.69e-1)" "unprognostic (1.51e-1)" "unprognostic (1.49e-1)" 1.1 1.9 3.3 4.4 47.3 1.0 2.3 4.1 8.9 3.4 5.2 7.2 2.7 3.3 4.2 7.2 4.1 9.5 3.9 1.3 5.4 7.4 2.0 5.0 5.9 5.3 3.5 3.7 6.7 3.7 7.3 7.9 3.0 4.5 8.6 3.4 24.1 3.2 9.2 1.6 1.5 3.6 4.0 3.4 4.3 3.7 1.7 6.6 0.4 4.2 0.5 7.5 5.1 2.4 0.0 0.0 0.0 0.0 3.7 11.0 1.4 0.2 0.0 1.0 0.1 0.1 0.2 0.0 0.0 2.1 0.0 0.2 0.1 0.0 0.7 1.6 0.0 0.1 0.0 0.1 0.2 22.9 0.5 9.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 11.0 0.0 2.8 0.0 1.0 7.4 0.0 0.0 0.0 3.6 0.0 3.7 0.0 0.0 0.0 1.4 3.3 47.3 4.1 4.5 5.4 7.4 3.5 3.7 4.5 6.6 RIMS2 "KIAA0751, OBOE, RAB3IP3, RIM2" ENSG00000176406 "Regulating synaptic membrane exocytosis 2" Q9UQ26 8 103500748-104256094 "Predicted intracellular proteins" Differentiation "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 51.1;brain: 28.7" "Cell line enhanced" "Detected in some" "AF22: 6.0;Daudi: 11.7;RT4: 8.4;SCLC-21H: 20.7;U-2 OS: 5.5" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA046538, HPA066498, CAB079049" Enhanced Supported Approved "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "CAB079049: , HPA046538: , HPA066498: " "unprognostic (2.98e-2)" "unprognostic (7.14e-2)" "unprognostic (4.47e-2)" "unprognostic (5.51e-2)" "unprognostic (2.82e-1)" "unprognostic (7.09e-3)" "unprognostic (2.02e-2)" "unprognostic (1.16e-2)" "unprognostic (7.61e-2)" "unprognostic (8.01e-3)" "unprognostic (1.40e-2)" "unprognostic (6.34e-2)" "unprognostic (1.67e-5)" "unprognostic (8.12e-4)" "unprognostic (1.04e-1)" "unprognostic (1.61e-1)" "unprognostic (9.08e-2)" 0.9 51.1 15.8 1.0 21.8 1.1 1.8 14.5 28.7 8.5 0.9 0.5 0.9 1.2 1.4 1.7 1.0 6.3 1.7 0.9 10.3 4.9 1.1 0.9 1.0 1.1 3.1 17.5 2.8 1.6 0.9 12.4 1.1 8.6 2.8 1.0 5.8 1.0 1.8 1.0 1.0 1.4 2.0 4.0 0.9 1.7 3.9 8.7 0.0 2.9 0.0 1.0 1.5 1.6 0.7 0.7 2.9 0.6 1.6 0.6 0.2 3.7 0.0 6.0 0.0 0.0 0.0 0.0 0.4 0.3 1.1 1.4 0.1 0.3 11.7 0.1 0.0 0.3 1.8 0.7 1.9 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.1 1.1 0.0 0.9 0.0 0.1 0.5 0.0 0.5 0.8 0.0 4.6 0.6 0.0 0.0 0.0 0.0 8.4 20.7 5.0 0.0 0.1 0.5 0.3 0.2 0.0 0.0 5.5 0.1 0.1 1.5 0.0 0.1 0.4 0.2 0.2 2.7 0.6 0.6 0.6 0.3 0.4 0.4 0.3 0.4 0.1 0.7 0.3 0.5 2.9 1.6 0.4 0.7 0.3 0.2 15.8 21.8 14.5 28.7 10.3 4.9 3.1 17.5 8.6 8.7 RLBP1 CRALBP ENSG00000140522 "Retinaldehyde binding protein 1" P12271 15 89209869-89221751 "Disease related genes, Predicted intracellular proteins" "Sensory transduction, Transport, Vision" "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 14 "retina: 164.1" "Cell line enriched" "Detected in single" 48 "SK-MEL-30: 21.4" "Group enriched" "Detected in some" 30 "glioma: 3.7;melanoma: 7.4" "Group enriched" "Detected in many" 4 "amygdala: 6.9;basal ganglia: 10.6;cerebral cortex: 7.0;hippocampal formation: 3.7" "Group enriched" "Detected in some" 7 "basophil: 3.3;neutrophil: 1.9" "Lineage enriched" "Detected in single" 9 "granulocytes: 3.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA042051, HPA044083" Enhanced Approved Supported Nucleoplasm,Centrosome,Cytosol Cytosol "Nucleoplasm, Centrosome" "HPA042051: , HPA044083: " "unprognostic (3.19e-2)" "unprognostic (2.66e-1)" "unprognostic (1.86e-1)" "unprognostic (1.25e-1)" "unprognostic (8.68e-2)" "unprognostic (1.76e-1)" "unprognostic (8.24e-3)" "unprognostic (5.21e-2)" "unprognostic (3.17e-1)" "unprognostic (2.63e-2)" "unprognostic (1.76e-1)" "unprognostic (2.78e-1)" "unprognostic (1.13e-1)" "unprognostic (8.42e-2)" 0.2 0.7 6.9 0.6 10.6 0.6 0.2 0.6 11.5 0.2 0.8 0.3 0.1 0.9 0.2 1.0 0.3 0.2 0.3 0.2 3.7 1.3 0.2 0.2 0.3 0.3 1.6 0.6 0.2 0.2 0.2 1.7 0.3 0.4 0.2 0.8 164.1 0.2 0.2 0.5 0.3 0.6 0.5 0.5 0.3 0.2 1.1 0.1 0.1 0.2 0.1 0.2 0.2 0.1 0.0 0.0 3.3 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 21.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 3.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.1 6.9 10.6 0.6 7.0 3.7 1.3 1.6 0.6 0.4 0.1 RPGRIP1 "CORD13, LCA6, RGI1, RPGRIP" ENSG00000092200 "RPGR interacting protein 1" Q96KN7 14 21287939-21351301 "Disease related genes, Predicted intracellular proteins" "Sensory transduction, Vision" "Ciliopathy, Cone-rod dystrophy, Disease mutation, Glaucoma, Leber congenital amaurosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 21 "blood: 10.8;testis: 34.8" "Cell line enhanced" "Detected in many" "RT4: 8.5" "Cancer enhanced" "Detected in single" "testis cancer: 1.0" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "neutrophil: 10.8" "Group enriched" "Detected in many" 11 "dendritic cells: 4.1;granulocytes: 10.8;monocytes: 4.4" "Not detected" "Not detected" "Low region specificity" "Detected in single" "HPA042955, HPA060190" Supported Supported "HPA042955: , HPA060190: " "unprognostic (9.02e-4)" "unprognostic (3.64e-2)" "unprognostic (1.89e-1)" "unprognostic (1.86e-1)" "unprognostic (7.35e-2)" "unprognostic (1.82e-2)" "unprognostic (2.99e-2)" "unprognostic (1.14e-1)" "unprognostic (2.92e-1)" "unprognostic (1.99e-1)" "unprognostic (3.94e-3)" "unprognostic (2.33e-1)" "unprognostic (7.31e-3)" "unprognostic (2.86e-2)" "unprognostic (2.87e-1)" "unprognostic (3.13e-1)" "unprognostic (1.83e-2)" 0.1 0.0 0.1 0.2 0.1 0.5 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.5 0.1 1.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.4 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.6 0.3 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.2 0.8 0.0 34.8 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.2 4.1 10.8 4.4 0.5 0.2 1.3 0.6 1.8 2.0 0.9 0.0 0.0 2.5 0.7 0.0 0.0 0.9 1.2 1.1 2.4 0.5 0.0 0.5 0.6 0.0 0.0 0.8 1.1 1.3 1.8 0.5 0.1 2.1 0.7 1.0 0.0 0.0 0.0 0.0 1.5 0.3 0.0 0.8 0.8 1.2 3.0 0.7 0.9 1.6 1.9 0.0 8.5 1.4 1.3 1.5 1.9 0.4 0.7 1.0 0.7 0.6 0.5 1.8 1.4 2.0 2.0 2.4 0.9 1.3 0.5 2.0 4.4 0.1 0.1 2.0 0.1 0.1 0.1 0.0 4.1 0.2 0.2 0.0 10.8 0.5 0.1 0.0 0.0 1.3 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.1 RPL9 L9 ENSG00000163682 "Ribosomal protein L9" P32969 4 39452521-39458949 "Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Ribosomal proteins" "Ribonucleoprotein, Ribosomal protein" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" HPA003372 Approved Approved Supported "Nucleoli,Endoplasmic reticulum,Cytosol" 24000 "Endoplasmic reticulum, Cytosol" Nucleoli "HPA003372: AB_1079843" "unprognostic (1.08e-3)" "unprognostic (2.14e-1)" "unprognostic (1.24e-1)" "unprognostic (8.06e-3)" "unprognostic (5.59e-2)" "unprognostic (1.27e-2)" "unprognostic (3.16e-2)" "unprognostic (2.14e-1)" "unprognostic (8.58e-2)" "unprognostic (6.68e-2)" "unprognostic (2.50e-2)" "unprognostic (7.85e-2)" "prognostic unfavourable (7.34e-4)" "unprognostic (1.34e-1)" "unprognostic (2.10e-2)" "unprognostic (1.97e-1)" "unprognostic (1.06e-2)" 52.6 35.2 42.2 73.9 44.4 179.1 202.3 35.7 51.6 63.0 59.8 34.5 42.2 69.8 50.4 226.8 49.9 48.1 69.7 58.2 42.3 27.6 47.4 73.2 35.8 48.7 34.7 51.7 158.5 126.2 37.4 44.7 38.7 42.5 47.8 59.1 31.7 93.7 71.4 66.3 62.9 38.8 49.5 34.0 45.2 46.5 56.9 25.9 36.0 63.2 70.1 59.0 46.0 56.6 118.3 72.5 26.2 41.4 63.0 145.0 148.9 3.2 2.8 122.4 2.8 6.6 9.0 4.7 57.6 87.0 71.9 54.6 8.0 65.4 142.9 6.6 57.9 65.1 5.4 6.2 78.7 52.0 115.0 4.5 24.1 7.8 8.5 9.3 37.8 11.9 180.9 4.4 82.7 5.4 109.2 66.7 5.0 4.3 77.5 9.8 109.2 3.8 71.6 122.7 4.9 89.4 3.7 4.6 48.8 1.9 47.3 7.3 104.4 6.7 4.1 3.0 4.6 83.7 7.9 102.5 143.9 124.1 83.1 86.9 3.3 26.2 41.4 12.3 52.1 40.1 101.2 118.3 102.2 71.4 57.2 103.8 145.0 111.7 6.9 63.0 31.2 72.5 77.0 148.9 42.2 44.4 35.7 51.6 42.3 27.6 34.7 51.7 42.5 25.9 RUNDC3A "RAP2IP, RPIP8" ENSG00000108309 "RUN domain containing 3A" Q59EK9 17 44308413-44318671 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 92.6" "Group enriched" "Detected in some" 6 "SCLC-21H: 34.1;SH-SY5Y: 21.8" "Cancer enhanced" "Detected in many" "glioma: 8.6" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "memory CD4 T-cell: 1.3" "Lineage enriched" "Detected in single" 4 "T-cells: 1.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA023548, HPA070733" Enhanced Supported Approved Vesicles Vesicles "HPA023548: AB_1856069, HPA070733: AB_2732162" "unprognostic (3.66e-2)" "unprognostic (3.77e-2)" "unprognostic (3.50e-3)" "unprognostic (1.58e-3)" "unprognostic (3.04e-1)" "unprognostic (2.02e-1)" "unprognostic (3.87e-3)" "unprognostic (2.29e-1)" "unprognostic (4.63e-2)" "unprognostic (3.43e-2)" "unprognostic (1.42e-3)" "unprognostic (1.34e-1)" "unprognostic (8.87e-3)" "unprognostic (1.07e-2)" "unprognostic (5.17e-2)" "unprognostic (9.39e-2)" "unprognostic (1.84e-1)" 1.4 12.9 40.5 1.6 28.5 2.8 1.5 33.0 92.6 1.3 1.8 4.8 0.0 2.2 1.6 1.5 1.5 1.5 1.6 1.8 40.9 20.6 1.7 1.3 1.5 1.4 22.0 23.2 1.7 4.3 2.4 16.1 2.5 15.6 1.5 1.8 1.6 1.4 1.6 1.3 4.1 2.2 1.8 8.0 1.5 3.3 5.2 4.4 0.0 2.4 0.0 1.4 1.5 0.0 0.3 0.1 0.0 0.2 0.1 1.3 0.0 0.0 0.2 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 2.3 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 4.4 0.0 0.1 0.0 0.1 0.0 0.0 0.3 0.0 0.4 0.1 0.0 0.2 0.2 0.0 0.0 0.5 0.1 0.0 34.1 21.8 0.2 0.0 0.2 0.3 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.3 0.0 0.2 0.0 0.1 0.0 0.0 0.3 1.3 0.3 0.1 0.1 0.2 0.5 0.0 0.1 0.0 0.0 0.0 0.0 40.5 28.5 33.0 49.2 40.9 20.6 22.0 23.2 15.6 4.4 S100B S100beta ENSG00000160307 "S100 calcium binding protein B" P04271 21 46598962-46605208 "Cancer-related genes, Candidate cardiovascular disease genes, Predicted intracellular proteins, Transporters" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 4 "brain: 342.0" "Group enriched" "Detected in some" 7 "SK-MEL-30: 81.0;WM-115: 159.2" "Group enriched" "Detected in all" 58 "glioma: 463.5;melanoma: 495.2" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "gdT-cell: 78.0" "Lineage enriched" "Detected in many" 7 "T-cells: 78.0" "Low region specificity" "Detected in all" "CAB000073, HPA015768, CAB078196" Enhanced Supported Supported Nucleoplasm,Vesicles,Cytosol 120000 "Nucleoplasm, Cytosol" Vesicles "CAB000073: AB_10013383, CAB078196: , HPA015768: AB_1856538" "unprognostic (5.67e-3)" "unprognostic (6.39e-3)" "unprognostic (2.08e-3)" "unprognostic (2.08e-2)" "unprognostic (4.54e-3)" "unprognostic (1.10e-2)" "unprognostic (1.01e-1)" "unprognostic (6.68e-3)" "unprognostic (2.03e-1)" "unprognostic (1.37e-1)" "unprognostic (8.57e-3)" "unprognostic (6.70e-2)" "unprognostic (4.41e-7)" "unprognostic (3.55e-2)" "unprognostic (7.56e-2)" "unprognostic (1.07e-1)" "unprognostic (1.74e-1)" 67.7 14.0 60.9 5.6 51.0 2.0 13.2 39.4 151.2 5.2 9.1 101.0 3.0 4.7 1.5 7.6 8.6 2.1 8.3 6.6 74.6 65.4 1.5 1.6 2.9 9.8 152.0 36.5 2.4 3.0 1.1 3.1 1.4 90.3 3.0 8.3 7.4 10.1 15.3 1.3 5.7 7.5 4.3 342.0 5.7 4.3 1.5 46.4 0.0 1.3 1.8 10.8 8.2 1.6 0.1 3.4 0.7 1.9 11.0 78.0 10.6 0.1 0.0 17.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 2.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 81.0 0.0 0.0 0.0 0.1 0.1 0.0 0.5 0.0 0.0 0.0 0.2 1.0 159.2 0.0 0.1 0.0 78.0 1.8 22.4 0.0 0.2 14.5 3.4 0.1 0.6 33.3 0.7 11.0 1.9 0.8 0.0 10.6 60.9 51.0 39.4 37.6 74.6 65.4 152.0 36.5 90.3 46.4 SAYSD1 "C6orf64, FLJ11101" ENSG00000112167 "SAYSVFN motif domain containing 1" Q9NPB0 6 39104064-39115189 "Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "testis: 52.7" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA007959 Approved Supported Vesicles Vesicles "HPA007959: AB_1078359" "unprognostic (2.65e-1)" "unprognostic (1.49e-2)" "unprognostic (2.03e-2)" "unprognostic (2.58e-1)" "unprognostic (3.70e-1)" "unprognostic (2.56e-1)" "unprognostic (9.90e-3)" "unprognostic (1.96e-2)" "unprognostic (6.50e-2)" "unprognostic (1.82e-3)" "unprognostic (5.08e-2)" "unprognostic (9.90e-2)" "unprognostic (2.54e-2)" "unprognostic (1.79e-1)" "unprognostic (9.78e-3)" "unprognostic (2.27e-1)" "unprognostic (2.00e-3)" 8.2 7.2 7.2 5.7 8.7 5.9 11.2 7.1 9.0 7.9 7.3 8.1 6.9 8.8 7.9 10.5 6.5 8.1 9.3 6.7 7.3 6.9 8.1 8.3 6.3 8.2 9.3 6.5 8.4 9.5 4.9 6.1 6.1 7.0 8.5 7.2 6.4 11.1 8.0 5.6 6.6 8.6 6.3 7.0 6.8 6.9 52.7 7.3 18.2 8.4 5.1 9.0 6.2 7.7 14.8 9.3 19.4 12.2 11.7 19.1 9.5 11.4 7.4 6.7 7.9 11.1 14.7 6.9 5.3 5.8 6.4 6.8 10.6 8.2 10.4 7.7 6.9 7.9 5.8 5.0 6.8 6.5 10.5 6.8 4.5 9.2 9.0 7.7 10.3 10.1 12.4 2.5 6.4 5.9 11.5 6.4 7.2 15.7 12.2 12.8 5.8 3.8 1.7 8.2 4.1 13.4 8.1 18.9 7.6 9.2 8.0 8.1 13.1 10.2 7.6 8.5 6.2 2.6 6.8 0.1 3.2 12.8 4.9 11.2 6.2 7.6 9.0 19.4 12.2 12.2 14.2 13.1 13.3 11.0 9.3 14.8 19.1 15.8 4.3 11.7 11.9 7.4 17.3 9.5 7.2 8.7 7.1 9.0 7.3 6.9 9.3 6.5 7.0 7.3 SCAMP1 SCAMP37 ENSG00000085365 "Secretory carrier membrane protein 1" O15126 5 78360583-78479071 "Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Protein transport, Transport" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA044753, CAB079009" Supported Approved "Nucleoplasm,Vesicles,Cell Junctions" "Nucleoplasm, Vesicles, Cell Junctions" "CAB079009: , HPA044753: " "unprognostic (8.25e-2)" "unprognostic (3.65e-2)" "unprognostic (1.40e-3)" "unprognostic (5.34e-3)" "unprognostic (2.60e-1)" "unprognostic (2.57e-3)" "unprognostic (5.51e-2)" "unprognostic (3.43e-2)" "unprognostic (1.31e-1)" "unprognostic (8.23e-3)" "unprognostic (2.35e-2)" "unprognostic (2.56e-1)" "prognostic favourable (1.92e-4)" "unprognostic (8.44e-3)" "unprognostic (7.56e-2)" "unprognostic (3.12e-2)" "unprognostic (4.99e-2)" 7.5 8.3 9.2 4.0 19.3 2.4 10.0 12.8 19.5 8.4 6.4 5.4 9.9 5.3 8.7 9.3 8.6 10.7 6.4 8.0 15.8 10.4 6.2 5.9 3.9 6.5 15.8 8.8 8.8 17.5 14.6 7.6 14.6 12.2 7.3 7.6 10.6 11.0 4.7 5.8 5.3 9.1 9.0 3.9 9.6 4.5 7.1 4.1 14.2 3.8 3.7 8.8 6.3 7.9 14.9 15.3 15.8 10.0 9.9 7.4 12.7 10.1 10.1 31.3 14.0 18.1 15.9 11.8 17.3 9.8 22.3 3.8 24.0 18.9 13.4 17.3 10.4 14.3 22.2 17.5 6.7 13.6 8.7 8.0 7.7 9.0 5.5 6.7 11.9 20.6 11.1 17.7 15.0 3.3 13.6 18.6 15.0 9.5 11.8 8.2 10.4 11.7 16.7 21.6 17.8 15.3 28.8 17.5 10.9 15.5 11.2 21.6 10.1 15.2 10.9 8.0 11.9 9.9 9.5 11.4 11.8 21.2 20.7 9.0 15.3 11.4 12.8 8.2 12.6 9.9 7.9 9.4 9.8 14.9 6.6 7.8 6.8 7.0 10.0 15.8 4.6 9.1 7.4 SCG2 "CHGC, SgII, SN" ENSG00000171951 "Secretogranin II" P13521 2 223596940-223602503 "Plasma proteins, Predicted secreted proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "adrenal gland: 133.0;brain: 94.1;pituitary gland: 76.5" "Cell line enhanced" "Detected in some" "ASC TERT1: 26.2;HSkMC: 22.4;SCLC-21H: 22.8;SH-SY5Y: 9.9;WM-115: 16.7" "Group enriched" "Detected in many" 8 "glioma: 70.0;pancreatic cancer: 52.9" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA011893, HPA075062" Enhanced Supported Approved "Golgi apparatus,Vesicles" "Secreted to blood" 54000 "Golgi apparatus" Vesicles "HPA011893: AB_1856656, HPA075062: AB_2732277" "unprognostic (2.93e-2)" "unprognostic (1.44e-2)" "unprognostic (1.23e-3)" "unprognostic (6.82e-4)" "unprognostic (2.51e-2)" "unprognostic (1.13e-2)" "unprognostic (2.77e-3)" "unprognostic (6.73e-2)" "unprognostic (1.08e-1)" "unprognostic (4.69e-2)" "prognostic favourable (5.58e-4)" "unprognostic (1.34e-1)" "prognostic unfavourable (7.01e-10)" "unprognostic (2.47e-3)" "unprognostic (4.02e-1)" "unprognostic (1.57e-2)" "unprognostic (1.90e-3)" 3.5 133.0 13.3 11.0 94.1 0.9 0.9 5.6 55.9 1.4 5.4 5.8 0.0 17.3 2.1 0.9 1.0 0.8 2.2 1.4 10.5 79.4 1.0 0.8 1.9 0.9 21.7 11.0 1.3 10.7 1.1 76.5 1.1 57.7 2.1 5.5 1.5 0.9 1.3 0.8 1.0 8.0 5.2 10.3 0.8 8.0 0.9 5.0 0.0 3.1 0.0 0.8 1.1 0.2 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 1.4 4.9 4.1 1.1 26.2 0.1 0.2 0.9 1.9 4.9 0.2 0.4 0.0 0.4 0.3 0.1 0.1 0.0 2.5 0.0 0.2 0.0 0.3 0.0 0.3 0.3 2.2 22.4 0.1 2.7 0.9 0.0 0.1 0.2 2.4 0.1 0.0 0.1 3.5 0.0 0.0 0.1 0.0 0.3 0.0 22.8 9.9 0.0 0.2 1.1 0.0 0.0 0.0 2.6 1.0 0.1 1.7 0.0 0.0 0.1 0.7 0.0 16.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 13.3 94.1 5.6 23.0 10.5 79.4 21.7 11.0 57.7 5.0 SCG3 "FLJ90833, SgIII" ENSG00000104112 "Secretogranin III" Q8WXD2 15 51681353-51721031 "Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "brain: 118.3" "Group enriched" "Detected in some" 7 "NTERA-2: 20.0;SCLC-21H: 47.9;SH-SY5Y: 22.6" "Group enriched" "Detected in many" 7 "glioma: 41.0;pancreatic cancer: 15.0" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA006880, CAB033274, HPA053715" Enhanced Supported Supported Vesicles "Secreted in brain" 4800000 Vesicles "CAB033274: AB_2302033, HPA006880: AB_1079898, HPA053715: " "unprognostic (1.38e-2)" "unprognostic (2.42e-1)" "unprognostic (1.40e-1)" "unprognostic (5.24e-5)" "unprognostic (1.59e-2)" "unprognostic (3.63e-2)" "unprognostic (1.74e-1)" "unprognostic (9.93e-2)" "unprognostic (1.40e-1)" "unprognostic (2.46e-1)" "unprognostic (1.71e-2)" "unprognostic (8.17e-2)" "unprognostic (1.03e-1)" "unprognostic (2.78e-1)" "unprognostic (2.78e-1)" "unprognostic (8.88e-2)" "unprognostic (1.27e-1)" 1.7 12.9 29.6 2.1 25.4 1.7 1.7 33.4 118.3 1.5 2.4 6.5 0.0 2.9 1.5 1.6 1.6 1.6 1.6 1.5 22.6 23.5 1.5 1.5 1.8 1.7 13.6 37.7 1.5 11.5 1.4 23.7 1.5 27.1 1.6 2.8 1.3 1.5 1.4 1.5 1.8 2.6 1.7 13.2 1.5 8.7 2.9 7.3 0.0 2.1 0.0 1.5 1.6 0.1 0.9 1.2 1.9 0.5 0.3 0.8 0.2 0.0 0.0 1.8 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 1.1 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.1 0.0 0.0 20.0 0.0 0.1 0.0 0.1 0.0 0.2 47.9 22.6 0.1 0.1 0.0 0.0 1.4 0.0 0.1 0.2 0.1 0.0 0.1 0.0 0.1 0.3 0.1 4.3 0.4 0.4 0.6 0.8 0.2 0.5 0.9 0.6 0.4 0.4 0.7 0.5 0.6 1.9 0.3 0.5 1.2 0.2 0.2 29.6 25.4 33.4 40.6 22.6 23.5 13.6 37.7 27.1 7.3 SCGN "CALBL, DJ501N12.8, SECRET, SEGN" ENSG00000079689 "Secretagogin, EF-hand calcium binding protein" O76038 6 25652201-25701783 "Plasma proteins, Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 22.3;pancreas: 39.7;pituitary gland: 47.9" "Cell line enriched" "Detected in some" 4 "SCLC-21H: 23.1" "Cancer enhanced" "Detected in many" "pancreatic cancer: 38.2" "Group enriched" "Detected in many" 11 "cerebellum: 22.3;hippocampal formation: 6.2;hypothalamus: 22.0" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 16 "olfactory region: 100.5" "Region enriched" "Detected in some" 9 "olfactory region: 282.4" "CAB004005, HPA006641, CAB044060, CAB062563, CAB068232" Enhanced Supported Supported Cytosol "Intracellular and membrane" Cytosol "CAB004005: , CAB044060: , CAB062563: , CAB068232: , HPA006641: AB_1079874" "unprognostic (8.15e-2)" "unprognostic (4.31e-3)" "unprognostic (1.46e-1)" "unprognostic (1.25e-2)" "unprognostic (4.70e-1)" "unprognostic (1.78e-2)" "unprognostic (2.01e-1)" "unprognostic (5.14e-2)" "unprognostic (5.41e-2)" "unprognostic (9.45e-2)" "unprognostic (1.19e-1)" 1.5 2.1 0.7 6.0 0.8 0.1 2.0 22.3 1.5 0.4 10.5 0.5 0.9 7.2 0.1 0.3 0.3 0.0 0.5 5.0 6.2 22.0 3.8 2.5 0.4 0.1 0.5 1.2 0.2 39.7 0.0 47.9 1.8 1.4 1.1 11.7 1.8 3.7 3.0 0.1 0.3 8.0 0.7 1.0 0.1 12.5 0.6 0.1 0.5 1.1 0.3 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.0 0.0 0.0 5.7 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.2 0.0 4.1 0.0 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 23.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.1 0.0 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.8 22.3 1.5 6.2 22.0 0.5 1.2 1.4 0.1 SDF4 Cab45 ENSG00000078808 "Stromal cell derived factor 4" Q9BRK5 1 1216908-1232031 "Plasma proteins, Predicted intracellular proteins, Transporters" Exocytosis "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA011249, HPA011895, CAB015227" Supported Supported Supported "Golgi apparatus" "Intracellular and membrane" 720000 "Golgi apparatus" "CAB015227: , HPA011249: , HPA011895: " "unprognostic (1.98e-1)" "prognostic unfavourable (5.89e-4)" "unprognostic (3.63e-1)" "unprognostic (2.38e-3)" "unprognostic (5.88e-2)" "unprognostic (7.95e-3)" "unprognostic (3.73e-3)" "unprognostic (1.06e-1)" "unprognostic (2.01e-1)" "unprognostic (8.70e-2)" "unprognostic (1.46e-2)" "unprognostic (1.07e-1)" "unprognostic (8.39e-3)" "unprognostic (1.09e-1)" "unprognostic (2.32e-1)" "unprognostic (1.42e-1)" "unprognostic (3.04e-2)" 34.7 36.0 17.9 37.3 22.7 19.7 56.3 20.6 33.2 30.3 49.9 21.3 46.6 48.5 35.5 53.4 26.2 26.9 57.5 50.8 18.7 18.5 36.3 73.8 55.8 46.2 19.7 21.3 33.1 56.4 25.9 31.1 47.9 18.2 30.3 25.6 26.5 46.7 52.1 30.7 25.5 56.2 27.6 18.0 33.8 32.9 30.0 18.1 20.5 35.1 28.5 19.6 28.5 44.8 11.5 16.0 20.6 15.9 19.6 22.0 7.0 28.3 25.8 14.3 45.2 69.9 35.3 17.1 55.7 51.1 41.0 34.4 30.4 49.6 18.0 43.2 53.6 29.2 16.3 24.4 12.6 30.1 27.6 31.5 39.8 42.4 32.2 31.7 42.7 43.4 12.6 30.8 17.5 32.7 25.9 47.8 20.1 20.5 15.6 32.0 13.0 34.7 17.5 18.5 47.6 27.2 13.8 51.9 18.4 37.0 44.1 36.6 22.9 36.4 41.5 42.4 23.0 31.8 31.6 29.5 27.8 29.5 48.1 59.8 18.3 10.4 14.9 20.6 15.0 9.9 11.6 9.4 21.5 22.0 16.0 11.5 12.4 10.7 12.7 19.6 15.9 10.0 16.5 7.0 17.9 22.7 20.6 33.2 18.7 18.5 19.7 21.3 18.2 18.1 SEC22B "ERS-24, sec22b, SEC22L1" ENSG00000265808 "SEC22 homolog B, vesicle trafficking protein (gene/pseudogene)" O75396 1 120150898-120176515 "Predicted intracellular proteins, Predicted membrane proteins" "ER-Golgi transport, Protein transport, Transport" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" CAB079017 Approved 980000 "CAB079017: " "unprognostic (2.21e-1)" "unprognostic (2.29e-2)" "unprognostic (5.02e-2)" "unprognostic (8.52e-2)" "unprognostic (1.13e-1)" "unprognostic (7.88e-2)" "unprognostic (1.54e-1)" "unprognostic (3.08e-1)" "unprognostic (3.30e-2)" "prognostic favourable (4.58e-4)" "unprognostic (1.21e-1)" "unprognostic (1.29e-1)" "prognostic unfavourable (3.34e-4)" "unprognostic (5.80e-2)" "unprognostic (2.48e-1)" "unprognostic (1.52e-2)" "unprognostic (2.15e-1)" 11.9 12.0 7.4 8.9 8.3 6.2 10.3 7.6 10.2 12.3 8.5 8.2 15.5 10.0 11.1 18.3 7.3 7.0 10.1 7.7 6.3 10.7 23.6 8.8 9.2 7.6 9.1 10.1 19.6 11.1 25.6 24.8 8.8 11.8 11.2 9.8 19.4 13.4 8.2 6.7 12.4 9.2 7.2 8.9 10.2 7.1 8.3 10.9 11.4 6.3 9.4 11.1 7.8 12.4 16.1 25.1 16.6 14.5 17.8 10.7 9.8 3.2 6.3 9.8 36.8 26.0 8.4 23.4 19.4 16.5 30.6 5.3 4.3 6.3 11.5 14.7 4.1 6.0 6.3 22.7 7.9 5.5 7.1 18.6 9.2 21.1 9.6 8.7 25.3 8.1 21.2 11.5 10.1 4.6 13.5 22.2 19.2 8.9 5.1 9.2 8.7 8.4 14.8 6.9 12.6 7.6 6.5 7.1 8.3 12.1 12.3 6.3 11.1 13.9 22.7 10.8 39.4 15.2 9.3 6.3 9.7 35.1 8.6 25.0 17.4 16.6 14.1 13.3 14.9 17.8 12.4 15.0 13.6 10.0 11.0 15.3 17.0 25.1 14.5 13.1 16.1 11.7 10.7 SEPT3 SEP3 ENSG00000100167 "Septin 3" Q9UH03 22 41969475-41998221 "Predicted intracellular proteins" "Cell cycle, Cell division" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 9 "brain: 101.6" "Cell line enhanced" "Detected in many" "AF22: 13.5;SCLC-21H: 36.5" "Cancer enhanced" "Detected in many" "glioma: 24.6" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "basophil: 2.1" "Group enriched" "Detected in many" 5 "dendritic cells: 1.2;granulocytes: 2.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003548, CAB017633" Enhanced Supported Approved "Nucleoplasm,Plasma membrane,Actin filaments" "Nucleoplasm, Plasma membrane" "Actin filaments" "CAB017633: AB_2301476, HPA003548: AB_1079908" "unprognostic (2.10e-1)" "unprognostic (4.67e-2)" "unprognostic (1.16e-2)" "prognostic unfavourable (1.78e-4)" "unprognostic (4.56e-2)" "unprognostic (1.13e-1)" "unprognostic (7.07e-3)" "unprognostic (2.37e-1)" "unprognostic (2.67e-3)" "unprognostic (3.09e-2)" "unprognostic (1.30e-2)" "unprognostic (6.30e-2)" "unprognostic (2.51e-2)" "unprognostic (9.15e-2)" "unprognostic (6.68e-2)" "unprognostic (5.50e-2)" "unprognostic (1.04e-1)" 1.3 4.4 31.3 1.4 26.9 1.3 2.0 35.9 101.6 1.4 1.5 5.6 0.0 1.4 1.4 2.2 1.3 1.2 1.5 1.2 28.9 17.2 1.4 1.2 1.7 1.5 13.2 24.3 1.2 2.0 10.7 1.0 4.9 13.4 2.1 1.5 1.0 1.3 1.2 1.2 2.2 1.4 1.4 7.3 1.3 1.5 2.4 5.3 0.0 1.7 0.0 1.5 1.4 0.1 0.3 1.2 2.1 0.0 0.1 0.2 0.0 0.7 0.8 13.5 10.1 0.1 0.0 6.7 0.1 0.1 0.9 0.4 0.2 1.5 10.9 0.4 0.1 0.0 7.0 0.0 0.3 4.5 2.3 0.0 0.2 0.0 0.1 0.0 0.4 0.1 0.5 0.0 0.0 0.0 0.0 1.7 0.0 1.1 1.8 0.1 9.2 0.3 8.7 0.0 0.6 0.0 1.3 36.5 7.6 5.4 0.0 8.9 1.3 3.3 0.0 0.0 4.8 0.4 0.5 7.2 6.2 0.1 0.1 4.4 1.4 2.1 0.0 0.1 0.1 0.0 0.2 0.3 0.2 0.0 1.2 0.0 0.2 0.1 0.0 0.1 0.0 0.9 0.2 0.0 31.3 26.9 35.9 42.1 28.9 17.2 13.2 24.3 13.4 5.3 SH3GL2 "CNSA2, EEN-B1, SH3D2A, SH3P4" ENSG00000107295 "SH3 domain containing GRB2 like 2, endophilin A1" Q99962 9 17579082-17797129 "Predicted intracellular proteins" Endocytosis "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 83.0" "Cell line enhanced" "Detected in some" "HEK 293: 5.7;HeLa: 13.8;RT4: 26.7;SCLC-21H: 17.4" "Cancer enhanced" "Detected in many" "glioma: 8.0" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010056, HPA026685, HPA063573" Enhanced Supported Approved "Microtubules,Cytokinetic bridge,Mitotic spindle" Microtubules "Cytokinetic bridge, Mitotic spindle" "CAB010056: AB_628099, HPA026685: AB_1856817, HPA063573: " "unprognostic (4.78e-2)" "unprognostic (3.24e-2)" "unprognostic (1.68e-2)" "unprognostic (5.05e-5)" "unprognostic (4.23e-2)" "unprognostic (3.40e-1)" "unprognostic (1.21e-1)" "unprognostic (5.90e-2)" "unprognostic (3.90e-1)" "unprognostic (5.07e-3)" "unprognostic (8.76e-3)" "unprognostic (1.26e-1)" "prognostic favourable (6.68e-12)" "unprognostic (2.65e-2)" "unprognostic (8.29e-2)" "unprognostic (2.25e-2)" "unprognostic (8.44e-2)" 1.1 1.2 16.7 1.1 17.3 1.0 1.1 68.4 83.0 3.1 1.5 1.6 0.0 1.2 2.8 2.1 1.4 2.6 1.1 4.1 17.1 11.3 13.7 1.1 1.9 1.0 9.1 22.2 2.5 3.4 1.2 6.6 1.0 12.8 2.5 1.6 1.6 1.0 1.1 1.1 1.1 1.5 2.4 6.3 1.1 4.5 5.8 2.2 0.0 2.2 0.0 1.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 1.2 4.8 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 5.7 0.0 13.8 0.0 0.1 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.6 1.5 0.0 0.0 0.0 0.0 26.7 17.4 0.0 0.2 0.0 0.5 0.0 0.0 0.0 0.0 1.4 0.0 0.9 0.0 0.2 0.0 0.8 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.7 17.3 68.4 41.1 17.1 11.3 9.1 22.2 12.8 2.2 SHTN1 "KIAA1598, shootin-1, shootin1" ENSG00000187164 "Shootin 1" A0MZ66 10 116881482-117126586 "Predicted intracellular proteins" "Developmental protein" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 67.8" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 31 "classical monocyte: 14.0;intermediate monocyte: 8.8;myeloid DC: 13.2;non-classical monocyte: 4.0;plasmacytoid DC: 8.9" "Group enriched" "Detected in many" 43 "dendritic cells: 13.2;monocytes: 14.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA037942, HPA037943" Enhanced Approved Approved "Nucleoplasm,Plasma membrane,Cytosol" Nucleoplasm "Plasma membrane, Cytosol" "HPA037942: AB_2675748, HPA037943: AB_10671637" "unprognostic (1.00e-1)" "unprognostic (2.50e-2)" "unprognostic (6.77e-3)" "unprognostic (2.81e-1)" "unprognostic (7.85e-2)" "unprognostic (1.61e-1)" "unprognostic (2.42e-2)" "unprognostic (1.03e-1)" "unprognostic (2.56e-1)" "unprognostic (1.35e-1)" "unprognostic (2.49e-1)" "prognostic unfavourable (5.07e-4)" "unprognostic (2.17e-2)" "unprognostic (1.48e-1)" "unprognostic (2.47e-1)" "unprognostic (1.85e-1)" "prognostic unfavourable (5.08e-6)" 3.5 6.5 51.5 6.8 50.1 1.6 8.7 9.8 34.1 5.5 7.0 42.3 0.3 6.7 4.4 8.4 5.4 5.2 6.5 2.6 58.9 37.0 7.8 12.1 9.8 4.5 67.8 22.7 6.8 10.9 18.6 20.4 5.4 36.3 7.3 8.6 2.0 9.9 3.0 0.9 9.6 7.8 3.8 67.4 7.0 9.0 9.9 54.5 0.4 11.9 1.4 4.1 4.0 2.4 0.0 13.2 0.3 14.0 0.0 0.2 3.5 15.6 8.8 0.9 1.9 0.0 0.0 8.8 1.3 3.5 2.7 5.2 9.9 10.4 0.0 2.7 4.9 8.1 7.0 5.9 2.8 0.0 7.3 0.0 9.3 6.1 1.2 2.8 2.5 0.4 5.2 2.7 5.1 6.5 4.3 0.0 1.9 6.3 0.0 0.1 3.4 6.0 0.0 11.9 3.5 7.3 2.1 9.8 3.9 10.6 15.4 9.6 12.4 2.5 11.2 0.9 6.6 0.0 7.7 1.7 0.0 0.0 4.9 0.0 4.8 0.0 14.0 0.1 0.0 8.8 0.0 0.0 0.0 0.0 13.2 0.0 0.1 0.0 0.3 0.0 4.0 8.9 0.2 3.5 51.5 50.1 9.8 30.2 58.9 37.0 67.8 22.7 36.3 54.5 SLC10A4 MGC29802 ENSG00000145248 "Solute carrier family 10 member 4" Q96EP9 4 48483343-48489196 "Predicted membrane proteins, Transporters" "Ion transport, Sodium transport, Symport, Transport" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 12.3;brain: 19.0" "Cell line enhanced" "Detected in some" "HAP1: 10.4;K-562: 10.4;SH-SY5Y: 27.6" "Cancer enhanced" "Detected in many" "glioma: 5.9" "Group enriched" "Detected in many" 7 "basal ganglia: 7.3;cerebral cortex: 6.3;hypothalamus: 6.3;midbrain: 19.0;pons and medulla: 15.3" "Cell type enhanced" "Detected in single" "naive CD4 T-cell: 1.0" "Lineage enriched" "Detected in single" 11 "T-cells: 1.0" "Group enriched" "Detected in many" 5 "basal ganglia: 19.0;midbrain: 63.0;pons and medulla: 27.5" HPA028835 Uncertain Supported "HPA028835: AB_10603025" "unprognostic (4.06e-1)" "unprognostic (1.19e-1)" "unprognostic (1.06e-1)" "unprognostic (3.05e-3)" "unprognostic (2.49e-1)" "unprognostic (3.46e-2)" "unprognostic (5.41e-2)" "unprognostic (3.67e-1)" "unprognostic (1.86e-1)" "unprognostic (4.08e-3)" "unprognostic (9.98e-3)" "unprognostic (1.46e-1)" "unprognostic (3.50e-1)" "unprognostic (5.14e-2)" "unprognostic (1.94e-1)" "unprognostic (1.72e-1)" "unprognostic (8.73e-2)" 0.4 12.3 1.4 2.7 7.3 3.4 0.5 0.5 6.4 2.9 1.6 0.7 0.0 0.8 0.4 0.2 0.4 0.4 0.6 0.6 1.2 6.3 0.3 0.2 1.1 0.3 19.0 0.8 0.3 0.3 0.4 7.5 0.4 15.3 0.4 1.5 4.0 4.9 0.9 0.9 0.4 1.3 0.6 1.1 0.4 0.8 1.2 0.7 0.0 1.5 0.0 0.3 0.4 0.7 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 2.5 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.1 0.0 0.0 10.4 0.0 0.1 0.0 2.2 4.5 0.1 0.1 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 10.4 0.0 0.0 0.0 0.0 0.2 3.0 0.3 0.0 0.0 0.0 0.0 0.5 0.7 27.6 0.5 0.0 0.1 0.0 4.5 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 7.3 0.5 6.3 1.2 6.3 19.0 0.8 15.3 0.7 SLC16A1 "MCT, MCT1" ENSG00000155380 "Solute carrier family 16 member 1" P53985 1 112911847-112957013 "Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters" "Symport, Transport" "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003324, CAB017489, HPA071055, CAB079035" Enhanced Supported Enhanced "Plasma membrane,Cell Junctions" "Plasma membrane, Cell Junctions" "CAB017489: AB_2189197, CAB079035: , HPA003324: AB_1856982, HPA071055: " "unprognostic (1.19e-1)" "unprognostic (1.61e-2)" "unprognostic (2.97e-1)" "prognostic unfavourable (8.37e-6)" "unprognostic (1.53e-1)" "unprognostic (2.89e-2)" "unprognostic (2.15e-3)" "prognostic unfavourable (4.05e-4)" "unprognostic (6.92e-2)" "unprognostic (6.31e-3)" "prognostic unfavourable (2.10e-4)" "unprognostic (1.18e-1)" "prognostic unfavourable (6.78e-8)" "unprognostic (1.30e-1)" "unprognostic (2.31e-1)" "unprognostic (1.04e-2)" "unprognostic (1.53e-3)" 11.6 7.2 17.4 8.7 19.5 3.1 4.4 10.0 24.0 4.6 23.4 12.7 3.3 18.4 19.3 15.1 10.4 8.7 8.3 39.0 19.5 12.3 6.5 26.9 3.2 5.8 19.2 6.5 6.0 1.9 5.6 3.7 18.8 16.6 8.3 18.1 22.8 2.5 6.5 31.4 7.5 9.5 20.0 16.1 4.8 14.5 17.9 22.5 4.9 5.4 17.7 6.2 9.6 6.2 3.0 5.9 0.6 3.2 2.0 11.4 2.4 19.9 4.7 14.4 12.3 10.0 8.5 47.4 10.8 8.2 8.5 13.7 15.8 11.6 21.9 15.1 9.7 19.1 20.1 20.1 16.1 13.7 20.4 18.0 12.8 18.3 17.7 22.9 1.9 11.9 24.6 12.6 24.7 20.5 22.7 14.6 9.5 3.9 13.5 11.5 46.6 15.0 12.0 22.8 15.1 10.5 0.3 16.0 8.4 20.9 0.6 16.0 0.9 8.7 13.8 8.2 14.5 16.1 15.9 7.7 6.7 22.1 23.8 14.5 10.1 0.6 3.2 0.0 4.1 2.6 6.3 3.0 4.1 4.4 5.9 2.1 4.4 3.8 0.3 2.0 0.7 1.0 11.4 2.4 17.4 19.5 10.0 24.0 19.5 12.3 19.2 6.5 16.6 22.5 SLC17A6 "DNPI, VGLUT2" ENSG00000091664 "Solute carrier family 17 member 6" Q9P2U8 11 22338097-22379503 "Predicted membrane proteins, Transporters" "Ion transport, Neurotransmitter transport, Sodium transport, Symport, Transport" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 14 "brain: 75.2" "Cell line enriched" "Detected in single" 222 "SCLC-21H: 26.0" "Not detected" "Not detected" "Group enriched" "Detected in many" 6 "hypothalamus: 20.2;pons and medulla: 75.2" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "basal ganglia: 54.1;hypothalamus: 163.2;midbrain: 206.4;pons and medulla: 90.5;thalamus: 180.7" "Low region specificity" "Detected in many" "CAB037130, HPA039226, CAB078204" Supported Supported "CAB037130: AB_477611, CAB078204: , HPA039226: " "unprognostic (1.39e-1)" "unprognostic (1.93e-1)" 0.5 0.5 7.6 0.5 1.1 0.5 0.5 0.2 13.8 0.5 0.5 1.3 0.0 0.5 0.5 0.5 0.5 0.5 0.5 0.5 1.1 20.2 0.5 0.5 0.5 0.5 7.1 2.1 0.5 1.5 0.5 5.3 0.5 75.2 0.5 0.5 1.4 0.5 0.5 0.5 0.5 0.5 0.5 5.9 0.5 0.5 0.5 0.0 0.0 0.5 0.0 0.5 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 26.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.6 1.1 0.2 8.4 1.1 20.2 7.1 2.1 75.2 0.0 SLC17A7 "BNPI, VGLUT1" ENSG00000104888 "Solute carrier family 17 member 7" Q9P2U7 19 49429401-49442360 "Predicted membrane proteins, Transporters" "Ion transport, Neurotransmitter transport, Sodium transport, Symport, Transport" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 16 "brain: 150.0" "Cell line enhanced" "Detected in some" "HMC-1: 20.7;K-562: 6.5;REH: 3.8;SCLC-21H: 4.8" "Cancer enriched" "Detected in some" 6 "glioma: 7.5" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 5 "amygdala: 281.0;cerebellum: 378.0;cerebral cortex: 391.3;hippocampal formation: 626.6" "CAB037183, HPA050458, HPA063679" Enhanced Supported "CAB037183: AB_261840, HPA050458: , HPA063679: " "unprognostic (1.79e-1)" "unprognostic (3.35e-1)" "unprognostic (1.29e-1)" "unprognostic (1.52e-2)" "unprognostic (9.12e-2)" "unprognostic (3.03e-2)" "unprognostic (1.44e-2)" "unprognostic (2.06e-1)" "unprognostic (1.30e-1)" "unprognostic (2.70e-3)" "unprognostic (8.32e-2)" "unprognostic (6.61e-2)" "unprognostic (4.26e-12)" "unprognostic (8.36e-4)" "unprognostic (4.27e-1)" "unprognostic (1.35e-2)" "unprognostic (6.17e-3)" 2.1 1.2 58.3 1.0 27.6 1.0 1.7 52.7 150.0 1.3 1.3 1.5 0.0 1.1 1.2 1.2 1.4 1.3 1.3 1.4 74.3 1.7 1.1 1.0 1.1 1.3 6.0 36.4 1.0 1.0 1.0 0.1 1.0 20.0 1.0 1.2 9.1 1.1 1.1 1.4 1.6 1.3 1.2 0.9 1.0 1.1 1.5 0.0 0.0 1.2 0.0 1.2 1.2 0.4 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.4 1.6 0.3 0.1 0.0 0.1 0.2 0.2 0.0 0.0 0.2 0.3 0.5 0.1 1.8 0.0 0.1 0.1 0.8 0.0 0.0 0.0 0.0 0.0 20.7 0.0 0.1 0.3 0.0 0.0 6.5 0.9 0.0 0.2 0.0 0.1 0.0 0.3 3.8 0.1 0.1 0.0 0.0 4.8 0.4 0.0 0.1 0.1 0.1 0.1 0.1 0.3 2.3 0.8 0.0 0.4 0.3 0.3 0.6 2.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 58.3 27.6 52.7 76.0 74.3 1.7 6.0 36.4 20.0 0.0 SLC17A8 "DFNA25, VGLUT3" ENSG00000179520 "Solute carrier family 17 member 8" Q8NDX2 12 100357079-100422059 "Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters" "Hearing, Ion transport, Neurotransmitter transport, Sodium transport, Symport, Transport" "Deafness, Disease mutation, Non-syndromic deafness" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "brain: 10.7;intestine: 12.4;lymphoid tissue: 3.9" "Cell line enhanced" "Detected in some" "AF22: 2.5;RPTEC TERT1: 1.3" "Cancer enhanced" "Detected in single" "glioma: 0.5" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" CAB079058 Supported "CAB079058: " "unprognostic (4.52e-3)" "unprognostic (2.18e-1)" "unprognostic (8.56e-2)" "unprognostic (1.32e-3)" "unprognostic (3.65e-1)" "unprognostic (7.67e-2)" "unprognostic (1.25e-1)" "unprognostic (1.71e-2)" "unprognostic (8.89e-2)" "unprognostic (3.55e-1)" 0.1 0.3 2.0 0.1 3.7 0.1 0.1 0.0 10.7 0.1 1.1 0.0 0.0 1.8 0.4 0.2 0.1 1.0 0.1 0.1 6.9 2.2 0.3 1.2 0.2 0.1 0.8 1.0 0.2 0.2 0.1 0.4 1.0 3.6 0.1 1.0 1.7 0.1 0.1 0.1 0.1 12.4 0.1 0.5 0.1 0.2 0.4 0.1 3.9 0.1 0.0 0.1 0.6 0.0 0.2 0.0 0.2 0.2 0.0 0.1 0.0 0.0 0.0 2.5 0.0 0.4 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 1.3 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.2 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 2.0 3.7 0.0 10.7 6.9 2.2 0.8 1.0 3.6 0.1 SLC18A3 VACHT ENSG00000187714 "Solute carrier family 18 member A3" Q16572 10 49610301-49612720 "Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Transport" "Congenital myasthenic syndrome, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 11.9" "Cell line enriched" "Detected in some" 4 "SH-SY5Y: 12.4" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in many" 7 "basal ganglia: 8.8;hypothalamus: 3.4;pons and medulla: 11.9" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Group enriched" "Detected in some" 13 "basal ganglia: 17.7;pons and medulla: 20.9" CAB079011 Supported "CAB079011: " "unprognostic (2.14e-4)" "unprognostic (1.55e-1)" "unprognostic (1.01e-1)" "unprognostic (9.39e-2)" "unprognostic (4.55e-2)" "unprognostic (3.00e-1)" "unprognostic (5.85e-3)" "unprognostic (7.56e-2)" "unprognostic (1.16e-1)" 0.1 0.3 0.0 2.2 8.8 0.1 0.1 0.0 0.5 0.1 1.5 0.0 1.1 1.3 0.3 0.1 0.1 0.1 0.2 0.1 0.0 3.4 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 1.7 3.4 11.9 0.4 0.3 1.4 0.4 0.6 0.2 0.1 1.9 1.5 3.1 0.1 1.2 0.2 1.2 0.2 0.1 0.0 0.1 0.5 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 12.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 8.8 0.0 0.5 0.0 3.4 0.1 0.0 11.9 1.2 SLC1A3 "EA6, EAAT1, GLAST" ENSG00000079215 "Solute carrier family 1 member 3" P43003 5 36606355-36688334 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters" "Amino-acid transport, Symport, Transport" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 11 "brain: 188.6" "Cell line enhanced" "Detected in many" "AF22: 21.2;CACO-2: 34.1;HaCaT: 25.8" "Cancer enriched" "Detected in all" 21 "glioma: 168.1" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 12 "classical monocyte: 4.3;intermediate monocyte: 2.1;myeloid DC: 3.4" "Group enriched" "Detected in many" 39 "dendritic cells: 3.4;monocytes: 4.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002573, HPA037467, HPA037468" Enhanced Supported Approved Nucleoli,Mitochondria Mitochondria Nucleoli "CAB002573: AB_564088, HPA037467: AB_10795027, HPA037468: AB_10671371" "unprognostic (1.23e-1)" "unprognostic (2.15e-2)" "unprognostic (2.58e-3)" "unprognostic (1.74e-2)" "unprognostic (1.02e-1)" "unprognostic (7.70e-2)" "unprognostic (3.89e-3)" "unprognostic (2.36e-1)" "unprognostic (1.24e-1)" "unprognostic (2.84e-2)" "unprognostic (4.17e-3)" "unprognostic (3.28e-1)" "unprognostic (2.46e-1)" "unprognostic (1.06e-1)" "unprognostic (4.17e-2)" "unprognostic (1.03e-1)" "unprognostic (1.31e-2)" 17.3 10.3 76.1 5.9 70.6 3.1 6.3 45.8 188.6 6.9 3.2 26.3 0.0 2.1 2.8 2.3 7.2 5.4 5.9 12.0 57.9 27.3 3.1 3.6 4.7 8.6 32.7 39.6 8.6 4.0 2.6 3.7 12.7 28.5 3.3 2.6 1.9 3.0 4.4 7.6 5.5 2.3 4.1 29.4 5.8 2.9 2.7 33.6 0.0 2.6 0.7 4.5 4.8 1.2 0.0 3.4 0.0 4.3 0.0 0.0 0.8 0.4 0.1 21.2 1.8 2.1 5.9 13.5 0.0 0.0 0.8 1.8 34.1 1.7 0.0 10.3 0.3 25.8 6.2 2.8 0.9 0.3 12.7 0.0 0.1 0.0 0.4 0.4 0.1 10.9 12.8 5.2 2.1 0.0 0.0 0.1 3.6 0.0 0.0 0.0 2.5 2.1 0.0 0.1 0.0 0.0 1.3 1.8 0.0 2.1 6.2 0.3 0.0 1.0 0.0 1.9 3.1 0.0 7.5 0.0 0.0 0.0 8.6 14.3 4.8 0.0 4.3 0.0 0.0 2.1 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.8 76.1 70.6 45.8 57.8 57.9 27.3 32.7 39.6 28.5 33.6 SLC2A1 "CSE, DYT18, DYT9, GLUT, GLUT1, HTLVR" ENSG00000117394 "Solute carrier family 2 member 1" P11166 1 42925375-42959176 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Sugar transport, Transport" "Cancer-related genes, Cataract, Disease mutation, Dystonia, Epilepsy, Hereditary hemolytic anemia, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 4 "placenta: 194.0" "Cell line enhanced" "Detected in many" "BEWO: 44.2;CACO-2: 71.8;Hep G2: 49.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB002759, HPA031345, HPA058494" Enhanced Supported Enhanced "Plasma membrane" 36000000 "Plasma membrane" "CAB002759: , HPA031345: , HPA058494: " "unprognostic (3.60e-2)" "unprognostic (5.85e-3)" "unprognostic (7.59e-2)" "unprognostic (1.31e-2)" "unprognostic (4.10e-3)" "unprognostic (3.22e-2)" "prognostic unfavourable (3.65e-8)" "prognostic unfavourable (1.09e-4)" "unprognostic (1.10e-1)" "unprognostic (4.84e-2)" "prognostic unfavourable (4.39e-5)" "unprognostic (1.87e-1)" "prognostic unfavourable (4.55e-9)" "unprognostic (1.11e-1)" "unprognostic (9.49e-2)" "unprognostic (1.17e-1)" "prognostic unfavourable (4.05e-4)" 4.2 3.7 12.4 3.9 16.9 45.2 4.1 6.7 15.5 15.2 4.8 15.1 4.3 2.4 7.6 3.4 28.8 8.5 8.6 5.0 15.4 13.7 7.6 2.1 2.4 5.3 18.2 5.0 3.4 3.7 7.3 2.9 194.0 15.5 5.2 3.3 44.2 8.4 7.9 1.8 42.1 2.9 2.5 17.8 3.4 5.5 2.5 12.5 1.8 4.0 11.5 12.0 22.2 24.5 8.4 14.7 1.3 0.2 3.0 7.5 2.7 10.6 15.3 12.7 3.2 1.5 0.5 44.2 7.0 15.2 8.6 12.8 71.8 29.7 4.0 21.0 2.1 9.9 2.8 16.3 3.8 2.4 2.6 6.6 8.9 49.0 4.4 3.6 1.9 1.8 12.6 5.4 5.9 1.4 14.8 0.9 3.9 18.9 1.6 2.5 8.1 3.9 1.6 4.1 5.6 7.9 5.2 6.7 4.7 8.2 26.0 3.0 1.1 4.6 3.2 7.9 5.7 1.4 15.8 0.7 1.5 2.4 15.6 2.5 6.4 0.3 0.2 1.3 7.5 0.2 6.9 8.4 4.1 5.1 2.9 7.3 3.2 4.7 1.0 3.0 0.1 14.7 4.7 2.7 12.4 16.9 6.7 15.5 15.4 13.7 18.2 5.0 15.5 12.5 SLC30A3 ZNT3 ENSG00000115194 "Solute carrier family 30 member 3" Q99726 2 27253684-27275817 "Predicted membrane proteins, Transporters" "Ion transport, Transport, Zinc transport" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "brain: 28.7;epididymis: 41.0;testis: 19.5" "Cell line enhanced" "Detected in some" "HAP1: 8.8;Hep G2: 11.7;REH: 18.9;RH-30: 9.8" "Low cancer specificity" "Detected in some" "Group enriched" "Detected in many" 9 "amygdala: 15.8;basal ganglia: 11.4;cerebral cortex: 28.7;hippocampal formation: 10.2;olfactory region: 12.1" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "amygdala: 135.1;basal ganglia: 48.1;cerebral cortex: 108.9;hippocampal formation: 75.6" "Group enriched" "Detected in many" 7 "amygdala: 43.9;cerebral cortex: 117.8;hippocampal formation: 91.9" "HPA060505, HPA067637, CAB079044" Enhanced Approved Approved Nucleoplasm,Nucleoli,Vesicles,Cytosol Vesicles "Nucleoplasm, Nucleoli, Cytosol" "CAB079044: , HPA060505: , HPA067637: " "unprognostic (2.05e-4)" "unprognostic (1.17e-1)" "unprognostic (6.84e-4)" "unprognostic (5.26e-2)" "unprognostic (2.34e-1)" "unprognostic (1.13e-1)" "unprognostic (1.43e-2)" "unprognostic (2.93e-2)" "unprognostic (2.64e-2)" "unprognostic (3.05e-1)" "unprognostic (2.20e-1)" "unprognostic (1.89e-1)" "unprognostic (4.65e-12)" "unprognostic (3.23e-2)" "unprognostic (1.76e-1)" "unprognostic (2.74e-2)" "unprognostic (2.63e-4)" 0.5 1.9 15.8 0.5 11.4 0.5 0.4 0.4 28.7 0.5 0.5 0.0 1.9 0.4 0.5 41.0 0.4 0.7 0.4 5.0 10.2 0.8 0.4 0.5 0.5 0.8 1.1 12.1 0.5 0.4 0.6 0.4 0.4 1.6 0.6 0.5 0.7 0.4 0.9 0.4 0.4 0.5 0.5 0.7 0.5 0.4 19.5 0.0 0.0 0.4 0.0 0.4 0.5 0.4 0.0 0.0 0.0 0.6 0.0 0.1 0.0 0.3 1.1 0.0 1.5 0.0 0.2 0.1 0.0 0.0 1.0 1.0 0.3 0.4 0.0 0.0 0.0 0.2 8.8 0.0 0.2 0.0 1.0 5.0 0.2 11.7 0.2 0.1 2.0 0.0 0.0 0.5 0.0 0.7 1.4 0.0 0.1 3.8 0.0 0.3 1.4 0.0 18.9 9.8 1.0 0.0 0.0 0.0 0.6 2.3 0.0 0.0 0.0 0.7 0.0 0.2 4.7 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 15.8 11.4 0.4 28.7 10.2 0.8 1.1 12.1 1.6 0.0 SLC32A1 "bA122O1.1, VGAT, VIAAT" ENSG00000101438 "Solute carrier family 32 member 1" Q9H598 20 38724462-38729372 "Predicted membrane proteins, Transporters" "Neurotransmitter transport, Transport" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 9 "brain: 38.3" "Group enriched" "Detected in some" 14 "MOLT-4: 5.4;SH-SY5Y: 1.6" "Cancer enhanced" "Detected in single" "glioma: 1.0" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 20 "plasmacytoid DC: 1.9" "Lineage enriched" "Detected in single" 20 "dendritic cells: 1.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB037156, HPA058859, HPA059985" Enhanced Supported "CAB037156: AB_532294, HPA058859: AB_2683836, HPA059985: AB_2684187" "unprognostic (1.13e-2)" "unprognostic (2.09e-1)" "unprognostic (1.17e-1)" "unprognostic (6.57e-2)" 1.0 1.1 4.6 1.0 38.3 1.5 1.0 4.9 25.8 1.0 1.0 0.8 0.0 1.0 1.0 1.0 1.0 1.1 1.0 1.0 3.9 9.7 1.0 1.0 1.0 1.0 4.4 6.8 1.0 1.1 1.0 4.1 1.0 10.4 1.0 1.0 0.7 1.0 1.0 1.0 1.0 1.1 1.0 4.4 1.0 1.0 1.6 7.9 0.0 1.0 0.0 1.0 1.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 4.6 38.3 4.9 11.9 3.9 9.7 4.4 6.8 10.4 7.9 SLC38A1 "ATA1, NAT2, SAT1" ENSG00000111371 "Solute carrier family 38 member 1" Q9H2H9 12 46183063-46270017 "Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Amino-acid transport, Ion transport, Sodium transport, Symport, Transport" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "U-698: 76.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA039460, HPA052272" Uncertain Supported "HPA039460: , HPA052272: " "unprognostic (8.92e-3)" "unprognostic (3.23e-2)" "unprognostic (9.47e-2)" "prognostic unfavourable (4.76e-6)" "unprognostic (1.00e-1)" "unprognostic (3.74e-1)" "prognostic unfavourable (6.95e-8)" "unprognostic (2.01e-3)" "unprognostic (1.38e-1)" "unprognostic (4.19e-3)" "unprognostic (2.44e-2)" "unprognostic (3.99e-2)" "unprognostic (1.19e-2)" "unprognostic (1.17e-1)" "unprognostic (2.56e-1)" "unprognostic (3.00e-1)" "unprognostic (5.55e-2)" 5.3 3.1 9.2 18.4 14.9 11.7 44.8 28.7 24.1 7.8 23.1 15.2 26.0 8.7 13.4 5.4 14.3 10.9 9.0 23.7 11.9 16.5 11.5 5.8 7.7 30.5 12.6 13.3 9.9 21.0 51.9 22.5 45.0 24.7 16.2 20.5 7.1 14.1 29.9 62.9 15.8 16.8 14.6 22.4 15.6 17.9 1.3 8.7 26.5 22.5 16.6 27.1 14.5 8.5 21.2 15.4 8.8 0.3 22.2 26.5 14.4 14.9 15.6 5.6 21.0 2.5 0.9 28.9 12.0 19.6 5.5 8.6 26.7 14.8 34.3 23.0 14.6 23.1 18.8 24.6 10.2 21.1 10.0 2.4 25.9 9.9 22.4 24.1 0.9 4.4 37.8 1.6 66.2 12.2 12.4 28.9 17.2 18.7 21.3 4.3 20.9 24.5 19.3 1.4 23.9 21.3 21.6 22.6 15.7 24.9 30.6 14.1 17.8 17.8 25.6 4.3 4.0 0.1 12.2 27.5 23.6 76.6 13.8 47.5 3.7 0.3 0.3 8.8 19.4 0.0 26.5 17.9 20.3 22.3 12.0 21.2 23.8 21.2 0.8 22.2 0.1 15.4 21.4 14.4 9.2 14.9 28.7 21.1 11.9 16.5 12.6 13.3 24.7 8.7 SLC6A11 GAT3 ENSG00000132164 "Solute carrier family 6 member 11" P48066 3 10816200-10940733 "Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "brain: 37.0;esophagus: 10.5;skin 1: 11.5" "Cell line enhanced" "Detected in some" "A-431: 4.6;HaCaT: 12.4;Hep G2: 14.3;hTCEpi: 11.2;NTERA-2: 6.3;T-47d: 4.7" "Cancer enhanced" "Detected in many" "glioma: 7.8" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA037981 Supported Supported Uncertain Nucleoplasm,Vesicles Nucleoplasm Vesicles "HPA037981: AB_10671383" "unprognostic (6.04e-2)" "unprognostic (8.01e-2)" "unprognostic (1.21e-7)" "unprognostic (8.60e-2)" "unprognostic (8.68e-2)" "unprognostic (9.72e-3)" "unprognostic (6.39e-3)" "unprognostic (9.77e-2)" "unprognostic (2.35e-1)" "unprognostic (3.92e-2)" "unprognostic (8.78e-2)" "unprognostic (1.51e-3)" "unprognostic (6.06e-2)" "unprognostic (4.44e-2)" "unprognostic (9.83e-2)" "unprognostic (2.31e-2)" 0.8 0.8 11.5 0.7 14.1 0.8 2.9 3.1 23.0 0.9 0.8 5.0 0.0 0.7 1.7 1.1 10.5 1.8 0.7 0.8 8.4 24.5 0.7 0.9 0.8 0.7 37.0 5.9 0.8 1.0 0.7 0.2 1.6 35.4 2.3 0.8 0.4 1.1 0.7 1.0 11.5 0.8 1.0 10.4 1.5 0.7 3.4 9.2 0.0 0.8 0.2 1.1 1.3 0.7 0.5 0.3 1.2 0.4 0.2 0.3 0.0 4.6 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.4 0.0 2.0 0.0 0.0 0.2 0.2 0.0 14.3 0.0 0.0 0.0 0.0 11.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.3 0.0 0.0 0.0 0.0 0.0 2.8 1.8 4.3 3.6 0.1 0.0 4.7 0.1 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.5 0.3 0.2 0.1 0.2 0.1 0.2 0.2 0.1 0.0 0.5 0.2 0.2 1.2 0.2 0.4 0.3 0.3 0.0 11.5 14.1 3.1 14.7 8.4 24.5 37.0 5.9 35.4 9.2 SLC6A2 "NAT1, NET, NET1, SLC6A5" ENSG00000103546 "Solute carrier family 6 member 2" P23975 16 55655604-55706192 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 20.4;placenta: 41.8" "Cell line enriched" "Detected in some" 30 "SH-SY5Y: 104.5" "Cancer enhanced" "Detected in some" "liver cancer: 1.9" "Region enriched" "Detected in single" 27 "pons and medulla: 9.7" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in some" 4 "pons and medulla: 8.2" "Region enriched" "Detected in single" 32 "pons and medulla: 23.1" "HPA004057, HPA076311, CAB078195" Enhanced Supported Approved Mitochondria,Cytosol Cytosol Mitochondria "CAB078195: , HPA004057: AB_1080012, HPA076311: " "unprognostic (9.58e-3)" "unprognostic (5.48e-2)" "unprognostic (1.26e-4)" "unprognostic (4.07e-1)" "unprognostic (4.16e-1)" "unprognostic (8.38e-2)" "unprognostic (2.97e-2)" "unprognostic (3.29e-1)" "unprognostic (2.31e-1)" "unprognostic (3.27e-1)" "unprognostic (2.12e-2)" "unprognostic (2.95e-2)" "unprognostic (1.72e-1)" "unprognostic (6.02e-2)" "unprognostic (8.48e-2)" "unprognostic (1.43e-2)" 2.4 20.4 0.3 0.1 0.1 0.0 1.8 0.1 0.3 3.2 0.3 0.3 0.1 0.0 4.5 7.2 0.8 0.4 0.4 0.1 0.1 0.0 0.4 1.0 0.5 0.1 0.1 0.1 0.2 0.1 0.0 0.1 41.8 9.7 0.5 0.1 0.1 1.6 1.7 0.1 11.4 0.4 1.0 0.2 0.1 0.2 8.3 0.2 0.1 0.2 0.9 0.5 0.5 1.7 0.0 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 1.0 0.8 104.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.1 0.3 0.1 0.0 0.1 0.1 9.7 0.2 SLC6A3 "DAT, DAT1" ENSG00000142319 "Solute carrier family 6 member 3" Q01959 5 1392790-1445430 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "Disease mutation, Dystonia, FDA approved drug targets, Neurodegeneration, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 14 "brain: 48.4" "Group enriched" "Detected in some" 5 "NTERA-2: 1.2;RPMI-8226: 2.0;SCLC-21H: 3.7" "Cancer enriched" "Detected in some" 18 "renal cancer: 25.7" "Region enriched" "Detected in some" 47 "midbrain: 48.4" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 8 "midbrain: 96.4;thalamus: 31.8" "Region enriched" "Detected in single" 139 "midbrain: 362.2" "HPA012763, HPA013602, CAB016249, CAB078172" Enhanced Supported Approved Vesicles Vesicles "CAB016249: AB_627402, CAB078172: , HPA012763: , HPA013602: AB_1847484" "unprognostic (2.25e-4)" "unprognostic (2.22e-1)" "unprognostic (8.45e-2)" "unprognostic (5.24e-2)" "unprognostic (7.75e-2)" "unprognostic (1.41e-2)" "unprognostic (4.64e-5)" "unprognostic (9.31e-2)" "unprognostic (7.89e-2)" "unprognostic (4.81e-2)" "unprognostic (1.30e-1)" "unprognostic (2.12e-2)" "prognostic unfavourable (3.40e-7)" "unprognostic (6.98e-2)" "unprognostic (1.64e-1)" "unprognostic (2.22e-2)" "unprognostic (4.74e-2)" 0.2 0.1 0.0 0.0 0.7 0.0 0.1 0.0 0.3 0.7 0.0 0.0 0.0 0.3 1.1 0.8 0.1 0.8 0.6 0.1 0.0 0.6 0.3 0.0 3.4 0.0 48.4 0.0 1.5 0.0 0.0 0.0 0.1 1.0 0.7 0.0 1.7 0.0 0.1 0.0 0.0 0.0 1.3 0.0 0.1 0.0 0.8 0.0 2.4 2.2 0.0 0.3 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 1.2 0.0 0.0 0.0 2.0 0.0 0.1 3.7 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.3 0.0 0.6 48.4 0.0 1.0 0.0 SLC6A4 "5-HTT, HTT, OCD1, SERT1" ENSG00000108576 "Solute carrier family 6 member 4" P31645 17 30194319-30236002 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "intestine: 25.0;lung: 50.5" "Cell line enhanced" "Detected in some" "BEWO: 2.8;CACO-2: 5.4;Hep G2: 14.4" "Cancer enhanced" "Detected in some" "breast cancer: 2.3" "Region enriched" "Detected in single" 36 "pons and medulla: 11.2" "Cell type enhanced" "Detected in single" "neutrophil: 1.0" "Low lineage specificity" "Detected in single" "Region enriched" "Detected in some" 5 "midbrain: 69.9" "Low region specificity" "Detected in all" "HPA054723, HPA071354, HPA074728" Supported Supported Supported "Golgi apparatus,Vesicles" "Golgi apparatus, Vesicles" "HPA054723: , HPA071354: , HPA074728: " "unprognostic (7.45e-2)" "unprognostic (7.13e-2)" "unprognostic (2.26e-1)" "unprognostic (3.72e-4)" "unprognostic (2.07e-1)" "unprognostic (8.42e-3)" "unprognostic (2.73e-2)" "unprognostic (3.39e-2)" "unprognostic (3.37e-3)" "unprognostic (1.17e-3)" "unprognostic (2.70e-3)" "unprognostic (1.16e-1)" "unprognostic (8.78e-2)" "unprognostic (4.98e-2)" "unprognostic (1.76e-1)" "unprognostic (4.05e-2)" "unprognostic (7.18e-2)" 0.2 0.1 0.1 0.1 0.1 0.0 0.2 0.2 0.3 0.2 0.2 0.1 0.1 6.3 0.1 0.3 1.6 0.9 0.1 0.7 0.1 0.1 0.3 0.1 50.5 0.1 0.1 0.1 0.1 0.6 0.0 0.1 11.3 11.2 0.1 0.0 0.2 0.7 0.1 0.1 0.4 25.0 0.4 0.1 0.1 0.5 0.3 0.1 0.1 0.2 0.1 0.3 0.1 0.3 0.0 0.1 1.0 0.2 0.4 0.3 2.3 0.0 0.0 0.0 0.1 0.0 0.0 2.8 0.0 0.0 0.0 0.0 5.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 14.4 1.4 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.2 0.0 0.0 0.1 0.0 0.1 0.0 0.4 0.1 0.1 0.0 1.0 0.0 0.8 0.0 0.0 0.1 0.2 0.2 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.3 0.1 0.1 0.3 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.2 0.1 1.0 0.4 0.2 0.1 0.0 2.3 0.1 0.1 0.2 0.3 0.1 0.1 0.1 0.1 11.2 0.1 SLC6A5 "GLYT2, NET1" ENSG00000165970 "Solute carrier family 6 member 5" Q9Y345 11 20599400-20659285 "Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "brain: 21.3" "Cell line enriched" "Detected in single" 5 "SCLC-21H: 2.5" "Not detected" "Not detected" "Region enriched" "Detected in some" 6 "pons and medulla: 21.3" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in some" 9 "pons and medulla: 51.6" "Region enriched" "Detected in some" 9 "pons and medulla: 33.2" CAB079052 Supported "CAB079052: " "unprognostic (6.94e-2)" "unprognostic (2.28e-1)" "unprognostic (4.75e-2)" 0.0 0.1 0.1 0.1 0.0 0.0 0.0 3.3 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.1 0.0 0.0 5.1 0.1 0.1 0.0 0.0 0.0 0.0 2.2 0.0 21.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 6.0 0.0 0.0 1.8 0.0 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 3.3 0.4 0.3 0.1 0.1 0.0 21.3 0.0 SNAP25 "bA416N4.2, dJ1068F16.2, RIC-4, RIC4, SEC9, SNAP, SNAP-25" ENSG00000132639 "Synaptosome associated protein 25" P60880 20 10218830-10307418 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters" "Congenital myasthenic syndrome, Disease mutation, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 22 "brain: 356.9" "Group enriched" "Detected in some" 4 "Karpas-707: 10.8;SCLC-21H: 35.7;SH-SY5Y: 21.3;U-87 MG: 25.7" "Group enriched" "Detected in many" 6 "glioma: 28.9;pancreatic cancer: 6.4" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "plasmacytoid DC: 1.6" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000360, HPA001830, HPA071013" Enhanced Supported Approved "Vesicles,Plasma membrane,Cytosol" "Plasma membrane, Cytosol" Vesicles "CAB000360: AB_2286342, HPA001830: AB_1080039, HPA071013: " "unprognostic (1.64e-3)" "unprognostic (7.26e-3)" "unprognostic (4.36e-2)" "unprognostic (2.49e-7)" "unprognostic (6.86e-3)" "unprognostic (5.87e-3)" "unprognostic (1.15e-2)" "unprognostic (9.94e-2)" "unprognostic (3.13e-1)" "unprognostic (5.82e-3)" "unprognostic (4.80e-3)" "unprognostic (8.06e-2)" "unprognostic (1.09e-1)" "unprognostic (6.18e-3)" "unprognostic (2.48e-1)" "unprognostic (6.28e-3)" "unprognostic (1.02e-2)" 2.2 16.4 81.0 3.3 60.0 2.1 3.4 202.9 356.9 2.2 2.8 3.4 3.7 3.2 4.6 6.4 2.2 4.0 2.8 2.4 86.5 37.1 2.5 2.3 2.6 2.2 46.7 65.2 3.7 4.1 2.1 5.5 2.3 97.7 3.1 2.8 4.0 2.2 11.9 2.1 2.2 3.3 4.7 13.9 2.1 4.3 3.2 7.4 0.0 2.3 0.0 2.2 2.6 0.1 0.0 1.6 0.7 0.0 0.0 0.6 0.3 0.0 2.1 1.7 0.0 0.2 0.0 0.0 0.9 0.0 2.2 0.6 0.0 0.0 0.0 1.9 0.0 0.4 0.2 0.0 4.4 0.2 0.1 0.0 2.9 0.3 1.6 0.0 0.2 2.0 0.0 1.8 0.0 0.0 0.0 10.8 0.7 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.4 0.0 35.7 21.3 0.3 0.0 0.0 0.0 2.9 0.0 2.3 3.1 0.0 1.0 0.0 5.5 0.0 25.7 0.0 2.1 0.0 0.0 0.7 0.1 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 1.6 0.6 0.3 81.0 60.0 202.9 163.5 86.5 37.1 46.7 65.2 97.7 7.4 SNCB ENSG00000074317 "Synuclein beta" Q16143 5 176620084-176630556 "Predicted intracellular proteins, Transporters" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 24 "brain: 134.8" "Cell line enriched" "Detected in some" 10 "SCLC-21H: 36.1" "Cancer enriched" "Detected in some" 8 "glioma: 11.1" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 5 "naive B-cell: 3.1" "Lineage enriched" "Detected in single" 12 "B-cells: 3.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002681, HPA035876" Enhanced Supported "CAB002681: , HPA035876: AB_10670592" "unprognostic (3.55e-2)" "unprognostic (1.05e-1)" "unprognostic (4.79e-2)" "unprognostic (1.46e-2)" "unprognostic (3.41e-3)" "unprognostic (2.95e-2)" "unprognostic (6.07e-2)" "unprognostic (3.41e-1)" "unprognostic (2.39e-1)" "unprognostic (2.29e-3)" "unprognostic (3.31e-1)" "unprognostic (5.41e-5)" "unprognostic (1.31e-3)" "unprognostic (8.57e-2)" "unprognostic (2.81e-1)" "unprognostic (8.42e-3)" 1.6 3.9 53.7 1.6 24.9 1.5 1.6 64.1 134.8 1.5 1.7 2.2 0.0 1.6 1.6 1.5 1.5 1.6 1.6 1.8 39.4 31.0 1.6 1.5 1.5 1.7 27.5 30.0 1.5 2.1 1.5 1.9 1.6 31.5 1.6 1.6 5.6 1.5 1.5 2.7 1.6 1.6 1.6 7.4 1.6 1.6 1.7 1.5 0.0 1.5 0.0 1.6 1.6 0.0 3.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.1 0.5 0.0 0.1 1.6 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.2 1.1 0.6 0.0 0.0 2.7 1.6 0.0 0.0 0.1 0.0 0.0 36.1 1.3 0.0 0.1 3.4 1.6 0.1 0.0 0.0 1.4 0.0 0.0 0.5 0.0 0.0 0.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 3.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 53.7 24.9 64.1 87.6 39.4 31.0 27.5 30.0 31.5 1.5 SNCG "BCSG1, persyn, SR" ENSG00000173267 "Synuclein gamma" O76070 10 86958618-86963260 "Predicted intracellular proteins, Transporters" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adipose tissue: 74.1;adrenal gland: 78.3;brain: 100.1;urinary bladder: 76.6" "Group enriched" "Detected in some" 4 "CAPAN-2: 93.7;RT4: 77.2" "Group enriched" "Detected in all" 8 "ovarian cancer: 84.1;urothelial cancer: 301.2" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "classical monocyte: 2.4;naive CD4 T-cell: 1.8" "Low lineage specificity" "Detected in many" "Region enhanced" "Detected in many" "pons and medulla: 292.8" "Low region specificity" "Detected in many" "CAB001452, HPA014404, CAB040581" Enhanced Supported Supported "Nuclear bodies,Centrosome" Centrosome "Nuclear bodies" "CAB001452: AB_564020, CAB040581: , HPA014404: AB_1857715" "unprognostic (2.06e-1)" "unprognostic (2.58e-1)" "unprognostic (6.87e-3)" "unprognostic (1.45e-2)" "unprognostic (1.10e-1)" "unprognostic (1.91e-1)" "unprognostic (4.76e-3)" "unprognostic (8.99e-2)" "unprognostic (1.27e-1)" "unprognostic (1.44e-1)" "unprognostic (3.85e-3)" "unprognostic (3.75e-1)" "prognostic unfavourable (2.29e-8)" "prognostic unfavourable (7.15e-4)" "unprognostic (2.35e-1)" "unprognostic (2.36e-2)" "unprognostic (3.77e-3)" 74.1 78.3 82.3 5.3 20.8 1.0 28.9 12.3 44.5 9.5 5.8 4.6 6.4 4.8 6.1 12.0 11.0 26.5 6.2 9.0 40.0 92.9 4.1 1.9 4.6 4.9 72.9 35.1 15.0 3.5 1.6 1.7 4.9 100.1 11.9 2.7 10.8 10.9 44.4 6.6 8.5 5.4 5.8 35.2 20.2 2.6 2.9 5.3 0.2 3.4 3.3 9.6 76.6 18.3 0.0 0.7 0.0 2.4 0.0 1.8 0.6 0.2 1.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.1 93.7 0.0 1.9 0.1 7.8 0.0 0.3 0.0 0.0 0.0 0.5 18.2 0.3 0.1 0.0 0.1 0.4 7.3 0.0 0.0 6.6 0.6 0.0 0.0 0.1 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 77.2 0.0 0.0 0.6 1.0 0.1 20.3 0.0 17.0 0.2 0.5 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.1 0.0 2.4 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.7 0.0 1.8 0.0 0.0 0.0 0.9 0.0 0.0 0.6 82.3 20.8 12.3 44.5 40.0 92.9 72.9 35.1 100.1 5.3 SOX2 ENSG00000181449 "SRY-box 2" P48431 3 181711924-181714436 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation, Microphthalmia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "brain: 80.1" "Cell line enhanced" "Detected in some" "AF22: 67.5;HAP1: 28.7;NTERA-2: 55.0;U-251 MG: 12.6" "Cancer enhanced" "Detected in many" "glioma: 136.5" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA045725, HPA062851, HPA071379, CAB079745" Enhanced Supported Enhanced Nucleoplasm Nucleoplasm "CAB079745: , HPA045725: , HPA062851: , HPA071379: " "unprognostic (1.80e-2)" "unprognostic (3.18e-3)" "unprognostic (5.69e-2)" "unprognostic (6.96e-2)" "unprognostic (2.74e-3)" "unprognostic (1.60e-1)" "unprognostic (1.79e-2)" "unprognostic (4.48e-3)" "unprognostic (1.71e-1)" "unprognostic (4.38e-3)" "unprognostic (1.83e-1)" "unprognostic (7.68e-2)" "unprognostic (3.81e-9)" "unprognostic (1.12e-1)" "unprognostic (2.12e-1)" "unprognostic (1.26e-1)" "unprognostic (1.12e-2)" 1.8 2.5 30.3 2.0 25.8 1.5 1.6 13.9 80.1 1.8 2.3 24.3 0.0 2.0 1.5 1.8 15.9 5.0 1.8 1.7 36.0 19.2 1.5 1.5 3.4 1.5 19.4 18.5 1.7 1.6 1.5 5.8 1.5 18.6 3.9 2.0 1.0 6.3 1.9 1.6 1.8 2.3 1.7 18.4 1.6 9.7 3.0 22.4 0.0 1.5 2.1 6.9 2.3 1.7 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 2.1 67.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.1 28.7 0.7 0.0 0.0 4.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 55.0 0.1 0.0 0.1 0.0 7.4 0.1 0.1 0.3 0.0 0.0 0.0 0.4 0.0 0.0 0.0 1.0 0.0 12.6 0.0 0.0 0.0 0.0 0.0 8.5 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 30.3 25.8 13.9 20.0 36.0 19.2 19.4 18.5 18.6 22.4 SP3 SPR-2 ENSG00000172845 "Sp3 transcription factor" Q02447 2 173906459-173965702 "Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004580, HPA032145, HPA032146" Supported Supported "CAB004580: AB_628274, HPA032145: , HPA032146: " "unprognostic (1.94e-1)" "unprognostic (1.18e-1)" "unprognostic (1.85e-1)" "unprognostic (2.39e-3)" "unprognostic (2.50e-1)" "unprognostic (4.92e-2)" "unprognostic (5.54e-3)" "unprognostic (6.36e-2)" "unprognostic (2.76e-3)" "unprognostic (3.27e-1)" "unprognostic (5.01e-3)" "unprognostic (1.68e-1)" "prognostic unfavourable (2.46e-5)" "unprognostic (2.78e-1)" "unprognostic (2.07e-1)" "unprognostic (8.02e-2)" "unprognostic (1.69e-1)" 29.0 12.3 13.6 29.5 14.7 46.2 27.6 26.0 13.8 29.3 23.3 10.9 19.9 12.5 25.1 23.9 19.9 20.8 16.5 15.6 12.8 11.7 19.5 19.2 20.8 41.4 16.0 12.7 23.1 15.0 26.3 21.0 31.9 13.3 23.5 20.4 14.1 20.5 24.2 20.4 21.3 23.0 20.1 15.0 28.8 14.9 14.2 16.2 73.4 30.7 18.1 27.3 24.0 25.7 9.6 10.2 29.5 9.8 20.0 14.0 9.2 17.5 17.5 34.2 19.4 40.9 38.4 35.9 21.2 32.4 30.3 32.3 27.6 25.8 27.9 17.5 30.5 17.6 27.5 21.6 43.1 24.2 9.7 29.3 16.8 22.1 20.1 26.7 21.7 28.3 22.7 35.1 29.8 22.4 21.9 37.4 27.8 20.3 37.0 18.5 27.1 17.7 31.7 30.9 21.3 20.5 27.0 30.4 21.0 29.7 15.7 21.0 12.6 30.1 20.0 30.5 26.9 19.9 20.4 26.1 19.5 38.4 23.2 17.0 28.7 9.6 9.8 13.6 12.5 6.6 13.0 9.6 12.5 12.5 10.2 8.4 14.0 12.0 29.5 20.0 9.0 5.0 12.5 9.2 13.6 14.7 26.0 13.8 12.8 11.7 16.0 12.7 13.3 16.2 SST SMST ENSG00000157005 Somatostatin P61278 3 187668906-187670399 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" Hormone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "brain: 102.8;intestine: 105.2;pancreas: 105.6;stomach 1: 90.4" "Cell line enhanced" "Detected in some" "EFO-21: 15.2;U-2 OS: 28.3;U-251 MG: 4.7;U-698: 5.9" "Group enriched" "Detected in many" 7 "ovarian cancer: 249.9;pancreatic cancer: 1039.3" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000075, HPA019472, CAB034105" Enhanced Supported "Secreted to blood" "CAB000075: AB_2688022, CAB034105: AB_2271061, HPA019472: AB_1857360" "unprognostic (2.44e-1)" "unprognostic (2.05e-1)" "prognostic unfavourable (1.93e-5)" "unprognostic (5.12e-3)" "unprognostic (1.54e-2)" "unprognostic (4.69e-1)" "unprognostic (3.31e-2)" "unprognostic (8.16e-3)" "unprognostic (1.63e-1)" "unprognostic (1.07e-3)" "unprognostic (8.47e-2)" "unprognostic (4.19e-1)" "unprognostic (3.27e-1)" "unprognostic (1.45e-1)" 2.0 13.0 28.6 1.9 53.8 1.7 0.7 0.1 47.9 0.7 45.1 1.8 21.9 105.2 0.9 0.7 1.1 0.7 1.0 0.9 17.5 102.8 2.5 0.7 0.7 1.0 6.2 15.4 0.8 105.6 0.7 1.5 0.7 16.1 1.5 7.4 0.4 0.7 7.5 0.7 3.1 36.1 1.4 18.4 0.7 90.4 0.7 8.6 0.0 0.9 0.0 0.7 4.6 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.2 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 28.3 0.3 4.7 0.0 1.6 5.9 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 28.6 53.8 0.1 47.9 17.5 102.8 6.2 15.4 16.1 8.6 STX1B "STX1B1, STX1B2" ENSG00000099365 "Syntaxin 1B" P61266 16 30989256-31010661 "Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Neurotransmitter transport, Transport" "Disease mutation, Epilepsy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 15 "brain: 64.9" "Cell line enhanced" "Detected in many" "BJ hTERT+ SV40 Large T+ RasG12V: 9.7;hTEC/SVTERT24-B: 11.8" "Cancer enriched" "Detected in some" 7 "glioma: 5.1" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA069176, CAB079008" Supported Approved "CAB079008: , HPA069176: " "unprognostic (1.43e-3)" "unprognostic (5.27e-2)" "unprognostic (2.40e-4)" "unprognostic (3.90e-3)" "unprognostic (3.98e-2)" "unprognostic (1.90e-2)" "unprognostic (2.21e-3)" "unprognostic (2.53e-2)" "unprognostic (1.72e-1)" "unprognostic (3.72e-3)" "unprognostic (1.73e-2)" "unprognostic (2.36e-1)" "unprognostic (1.02e-3)" "unprognostic (1.07e-1)" "unprognostic (1.58e-1)" "unprognostic (7.93e-2)" "unprognostic (1.57e-2)" 1.6 1.9 12.7 1.9 31.8 1.3 1.8 45.8 64.9 1.2 1.4 2.9 0.0 1.4 2.7 4.2 1.9 1.4 1.3 2.1 10.5 10.0 1.4 2.5 1.2 2.4 6.8 26.2 1.3 1.3 1.3 2.2 1.2 39.3 1.8 1.4 1.0 1.9 2.8 1.3 4.0 1.8 2.5 3.8 2.2 1.3 3.2 4.5 0.0 1.3 0.0 2.3 1.3 0.7 0.6 0.3 1.3 0.4 0.5 1.7 0.1 0.1 3.2 5.0 0.8 0.5 0.2 0.2 4.4 6.7 5.5 9.7 0.0 3.6 0.8 0.2 5.8 0.8 2.2 0.6 6.6 2.6 0.4 0.4 2.6 2.5 0.4 0.2 3.1 1.8 0.2 11.8 1.1 0.0 0.5 0.2 5.8 1.3 2.0 0.2 2.5 0.3 7.2 0.2 0.2 0.5 0.0 6.8 4.3 0.5 0.2 0.0 0.8 0.1 0.9 3.2 2.6 0.4 0.2 0.3 0.2 0.3 3.5 0.3 0.1 0.9 0.4 0.7 0.3 0.2 0.1 0.5 1.7 0.3 0.1 0.6 0.3 0.4 1.3 0.5 0.1 0.3 0.2 0.1 12.7 31.8 45.8 60.5 10.5 10.0 6.8 26.2 39.3 4.5 STX2 "EPIM, EPM, STX2A, STX2B, STX2C" ENSG00000111450 "Syntaxin 2" P32856 12 130789600-130839266 "Cancer-related genes, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA038189, HPA069176, CAB079007" Uncertain Supported Approved Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB079007: , HPA038189: , HPA069176: " "unprognostic (1.56e-2)" "unprognostic (3.43e-2)" "unprognostic (8.29e-2)" "unprognostic (2.22e-1)" "unprognostic (3.38e-2)" "unprognostic (9.85e-2)" "unprognostic (2.11e-2)" "unprognostic (4.16e-2)" "unprognostic (2.83e-1)" "unprognostic (7.62e-2)" "unprognostic (1.30e-2)" "unprognostic (5.69e-2)" "prognostic unfavourable (5.15e-5)" "unprognostic (3.81e-2)" "unprognostic (2.19e-1)" "unprognostic (1.63e-2)" "unprognostic (3.41e-3)" 15.9 14.5 16.0 15.4 13.4 8.8 27.0 12.5 18.7 13.1 18.8 15.3 8.8 6.1 18.1 15.4 9.6 19.4 14.5 16.4 15.5 11.4 12.2 12.0 18.3 11.9 12.7 12.4 16.0 10.7 11.9 16.3 18.0 17.9 10.2 10.2 9.8 5.2 15.7 6.3 6.1 10.7 23.5 24.8 12.3 11.7 23.2 12.3 9.7 12.6 6.9 9.4 13.5 22.2 2.6 1.6 4.6 2.4 1.4 3.1 0.9 4.7 9.5 13.8 10.7 12.8 29.1 1.4 20.1 16.2 24.9 16.5 2.6 3.3 6.1 3.2 22.0 1.3 12.6 3.3 25.9 9.2 4.3 3.2 8.3 7.4 13.8 4.7 8.0 10.8 4.1 12.1 9.7 12.2 12.7 5.7 21.2 2.8 6.6 4.8 9.2 13.1 7.0 9.0 3.2 13.7 1.0 13.2 12.9 10.2 0.9 8.5 3.2 3.0 16.4 14.3 10.1 15.7 8.8 4.2 3.3 4.0 16.5 5.2 11.2 4.6 2.2 2.8 2.4 2.4 2.4 2.6 2.7 2.7 1.5 1.7 2.9 3.1 3.0 1.4 1.2 1.6 1.9 0.9 16.0 13.4 12.5 18.7 15.5 11.4 12.7 12.4 17.9 12.3 STXBP5 "LLGL3, tomosyn" ENSG00000164506 "Syntaxin binding protein 5" Q5T5C0 6 147204425-147390476 "Predicted intracellular proteins" "Exocytosis, Protein transport, Transport" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "parathyroid gland: 82.7" "Cell line enhanced" "Detected in many" "HEL: 55.4;HMC-1: 60.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "eosinophil: 11.2" "Lineage enriched" "Detected in many" 6 "granulocytes: 11.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA039991, HPA049727, CAB079016" Enhanced Supported Enhanced Cytosol 11000 Cytosol "CAB079016: , HPA039991: AB_10673368, HPA049727: " "prognostic unfavourable (4.48e-4)" "unprognostic (4.60e-3)" "unprognostic (2.28e-3)" "unprognostic (1.14e-1)" "unprognostic (2.21e-1)" "unprognostic (1.52e-1)" "unprognostic (9.56e-4)" "unprognostic (6.01e-2)" "unprognostic (3.60e-1)" "unprognostic (2.74e-2)" "unprognostic (1.70e-2)" "unprognostic (6.37e-3)" "prognostic unfavourable (2.74e-7)" "unprognostic (8.01e-2)" "unprognostic (1.74e-1)" "unprognostic (2.55e-1)" "unprognostic (1.35e-3)" 4.4 9.1 4.3 6.6 5.9 14.0 9.0 7.8 9.0 6.7 17.6 2.0 22.1 3.9 4.6 6.5 10.2 3.8 9.2 3.5 3.6 4.3 2.0 2.4 3.8 3.5 3.3 4.7 3.0 10.9 82.7 15.5 3.1 4.3 5.7 7.8 6.5 5.7 21.0 7.0 10.9 35.1 5.3 2.7 4.7 4.0 9.6 2.3 2.2 4.2 5.6 4.6 5.3 9.1 0.9 0.5 11.2 0.6 0.5 1.7 0.3 2.8 2.5 1.3 4.5 6.5 13.8 1.5 6.5 9.8 4.9 5.5 2.1 1.9 2.0 1.5 13.0 3.4 3.8 5.8 6.0 4.4 3.0 55.4 7.3 2.3 7.5 18.9 60.6 10.0 4.1 9.7 20.0 6.2 14.9 2.6 9.6 4.1 3.0 4.9 1.0 5.8 0.4 6.9 0.7 2.6 4.9 2.9 2.1 5.1 3.6 2.2 1.0 7.4 7.2 7.0 2.5 3.4 5.9 2.1 0.0 2.4 3.9 6.9 5.0 4.7 0.3 11.2 1.2 0.5 1.3 0.5 0.7 1.4 0.5 0.9 1.2 1.7 4.0 0.5 0.6 0.4 0.3 0.3 4.3 5.9 7.8 9.0 3.6 4.3 3.3 4.7 4.3 2.3 SUCLA2 ENSG00000136143 "Succinate-CoA ligase ADP-forming beta subunit" Q9P2R7 13 47745736-48037968 "Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Tricarboxylic acid cycle" Ligase "Disease mutation, Primary mitochondrial disease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 89.0" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA039435, HPA039536, HPA061528" Enhanced Supported Enhanced Mitochondria 6600 Mitochondria "HPA039435: AB_10673144, HPA039536: AB_2676561, HPA061528: AB_2684553" "unprognostic (5.66e-3)" "unprognostic (1.72e-2)" "unprognostic (1.14e-1)" "unprognostic (8.76e-2)" "unprognostic (1.60e-1)" "unprognostic (3.45e-2)" "unprognostic (2.48e-1)" "unprognostic (1.71e-1)" "unprognostic (4.70e-2)" "unprognostic (1.41e-2)" "unprognostic (1.10e-1)" "unprognostic (1.38e-1)" "prognostic favourable (7.59e-14)" "unprognostic (3.53e-1)" "unprognostic (2.19e-1)" "unprognostic (2.29e-1)" "prognostic unfavourable (1.22e-4)" 21.6 18.5 19.2 8.6 22.1 5.2 17.5 29.7 32.4 15.3 15.7 11.7 15.6 24.5 12.7 12.1 14.6 11.3 9.4 42.1 20.0 21.6 34.0 12.9 7.9 11.4 22.6 19.1 14.4 10.8 19.8 14.9 12.2 28.7 16.2 16.5 8.9 13.9 14.8 89.0 10.0 22.7 14.7 18.3 9.7 12.3 8.0 15.4 15.6 16.9 25.6 10.2 11.0 12.6 17.1 29.5 12.4 25.0 23.4 25.2 17.2 17.2 20.0 25.4 15.2 29.1 22.0 15.3 26.4 29.6 27.5 18.7 35.5 19.6 24.2 20.2 25.8 24.0 33.5 25.1 34.9 23.1 28.7 27.2 19.0 23.0 20.3 27.5 15.9 20.7 29.6 18.7 22.1 20.2 18.3 8.8 27.3 11.9 28.3 31.5 26.3 25.6 24.1 23.2 18.7 39.7 16.7 14.1 16.8 22.0 20.4 15.5 18.1 24.4 15.4 15.3 9.9 21.7 18.3 9.1 14.2 28.2 9.5 20.1 22.4 5.7 24.5 12.4 17.6 25.0 21.2 17.1 19.7 21.6 29.5 16.3 25.2 24.9 4.5 23.4 20.0 24.3 21.6 17.2 19.2 22.1 29.7 32.4 20.0 21.6 22.6 19.1 28.7 15.4 SYN2 "SYNII, SYNIIa, SYNIIb" ENSG00000157152 "Synapsin II" 3 12004402-12191400 "Predicted intracellular proteins" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in many" 20 "brain: 72.5" "Cell line enhanced" "Detected in some" "HAP1: 3.4;HEK 293: 3.3;HMC-1: 6.1;NTERA-2: 5.1;SCLC-21H: 4.1;SH-SY5Y: 16.2" "Cancer enhanced" "Detected in many" "glioma: 4.5" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA037012, CAB079005" Supported Approved Nucleoplasm Nucleoplasm "CAB079005: , HPA037012: " "unprognostic (1.62e-3)" "unprognostic (1.60e-2)" "unprognostic (7.54e-2)" "unprognostic (9.87e-3)" "unprognostic (1.73e-1)" "unprognostic (3.19e-1)" "unprognostic (6.32e-3)" "unprognostic (1.08e-1)" "unprognostic (1.03e-1)" "unprognostic (1.32e-1)" "unprognostic (3.68e-2)" "unprognostic (1.24e-1)" "unprognostic (9.77e-2)" "unprognostic (4.89e-4)" "unprognostic (9.94e-2)" "unprognostic (7.35e-2)" "unprognostic (1.78e-2)" 3.7 2.7 28.2 0.7 23.3 0.5 1.4 9.2 72.5 1.0 0.8 0.2 0.0 0.8 1.2 1.2 0.5 0.8 0.7 0.7 15.4 1.4 0.4 0.8 0.5 0.0 33.4 1.5 0.5 1.8 0.0 2.3 15.3 0.7 0.9 0.0 0.9 0.6 0.9 0.9 1.2 1.9 2.2 0.8 1.2 2.4 1.6 0.0 0.5 0.0 0.5 0.5 0.0 0.0 0.0 0.8 0.5 0.0 0.0 0.0 0.0 0.3 0.0 0.0 2.3 0.7 1.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 3.4 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 6.1 0.1 0.0 0.1 0.4 0.5 0.0 0.3 0.0 0.0 0.0 0.0 5.1 0.4 0.0 0.0 0.0 0.0 0.2 4.1 16.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.4 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 SYNJ2BP Arip2 ENSG00000213463 "Synaptojanin 2 binding protein" P57105 14 70366496-70417061 "Predicted membrane proteins, Transporters" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA000866 Approved Supported Approved Mitochondria Mitochondria "HPA000866: AB_2276678" "unprognostic (2.68e-1)" "unprognostic (1.76e-1)" "unprognostic (2.67e-1)" "unprognostic (3.31e-1)" "unprognostic (1.28e-1)" "unprognostic (1.04e-1)" "unprognostic (1.65e-1)" "unprognostic (1.60e-2)" "unprognostic (5.70e-2)" "unprognostic (6.14e-2)" "unprognostic (6.35e-3)" "unprognostic (1.44e-2)" "prognostic favourable (1.11e-16)" "unprognostic (2.81e-1)" "unprognostic (1.38e-1)" "unprognostic (5.35e-3)" "unprognostic (1.14e-2)" 12.0 13.8 10.8 8.2 13.0 1.7 11.2 15.8 13.7 11.8 20.1 14.1 14.1 21.0 12.5 10.4 16.3 9.5 11.7 15.7 10.5 8.9 32.0 25.9 10.4 6.8 11.0 6.4 10.3 11.0 28.9 22.2 12.0 13.4 15.3 16.7 11.6 13.2 15.0 27.4 6.7 32.2 15.2 12.4 11.3 16.8 16.9 9.9 7.0 16.9 14.4 7.9 15.4 9.1 4.6 5.1 0.6 5.3 3.8 7.4 1.9 9.6 6.2 10.9 7.3 8.4 9.8 7.6 7.4 7.7 5.3 6.0 6.0 9.1 0.0 7.1 8.5 8.3 10.9 8.1 12.6 1.3 5.5 3.5 9.5 7.8 7.4 0.0 1.2 7.6 6.7 6.6 3.7 11.5 2.0 2.0 9.4 6.9 4.9 1.4 7.9 7.6 6.2 15.8 2.6 11.5 14.5 8.0 13.9 10.2 8.6 6.0 16.0 2.5 12.6 12.6 8.8 4.8 6.0 2.7 10.1 0.0 11.2 1.2 10.4 0.6 5.3 0.1 4.3 5.1 4.9 4.6 5.2 5.0 5.1 3.9 7.4 5.9 0.6 3.8 3.3 3.2 3.9 1.9 10.8 13.0 15.8 13.7 10.5 8.9 11.0 6.4 13.4 9.9 SYNJ2BP-COX16 ENSG00000258644 "SYNJ2BP-COX16 readthrough" 14 70326064-70417074 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "U-2 OS: 33.1" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000866, HPA062659" Approved Supported Approved Mitochondria Mitochondria "HPA000866: AB_2276678, HPA062659: " "unprognostic (9.44e-2)" "unprognostic (2.42e-1)" "unprognostic (4.33e-2)" "unprognostic (1.68e-2)" "unprognostic (1.06e-1)" "unprognostic (1.34e-1)" "unprognostic (8.70e-2)" "unprognostic (2.02e-1)" "unprognostic (1.96e-2)" "unprognostic (3.00e-1)" "unprognostic (2.21e-2)" "unprognostic (6.41e-2)" "unprognostic (6.73e-4)" "unprognostic (6.68e-2)" "unprognostic (6.93e-2)" "unprognostic (2.55e-1)" "unprognostic (2.12e-2)" 5.5 7.1 3.8 4.7 5.7 7.7 5.7 7.1 7.4 5.1 9.3 6.2 6.2 8.2 4.3 4.3 7.4 2.1 5.4 7.0 3.9 15.4 12.3 4.1 4.9 3.4 2.3 4.7 14.0 0.9 10.4 5.2 5.9 6.9 3.6 5.0 3.4 6.7 30.7 2.5 15.5 6.8 3.6 5.4 7.3 16.3 4.1 2.6 7.7 6.4 3.1 6.9 1.6 16.2 18.2 11.1 13.4 18.3 15.8 13.5 18.2 3.4 14.9 9.8 2.4 1.8 10.2 13.2 4.7 5.9 4.0 1.4 19.0 2.2 8.5 3.2 9.6 1.8 1.8 6.9 0.4 2.0 6.0 6.0 2.5 3.1 3.5 9.6 3.1 1.6 4.4 2.5 3.4 2.3 10.2 2.4 3.1 19.6 7.0 14.9 2.7 13.8 9.8 2.6 3.6 9.7 9.6 7.6 7.8 20.0 13.7 20.7 13.7 7.6 13.1 33.1 12.2 5.6 13.2 7.0 11.8 15.0 3.9 14.6 11.1 12.1 0.9 11.8 13.4 12.9 16.2 15.6 12.4 14.8 15.7 13.8 14.4 0.4 18.3 8.9 18.2 15.8 13.5 SYP MRX96 ENSG00000102003 Synaptophysin P08247 X 49187804-49200259 "Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters" "Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 8 "brain: 179.2" "Cell line enhanced" "Detected in some" "K-562: 8.5;SCLC-21H: 45.7;SH-SY5Y: 16.5" "Group enriched" "Detected in many" 6 "glioma: 12.8;pancreatic cancer: 5.7" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 5.3" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000076, HPA002858, CAB055505, CAB078999" Enhanced Supported "CAB000076: AB_2315411, CAB055505: AB_564017, CAB078999: , HPA002858: AB_1080153" "unprognostic (2.08e-1)" "unprognostic (8.72e-2)" "unprognostic (1.56e-1)" "unprognostic (5.37e-3)" "unprognostic (4.37e-2)" "unprognostic (2.11e-1)" "unprognostic (1.87e-1)" "unprognostic (6.46e-5)" "unprognostic (8.52e-3)" "unprognostic (1.62e-1)" "unprognostic (3.44e-3)" "unprognostic (8.26e-2)" "unprognostic (2.41e-2)" "unprognostic (1.95e-1)" "unprognostic (3.54e-1)" "unprognostic (1.79e-2)" "unprognostic (1.94e-1)" 2.7 21.4 34.5 3.2 42.5 1.9 1.9 53.8 179.2 2.0 3.6 7.2 0.0 7.4 2.2 2.6 2.2 2.0 2.0 2.3 44.4 45.3 2.7 1.8 2.8 2.0 25.5 39.0 2.1 5.2 1.9 17.4 2.0 46.7 2.1 3.5 11.5 2.0 2.1 2.4 2.3 8.1 2.5 15.5 2.4 3.9 2.0 4.0 0.0 2.1 0.0 1.9 1.8 0.2 1.3 1.6 5.3 0.8 0.5 0.7 0.1 0.4 1.7 1.3 2.6 1.4 0.2 0.2 0.1 0.0 0.3 0.3 1.5 0.9 1.3 0.2 0.0 1.3 1.3 0.1 0.3 2.7 1.5 2.1 0.5 0.5 0.0 0.2 4.7 0.2 0.0 0.2 0.3 0.1 8.5 3.3 0.3 0.5 0.7 0.1 4.2 0.3 0.3 0.2 0.6 0.1 0.2 45.7 16.5 0.5 0.2 0.6 0.8 0.8 0.2 0.3 1.4 0.4 0.2 0.2 2.8 0.3 0.7 0.5 1.4 1.7 0.8 0.4 0.2 0.7 0.4 0.7 0.5 0.7 0.4 1.3 0.5 0.5 5.3 0.5 0.4 1.6 0.3 0.1 34.5 42.5 53.8 84.8 44.4 45.3 25.5 39.0 46.7 4.0 SYT1 "P65, SVP65, SYT" ENSG00000067715 "Synaptotagmin 1" P21579 12 78863993-79452008 "Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Differentiation "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 11 "brain: 141.7" "Cell line enhanced" "Detected in many" "hTERT-HME1: 22.5;LHCN-M2: 18.0;SH-SY5Y: 17.4;WM-115: 16.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "classical monocyte: 2.3;memory B-cell: 3.3;naive B-cell: 3.4" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008394, HPA064788" Enhanced Supported "HPA008394: AB_1857696, HPA064788: AB_2685351" "unprognostic (1.02e-3)" "unprognostic (2.55e-1)" "unprognostic (4.21e-3)" "unprognostic (3.77e-2)" "unprognostic (3.16e-2)" "unprognostic (3.68e-5)" "unprognostic (2.78e-2)" "unprognostic (1.83e-2)" "unprognostic (7.65e-2)" "unprognostic (1.83e-1)" "unprognostic (1.11e-1)" "unprognostic (6.14e-3)" "unprognostic (3.05e-8)" "unprognostic (2.89e-2)" "unprognostic (8.26e-2)" "unprognostic (1.43e-1)" "unprognostic (1.53e-2)" 1.3 11.5 23.9 2.1 31.8 1.3 1.4 44.3 141.7 1.8 2.3 1.8 0.0 1.8 5.6 1.4 1.4 1.4 1.7 1.1 32.4 22.9 2.0 2.0 1.5 1.2 23.1 38.6 3.6 1.2 1.1 1.4 2.3 28.9 4.3 2.5 2.7 1.2 3.8 1.1 1.2 2.6 12.9 2.5 2.2 1.8 1.4 3.6 0.0 1.2 0.0 1.2 1.3 0.7 3.4 0.9 0.0 2.3 0.0 0.0 0.1 0.0 10.5 7.9 0.0 0.8 2.3 0.0 0.7 0.9 0.6 0.6 0.5 0.3 0.0 1.6 0.1 0.3 0.1 1.2 0.9 0.1 0.4 0.6 0.2 0.0 2.0 0.0 0.1 0.6 0.8 2.9 22.5 7.5 0.4 1.2 18.0 1.6 1.0 0.0 5.8 3.0 0.0 8.2 0.0 0.0 3.0 10.5 17.4 0.0 1.3 0.2 3.9 0.0 3.0 1.1 0.4 0.0 3.3 1.9 4.2 0.0 2.6 0.0 16.2 0.0 2.3 0.0 0.0 0.2 0.0 3.3 0.0 0.0 0.9 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 23.9 31.8 44.3 74.8 32.4 22.9 23.1 38.6 28.9 3.6 SYT2 ENSG00000143858 "Synaptotagmin 2" Q8N9I0 1 202590596-202710417 "Disease related genes, FDA approved drug targets, Predicted membrane proteins" Differentiation "Congenital myasthenic syndrome, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 40.1" "Cell line enhanced" "Detected in some" "AF22: 12.4;NTERA-2: 8.6;U-2 OS: 2.6" "Cancer enriched" "Detected in some" 7 "testis cancer: 3.8" "Group enriched" "Detected in many" 5 "cerebellum: 36.2;cerebral cortex: 14.7;pons and medulla: 40.1" "Cell type enriched" "Detected in single" 8 "neutrophil: 2.4" "Lineage enriched" "Detected in single" 8 "granulocytes: 2.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA063655 Enhanced Supported "HPA063655: " "unprognostic (1.32e-2)" "unprognostic (4.99e-2)" "unprognostic (4.89e-2)" "unprognostic (1.03e-2)" "unprognostic (2.21e-1)" "unprognostic (2.24e-2)" "unprognostic (3.00e-1)" "unprognostic (2.35e-3)" "unprognostic (8.81e-3)" "unprognostic (1.17e-1)" "unprognostic (1.53e-2)" "unprognostic (6.33e-2)" "unprognostic (1.56e-2)" "unprognostic (6.23e-2)" "unprognostic (3.26e-1)" "unprognostic (2.54e-1)" "unprognostic (5.17e-3)" 1.1 6.1 0.4 1.1 5.9 0.5 0.3 36.2 14.7 0.6 0.7 0.3 0.0 1.1 1.7 4.1 0.4 0.8 1.1 1.5 0.6 1.5 0.5 0.4 0.6 0.7 5.5 0.4 3.1 0.4 0.2 0.3 0.5 40.1 0.9 0.7 1.6 1.1 0.5 1.1 0.7 1.3 0.5 7.1 1.2 0.7 2.4 1.1 0.0 0.6 0.0 0.5 1.0 0.3 0.1 0.0 2.4 0.1 0.1 0.2 0.0 0.0 0.2 12.4 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.5 0.0 0.2 1.6 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 8.6 0.0 0.0 0.0 0.1 0.0 0.2 0.2 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 2.4 0.1 0.0 0.0 0.0 0.0 0.4 5.9 36.2 14.7 0.6 1.5 5.5 0.4 40.1 1.1 TAC3 "NKB, NKNB, ZNEUROK1" ENSG00000166863 "Tachykinin 3" Q9UHF0 12 57010000-57028883 "Disease related genes, Predicted secreted proteins" Neuropeptide "Disease mutation, Hypogonadotropic hypogonadism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 7 "placenta: 133.5" "Cell line enriched" "Detected in some" 5 "K-562: 17.2" "Cancer enriched" "Detected in many" 7 "urothelial cancer: 40.3" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA045919 Supported Supported Approved Vesicles "Secreted in female reproductive system" Vesicles "HPA045919: AB_10960533" "unprognostic (4.53e-2)" "unprognostic (1.97e-2)" "unprognostic (8.41e-2)" "unprognostic (3.00e-2)" "unprognostic (3.61e-2)" "unprognostic (1.76e-2)" "unprognostic (5.99e-2)" "unprognostic (8.41e-2)" "unprognostic (1.34e-1)" "unprognostic (2.03e-1)" "unprognostic (5.28e-2)" "unprognostic (4.71e-14)" "unprognostic (1.58e-2)" "unprognostic (1.76e-1)" "unprognostic (1.01e-1)" "unprognostic (2.39e-1)" 0.5 0.6 3.9 1.5 20.0 0.8 0.5 0.0 11.0 0.5 1.2 0.1 0.0 1.5 0.6 0.5 0.5 0.5 0.6 0.5 4.4 9.5 0.5 0.5 0.5 0.5 0.8 2.1 0.5 0.7 0.5 0.0 133.5 1.5 0.5 1.0 0.3 0.5 0.5 0.5 0.7 3.2 2.0 9.4 0.5 8.1 0.8 0.2 0.0 0.5 0.0 0.6 2.2 0.5 0.0 0.1 0.0 0.1 0.0 0.7 0.0 0.0 0.1 0.0 0.5 0.0 0.0 1.6 0.0 1.3 0.4 0.0 3.4 0.0 1.0 0.0 0.1 0.0 0.2 0.0 0.4 0.0 0.0 1.5 0.0 0.0 0.4 0.0 0.0 0.0 0.3 0.3 0.0 0.0 17.2 0.4 0.0 0.0 0.0 0.2 2.3 0.0 0.0 0.0 0.0 0.0 1.7 2.9 0.8 0.0 1.0 0.1 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 3.9 20.0 0.0 11.0 4.4 9.5 0.8 2.1 1.5 0.2 TBC1D25 OATL1 ENSG00000068354 "TBC1 domain family member 25" Q3MII6 X 48539457-48562609 "Predicted intracellular proteins" Autophagy "GTPase activation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA029197 Approved Approved "HPA029197: " "unprognostic (2.16e-1)" "unprognostic (5.13e-2)" "unprognostic (1.05e-2)" "unprognostic (5.12e-3)" "unprognostic (1.19e-1)" "unprognostic (9.18e-3)" "unprognostic (1.73e-2)" "unprognostic (1.32e-1)" "unprognostic (1.33e-1)" "unprognostic (7.29e-2)" "unprognostic (1.91e-1)" "unprognostic (2.57e-1)" "unprognostic (1.21e-1)" "unprognostic (8.07e-2)" "unprognostic (8.66e-2)" "unprognostic (1.13e-1)" "unprognostic (8.75e-2)" 11.0 11.1 10.9 9.1 18.5 14.6 9.7 17.5 26.3 9.5 9.5 9.5 5.4 7.5 9.5 7.1 10.6 10.4 9.3 16.0 10.2 9.8 7.6 9.2 9.9 10.4 8.0 14.2 11.9 16.8 16.0 10.1 14.8 12.6 10.2 7.9 9.5 8.5 10.2 10.7 13.0 8.4 12.5 6.7 12.2 9.2 11.0 5.0 12.8 9.4 9.6 11.0 9.6 8.7 7.0 3.5 7.3 3.8 5.9 10.0 5.6 6.2 6.3 2.5 7.3 9.8 9.4 3.3 4.3 8.2 7.8 8.6 4.0 5.7 6.7 3.2 11.5 6.1 11.6 11.9 7.7 11.9 7.1 3.3 9.8 3.7 10.0 4.2 8.8 9.4 12.0 11.4 14.0 8.3 2.6 9.9 9.5 5.4 8.1 7.8 3.8 11.7 4.2 4.6 8.6 7.3 3.2 6.8 4.6 7.6 6.2 6.0 6.7 1.4 7.7 5.1 7.8 15.8 5.0 9.7 5.0 4.8 8.5 5.5 4.8 2.2 2.7 7.3 10.0 3.8 8.1 6.5 6.7 8.5 3.1 7.0 7.3 7.4 6.3 5.9 3.0 3.5 5.8 5.6 10.9 18.5 17.5 26.3 10.2 9.8 8.0 14.2 12.6 5.0 TBL3 "SAZD, UTP13" ENSG00000183751 "Transducin beta like 3" Q12788 16 1972037-1982933 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA042562, HPA055695" Enhanced Supported Enhanced Nucleoli Nucleoli "HPA042562: AB_10964911, HPA055695: " "unprognostic (1.96e-1)" "unprognostic (5.49e-3)" "unprognostic (8.49e-2)" "unprognostic (1.56e-1)" "unprognostic (4.67e-1)" "unprognostic (2.65e-1)" "unprognostic (2.97e-2)" "unprognostic (1.17e-1)" "unprognostic (3.78e-2)" "unprognostic (8.03e-2)" "unprognostic (2.14e-2)" "unprognostic (8.32e-2)" "prognostic favourable (7.33e-4)" "unprognostic (3.65e-2)" "unprognostic (1.87e-1)" "unprognostic (2.32e-1)" "unprognostic (3.77e-1)" 8.9 7.9 6.0 9.5 8.3 6.0 5.8 16.3 9.6 6.2 6.8 8.8 6.8 7.7 7.1 6.3 9.4 5.4 6.0 7.5 6.6 6.1 7.2 8.7 6.9 7.2 7.0 7.3 7.7 8.9 10.5 5.5 7.3 5.7 5.7 3.6 5.6 10.5 6.0 18.2 9.5 7.8 5.9 4.8 6.7 9.5 20.5 6.5 9.5 7.2 11.5 9.3 5.1 5.4 8.5 11.2 5.8 12.0 14.8 12.1 8.5 5.5 10.7 3.0 5.8 2.9 2.3 9.7 5.1 3.3 4.4 3.6 13.7 10.7 7.3 12.1 3.9 15.0 4.8 6.0 2.3 5.4 6.8 4.6 5.4 5.2 3.3 8.0 4.4 2.4 4.5 5.5 3.3 5.5 9.3 5.5 2.6 8.9 10.2 4.5 7.0 4.4 17.8 5.5 12.3 2.2 2.1 6.9 5.4 4.6 11.9 4.4 9.0 5.4 8.6 6.1 7.3 5.4 9.9 9.9 4.3 11.6 3.6 5.1 7.0 4.8 10.2 5.8 12.1 12.0 10.7 7.5 8.9 11.8 11.2 8.5 11.4 8.6 2.5 14.8 11.7 5.7 9.6 8.5 6.0 8.3 16.3 9.6 6.6 6.1 7.0 7.3 5.7 6.5 TBR1 ENSG00000136535 "T-box, brain 1" Q16650 2 161416094-161425870 "Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Autism spectrum disorder, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 26 "brain: 34.9" "Cell line enhanced" "Detected in some" "HAP1: 1.6;HMC-1: 1.3;Karpas-707: 1.0;SCLC-21H: 1.7;U-266/84: 1.5" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 6 "amygdala: 45.6;basal ganglia: 28.5;cerebral cortex: 70.3;hippocampal formation: 50.1" "Region enhanced" "Detected in many" "cerebral cortex: 63.6" "HPA051256, HPA078644, HPA078657" Enhanced Supported "HPA051256: , HPA078644: AB_2732387, HPA078657: AB_2732388" "unprognostic (3.08e-2)" "unprognostic (5.45e-2)" "unprognostic (1.13e-1)" "unprognostic (1.35e-2)" "unprognostic (7.43e-3)" "unprognostic (1.95e-1)" "unprognostic (1.83e-2)" "unprognostic (1.14e-1)" "unprognostic (1.39e-9)" "unprognostic (5.72e-2)" "unprognostic (1.72e-1)" "unprognostic (5.37e-2)" 0.6 0.5 11.2 0.5 13.7 0.5 0.5 0.3 34.9 0.6 0.5 0.0 0.0 0.5 0.5 0.6 0.5 0.6 0.5 0.5 6.1 1.3 0.5 0.5 0.5 0.5 0.8 21.0 0.5 0.6 0.6 0.3 0.5 0.0 0.5 0.6 0.0 0.5 0.7 0.5 0.5 0.5 0.5 0.4 0.5 0.5 1.3 0.0 0.0 0.5 0.0 0.5 0.5 0.3 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 1.6 0.0 0.1 0.3 0.0 0.1 0.1 0.0 0.0 0.0 1.3 0.0 0.2 0.2 0.0 0.0 0.1 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 1.7 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.6 0.0 0.2 0.5 1.5 0.0 0.2 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 11.2 13.7 0.3 34.9 6.1 1.3 0.8 21.0 0.0 0.0 TH DYT5b ENSG00000180176 "Tyrosine hydroxylase" P07101 11 2163929-2171877 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Catecholamine biosynthesis, Neurotransmitter biosynthesis" "Monooxygenase, Oxidoreductase" "Disease mutation, Dystonia, FDA approved drug targets, Parkinson disease, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 31 "adrenal gland: 83.5;brain: 41.4" "Group enriched" "Detected in some" 32 "PC-3: 35.1;SK-BR-3: 12.5" "Cancer enhanced" "Detected in some" "urothelial cancer: 4.0" "Group enriched" "Detected in many" 6 "hypothalamus: 15.5;midbrain: 41.4;pons and medulla: 41.2" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in many" "olfactory region: 220.1" "Region enriched" "Detected in many" 19 "midbrain: 692.0" "CAB002522, HPA013768, HPA014010, HPA061003, CAB072340" Enhanced Supported Approved Cytosol Cytosol "CAB002522: AB_564047, CAB072340: , HPA013768: , HPA014010: , HPA061003: " "unprognostic (1.31e-1)" "unprognostic (1.30e-1)" "unprognostic (9.08e-2)" "unprognostic (1.75e-4)" "unprognostic (8.82e-3)" "unprognostic (5.88e-2)" "unprognostic (1.93e-1)" "unprognostic (1.74e-3)" "unprognostic (3.83e-2)" "unprognostic (4.39e-4)" "unprognostic (4.97e-1)" "unprognostic (3.61e-2)" "unprognostic (1.92e-1)" "unprognostic (1.60e-1)" "unprognostic (2.43e-1)" "unprognostic (2.70e-2)" "unprognostic (2.18e-2)" 1.3 83.5 0.0 0.3 5.4 0.2 0.2 0.0 0.7 1.8 0.2 6.2 0.0 0.2 0.3 0.3 0.2 0.3 0.4 0.2 0.3 15.5 0.2 0.2 0.2 0.2 41.4 0.0 0.3 0.3 0.2 0.2 0.9 41.2 0.6 0.2 0.3 0.2 2.0 0.2 0.5 0.4 0.2 0.0 0.3 0.2 0.3 1.5 0.0 0.2 0.0 0.2 0.9 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 35.1 0.0 0.0 0.0 0.1 0.0 0.6 0.1 0.0 12.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.4 0.0 0.7 0.3 15.5 41.4 0.0 41.2 1.5 TMEM145 FLJ90805 ENSG00000167619 "Transmembrane protein 145" Q8NBT3 19 42313325-42325062 "Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in many" 5 "brain: 74.5" "Cell line enhanced" "Detected in many" "HMC-1: 11.7;SCLC-21H: 22.2;SH-SY5Y: 10.6" "Cancer enhanced" "Detected in many" "glioma: 8.8" "Region enriched" "Detected in all" 4 "cerebellum: 74.5" "Group enriched" "Detected in some" 8 "basophil: 4.5;neutrophil: 15.5" "Lineage enriched" "Detected in many" 12 "granulocytes: 15.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA060462 Enhanced Approved Approved Vesicles Vesicles "HPA060462: " "unprognostic (9.56e-3)" "unprognostic (8.61e-2)" "unprognostic (6.65e-2)" "unprognostic (1.19e-1)" "unprognostic (2.96e-1)" "unprognostic (3.02e-1)" "unprognostic (1.47e-1)" "unprognostic (6.62e-2)" "unprognostic (2.14e-1)" "unprognostic (4.27e-3)" "unprognostic (1.53e-2)" "unprognostic (9.85e-2)" "unprognostic (4.20e-4)" "unprognostic (7.35e-2)" "unprognostic (7.64e-2)" "unprognostic (2.30e-1)" "unprognostic (6.31e-2)" 1.6 6.2 8.0 1.2 7.7 2.5 1.3 74.5 30.5 0.6 1.2 3.8 0.0 1.7 1.1 1.6 1.0 1.1 1.4 1.3 5.8 8.5 0.9 1.4 0.8 1.5 5.1 7.6 1.2 3.7 3.0 6.4 0.6 9.3 1.2 1.2 2.8 1.1 0.9 2.3 3.3 1.1 1.2 3.9 1.5 2.0 3.3 3.2 0.0 1.3 0.0 1.1 1.0 0.3 1.3 0.8 15.5 0.9 0.6 0.9 0.8 0.5 2.7 2.1 6.4 0.2 0.2 0.8 0.2 0.1 1.0 2.6 0.5 0.7 1.5 0.3 0.6 0.2 1.5 0.4 1.2 6.7 1.6 2.8 2.5 2.4 0.2 1.6 11.7 0.5 0.5 0.4 0.6 1.1 1.5 5.5 0.1 0.6 0.4 1.9 1.3 8.6 0.2 0.6 5.2 0.1 1.0 22.2 10.6 0.9 0.7 1.3 1.9 1.8 0.3 1.8 1.9 1.3 0.7 1.2 3.0 1.4 0.7 1.1 5.1 4.5 0.9 0.9 0.6 0.8 0.3 1.0 0.6 0.4 0.2 1.3 0.6 0.9 15.5 0.6 0.7 0.8 0.4 0.8 8.0 7.7 74.5 18.1 5.8 8.5 5.1 7.6 9.3 3.2 TOP2A TOP2 ENSG00000131747 "DNA topoisomerase II alpha" P11388 17 40388516-40417950 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Biological rhythms" "DNA-binding, Isomerase, Topoisomerase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "lymphoid tissue: 146.3;testis: 36.8" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "T-reg: 5.7" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "CAB002448, HPA006458, HPA026773" Enhanced Approved Supported Nucleoplasm,Nucleoli Nucleoplasm Nucleoli "CAB002448: AB_564035, HPA006458: AB_1858189, HPA026773: AB_1858190" "unprognostic (2.09e-1)" "unprognostic (1.24e-1)" "unprognostic (2.28e-3)" "unprognostic (9.42e-3)" "unprognostic (1.80e-1)" "unprognostic (1.52e-1)" "prognostic unfavourable (5.92e-6)" "prognostic unfavourable (4.99e-4)" "unprognostic (6.21e-3)" "unprognostic (2.09e-1)" "prognostic unfavourable (3.83e-5)" "unprognostic (5.03e-2)" "prognostic unfavourable (0.00e+0)" "unprognostic (7.46e-2)" "unprognostic (1.07e-1)" "unprognostic (2.18e-1)" "unprognostic (2.29e-1)" 2.7 2.0 0.4 20.0 0.5 14.6 4.1 0.4 0.5 3.0 6.9 0.5 0.5 7.0 2.0 3.4 18.2 0.7 2.4 2.3 0.6 0.5 1.4 1.9 5.5 15.4 0.6 0.4 1.2 1.1 0.0 0.4 10.7 0.6 1.2 8.0 0.6 3.2 0.3 0.6 5.9 9.2 2.6 1.8 7.3 4.5 36.8 0.3 146.3 0.9 11.8 16.7 3.2 5.7 1.3 0.3 0.3 0.3 3.2 5.7 1.1 33.7 44.9 57.2 26.1 2.8 5.8 12.7 46.4 25.0 42.7 37.9 21.0 25.9 54.5 23.6 15.7 53.8 43.9 18.5 57.4 29.1 29.3 36.0 28.7 35.1 0.2 50.4 38.3 1.2 1.5 30.0 30.6 22.4 38.9 37.4 46.1 11.7 58.4 33.9 23.7 17.9 49.6 88.8 22.6 10.3 21.6 33.8 24.3 37.4 46.7 14.7 39.2 23.2 14.7 28.2 39.7 32.5 44.5 21.5 24.3 47.6 15.9 34.8 46.9 0.3 0.0 0.0 0.6 0.0 0.0 1.3 0.9 0.9 0.3 0.4 0.2 0.1 0.3 3.2 0.3 0.0 5.7 1.1 0.4 0.5 0.4 0.5 0.6 0.5 0.6 0.4 0.6 0.3 TPRG1L "FAM79A, FLJ21811, RP11-46F15.3" ENSG00000158109 "Tumor protein p63 regulated 1 like" Q5T0D9 1 3625002-3630127 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA063163, CAB079051" Supported Approved Vesicles,Cytosol "Vesicles, Cytosol" "CAB079051: , HPA063163: " "unprognostic (1.92e-1)" "unprognostic (3.26e-3)" "unprognostic (4.46e-2)" "unprognostic (7.99e-2)" "unprognostic (4.50e-2)" "unprognostic (3.35e-1)" "unprognostic (1.46e-1)" "unprognostic (1.34e-1)" "unprognostic (1.77e-1)" "unprognostic (5.37e-2)" "unprognostic (1.50e-1)" "unprognostic (7.83e-3)" "prognostic favourable (1.76e-9)" "unprognostic (1.53e-1)" "unprognostic (2.01e-1)" "unprognostic (1.57e-1)" "unprognostic (1.60e-1)" 18.3 19.1 34.3 9.7 46.6 14.5 17.4 23.1 57.7 19.3 24.0 12.9 17.2 24.5 16.5 21.2 28.7 24.8 19.3 25.0 32.9 32.8 32.1 34.9 16.8 14.6 25.7 41.7 25.9 17.4 11.7 20.5 12.7 41.4 17.1 23.4 19.1 18.7 25.0 29.5 25.4 28.3 18.1 13.2 13.4 17.4 8.7 13.6 8.0 21.9 17.3 18.2 17.1 16.3 5.1 7.9 17.0 3.2 2.6 7.1 3.2 11.3 8.1 5.0 8.9 38.1 26.5 4.6 16.9 23.4 15.7 10.4 15.2 10.4 4.2 15.1 23.0 17.9 6.0 15.6 13.3 13.3 9.6 5.8 9.5 17.6 23.1 8.5 6.9 19.9 23.0 13.0 13.3 22.1 4.1 15.0 21.8 5.2 6.1 8.8 6.7 19.1 5.1 7.5 10.0 16.2 11.9 14.1 13.9 9.0 18.8 17.9 11.7 7.4 25.1 13.2 3.9 30.0 4.7 13.6 17.6 4.7 7.8 18.7 1.7 12.8 3.2 4.9 5.6 2.6 7.1 4.2 6.4 5.5 2.8 5.1 5.9 6.8 17.0 2.6 2.5 7.9 3.4 3.2 34.3 46.6 23.1 57.7 32.9 32.8 25.7 41.7 41.4 13.6 TUFT1 ENSG00000143367 "Tuftelin 1" Q9NNX1 1 151540305-151583583 "Predicted intracellular proteins, Predicted secreted proteins" Biomineralization "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skin 1: 54.9" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Region enriched" "Detected in some" 8 "cerebellum: 72.2" "HPA028112, HPA054301" Approved Approved Approved Vesicles "Secreted - unknown location" Vesicles "HPA028112: AB_10603224, HPA054301: " "unprognostic (6.16e-2)" "unprognostic (3.76e-1)" "unprognostic (1.38e-1)" "prognostic unfavourable (4.83e-4)" "unprognostic (4.49e-3)" "unprognostic (1.12e-1)" "unprognostic (2.30e-2)" "unprognostic (1.37e-2)" "unprognostic (8.29e-3)" "unprognostic (9.06e-2)" "unprognostic (6.70e-3)" "unprognostic (7.88e-2)" "unprognostic (2.58e-3)" "unprognostic (1.41e-1)" "unprognostic (1.32e-1)" "unprognostic (1.82e-3)" "unprognostic (4.53e-2)" 3.4 4.0 2.7 3.3 2.5 3.8 11.6 8.5 4.5 13.3 8.1 1.1 6.7 4.6 5.9 6.9 23.4 3.1 9.7 3.0 2.0 4.0 9.4 3.9 5.3 2.2 1.9 3.9 5.4 9.3 7.8 5.7 33.1 3.3 7.5 8.3 3.3 18.8 9.4 1.7 54.9 9.8 9.6 1.8 1.1 7.4 5.0 1.5 0.5 3.6 12.0 14.4 11.9 12.2 1.2 1.6 6.5 1.1 0.2 6.0 0.9 14.3 4.9 3.7 4.2 0.8 0.7 23.4 3.8 3.4 15.3 14.8 15.6 11.5 1.2 24.1 4.5 16.8 6.4 5.9 11.3 9.5 3.2 0.7 8.3 2.3 12.2 0.3 1.7 2.4 7.0 12.0 26.8 1.2 1.2 9.9 4.7 5.9 0.6 0.1 4.3 4.2 0.0 10.4 4.9 12.8 22.3 7.2 2.9 24.7 16.9 2.9 13.4 0.7 3.1 2.7 19.4 17.0 25.6 2.4 4.7 0.1 2.3 0.3 1.7 6.5 1.1 1.1 0.7 0.3 1.4 1.2 1.9 1.0 1.6 0.6 1.7 0.6 4.5 0.2 0.6 0.2 6.0 0.9 2.7 2.5 8.5 4.5 2.0 4.0 1.9 3.9 3.3 1.5 TXNL1 "TRP32, Txl, TXNL" ENSG00000091164 "Thioredoxin like 1" O43396 18 56597208-56651600 "Plasma proteins, Predicted intracellular proteins" "Electron transport, Transport" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002828, HPA002829, CAB016446" Supported Supported Enhanced Cytosol 1500000 Cytosol "CAB016446: , HPA002828: AB_1858358, HPA002829: AB_1858359" "unprognostic (2.05e-1)" "unprognostic (2.97e-1)" "unprognostic (3.38e-3)" "unprognostic (4.54e-2)" "unprognostic (2.51e-1)" "unprognostic (1.78e-1)" "prognostic unfavourable (9.62e-6)" "unprognostic (1.83e-1)" "unprognostic (1.03e-2)" "prognostic favourable (6.26e-5)" "unprognostic (1.44e-1)" "unprognostic (2.79e-1)" "unprognostic (3.29e-3)" "unprognostic (1.24e-1)" "unprognostic (1.26e-1)" "unprognostic (2.62e-1)" "unprognostic (1.51e-1)" 20.5 31.9 27.9 17.8 30.0 34.0 24.4 20.6 34.5 22.5 20.1 21.5 17.3 20.1 22.1 33.8 29.6 18.0 19.8 37.2 27.7 28.5 28.0 38.5 16.4 21.7 27.7 22.8 26.1 34.3 21.5 23.3 26.8 32.1 23.1 21.6 17.6 22.4 20.9 64.4 17.6 21.1 26.5 23.4 20.4 24.0 19.3 21.1 22.3 96.0 27.7 23.3 27.7 18.9 22.2 29.9 39.0 35.3 23.4 23.0 30.9 24.8 24.5 33.3 34.2 28.9 42.4 23.6 29.7 30.5 38.3 32.5 21.8 24.5 27.0 26.5 32.2 31.0 31.4 26.8 39.7 27.5 14.4 37.0 20.5 40.7 33.9 53.8 24.2 32.1 27.8 36.0 33.1 30.8 27.0 45.4 38.7 23.8 31.1 35.2 24.1 26.4 25.5 22.4 46.9 44.7 38.8 27.6 25.2 16.8 23.7 28.0 25.8 28.9 24.4 40.3 21.3 14.0 28.8 44.1 47.2 42.2 26.3 41.3 29.4 39.0 35.3 25.3 15.9 29.6 21.7 22.2 19.7 20.8 29.9 19.3 19.4 19.6 26.5 23.4 27.9 25.5 23.0 30.9 27.9 30.0 20.6 34.5 27.7 28.5 27.7 22.8 32.1 21.1 U2AF2 U2AF65 ENSG00000063244 "U2 small nuclear RNA auxiliary factor 2" P26368 19 55654146-55674715 "Plasma proteins, Predicted intracellular proteins" "mRNA processing, mRNA splicing" "Repressor, RNA-binding" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010910, HPA041943, HPA043562" Supported Supported Enhanced "Nucleoplasm,Nuclear speckles" "Nuclear speckles" Nucleoplasm "CAB010910: AB_262122, HPA041943: , HPA043562: " "unprognostic (2.37e-1)" "unprognostic (2.22e-1)" "unprognostic (3.12e-1)" "unprognostic (9.60e-2)" "unprognostic (6.94e-2)" "unprognostic (4.01e-2)" "prognostic unfavourable (1.54e-6)" "unprognostic (9.46e-2)" "unprognostic (1.36e-2)" "unprognostic (8.00e-2)" "unprognostic (3.33e-2)" "unprognostic (4.25e-3)" "unprognostic (2.19e-2)" "unprognostic (4.80e-2)" "unprognostic (9.88e-2)" "unprognostic (1.14e-1)" "unprognostic (3.08e-2)" 32.1 39.3 40.0 51.9 40.0 68.2 34.1 53.4 44.1 39.6 43.7 41.2 37.0 46.2 45.0 32.5 47.9 43.6 35.4 33.8 35.0 29.4 36.5 39.1 35.6 59.6 41.1 33.7 51.4 38.3 37.7 48.1 42.9 31.5 36.8 29.7 35.9 36.4 39.5 33.3 42.7 43.0 34.7 32.4 58.1 37.4 104.4 41.4 68.4 42.0 34.0 50.4 36.3 42.9 3.0 4.1 5.5 4.0 1.4 3.0 1.7 43.9 72.1 44.1 36.2 20.9 21.3 47.7 35.7 33.5 61.3 59.7 41.9 41.8 53.2 29.0 30.1 36.1 54.8 49.6 27.3 40.0 91.6 44.5 32.3 38.4 34.0 50.6 51.1 28.9 30.1 45.8 30.3 35.2 53.1 34.3 31.0 41.3 70.2 44.5 48.6 57.4 76.7 28.5 42.5 33.6 51.5 52.5 40.8 39.1 37.0 22.5 36.1 53.6 30.1 54.0 39.2 24.8 75.3 31.3 42.3 63.1 24.0 50.2 45.9 0.2 2.6 2.2 3.0 4.0 2.6 2.1 2.7 2.4 2.4 3.0 2.2 2.0 5.5 1.4 2.6 4.1 2.9 1.7 40.0 40.0 53.4 44.1 35.0 29.4 41.1 33.7 31.5 41.4 UBTF "NOR-90, UBF, UBF1, UBF2" ENSG00000108312 "Upstream binding transcription factor, RNA polymerase I" P17480 17 44205033-44221626 "Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Disease mutation, Mental retardation, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004611, HPA006385" Supported Supported Enhanced "Nucleoli fibrillar center" "Nucleoli fibrillar center" "CAB004611: AB_671403, HPA006385: AB_1080447" "unprognostic (1.37e-3)" "unprognostic (1.12e-3)" "unprognostic (2.54e-1)" "unprognostic (1.12e-2)" "unprognostic (3.15e-1)" "unprognostic (8.54e-3)" "unprognostic (1.35e-3)" "unprognostic (4.10e-2)" "unprognostic (5.39e-2)" "unprognostic (1.15e-1)" "unprognostic (1.12e-2)" "unprognostic (2.10e-1)" "unprognostic (1.96e-3)" "unprognostic (5.44e-2)" "unprognostic (9.01e-2)" "unprognostic (1.91e-2)" "unprognostic (2.00e-1)" 21.9 25.4 27.8 33.0 29.4 32.8 25.1 43.6 37.1 28.0 29.2 31.7 34.8 22.8 35.3 29.4 27.2 28.2 30.5 25.3 24.4 21.0 22.9 22.9 22.2 42.7 23.3 28.5 30.9 32.3 35.9 24.8 20.5 18.8 27.9 20.0 26.5 25.5 46.2 37.9 32.9 26.8 26.6 23.3 34.0 22.4 13.7 26.0 69.6 33.0 21.1 36.4 27.3 27.7 14.0 11.9 9.2 9.6 13.4 16.4 9.4 17.8 28.0 21.0 25.5 13.9 16.1 19.3 18.5 12.6 19.3 14.4 13.5 14.8 65.7 18.5 17.5 16.9 26.9 15.9 16.0 38.2 29.1 26.2 19.6 21.9 9.3 49.6 23.2 16.2 14.7 12.2 18.2 16.1 30.1 20.7 16.1 30.6 48.6 19.8 19.9 22.1 48.3 28.5 29.6 11.3 14.5 32.9 25.1 18.5 16.9 14.8 24.6 32.3 19.6 30.3 36.8 17.7 24.8 18.1 15.6 40.4 18.1 22.9 27.0 7.5 5.2 5.3 15.1 5.8 16.4 11.1 10.7 15.8 6.1 14.0 12.5 13.0 9.2 13.4 9.6 11.9 8.7 9.4 27.8 29.4 43.6 37.1 24.4 21.0 23.3 28.5 18.8 26.0 UCHL1 "PARK5, PGP9.5, Uch-L1" ENSG00000154277 "Ubiquitin C-terminal hydrolase L1" P09936 4 41256413-41268455 "Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Ubl conjugation pathway" "Hydrolase, Protease, Thiol protease" "Disease mutation, Hereditary spastic paraplegia, Neurodegeneration, Parkinson disease, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 225.8" "Cell line enhanced" "Detected in many" "EFO-21: 97.1;SCLC-21H: 96.9;U-251 MG: 88.7;U-266/84: 85.5;U-87 MG: 94.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "memory B-cell: 3.6" "Lineage enriched" "Detected in single" 37 "B-cells: 3.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002580, HPA005993, CAB079024" Enhanced Supported Supported Nucleoplasm,Cytosol 440000 Cytosol Nucleoplasm "CAB002580: AB_563981, CAB079024: , HPA005993: AB_1858560" "unprognostic (1.54e-1)" "unprognostic (1.96e-1)" "unprognostic (1.12e-1)" "prognostic unfavourable (4.08e-5)" "unprognostic (2.34e-1)" "unprognostic (1.98e-1)" "unprognostic (6.28e-3)" "unprognostic (1.09e-2)" "unprognostic (4.31e-2)" "unprognostic (8.77e-3)" "unprognostic (3.56e-3)" "unprognostic (3.70e-2)" "unprognostic (1.82e-3)" "unprognostic (1.24e-2)" "unprognostic (7.12e-3)" "unprognostic (2.10e-2)" "prognostic unfavourable (1.93e-4)" 8.2 40.2 52.4 8.9 65.1 2.0 3.1 17.5 225.8 4.5 6.3 11.5 0.0 5.5 6.0 1.8 2.7 5.7 6.5 5.4 53.4 97.4 14.0 2.0 2.7 6.5 62.0 57.1 15.4 6.3 1.8 30.5 2.7 100.6 5.3 4.7 6.0 3.0 4.4 7.5 2.7 8.6 5.2 38.6 2.3 2.8 8.0 8.3 0.0 3.9 0.0 4.5 5.6 2.8 3.6 0.0 0.0 0.0 0.0 0.0 0.6 0.2 55.0 11.4 0.0 1.5 1.9 0.0 57.6 29.7 20.4 20.6 11.1 0.0 0.0 97.1 29.3 0.1 21.0 0.0 8.3 0.1 8.6 0.0 0.3 0.0 44.0 0.0 0.0 10.6 0.2 16.3 0.0 0.1 0.0 0.2 10.8 0.0 0.0 0.9 32.9 62.2 0.0 24.4 0.0 30.8 0.0 96.9 60.9 0.3 0.2 0.1 0.0 0.4 0.3 1.3 0.4 0.0 88.7 45.5 85.5 0.2 94.2 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 52.4 65.1 17.5 92.6 53.4 97.4 62.0 57.1 100.6 8.3 USP11 UHX1 ENSG00000102226 "Ubiquitin specific peptidase 11" P51784 X 47232690-47248328 "Enzymes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Ubl conjugation pathway" "Hydrolase, Protease, Thiol protease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 74.0" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003103, HPA037536" Enhanced Supported Supported Nucleoplasm "Intracellular and membrane" Nucleoplasm "HPA003103: AB_10671088, HPA037536: AB_10672904" "unprognostic (1.60e-1)" "unprognostic (2.77e-3)" "unprognostic (5.84e-2)" "prognostic unfavourable (2.95e-4)" "unprognostic (3.08e-2)" "unprognostic (2.02e-1)" "unprognostic (6.11e-3)" "unprognostic (9.21e-2)" "unprognostic (3.18e-2)" "unprognostic (3.52e-1)" "unprognostic (3.29e-3)" "unprognostic (3.74e-2)" "prognostic favourable (4.13e-5)" "unprognostic (3.14e-2)" "unprognostic (9.23e-2)" "unprognostic (9.51e-2)" "unprognostic (7.11e-2)" 11.5 17.3 32.9 11.5 55.0 4.9 9.4 35.7 74.0 17.5 9.1 19.9 5.8 6.0 22.6 12.7 9.7 26.6 12.8 20.6 27.0 44.0 13.6 6.7 12.5 13.8 23.1 47.4 38.2 13.8 28.4 32.3 12.6 27.8 15.7 7.6 17.9 9.3 21.3 13.7 7.8 7.3 19.1 17.0 13.5 9.1 19.2 14.6 19.0 27.2 4.3 14.3 11.0 9.8 21.0 20.6 22.8 8.7 19.8 31.7 16.4 14.3 22.6 38.9 26.5 14.7 9.9 10.8 11.0 17.3 21.9 24.5 21.5 11.8 9.5 8.7 19.8 17.1 31.5 7.7 19.5 14.7 23.9 11.1 17.9 19.1 17.1 12.4 23.2 14.2 3.2 23.1 9.9 8.7 8.3 1.3 17.0 21.8 24.1 13.3 28.9 20.2 27.2 38.1 7.9 10.7 19.8 22.0 37.8 20.1 4.1 11.9 8.5 7.2 9.1 18.5 19.5 26.0 12.5 17.7 11.1 16.6 11.4 15.5 16.4 22.8 3.5 7.4 22.6 7.4 19.9 20.1 10.2 22.1 4.6 21.0 15.4 31.7 2.2 19.8 8.7 20.6 12.7 16.4 32.9 55.0 35.7 74.0 27.0 44.0 23.1 47.4 27.8 14.6 USP20 KIAA1003 ENSG00000136878 "Ubiquitin specific peptidase 20" Q9Y2K6 9 129834698-129881838 "Enzymes, Predicted intracellular proteins" "Endocytosis, Ubl conjugation pathway" "Hydrolase, Protease, Thiol protease" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "K-562: 30.4;MOLT-4: 27.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA006287, HPA007008" Uncertain Supported Approved "Nucleoplasm,Plasma membrane,Cytosol" "Nucleoplasm, Plasma membrane, Cytosol" "HPA006287: AB_1080510, HPA007008: " "unprognostic (2.64e-2)" "prognostic favourable (8.01e-4)" "prognostic unfavourable (2.48e-4)" "prognostic favourable (4.01e-4)" "unprognostic (4.69e-1)" "unprognostic (1.89e-2)" "unprognostic (2.25e-1)" "unprognostic (2.55e-3)" "unprognostic (1.24e-1)" "unprognostic (7.89e-2)" "prognostic favourable (1.54e-7)" "unprognostic (2.09e-1)" "prognostic favourable (5.65e-5)" "unprognostic (1.76e-2)" "unprognostic (1.20e-1)" "unprognostic (1.19e-2)" "unprognostic (1.24e-2)" 7.8 13.2 10.5 15.2 14.6 24.4 8.5 23.0 19.6 13.2 12.1 12.7 10.2 9.7 13.3 6.2 9.3 11.6 12.5 8.8 10.5 13.7 8.0 7.3 9.1 19.6 9.6 16.1 16.8 12.9 11.5 19.0 8.0 11.9 14.9 6.1 10.8 13.7 17.2 10.2 14.0 11.8 20.0 8.8 14.6 10.2 14.0 8.8 51.5 19.3 4.2 15.3 15.6 10.0 3.8 2.4 4.8 1.7 9.0 10.7 5.4 3.0 2.9 5.2 7.0 6.8 5.8 7.4 4.9 4.1 3.7 2.6 2.4 3.3 4.1 4.2 4.7 7.6 3.1 3.5 1.5 22.2 4.1 7.6 8.0 1.6 4.8 7.1 5.7 5.1 5.1 4.9 3.7 4.0 30.4 5.1 2.2 8.0 27.8 16.9 4.1 7.0 4.7 5.8 7.0 2.9 3.3 1.1 5.8 5.7 7.2 4.6 7.5 10.0 5.9 4.1 1.9 5.5 3.2 5.1 7.4 2.9 8.2 9.4 3.8 1.0 1.7 4.8 8.6 1.4 9.3 3.7 8.8 8.3 2.4 3.8 10.4 8.9 2.8 9.0 1.3 2.1 10.7 5.4 10.5 14.6 23.0 19.6 10.5 13.7 9.6 16.1 11.9 8.8 USP21 "USP16, USP23" ENSG00000143258 "Ubiquitin specific peptidase 21" Q9UK80 1 161159450-161165723 "Enzymes, Predicted intracellular proteins" "Transcription, Transcription regulation, Ubl conjugation pathway" "Activator, Chromatin regulator, Hydrolase, Protease, Thiol protease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA028397 Uncertain Approved Supported "Nucleoplasm,Plasma membrane,Cytosol" Cytosol "Nucleoplasm, Plasma membrane" "HPA028397: AB_10603227" "unprognostic (9.17e-2)" "unprognostic (1.44e-1)" "unprognostic (3.95e-2)" "prognostic unfavourable (7.05e-4)" "unprognostic (1.22e-2)" "unprognostic (1.26e-2)" "prognostic unfavourable (1.68e-4)" "unprognostic (5.35e-2)" "unprognostic (6.73e-2)" "unprognostic (2.76e-2)" "unprognostic (3.87e-3)" "unprognostic (1.31e-2)" "prognostic unfavourable (9.50e-6)" "unprognostic (2.45e-1)" "unprognostic (3.28e-1)" "unprognostic (2.13e-2)" "prognostic favourable (3.35e-5)" 11.8 16.4 22.1 12.8 21.2 15.3 19.1 23.6 24.8 18.1 16.1 25.5 14.0 15.5 19.7 14.6 18.3 33.3 14.1 13.7 20.9 12.1 15.4 10.6 14.0 16.7 26.4 14.1 28.3 19.0 24.4 17.2 15.2 20.5 18.1 13.1 17.1 19.0 25.3 19.4 23.5 15.4 15.1 17.0 18.7 16.0 17.0 22.9 16.0 24.5 9.6 15.6 17.9 19.2 14.1 12.0 18.3 11.1 13.4 17.2 10.7 7.4 12.8 16.9 16.3 13.5 11.3 10.4 5.5 9.0 15.2 11.9 11.8 14.7 9.7 9.5 6.8 12.9 10.9 10.7 8.4 18.5 18.3 11.6 18.5 9.2 9.7 10.3 8.7 9.5 14.4 10.4 15.0 10.7 17.1 13.6 9.6 13.7 18.2 16.2 15.8 16.3 17.3 5.6 16.3 8.9 8.9 15.4 19.8 10.3 10.8 8.3 23.8 16.6 6.2 10.9 9.7 7.6 9.4 27.5 21.3 14.4 10.0 8.9 9.8 13.0 11.1 18.3 14.9 7.1 17.2 12.8 13.8 15.4 12.0 14.1 16.0 14.6 9.6 13.4 7.7 12.0 13.3 10.7 22.1 21.2 23.6 24.8 20.9 12.1 26.4 14.1 20.5 22.9 USP36 "FLJ12851, KIAA1453" ENSG00000055483 "Ubiquitin specific peptidase 36" Q9P275 17 78787381-78841441 "Enzymes, Plasma proteins, Predicted intracellular proteins" "Ubl conjugation pathway" "Hydrolase, Protease, Thiol protease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA012082, HPA012395, HPA052860" Uncertain Supported Enhanced "Nucleoli,Nuclear speckles" Nucleoli "Nuclear speckles" "HPA012082: AB_1858682, HPA012395: , HPA052860: " "unprognostic (1.94e-2)" "unprognostic (2.80e-2)" "unprognostic (1.07e-1)" "prognostic unfavourable (5.18e-5)" "unprognostic (9.35e-2)" "unprognostic (1.98e-1)" "unprognostic (2.50e-3)" "unprognostic (1.35e-1)" "unprognostic (2.04e-1)" "unprognostic (1.33e-1)" "unprognostic (1.68e-2)" "unprognostic (2.78e-2)" "unprognostic (1.31e-2)" "unprognostic (1.45e-1)" "unprognostic (1.81e-1)" "unprognostic (4.03e-3)" "unprognostic (1.78e-1)" 26.3 23.4 12.9 21.3 16.0 36.5 28.1 28.3 17.4 17.2 16.4 25.4 19.2 12.3 25.1 22.2 14.6 18.0 21.9 17.4 10.4 11.2 15.9 16.4 20.0 17.2 17.5 16.0 41.3 33.6 19.6 30.0 23.4 14.6 21.0 15.1 20.4 21.8 45.5 19.5 29.3 15.1 25.2 14.5 18.2 17.3 20.8 13.7 12.8 19.3 11.2 22.2 24.6 18.1 6.7 12.4 8.9 5.3 5.6 8.8 2.5 15.7 19.1 5.6 10.4 12.1 13.5 10.8 13.0 13.2 12.5 8.4 18.5 8.0 20.2 6.6 11.5 11.6 13.2 9.6 22.4 4.8 20.0 18.4 27.8 19.2 12.4 20.1 10.1 11.7 16.0 17.8 39.9 10.8 14.6 21.3 10.3 12.1 18.3 20.4 8.7 15.3 14.1 12.3 13.5 7.9 16.6 16.6 10.1 9.3 43.5 23.6 11.2 12.8 9.2 29.5 13.7 17.1 22.9 15.8 6.2 24.8 11.6 15.8 9.2 8.9 3.9 3.1 7.6 5.3 8.8 6.4 7.2 6.4 2.3 6.7 8.0 7.7 5.7 5.6 3.3 12.4 4.8 2.5 12.9 16.0 28.3 17.4 10.4 11.2 17.5 16.0 14.6 13.7 USP39 "CGI-21, SAD1, SNRNP65" ENSG00000168883 "Ubiquitin specific peptidase 39" Q53GS9 2 85602856-85649282 "Enzymes, Predicted intracellular proteins" "Cell cycle, Cell division, mRNA processing, mRNA splicing" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA034823, HPA077350" Supported Supported Supported Nucleoplasm Nucleoplasm "HPA034823: AB_10602488, HPA077350: " "unprognostic (1.10e-2)" "unprognostic (3.31e-3)" "unprognostic (1.83e-1)" "prognostic unfavourable (5.52e-4)" "unprognostic (8.46e-3)" "unprognostic (3.67e-2)" "prognostic unfavourable (2.84e-6)" "unprognostic (1.10e-2)" "unprognostic (1.69e-1)" "unprognostic (1.89e-1)" "unprognostic (5.17e-3)" "unprognostic (3.14e-2)" "prognostic unfavourable (4.05e-7)" "unprognostic (3.95e-3)" "unprognostic (2.25e-1)" "unprognostic (2.52e-2)" "unprognostic (2.52e-1)" 19.0 15.1 14.5 23.5 16.8 30.4 18.3 14.9 20.8 20.2 24.1 18.7 11.8 14.7 22.1 24.1 20.7 16.8 20.6 25.5 13.7 13.7 17.8 20.8 18.5 20.8 15.2 14.5 19.2 15.0 17.7 13.7 28.0 15.8 21.6 20.5 18.0 17.2 20.0 44.2 20.2 17.8 19.0 15.0 21.0 18.1 17.2 13.0 56.5 24.7 23.9 27.0 23.0 26.0 25.3 28.8 29.8 29.7 26.4 37.3 28.2 21.7 22.2 22.7 24.9 16.5 13.0 25.5 18.4 17.4 27.4 24.5 35.4 15.8 25.8 17.4 17.3 15.7 43.4 19.8 34.9 25.9 27.6 32.0 13.3 31.2 16.3 38.8 21.9 9.1 15.9 21.1 19.0 21.8 39.2 15.2 20.1 25.3 38.2 29.2 30.0 20.6 35.3 48.7 19.5 14.7 17.0 20.9 17.0 11.5 18.9 15.8 12.7 19.0 13.9 17.0 21.2 20.2 30.4 13.5 24.9 27.6 14.5 41.0 20.3 28.0 25.5 29.8 30.3 29.7 35.2 24.3 31.8 31.2 28.8 25.3 31.4 28.5 16.4 26.4 26.9 22.5 37.3 28.2 14.5 16.8 14.9 20.8 13.7 13.7 15.2 14.5 15.8 13.0 VAMP1 "SYB1, VAMP-1" ENSG00000139190 "Vesicle associated membrane protein 1" P23763 12 6462237-6470987 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Congenital myasthenic syndrome, Disease mutation, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 38.7;brain: 85.2" "Cell line enriched" "Detected in many" 6 "U-698: 66.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002779, CAB016119, CAB079000" Approved Supported "CAB002779: , CAB016119: AB_628309, CAB079000: " "unprognostic (2.33e-1)" "unprognostic (6.72e-3)" "prognostic unfavourable (6.37e-5)" "unprognostic (8.09e-3)" "unprognostic (2.17e-1)" "unprognostic (1.14e-3)" "prognostic unfavourable (6.97e-4)" "unprognostic (1.22e-2)" "unprognostic (6.33e-2)" "unprognostic (1.05e-1)" "unprognostic (1.40e-3)" "unprognostic (3.48e-2)" "prognostic unfavourable (1.04e-11)" "unprognostic (1.47e-2)" "unprognostic (5.99e-2)" "unprognostic (1.62e-1)" "unprognostic (3.65e-2)" 3.4 6.8 10.2 13.7 12.8 38.7 4.2 9.8 53.1 5.7 8.0 11.1 1.6 4.7 8.7 5.4 3.9 5.1 5.2 4.0 14.1 25.4 3.2 4.3 5.3 24.3 33.5 10.0 3.8 2.4 1.1 3.1 2.4 85.2 8.6 8.8 4.8 6.3 7.6 4.0 4.2 7.9 7.7 31.3 12.4 5.4 3.7 8.3 3.7 7.9 0.8 23.0 5.0 4.7 5.5 2.5 13.4 1.0 2.1 7.0 2.5 0.9 3.4 1.8 2.6 5.6 6.4 2.2 1.8 3.4 1.9 5.4 1.1 3.1 9.7 0.4 4.4 2.9 2.3 1.0 2.8 7.6 5.4 1.5 10.2 1.2 2.6 3.7 3.7 4.7 0.4 2.4 1.4 1.7 0.5 2.8 4.2 1.0 4.9 4.3 9.2 1.5 5.4 3.0 1.8 1.2 1.3 0.4 0.8 3.7 1.9 1.4 0.6 1.4 2.0 0.8 2.9 1.9 1.2 2.5 1.0 66.4 3.5 7.8 0.7 6.9 1.0 13.4 6.7 0.4 5.3 5.5 5.5 6.2 1.1 1.3 5.8 4.8 5.5 2.1 0.5 2.5 7.0 2.5 10.2 12.8 9.8 53.1 14.1 25.4 33.5 10.0 85.2 8.3 VAMP2 "SYB2, VAMP-2" ENSG00000220205 "Vesicle associated membrane protein 2" P63027 17 8159149-8163546 "FDA approved drug targets, Predicted membrane proteins, Transporters" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 168.0" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" CAB078785 Supported "CAB078785: " "unprognostic (8.25e-2)" "unprognostic (4.41e-2)" "unprognostic (1.58e-2)" "prognostic favourable (1.08e-4)" "unprognostic (2.81e-2)" "unprognostic (1.15e-1)" "unprognostic (1.43e-2)" "unprognostic (7.28e-2)" "unprognostic (5.15e-2)" "unprognostic (1.55e-1)" "prognostic favourable (3.83e-6)" "unprognostic (8.27e-2)" "prognostic favourable (9.76e-8)" "unprognostic (1.21e-2)" "unprognostic (7.00e-2)" "unprognostic (1.54e-1)" "unprognostic (1.08e-1)" 22.0 38.3 65.1 16.2 111.7 57.4 20.2 72.2 168.0 20.1 16.3 51.6 11.6 15.7 27.4 24.1 11.6 26.8 14.4 22.1 61.7 56.5 23.5 11.4 21.0 23.1 52.7 71.1 48.4 22.6 52.2 40.6 15.4 88.4 25.1 19.3 37.5 19.5 27.0 33.6 25.0 17.9 25.2 30.7 27.2 17.4 15.1 35.1 9.2 22.0 8.8 22.8 11.7 16.0 25.1 15.4 37.8 8.8 25.1 33.4 9.3 14.1 10.6 26.5 14.1 23.2 18.2 11.9 13.3 16.9 13.6 18.8 4.2 9.7 16.2 9.5 21.3 17.3 17.3 14.3 15.8 18.7 18.9 11.3 27.3 5.8 20.9 7.5 17.5 20.1 21.6 15.6 23.6 13.2 8.7 18.9 23.0 7.5 19.6 10.4 6.1 7.8 24.9 12.0 12.7 17.6 9.6 12.3 19.6 10.4 5.9 13.0 13.3 9.7 20.2 8.3 11.5 15.1 12.3 20.7 11.7 11.7 21.1 13.1 18.8 13.7 7.4 24.5 28.4 6.9 24.4 25.1 28.2 30.0 5.7 22.1 33.4 30.8 37.8 25.1 8.8 15.4 20.1 9.3 65.1 111.7 72.2 168.0 61.7 56.5 52.7 71.1 88.4 35.1 VIP ENSG00000146469 "Vasoactive intestinal peptide" P01282 6 152750798-152759765 "Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins" Hormone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 32.5;lymphoid tissue: 64.7" "Group enriched" "Detected in some" 4 "HeLa: 2.1;SH-SY5Y: 6.8;TIME: 4.8;U-2 OS: 2.0" "Group enriched" "Detected in some" 6 "colorectal cancer: 3.7;pancreatic cancer: 4.3;stomach cancer: 2.6" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA017324, CAB018649, HPA072701, CAB079780" Supported Supported Approved "Endoplasmic reticulum" "Secreted to blood" 121550 "Endoplasmic reticulum" "CAB018649: AB_2304501, CAB079780: , HPA017324: AB_1858754, HPA072701: " "unprognostic (9.58e-2)" "unprognostic (2.29e-2)" "unprognostic (2.60e-2)" "unprognostic (1.13e-1)" "unprognostic (3.34e-2)" "unprognostic (3.33e-2)" "unprognostic (2.48e-2)" "unprognostic (7.21e-2)" "unprognostic (2.22e-2)" "unprognostic (2.89e-2)" "unprognostic (2.36e-1)" "unprognostic (3.62e-1)" "unprognostic (2.92e-3)" "unprognostic (7.47e-2)" "unprognostic (1.94e-1)" "unprognostic (1.30e-1)" "unprognostic (5.90e-2)" 1.2 5.7 9.7 64.7 8.3 0.3 0.9 1.5 20.1 0.6 31.5 0.5 0.3 7.5 0.7 0.4 13.1 0.5 4.2 1.1 12.4 7.7 0.9 0.6 1.7 0.4 2.7 8.3 0.4 3.8 0.5 0.4 0.5 1.6 6.3 28.3 3.2 0.4 6.9 0.8 0.4 32.5 18.0 0.4 5.2 13.2 0.5 0.1 0.0 1.3 0.5 0.4 9.1 4.3 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.1 0.9 0.1 0.4 0.8 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.1 6.8 0.0 0.0 0.0 0.0 0.0 4.8 0.0 2.0 0.2 0.1 0.5 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 9.7 8.3 1.5 20.1 12.4 7.7 2.7 8.3 1.6 0.1 WASF1 "KIAA0269, SCAR1, WAVE, WAVE1" ENSG00000112290 "WAS protein family member 1" Q92558 6 110099819-110180004 "Predicted intracellular proteins" Actin-binding "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "brain: 63.3;ovary: 17.7;testis: 55.4" "Cell line enhanced" "Detected in many" "hTERT-HME1: 41.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 8 "memory B-cell: 3.9;naive B-cell: 5.9;plasmacytoid DC: 10.7" "Group enriched" "Detected in many" 10 "B-cells: 5.9;dendritic cells: 10.7" "Low region specificity" "Detected in all" "HPA004105, CAB022161" Approved Supported "CAB022161: , HPA004105: AB_1080583" "unprognostic (8.22e-2)" "unprognostic (1.07e-1)" "unprognostic (8.02e-2)" "unprognostic (1.30e-3)" "unprognostic (5.50e-2)" "unprognostic (2.28e-1)" "prognostic unfavourable (2.82e-8)" "unprognostic (9.20e-2)" "unprognostic (5.06e-2)" "unprognostic (2.52e-1)" "unprognostic (3.33e-3)" "unprognostic (2.73e-1)" "prognostic unfavourable (2.79e-5)" "unprognostic (1.95e-2)" "unprognostic (3.09e-2)" "unprognostic (9.03e-2)" "unprognostic (3.38e-1)" 5.4 7.6 19.8 3.4 44.3 7.1 5.5 18.0 63.3 5.4 3.9 10.9 0.5 2.3 9.9 5.1 6.1 4.9 6.6 1.8 43.8 10.3 6.5 4.6 2.6 3.3 10.6 26.7 17.7 4.6 4.1 5.8 2.8 17.0 4.3 3.5 0.9 3.3 4.3 1.3 4.3 2.7 10.5 12.8 2.4 3.0 55.4 9.3 1.0 2.3 0.6 3.4 4.6 2.8 5.9 10.7 0.1 0.8 0.6 0.3 0.5 3.3 3.8 20.2 16.4 8.7 11.3 2.2 7.1 8.2 6.1 10.7 6.5 3.2 19.3 4.6 11.1 3.8 31.4 9.7 10.6 0.3 14.8 37.7 7.4 5.9 15.7 2.2 5.8 8.9 13.8 8.4 41.8 9.2 14.2 4.5 7.0 2.8 19.8 0.6 18.2 5.0 18.3 7.4 0.7 9.8 3.9 16.3 25.3 5.0 3.7 4.6 4.7 9.7 6.8 5.6 5.8 16.4 9.5 0.1 3.0 16.9 6.3 16.3 4.1 0.0 0.7 0.0 0.1 0.2 0.3 3.9 0.3 0.0 0.8 5.9 0.1 0.1 0.1 0.6 0.8 10.7 0.0 0.5 19.8 44.3 18.0 48.9 43.8 10.3 10.6 26.7 17.0 9.3 YWHAG PPP1R170 ENSG00000170027 "Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma" P61981 7 76326794-76359031 "Disease related genes, Plasma proteins, Predicted intracellular proteins" "Disease mutation, Epilepsy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 117.8;skeletal muscle: 91.8" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013274, CAB018389, HPA026918, HPA061603" Approved Approved Supported Nucleoplasm,Nucleoli,Cytosol 160000000 Cytosol "Nucleoplasm, Nucleoli" "CAB013274: , CAB018389: AB_2217962, HPA026918: AB_10610566, HPA061603: " "unprognostic (3.71e-2)" "prognostic unfavourable (4.53e-4)" "unprognostic (3.88e-2)" "unprognostic (1.25e-2)" "unprognostic (6.28e-3)" "unprognostic (2.40e-3)" "unprognostic (8.98e-3)" "prognostic unfavourable (5.34e-4)" "unprognostic (1.63e-1)" "unprognostic (1.64e-1)" "prognostic unfavourable (7.44e-4)" "unprognostic (3.03e-2)" "prognostic unfavourable (4.01e-4)" "unprognostic (9.31e-2)" "unprognostic (1.51e-1)" "unprognostic (2.45e-2)" "unprognostic (1.70e-1)" 52.4 31.2 46.3 17.7 54.6 7.3 17.2 36.2 117.8 13.4 14.2 13.3 4.6 14.4 15.0 7.0 18.6 9.0 17.0 33.1 50.2 56.2 15.9 22.0 12.9 12.1 45.9 49.8 13.3 18.0 14.8 7.8 16.6 74.6 14.7 14.0 8.6 10.0 13.3 91.8 11.7 12.5 20.2 22.8 12.7 11.2 8.9 13.5 6.8 8.8 13.8 14.3 14.7 13.2 3.1 5.9 3.2 5.0 1.1 3.3 1.7 37.1 46.7 41.4 52.5 42.4 24.5 18.7 43.2 21.4 26.8 29.2 29.3 40.0 52.4 14.9 38.3 34.8 51.8 47.7 37.8 35.5 22.6 49.6 32.0 32.5 38.7 60.5 48.6 26.8 45.8 31.3 64.9 42.6 68.1 59.3 40.0 35.0 43.2 44.7 45.9 32.8 50.7 41.9 57.9 42.1 25.4 22.2 61.7 47.9 61.4 30.6 42.7 36.7 44.9 52.4 30.5 46.4 57.7 19.7 36.9 80.7 47.1 57.3 55.8 3.2 5.0 1.1 2.1 4.6 3.3 3.1 2.4 2.6 5.2 1.8 1.8 2.0 1.1 1.1 3.8 5.9 2.0 1.7 46.3 54.6 36.2 88.9 50.2 56.2 45.9 49.8 74.6 13.5 ZNF3 "A8-51, FLJ20216, HF.12, KOX25, PP838, Zfp113" ENSG00000166526 "Zinc finger protein 3" P17036 7 100064033-100082548 "Predicted intracellular proteins, Transcription factors" "Differentiation, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA003719 Supported Supported Approved Nucleoplasm Nucleoplasm "HPA003719: AB_1080701" "unprognostic (5.92e-2)" "unprognostic (3.82e-2)" "unprognostic (1.00e-1)" "unprognostic (1.01e-1)" "unprognostic (3.19e-2)" "unprognostic (2.76e-2)" "unprognostic (1.10e-1)" "prognostic favourable (5.73e-4)" "prognostic unfavourable (1.59e-4)" "unprognostic (2.65e-1)" "unprognostic (2.50e-3)" "unprognostic (7.54e-2)" "unprognostic (3.71e-2)" "unprognostic (8.22e-3)" "unprognostic (1.24e-1)" "unprognostic (3.41e-2)" "prognostic favourable (2.20e-4)" 16.1 12.8 12.8 9.8 16.8 20.7 19.2 18.3 22.6 18.6 16.4 39.5 16.6 19.3 23.9 20.5 15.2 33.9 11.6 11.5 14.8 11.2 15.0 19.3 11.7 11.1 20.8 11.1 22.5 18.9 17.9 17.8 13.3 21.1 15.6 17.8 19.7 16.4 16.3 18.9 15.4 22.1 14.6 18.0 15.6 16.0 11.8 21.9 21.4 17.6 11.1 16.6 16.7 15.5 16.2 11.2 17.9 12.2 17.3 17.2 9.4 6.1 6.9 19.0 27.1 9.6 7.5 11.1 7.8 8.9 12.0 10.2 8.6 9.2 8.8 14.3 7.5 8.4 14.0 8.5 9.8 9.7 11.8 7.2 8.9 11.6 11.4 12.8 6.7 9.3 10.7 8.0 18.7 10.6 19.9 14.0 10.8 16.5 30.0 12.8 26.1 12.6 12.8 15.3 21.9 10.7 12.1 21.3 29.6 9.2 27.4 12.1 8.1 13.0 8.1 14.9 10.7 10.6 10.1 18.9 21.3 17.6 7.5 11.5 13.9 12.3 9.8 17.9 14.2 9.6 17.2 13.3 12.5 14.9 9.9 16.2 14.2 15.5 4.1 17.3 12.2 11.2 11.5 9.4 12.8 16.8 18.3 22.6 14.8 11.2 20.8 11.1 21.1 21.9